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ABSTRACT 
 
Stephen Michael Campbell: Predicting Risk Of Recurrent Stroke  
Based On Changes In Risk Factors: The VISP Study 
(Under the direction of Gerardo Heiss) 
 
Background: Recurrent stroke carries a greater risk of disabling or fatal aftereffects (1,2,3) 
and poor quality of life compared to first-ever stroke 1.  Secondary stroke prevention has 
been successful in controlled trials but less so in the general population 4. Improvements in 
secondary stroke prevention may be realized through optimization of the management of risk 
factors following a stroke (5,6,7).  The objective of this study was to examine whether 
recurrent stroke risk can be predicted from risk factor profile changes and to determine 
whether improvements in care guideline adherence resulted in a reduction of recurrent stroke 
risk.  Methods: We analyzed data from the VISP trial. VISP’s methods and results have been 
described previously 8, 9. Demographic, clinical and laboratory data were collected at baseline 
and at six-month intervals. Participants on heparin (n= 36), from the Glasgow clinic (n= 46), 
or with irremediable missing data (n=274) were excluded, leaving 3324 participants with 
14142 observations for use in the first analysis.  For the second analysis, the dataset was 
further restricted to those participants with a baseline and a twelve-month follow-up visit 
(N=2750).  Results: We developed and calibrated two recurrent stroke risk models using 
repeat measurements of risk factors. Whites with untreated Type 2 diabetes or high 
homocysteine levels, nonwhites with strokes prior to the VISP eligibility stroke, and 
individuals with any dependency or any disability had an increased recurrent stroke risk; 
iv 
 
aspirin use showed a protective effect in nonwhites. Care guideline adherence post-index 
stroke was heterogeneous, with changes in adherence nearly exactly balanced between 
adherence and non-adherence.  Participants not using aspirin were at a significantly higher 
recurrent stroke risk if after their stroke they did not use anti-diabetic medications (within the 
first six months ) or started using diabetic medications or maintained a BMI of 25 kg/m2 or 
greater during the first twelve months   Conclusion: We have established that it is possible to 
predict recurrent stroke risk using repeat measurements of risk factors and that lack of 
adherence to medication adherence guidelines results in a higher risk of recurrent stroke.  
Psychoneurological factors appear to influence recurrent stroke risk.  
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CHAPTER I: BACKGROUND AND INTRODUCTION 
 
Overview of Study Background, Specific Aims, and Study Questions 
 
Recurrent stroke carries with it a greater risk than first-ever stroke for disabling or 
fatal aftereffects. (1, 2, 3) As mortality from first-ever strokes has decreased over the past four 
decades, 10 the numbers of those at risk for recurrent stroke has increased, with a concomitant 
increase in morbidity and health care costs. (1, 11) Secondary stroke prevention has been 
successful in controlled trials but less so in the general population. 4  It has been suggested 
that improvements in treatment modalities could come about through optimizing the 
management of stroke risk factors. (5,6)  However, it is difficult to estimate the potential 
decrease in stroke risk resulting from altering one or more risk factors, since the current 
stroke risk prediction equations do not incorporate repeat measures or information collected 
after the first stroke.  The development of a prediction equation, incorporating information 
obtained at the first stroke and subsequent changes in stroke risk factor profiles, could help 
clinicians customize treatment options for individual patients on the basis of the greatest 
possible reduction in stroke risk, thereby potentially improving stroke outcome and reducing 
health care expenditures. 
The majority of stroke risk prediction equations have been developed to determine the 
risk of first-ever stroke; relatively few have been developed for recurrent stroke, and most 
utilize only risk factor information obtained at the first stroke and so are not sensitive to 
changes in risk subsequent to alterations in risk factor profile. In order to be most effective 
2 
and efficient, the statistical tools used by clinicians as a part of treatment prescription and 
patient counseling for secondary prevention of stroke should be adaptive to changes in risk 
factors over time. Therefore, the objective of this project was to develop a clinical tool 
capable of aiding neurologists and other clinicians in prescribing the most effective treatment 
modality to reduce the risk of recurrent stroke while at the same time addressing issues of 
patient treatment adherence, cost, and morbidity. 
The primary objective of this project was to predict variations in recurrent stroke risk 
based on risk factor changes occurring after the initial stroke. A more effective “targeting” of 
the most significant risk factors (ones in which a change has the greatest effect on recurrent 
stroke risk) will help clinicians reduce treatment costs, decrease the effort involved for both 
physician and patient (in treatment adherence), reduce the number of side effects, and 
diminish morbidity and mortality. To aid clinicians in targeting the most influential risk 
factors, the project planned to develop and validate a clinical tool to aid physicians’ 
experience in prescribing treatment modalities post-first-ever stroke. To produce the tool, a 
prediction equation was developed using changes in risk of recurrent stroke using risk factor 
profile information obtained at the first stroke and changes to the profile obtained at intervals 
after the first stroke. After initial development, the model was assessed for sensitivity and 
specificity using the appropriate methods (possibly including ROC curve analyses) and its 
validity was tested using random subsets of the source and external populations. After these 
tests have been conducted, a “clinical risk score system” was planned to be developed using 
the coefficients from the equation and displayed in a “lookup table” designed to permit 
assessment of risk of recurrent stroke given multiple changes in treatment or lifestyle factors.  
The project also planned to develop a visual aid in the form of a graph of approximate 
3 
predicted recurrent stroke risk versus clinical risk score in order to facilitate a quick 
assessment of a patient’s current recurrent stroke risk.   
Specific Aims and Study Questions 
 
This project addressed the following three research questions: 
 Research Question 1: Which risk factors influence risk of recurrent ischemic stroke in 
the VISP population? 
 Research Question 2: Do short-term changes (e.g., six-month) in risk factors after an 
ischemic stroke influence the risk of recurrent ischemic stroke?  
 Research Question 3: Can repeat assessments of risk factors be used to optimize the 
outcome of an ischemic stroke?  
In order to accomplish the objective and answer the research questions the following 
specific aims were addressed:  
1. Specific Aim 1 (addresses research questions 1 and 2): Develop a robust well-fit 
prediction equation for recurrent ischemic stroke (using the Andersen-Gill form of the 
Cox proportional hazards approach) which incorporates known invariant risk factors 
(gender, race/ethnicity, age), modifiable risk factors measured at the time of the first 
stroke and at followup visits (e.g., obesity, smoking status, medication use), the 
sequelae of the first stroke (assessed by Rankin, Barthel and Mini-Mental data), and 
stroke status (first-ever, multiple previous strokes). Risk factors were selected for 
consideration based on literature review and were tested if present in the VISP 
database at baseline visit or at follow-up visit(s) and if considered clinically- or 
neurologically-relevant based on clinical input.   
4 
Other tasks which were necessary as part of the work addressing Specific Aim 1 
include the following:  a) an assessment of model goodness-of-fit and discriminatory ability 
(sensitivity, specificity) using the Receiver Operating Curve (ROC) and the Area Under the 
Curve (AUC) – or c – statistic and standard statistical tests; b) validation of the model 
prospectively, chronologically, geographically and independently (calibration and ROC 
curves) following the methods of Justice et. al. 12 – internally using subsets of the model 
source dataset, prospectively using datasets collected subsequent to the model’s source 
dataset, independently using other study datasets with different measures of risk factors 
(likely collected in a different time period), and geographically by testing the model on 
populations from different geographic locations;  
2. Specific Aim 2 (addresses research question 3): Develop a “scoring system” based on 
the validated prediction equation which can be used by clinical personnel to optimize 
patient counseling and care by determining the likely outcomes of differential risk 
reduction strategies and targeting those risk factors which have a larger impact on 
recurrent stroke risk. 
Component tasks of Aim 2 include the following items: a) the definition and 
development of the necessary elements (usability, functionality, clinical applicability; b) 
definition of the components of the equation, e.g., by using the model coefficients as “scores” 
in a simple addition that sums the coefficients for risk factors present in a patient’s risk 
profile and yields a total “risk score”; c) assessment of the goodness-of-fit of the equation; d) 
assessment of the internal validity of total score using different risk factor combinations; e) 
validation of the score system on other levels; f) the creation of a simple lookup table and 
5 
graph of approximate predicted recurrent stroke risk for use with the calculated “risk score”, 
e.g., by using an interactive calculation system, such as a spreadsheet with graphical ability.   
After the score system has been developed and initial testing completed, independent 
medical personnel were to be asked to conduct additional tests of the system using medical 
history information with blinded stroke outcome to assess ease of use, accuracy, and 
repeatability.  Finally, a Web-based application similar to that produced by the ARIC study 
for initial stroke risk – URL: http://aricnews.net/strokecalc/html/s_RC1.html – was to be 
developed to allow remote users to enter relevant data and obtain estimates of recurrent 
stroke risk. 
Background and Significance 
 
Introduction   
Although recurrent stroke is less prevalent than first-ever stroke, it is associated with 
a greater risk for disabling or fatal consequences, (1, 2, 3) its other aftereffects are often more 
costly economically, and survivors report lower quality of life. 1  Fatality from first-ever 
strokes has decreased over the past four decades as medical interventions have improved, 10 
however, this has resulted in an increase in the numbers of those at risk for recurrent stroke 
together with the predictable increase in morbidity and health care costs. (1, 11) While 
prevention of recurrent stroke has been achieved in clinical trials, secondary stroke 
prevention has been less successful in the general stroke survivor population. 4  Some authors 
have posited that optimizing the management of stroke risk factors could yield additional 
improvements in treatment modalities and reduction in recurrent stroke risk, (5,6) however it is 
difficult to estimate the effect of modifying one or more risk factors on the risk of recurrent 
stroke since the current stroke risk prediction equations do not utilize detailed risk-factor-
6 
specific changes measured through repeated assessments of the risk factor profile obtained 
after the first stroke. Consequently, the creation of a risk prediction model based on risk 
factor profiles measured at the time of first stroke together with changes in risk factors 
determined from repeat measures of stroke risk factor profiles could aid clinicians in 
targeting those risk factors with the greatest influence on a patient’s risk of recurrent stroke, 
and using that information either to provide the patient with that information (to aid in risk 
management decision-making) or to allow the patient to choose the risk factors they are most 
comfortable modifying, with an eye towards maximizing risk reduction.  
Total stroke mortality and recent changes in stroke mortality 
Stroke – including primary and recurrent – is the third leading cause of death in the 
United States 11 and contributes heavily towards mortality rates in other developed and 
developing countries. Reports from the Global Burden of Disease 2000 project and the World 
Health Report 2001 indicated that stroke accounted for roughly 42.9% of years of lost life 
caused by brain diseases (48.8% when psychiatric diseases were removed from the total). 13  
(The observant reader may notice that in this report the percentage of years of lost life, when 
summed over all causes, is greater than 100; the authors comment that this is due to “residual 
categories.”) Although stroke mortality rates had declined generally in the United States 10 
between 1900 and roughly 1990, not all regions have experienced an equivalent decrease – 
the Minnesota Heart Survey documented a varying decline in mortality rates between 1960 
and 1984 14 and some areas in the Mississippi River region showed no change. 15  In addition, 
although the 28-day case hospital-based case fatality rate has decreased, 14 still roughly half 
of first-ever stroke survivors may die within 5 years of stroke onset. 15 Finally, the decrease 
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in stroke-related mortality appears to have slowed both nationally and regionally, (14, 16, 17) 
and may have plateaued, indicating that stroke will continue to be a leading cause of death. 
Increases in total stroke prevalence 
Over the same time period that a decrease in the stroke mortality rate occurred, the 
incidence rates for stroke did not change significantly, (11, 14) resulting in an increase in stroke 
prevalence.  Muntner et. al. estimated that there was a roughly 30% increase in stroke 
prevalence between 1973 and 1991, using self-report data from NHANES I, II, and III and 
reported that the number of stroke survivors younger than age 75 increased by 930,000 
during the same time period, resulting in an estimated prevalence of 2.4 million individuals 
living with stroke. 10 A similar increase in stroke hospitalizations of 38.6% (age-adjusted, 
18.6%) between 1988 and 1997 was documented by Fang et. al. using the National Hospital 
Discharge Survey. 18  Since stroke is not only an acute condition, the increase in prevalence 
implies that there have been and will be rising social, economic and societal stroke-related 
costs. 
Stroke-related morbidity 
Stroke is also one of the leading causes of adult disability – including memory 
deficits, aphasia, dementia, and hemiparesis – in the United States 11 and in other developed 
countries. Reports from the Global Burden of Disease 2000 project and the World Health 
Report 2001 indicated that stroke was the second leading cause of disability-adjusted life 
years (DALYs). 13 It is not entirely clear whether the severity of stroke has decreased over 
the past twenty years – in the United States, the Framingham Study population appears to 
have experienced less severe strokes in recent years, 19 while the Minnesota Heart Study and 
Rochester Epidemiology Project populations have had a more mixed experience (15, 20, 21) – 
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and whether the advent of various therapies such as warfarin, statins, tissue plasminogen 
activator, and aspirin has significantly changed the case mix. Prevalence and incidence of 
disabilities is still high in stroke survivors, despite new therapies and improvements in 
rehabilitation methods. For example, Hankey and colleagues noted that 36% of first-ever 
stroke patients between 1989 and 1990 in the Perth Community Study, who had not been 
disabled at the time of their stroke, were disabled five years after stroke onset. 22  The relative 
risk (RR) for incident dementia associated with stroke was 8 times higher for a stroke cohort 
than for a control group in New York City. 23  Lastly, Roth and colleagues at the 
Rehabilitation Institute of Chicago found that although updated rehabilitation methods 
improved disability levels, the frequencies of many secondary medical complications 
increased over time. 24 To sum up, despite progress in acute and long-term care for stroke, 
there are still many serious aftereffects of a first-ever or recurrent stroke. 
Costs of primary and recurrent stroke 
Such consequences are accompanied by high social and economic costs, on an 
individual and societal basis.  The lasting effects of stroke hinder recovery, functionality, and 
productivity while increasing dependence and the burden on caregivers, and the necessity of 
hospitalization at stroke onset and possible institutionalization after stroke increase the 
economic costs to patients, their families, and society. Swedish researchers at Goteborg 
University found that even for mild stroke cases (in persons less than 75 years old) life 
satisfaction was well below normal values in terms of overall satisfaction as well as the 
ability to manage one’s own personal care. 25  On an economic level, the Copenhagen Stroke 
Study found that cost outcomes varied with the severity of the stroke – mild and moderate 
cases helped to reduce overall costs through shorter hospital stays, but severe cases had 
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increased expenses because they were discharged to nursing facilities and had higher costs of 
acute care and rehabilitation. 26 Confirming this, Caro et. al., modeling treatment costs of 
stroke based on the Barthel Index score at the time of presentation or shortly thereafter (using 
data from two international trials of stroke treatment in persons 18 years or older), found that 
a 5-point shift in the Barthel score resulted in a roughly 10% change in treatment costs. 27 In 
addition, because the aftereffects of stroke can be life-long, the cumulative costs can also be 
very high – in the United States, Taylor and colleagues calculated that the lifetime cost per 
person of first-ever strokes in 1990 was roughly $228,030 for subarachnoid hemorrhage, 
$123,565 for intracerebral hemorrhage, $90,981 for ischemic stroke, and $103,576 averaged 
across the three sub-groups. 28 Finally, individual costs add up to a large societal expenditure 
– according to the Morbidity and Mortality Weekly Report, roughly 50% of hospitalized 
stroke patients are discharged to home and 40% are discharged to a skilled nursing or other 
facility, 29 resulting in a national projected cost (for 2003) of $51 billion, $12 billion of which 
was due to nursing home expenses.   
Recurrent stroke 
The discussion to this point has mainly been concerned with total stroke, which is 
composed of approximately 65-75% first-ever stroke and 25-35% recurrent stroke. (30, 11)  
However, these two types of stroke, while they share many etiological risk factors and 
common results, can differ significantly in the severity of outcomes and associated costs. 
Hardie et. al. found that the 30-day case fatality for recurrent stroke in the Perth Community 
Stroke Study was 41%, significantly greater than the 22% associated with first-ever stroke. 31 
Similarly, the Copenhagen Stroke Study found that mortality among recurrent stroke patients 
was nearly twice that of first-ever stroke cases; in addition, they determined that recurrence 
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on the opposite side of the head from the original first-ever stroke resulted in a more severe 
functional disability. 2 Modrego and colleagues found a majority of deaths (in their cohort of 
first-ever stroke survivors from Teruel, Spain) were among recurrent strokes occurring at 
longer intervals post-first stroke and that functional status was worse after the recurrent 
stroke than after the first-ever stroke. 32  Looking at individual risk factors and their 
contribution to stroke occurrence, Sacco, in his 1998 review, 33 pointed out that, while the 
management of certain risk factors (such as hypertension, cigarette smoking, and heavy 
alcohol use) in high risk patients could require more expensive diagnostic screening and 
active preventive treatment, potentially large reductions in stroke occurrence could be 
obtained. On an societal economic level, Samsa and colleagues estimated that the total costs 
for care after recurrent stroke were roughly $375 higher per month than for first-ever stroke, 
with most of the difference due to nursing home utilization and acute hospitalization. 1  They 
commented that the difference between first-ever and recurrent strokes had potentially 
important health policy implications: for example, they projected that for a sample of 
100,000 Americans with recurrent stroke in a given year (20% of the estimated 500,000 
annual stroke incidence) with an estimated 8.4% difference in 2-year survival (for recurrent 
stroke versus first-ever stroke) there could be an error of about 8400 in the expected number 
of persons surviving at least 2 years; applying the $375 per month difference in costs and 
taking a median survival time of 15 months could result in a cost difference of $562 million 
(100,000 * 15 * $375).  Even allowing for less-than-conservative calculations, this suggests 
that any increase in the prevalence of recurrent stroke could have significant implications for 
individuals and society.  
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Challenges in secondary prevention of stroke 
Although recurrent stroke is known to have more serious outcomes than the first-ever 
stroke, which suggests that a high degree of patient adherence to prescribed treatments and 
lifestyle changes would be desirable, secondary prevention of stroke may be paradoxically 
more difficult than primary prevention.  There are probably several reasons for this, one of 
which is that there is a much shorter time window within which to work.  The Perth 
Community Stroke study found that the risk of recurrent stroke was highest in the first six 
months after initial stroke and that between 30-40% of initial stroke survivors had a recurrent 
stroke within five years. 34 Boysen and Truelsen documented other studies which confirmed 
the Perth percentage. 35 The absolute risk for recurrent stroke is higher than that for first-ever 
stroke – between 15% and 40% of first-ever stroke survivors have a recurrent stroke, 
although the exact rate varies with the subtype (34, 35, 36) – and those suffering recurrent stroke 
are often older and have poorer health generally (e.g., 9.7% of those with recurrent strokes 
had a history of TIA versus 3.6% of those with a primary stroke). (1, 3, 23)  
In addition, while therapeutic approaches to secondary prevention often work well 
under controlled circumstances, lack of patient adherence to clinical recommendations often 
seems to result in no effective modification of existing risk factors.  For example, 
randomized controlled trials testing anti-hypertensive medications demonstrated a reduction 
of approximately 24% in fatal recurrent stroke and approximately 20-25% in nonfatal 
recurrent stroke, 37 which would suggest that medication adherence and hypertension control 
would be important for preventing recurrent stroke.  However, among other results from 
NHANES III data, Qureshi and colleagues found that hypertension was uncontrolled in 53% 
of those with known history of hypertension who had survived an MI, stroke, or both. 4 
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Quilliam et. al. found that many stroke survivors who were nursing home residents were not 
receiving adequate treatment to prevent recurrent stroke. 38 Inadequate control of known risk 
factors is not limited to hypertension – data from the South London Stroke Register showed 
that even at one year after stroke 22% of patients still smoked, 4% drank excessive amounts 
of alcohol, and 36% were obese. 39 There have been studies which focused on controlling 
risk factors.  One such example is that of Leonberg and colleagues who recruited 88 patients 
(aged 38 to 77 years, average age 60 years at onset, 24 female, 21 black), 73 of whom had an 
ischemic stroke and 15 of whom had an embolic event, and followed them at intervals of one 
to three months for an average of five years.  They attempted to ensure that at least some risk 
factors (including hypertension, diabetes, hyperlipidemia, obesity) were brought under better 
control, and were able to achieve an approximately 16-17% reduction in expected mortality 
despite admittedly mixed success at risk factor control.  However, this study was much 
smaller than others (cited in their paper), suggesting that such interventions work better on a 
small group level (possibly due to the higher degree of patient monitoring resulting from 
study participation) than for patients in the general population, who may not be as well 
followed. 40  
However, even the controlled conditions of an intervention study are not necessarily a 
guarantee of success in reducing recurrent stroke risk – an example of this is the Vitamin 
Intervention for Stroke Prevention Study (VISP), a clinical trial (with forty-four centers in 
the United States, eleven in Canada, and one in Scotland) intended to lower homocyst(e)ine 
levels and thereby reduce recurrent stroke risk.  The intervention and control groups of the 
VISP study – the first receiving high doses of vitamins B6, B12, and folate, the latter receiving 
much lower doses of the same micronutrients – did not show a significant difference in 
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reduction of recurrent stroke risk. 9 Repeated findings of inadequate secondary prevention 
have led reviewers, including Leys and colleagues, to conclude that “optimal management of 
risk factors for stroke is crucial to reduce the risks of first-ever stroke [and] recurrent stroke” 
and that “acute stroke therapies that are effective at the individual level have only a little 
impact in term[s] of public health.” 5   
Changes in secondary stroke prevention methods 
However, as part of their review, Leys et. al. also point out that surgical and 
pharmaceutical treatment “used for stroke prevention carry some risk and may be limited by 
cost” and suggest that “prevention should, therefore, be targeted at those individuals who 
have the highest absolute risk, and are the most likely to gain the greatest benefit.” 5 They 
designate three groups at high risk: those with a previous vascular event, those with a 
potential cause of stroke (e.g., carotid artery stenosis), and those with risk factors for stroke. 
 Consequently, one key to the prevention of recurrent stroke is likely to be the 
assessment of etiologically important factors and the predicted stroke risk associated with 
each so that treatment can be individualized to a given patient’s risk profile, as suggested by 
O’Neill et. al. 41 – in fact, these authors stated that the “careful identification and reduction of 
[risk factors for stroke] may greatly reduce the risk of recurrent stroke [and that] educating 
the patient and family about how to reduce risk and modify lifestyle should be integrated into 
the patient’s comprehensive stroke rehabilitation program.”  Halar points out that it should be 
possible to assign points to risk factors present after an initial stroke (in a system based on 
the prediction equations produced by the Framingham Study) and to use the resulting scores 
to determine the most efficacious approach to reducing stroke risk over a ten-year period. 42 
One important element of any such approach to optimization is the ability to predict the 
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outcome of targeting one or more risk factors, either singly or in combination, and providing 
clinicians with that information so that they can prescribe treatment more effectively.  Short 
and colleagues demonstrated that a computerized system based on patient profiles 
(describing groups of patients rather than individuals) could be used to guide primary care 
physicians in the decision to prescribe aspirin as part of the management of stroke patients. 
Although their application of this approach was limited in scope and the results assessed 
qualitatively, access to their system appeared to reduce potential conflicts in decision-making 
for the general practitioners who used the system, and “practitioners were very positive about 
the potential … to address uncertainty among [general] practitioners.” 43 However, most 
stroke risk prediction equations utilize risk factor profile information obtained either prior to 
the first stroke (if predicting initial stroke) or just after the first stroke (if predicting recurrent 
stroke).  
Predicting first-ever stroke risk 
Numerous etiological models and prediction equations have been developed to 
predict the risk of first-ever stroke based on existing risk factor information.  Framingham 
has developed and published prediction equations for incident stroke at regular intervals over 
the past few decades, such as those presented by Anderson and colleagues 44 and Wolf et. al.; 
45  although there has been the occasional debate over the applicability of these equations in 
other populations (46, 47), they do well in predicting stroke risk. The basic point system for 
first-ever stroke risk prediction, as outlined by Wolf, was stratified by gender and based on 
age, systolic blood pressure, hypertensive medication use, diabetes mellitus, cigarette 
smoking, cardiovascular disease, atrial fibrillation, and left ventricular hypertrophy. Most 
risk factors were scored on a two-level basis (0 for “not-present”, a single point score 
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between 2 and 6 for “present”) and increasing age yielded points between 0 (54-56 years) 
and 10 (84-86 years). For men, the total point scores translated into a 10-year stroke risk 
probability which ranged from 2.6% (at 1 point) up to 87.9% (at 30 points).  For women, the 
same point scores translated into a range of 1.1% to (at 27 points, the maximum shown) 
84.4%.  
The Framingham equations have been modified and adjusted to account for new 
developments – an example of this are the updates made to adjust for antihypertensive 
medication 48 – which has likely improved their sensitivity and specificity.  Due perhaps to 
the debate over applicability of prediction equations to groups other than those for which 
they were developed, a plethora of other predictive models has been developed for incident 
and recurrent stroke, ranging from paper instruments to customized software applications to 
Web-based forms.  Another illustration of a first-ever stroke risk prediction equations (or risk 
profiles) found in the Riscard 2002 software package based on Italian cohort data and 
validated using the Gubbio Population Study and the ECCIS study 49 (the equations 
contained in the software do not appear to have been published). A third example of a 
incident stroke risk prediction model is the Cardiovascular Health Study’s (CHS) Web-based 
application found at http://chs3.chs.biostat.washington.edu/chs/stroke.htm 50 which allows a 
user to enter clinical information and obtain a “stroke risk score” for primary stroke. 
 The point assignments for the stroke risk score varied with the risk factor – for 
example, systolic blood pressure starts with 0 points if the blood pressure was < 120 mm Hg 
and increases by 1 point for each increase of 10 units, while age and history of heart disease 
are sex-specific point scores without a range. The risk factors included in the application are 
systolic blood pressure, 15-foot walk time, left ventricular hypertrophy  by ECG, creatinine > 
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1.25 mg/dl, ADA diabetic grade, age, history of heart disease, and atrial fibrillation. Total 
risk scores are then translated to 5-year stroke risks which range from (men, women) 2.0%, 
1.5% at 0-5 points up to 53%, 41% at 41-45 points. Parenthetically, although the CHS’s 
score system goes up to 49 points or more, percent risks were not listed above 45 points.  
Predicting recurrent stroke risk  
Models have also been developed for recurrent stroke risk prediction. One such 
example is the SPI–I and its successor (SPI–II), which are software and paper instruments 
used to predict recurrent stroke 51 developed using the WEST trial and validated using 3 
other cohorts, the UK-TIA Aspirin trial, the CAPRIE trial, and the NoMaSS study). The 
scoring system for Stroke Prognostic Instrument I was as follows: age >65 years (3 points), 
diabetes (3 points), severe hypertension (2 points), distinction between stroke and TIA (2 
points for stroke), and coronary artery disease (1 point).  A patient’s total score determined 
his or her risk group assignment – 0 to 2 points for group I (low risk), 3 to 6 points for group 
II (medium risk), and 7 to 11 points for group III (high risk). Stroke Prognostic Instrument II 
added the following components to Stroke Prognostic Instrument I’s point assignments: 
congestive heart failure (3 points) and prior stroke (3 points). Stroke Prognostic Instrument 
II’s point totals for groups I, II, and III were slightly different – 0 to 3 points for group I, 4 to 
7 points for group II, and 8-15 points for group III.  The Kaplan-Meier 2-year percentages for 
Stroke Prognostic Instrument I and Stroke Prognostic Instrument II for the four cohorts in 
which they were tested are shown in Table 1.1 (note that whether “death” was all-cause 
mortality or a stroke case fatality rate was not specified).  
The Lehigh Valley Recurrent Stroke Study has published estimates of the effect of 
controlled hypertension on the risk of recurrent stroke, using four repeat measures of systolic 
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blood pressure over a four-year period; on the surface of it, this would suggest that the 
equation they developed would be capable of assessing the effect on stroke outcome risk 
based on changes in risk factor profile post-first stroke, however, their models used the 
average and standard deviation of the four measures rather than the individual repeated 
measures 52 so they technically did not use repeat measures. 
All of the above equations (except for the Lehigh Valley model) have been validated 
and perform well, but none of them incorporate adjustments to stroke risk based on repeat 
measures of risk factors.  One exception to this is the model produced by Davis et. al. which 
used time-dependent covariates measuring the appearance of new risk factors during a 13-
year followup of a Mayo Clinic cohort to assess the effect of change in risk factors on the 
risk of recurrent stroke. However, this model looked only at the presence of risk factors and 
the development of new risk factors and their association with recurrent stroke risk and did 
not assess the effects of controlling, eliminating or ameliorating existing risk factors. 53   
Moreover, Davis and colleagues did not publish a system by which clinicians could 
estimate the effects on recurrent stroke risk of changes in risk factors. Consequently, since 
the equations listed above either predict 2-, 5-, or 10-year stroke risk based on one-time risk 
factor information, or predict stroke risk based on the presence of known risk factors and the 
addition of new risk factors, an equation which takes into account the presence of existing 
risk factors, the accumulation of new risk factors, and changes in both in a manner which is 
applicable in a “hands-on” method would seem to be of potential benefit in managing stroke 
patient care. Such an equation could potentially indicate the risk factors that were the most 
significant for a given patient (with caveats as indicated by Rockhill 54), which would be of 
use to both clinician and patient (more details on this given below). 
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Adaptability in predicting stroke risk 
Most of the prediction equations developed to date for recurrent stroke have utilized 
only risk factor measurements taken at the time of the first stroke, and the one that 
incorporated subsequent changes in risk factors did not examine removal or amelioration of 
risk factors into account in adjusting predictions of recurrent stroke.  This is contrary to 
clinical practice – neurologists and other clinical personnel adapt their treatment approaches 
and patient advice on the basis of changes in risk factor profiles (for better and for worse) as 
the changes occur.  For several reasons, a good risk prediction equation for recurrent stroke 
should be similarly adjustable.  The first of these reasons is that an adaptive equation would 
be more clinically relevant and more useful – the predicted risk produced would be updated 
based on the new information rather than a “stock answer” which then must be modified by a 
clinical practitioner.  (While it is true that the predicted risk could be interpreted as “you’re at 
risk” if the predicted risk was greater than a certain cutpoint or “you’re not at risk” if less 
than that cutpoint, the incorporation of multiple risk factors and a range of predicted stroke 
risks would also allow for a more gradated interpretation which was based on future changes 
to modifiable risk factors – e.g., “You’d reduce your risk by a lot more if you stopped 
smoking and lost weight compared with the reduction if you just stopped smoking.”) Second, 
an adaptable equation could be more “portable” across populations and across time, since 
factors could be built in to the equation that accounted for the differences in absolute risk 
seen in different populations.  Finally, an adaptive equation could help clinicians titrate the 
interventions based on the predicted effects of a change in the patient’s particular risk profile, 
determine the most successful approach to reducing stroke risk based on predicted effects 
and patient preferences (or likely compliance to behavioral modification), and update a 
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patient’s predicted recurrent stroke risk based on new information obtained at each post-
event encounter (even if no changes were made or contemplated with respect to treatment or 
lifestyle options). 
An ideal recurrent stroke risk prediction model  
The likelihood of a recurrent stroke is influenced by three primary components. The 
first component, the risk factors present prior to and after the first stroke, as well as any 
changes in those risk factors, likely influence recurrent stroke risk in the same manner (5, 55) as 
for the first stroke. (According to Sacco’s review in Neurology33, hypertension, cardiac 
disease, and alcohol abuse have been identified as risk factors for both first stroke and 
recurrent stroke, but the statement that other risk factors influence recurrent stroke risk in the 
same manner as the first stroke should be regarded as a simplifying assumption.) The second 
component is the severity of the first stroke, which acts directly and indirectly, through its 
effects, both immediate and chronic, on an individual’s body (circulatory changes, effects on 
speech and memory, dementia, and disability) to influence the risk of a recurrent stroke. The 
third component is the acute and long-term treatment provided to the individual along with 
prescribed lifestyle modification(s), during and after the first stroke, in the attempt to 
minimize recurrent stroke risk by reducing the effects of the first two components.  
Chronological time is implicit in the prediction of a recurrent stroke, since it is an element of 
the hazard or risk of an event and influences the likelihood of stroke according to the length 
of follow-up specified by the study design. Further, risk factor severity may increase, 
decrease, or remain at the same strength as time passes, and the type and intensity of care 
may vary over time in response to changes in the risk factors.  Consequently, a model 
intended to predict recurrent stroke risk should include the three components as independent 
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variables measured prior to, at the time of, and after the first stroke, along with time as a 
structural element (e.g., in a proportional hazards model), so that the effects of changes in the 
three primary components on the risk of recurrent stroke can be estimated.   In the following 
paragraphs, the “ideal” model will be explored in order to determine the risk factors and 
other elements desirable in a recurrent stroke risk prediction model; at the conclusion of this 
section, this “ideal” model will be “reduced” to one based on data more easily obtainable in a 
clinician’s office and one which is more effectively developed and implemented.   
Recurrent stroke is the result of an infarct, a biological event, but stroke risk factors 
and prevention operate on both the biological and psychosocial levels.  Psychosocial factors 
include isolation/social support, impaired cognition, access to medical care, compliance with 
treatment prescriptions, and the inability to perform self-care, all of which may interact to 
increase recurrent stroke risk.  For example, psychosocial isolation has been found to 
increase recurrent stroke risk, 56 possibly operating through poor compliance, depression, or 
stress.  Dementia may act to increase recurrent stroke risk either before the first stroke 
(possibly due to biological factors affecting both dementia and stroke) 57 or, similarly to 
isolation, after the first stroke, e.g., through noncompliance to treatment or to differential 
treatment of such individuals. 58  Lack of compliance with treatment prescriptions, 
independent of isolation or dementia, may also act to increase recurrent stroke risk due to 
inadequate management of known biological or behavioral risk factors. (39, 59)  The inability 
to perform self-care (or other activities of daily living) has been associated with an increased 
rate of readmission for stroke. 60 Consequently, since psychosocial factors appear to affect 
the effectiveness of stroke treatment and (biological) risk factor management, which in turn 
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may influence recurrent stroke risk, a good recurrent stroke prediction model should include 
psychosocial factors.   
In addition to psychosocial risk factors, there are behavioral and biological elements 
both well-known and perhaps less well-known, including genetic, atherosclerosis, physical 
activity (leisure-time and work-related), diet, use or non-use of tobacco, alcohol or other 
substances, and other chronic conditions (e.g., hypertension and diabetes).  Genetic elements 
have been found which increase the risk of a stroke – examples include alleles for platelet 
glycoprotein and alpha-fibrinogen 61 - and which decrease the risk of a stroke, e.g., the 4G 
allele of the PAI-I gene, which may act to stabilize atherosclerotic plaques, 62 and the M280 
allele of fractalkine (which may induce leukocyte adhesion and migration at a lower rate than 
other alleles, thus resulting in hard plaques, considered more stable than soft ones) 63 
Lifestyle components such as physical activity (leisure-time and work-related) have been 
shown to reduce the risk of stroke, (64-66) and physical inactivity has been inferred to increase 
the risk of stroke 67 through its effects on the metabolic syndrome (defined as “the 
association of hyperinsulemia, dyslipidemia, hypertension, hyperglycemia and abdominal 
obesity” 67). A healthy diet, e.g., one in accordance with the AHA Dietary Guidelines and the 
USDA Dietary Guidelines for Americans 2000, has been associated with a lower odds for 
carotid atherosclerosis (an indicator of subclinical atherosclerosis) in women 68 and, on a 
more specific level, drinking milk (69-71) and consumption of tuna fish 72 have been associated 
with a reduced risk of stroke.  Use of tobacco has been linked to an increased risk for stroke, 
73 as has passive tobacco exposure, 74 and alcohol use has also been associated with an 
increased risk for stroke 75 (although this effect was found to be modified by apolipoprotein-
E levels). Although the metabolic syndrome’s relationship to stroke risk indirectly has been 
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referred to above, some studies have found an association between the syndrome and an 
increased risk of stroke; 76 additionally, studies of the individual components of the metabolic 
syndrome have found apparently independent associations with increased risk of stroke, 
including diabetes (hyperinsulemia, hyperglycemia, although hyperglycemia’s association 
appears to be more controversial than that for hyperinsulinemia),77 hypertension,78 and 
dyslipidemia.79   As with the psychosocial factors, these elements, having been found to have 
an influence on stroke risk, should be incorporated into the ideal recurrent stroke risk 
prediction model. 
First stroke survivors are known to have a higher risk of recurrent stroke than the 
general population has of a first stroke, suggesting that the sequelae, or effects, their degree, 
and the type (ischemic, hemorrhagic, lacunar), location, and extent of a first stroke can affect 
the risk of a recurrent stroke (likely because the latter influences the former). Increasing 
clinical severity of the first stroke, as measured by the degree of cerebral artery stenosis, has 
been found to increase both the 30-day and longterm risk for recurrent stroke, 80 and this 
association has also held when severity was measured using the Barthel Index or the MMSE 
score. 81 However, even after adjustment for stroke severity (assessed using the RSS), the 
subtype of stroke has been shown to affect the 30-day risk of recurrent stroke – stroke due to 
large-vessel or intracranial atherosclerosis had a higher risk of recurrent stroke than did 
lacunar or stroke of unknown cause. 36 Similarly, subarachnoid hemorrhage or brain 
hemorrhage appears to differ from brain infarction in the pattern of stroke recurrence rate – 
in a study of Hisayama, Japan, residents, most recurrent episodes after hemorrhagic stroke 
occurred within a year, while those occurring after infarction increased consistently over 
time. 82 This association of stroke subtype with recurrent stroke risk may have a parallel 
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association in that of the degree and extent of stroke lesions with recurrent stroke risk: for 
example, the risk of recurrent stroke has been shown to vary with site of the lesion resulting 
from the first stroke – lesions in the basal ganglion and corona radiata regions were 
associated with a higher risk for recurrent stroke 83 than the middle cerebral artery region, 
and both of the former regions also showed a higher cumulative recurrence rate than did the 
latter at the same time points after first stroke. Stroke due to large-vessel atherosclerosis 
showed higher odds of stroke recurrence at seven days compared with other subtypes, 84 and 
the grade of carotid stenosis and plaque ulceration have been positively related to recurrent 
stroke event rate. 85 Ideally, measures of stroke extent and lesion type would be included in a 
recurrent stroke prediction model, to account for their influence on recurrent stroke risk; 
however, since it is not always feasible to assess the degree of white matter hyperintensities 
or atherosclerotic plaque in studies of first-ever stroke survivors and the Barthel Index, RSS, 
and MMSE scores can be used to assess stroke severity, if they can be or are obtained 
routinely in a clinical setting, a recurrent stroke risk prediction model should include at the 
least these measures of first stroke severity to improve prediction performance.  
Finally, the acute and long-term care given to the survivor of a first stroke should 
influence the risk of a recurrent stroke as such care is intended to address both the risk factors 
which may have precipitated the first stroke and the sequelae of the first stroke. Ticlopidine, 
an anti-thrombotic agent, has been found to reduce the risk of a recurrent stroke, 86 although 
it has severe complications; low-dose aspirin, clopidrogel, and warfarin similarly have been 
shown to be effective in preventing recurrent stroke, 87 although the preventive effects vary 
with the medication or combinations thereof.  However, pharmacological treatment is a two-
edged sword – some anti-thrombotics or combinations of agents have also been shown to 
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increase the risk of recurrent (hemorrhagic) stroke: 87 specifically, warfarin has been found to 
increase the risk for recurrent events when compared to aspirin, 88 and aspirin and 
clopidrogel taken together placed patients at a higher risk for intracranial hemorrhage. 89   
Administration of tPA has been linked to an increased risk for intracranial hemorrhage. (90, 91)  
Consequently, as the effects of pharmacological treatment on recurrent stroke risk vary with 
the type (and, likely, duration) of treatment, measures of treatment should be included in a 
recurrent stroke risk prediction model. 
The components described above – risk factors, sequelae of the first stroke, and the 
care given to first stroke survivors – change over time: for example, if risk factors are not 
successfully managed or disability worsens, additional treatments may be prescribed to 
address the possible increase in recurrent stroke risk. Predicting recurrent stroke risk should 
therefore be based, in addition to the elements mentioned previously, on the presence or 
modification of factors influencing recurrent stroke risk, and should include time as a 
structural element. Models based on predicting recurrent stroke risk based on pre-existing or 
newly developed risk factors exist (mentioned above).  However, many of these appear to be 
non-generalizable models limited solely to estimating the effects of a given risk factor within 
a given population. Examples of models of the association between components existing 
prior to first stroke and recurrent stroke risk include: Alvarez-Sabin’s (Barcelona, Spain) 
model of the effects of hyperglycemia and history of diabetes mellitus prior to or at the time 
of administration of tPA; 92  Ka Sing Wong and Huan Li, at Prince of Wales Hospital in 
Hong Kong, and their Cox proportional hazards model of the influence of intracranial and 
extracranial arterial (atherosclerotic) lesions; 93 and Petty and colleagues’ (Rochester, 
Minnesota) Cox model of the effects of diabetes at first stroke. 21 Examples of models of 
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recurrent stroke risk including risk factors present after the first stroke are: the SPI-I and SPI-
II, software and paper instruments used to assess the influence of diabetes, severe 
hypertension, age, and coronary artery disease; 51 and the Lehigh Valley Recurrent Stroke 
Study’s modeled estimates of  the effect of controlled hypertension (after first stroke), using 
the average and standard deviation of four repeat measures of systolic blood pressure over a 
four-year period. 52 However, none of these models took into account changes in risk factors 
subsequent to the first stroke (which have been found to also influence subsequent stroke 
risk), and none incorporated measures of baseline stroke severity or care. 
Some models have been produced which examine recurrent stroke risk using changes 
in risk factors appearing after the first stroke (e.g., factors or conditions newly diagnosed 
post-first-stroke such as hypertension, congestive heart disease, diabetes mellitus), some of 
which have been alluded to above; one such is the model produced by Davis and colleagues 
which incorporated the appearance of new risk factors – including transient ischemic attack, 
hypertension, hypertensive heart disease, coronary heart disease, atrial fibrillation, diabetes 
mellitus – during follow-up after first stroke, 53 but this model did not examine the effects of 
controlling or eliminating risk factors after first stroke.  Among more “population-based” 
examples is that of Chambers and colleagues, who developed the Stroke Outcome Model (94, 
95) (a semi-Markov state-transition model) based on meta-analyses as well as existing stroke 
cohorts and clinical trials in four countries to estimate the effects on recurrent stroke risk of 
changes in health states (defined by therapy), disability, and stroke care (thrombolytic 
therapy, stroke care units); the model consisted of two modules, one for acute care and one 
for long-term care/prevention of recurrent stroke among survivors. However, this model did 
not apparently assess the impact of risk factors per se (health states were based on disability 
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status and antiplatelet medication usage), projected recurrent stroke event rates based on 
existing cohort data, limited recurrence to a maximum of one immediately recurrent event 
and one subsequent event, and focused on resource use due to recurrent stroke as an 
outcome.  Another “population-based” example is the Stroke Prevention Policy Model of 
Samsa and colleagues at Duke: 96 they simulated the long-term outcomes after a hypothetical 
randomized controlled trial of an acute stroke treatment using a semi-Markov transition 
approach applied to data from epidemiologic studies, intervention trials, claims databases, 
and patient interviews. In essence, their model simulates the natural history of a group of 
patients, following individuals for relevant health events and adjusting the resulting levels of 
costs and quality-adjusted life years, and, in the end, estimating a survival time, a quality-
adjusted survival time, and a cost for each individual.  Although this model theoretically 
could be used on data from a single cohort study to estimate the changes in recurrent stroke 
risk based on changes in health state, Samsa and colleagues used it to simulate a group of 
approximately 50,000 patients, aged 70 years, with an RSS score of 0-1 after an initial stroke, 
then, using underlying parameters of the model (not truly random chance), followed all of the 
simulated individuals until death; the process was repeated using a RSS score of 2, and 
sensitivity analyses were then conducted on the results of the two simulations. Finally, the 
results of the sensitivity analyses were “linked to [those] of a hypothetical random trial.” As a 
result, this model did not actually assess the effects of risk factors but was instead limited to 
the effects of the first stroke and subsequent changes in health state based on RSS scores 
assessed over time. As the researchers point out, this is essentially a simulation based on a 
combination of cohort data, expert opinion (as to the length of time necessary to achieve a 
steady-state RSS score and other factors), and event rate data (possibly deriving from small 
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samples), and could not therefore make use of patient-specific covariates.  Additionally, the 
model could not be presented (unlike that based on real trial data) from different perspectives 
or over different time frames, and, due to its limitations on Rankin score values, may not 
have been entirely representative of participants in a real randomized trial. Consequently, a 
model of recurrent stroke risk incorporating patient-specific measurements of risk factors, 
first stroke sequelae, and effects of care would seem to be the next logical step in risk 
prediction development. 
An “ideal” model incorporating those components present in the “state of being” of 
an individual stroke survivor would include risk factor assessments made prior to the first 
stroke, (multiple) follow-up assessments made after the first stroke and resulting estimated 
changes in risk factors, along with the sequelae of the first stroke and any treatment provided 
subsequent to the first stroke. It would permit the assessment of recurrent stroke risk based 
on any of the following:  management, elimination, or new development of risk factors; 
amelioration, worsening, or steady-state nature of first stroke sequelae; and effects of 
pharmacological and other treatments (lifestyle modifications, behavioral changes) 
prescribed to control risk factor and sequelae influences.  It would allow a physician to assess 
the likelihood of a recurrent stroke based on changes to one or more components, to 
determine the approach and the risk factors/sequelae to target for the most effective reduction 
of a patient’s risk of recurrent stroke based on patient preferences and available information 
concerning the effectiveness of pharmacological treatment and other prescribable therapeutic 
approaches, and to estimate the change in recurrent stroke risk based on changes in the 
previously-determined most effective approach (if conditions subsequently change).  
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The model described above, while desirable in a world with comprehensive and 
complete data, is not one easily developed and implemented – the comprehensive data 
required is simply not easily available in most clinical settings, although repeated 
assessments of risk factors (e.g., worsening, improving, stable) are routinely obtained 
clinically.  Consequently, some of the components mentioned above should be eliminated 
from the conceptual model developed above so that an effective and useful model can be 
developed.  For example, CT scan data – assessing stroke lesion site and extent – or MRI 
scan data (which can be used to assess plaque ulceration and carotid narrowing) is not 
necessarily available on a routine basis in a clinician’s office, so should be removed from the 
“ideal” model to facilitate model development and implementation.  A similar argument can 
be made for removing the Barthel Index, MMSE, and RSS instruments – if they are not 
easily or routinely obtained in a clinical setting, then they will hinder model development and 
implementation and should therefore be removed. Genetic risk factors likely do not affect a 
large proportion of the population, so should be eliminated from consideration.  Data on 
some lifestyle elements – e.g., physical activity and diet – may not be readily available in a 
clinical setting, so would be of less use to clinicians using a stroke risk prediction model and 
therefore should be dropped from the list of useful independent variables. Information 
provided by patients to physicians in the areas of compliance with treatment prescriptions or 
ability to provide self-care may be “edited” to present the best picture to their physicians, and 
perhaps should be removed from consideration as being less verifiable and less useful.  
Finally, still more of the risk factors and conditions may be eliminated during model 
development, if they are not found to be effective predictors of recurrent stroke risk.  
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 The next step in further reducing the model is the restrictions imposed by available 
datasets with which to develop and test the model. One such dataset, that of the VISP clinical 
trial, the focus of which was the testing of the hypothesis that administration of high doses of 
Vitamin B6, Vitamin B12 and folic acid reduces the risk of recurrent stroke, contains many of 
the desired elements necessary for the pragmatic version of the ideal model (shown in Table 
1.2).  Although the VISP dataset does not contain elements detailing acute or long-term care 
received by the trial participants, nor is information available on physical activity, genetic 
elements, metabolic syndrome, or several other components of the “ideal” model, it does 
contain most of the elements readily available to a clinician, together with additional 
information on the initial stroke’s severity (Barthel, RSS, and MMSE assessments as well as 
CT scan information).  Risk factor profiles are available at or shortly after the initial stroke as 
well as up to four times at regular intervals after the first stroke.     
Consequently, this study intended to produce a version of the reduced pragmatic 
model using the VISP cohort dataset.  Since a model is in and of itself not as useful to the 
clinicians who may benefit from this work, a score system was intended to be developed by 
which a clinician may estimate a patient’s risk of recurrent stroke both with and without 
modification(s) of known risk factors and other treatment effects. 
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TABLES 
 
Table 1.1. Stroke Prognostic Instrument I and Stroke Prognostic Instrument II Kaplan-
Meier two-year percentages for stroke or death 
Instrument Points Cohort 
WEST CAPRIE NoMaSS UK-TIA 
% % % % 
Stroke Prognostic Instrument I      
Group I (low risk) 0-2 11 9 20 8 
Group II (medium risk) 3-6 18 15 25 15 
Group III (high risk) 7-11 32 23 32 13 
Stroke Prognostic Instrument II      
Group I (low risk) 0-3 9 9 16 11 
Group II (medium risk) 4-7 19 17 24 19 
Group III (high risk) 8-15 42 26 42 17 
 
Table 1.2. List of risk factor information available in the VISP cohort dataset, with 
frequency of measurement  
 
Risk factor Frequency of 
measurement (once, 
repeated) 
Available from 
VISP  
(Yes/No) 
Gender Once-only Yes 
Age Repeated Yes 
Weight, height (obesity) Repeated Yes 
Diabetes Repeated Yes 
Diabetes medication use (*) Repeated Yes 
Blood pressure Repeated Yes 
Blood pressure medication use Repeated Yes 
Cholesterol Repeated Yes 
Lipid-lowering medication use Repeated Yes 
Atrial fibrillation Repeated Yes1 
Homocyst(e)ine Repeated Yes 
Stroke history Repeated Yes 
Alcohol consumption Repeated Yes 
Care at first stroke Once-only No 
Care post-first stroke  Repeated No 
Severity of first stroke Once-only Yes 
First stroke infarct/lesion location (CT scan) Once-only Yes 
Genetic information Once-only No 
Geographic area Once-only Yes 
Social support Repeated Yes1 
Dietary information Repeated Yes 
1 Information available is limited; e.g., social support would only be tangentially indicated by marital status at baseline or by 
the respondent during follow-up (e.g., FSS form: spouse, sibling, parent, child, other relative, other). Atrial fibrillation 
diagnoses would be limited to diagnoses from hospitalization abstract forms, ECG forms (either in-clinic or in-hospital), or 
Medical Follow-Up forms (“arrhythmia or irregular heart beat”)  
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CHAPTER II: RESEARCH METHODS AND DESIGN 
 
Introduction 
 
The development of a recurrent stroke risk prediction model based on repeated measures of 
risk factor information requires prospective data collected at several points during follow-up 
over at least two years of subjects who have had at least one stroke prior to the start of data 
collection, and who will have had one or more recurrent strokes during follow-up. Follow-up 
data on a large cohort of first-stroke survivors or a clinical trial testing secondary prevention 
strategies would constitute the best source of information for producing the risk prediction 
equations, as all cohort members would have had at least one stroke prior to follow-up, the 
data from such a study would be of very high quality, participants would be followed at 
regular intervals for at least a year or two after the first stroke with repeat measures of risk 
factor information obtained at each follow-up visit, and, particularly for the clinical trial, 
stroke at intake and during the follow-up period would be carefully ascertained and classified 
(thus reducing the potential admixture of stroke sub-types which might occur even in a large  
prospective cohort). The choice of analytic approach required by the project’s objective must 
include multivariate statistical methods capable of handling repeat measures of risk factor 
information, along with any possible correlations between risk factors at multiple time points.  
Study population 
 
The preferred characteristics of the study population thus include the following: a) 
Prospective study design, preferably a clinical trial of secondary stroke prevention methods 
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(to ensure high quality and standardized data collection methods); b) At least one stroke prior 
to follow-up; c) Neurologist-classified and confirmed stroke endpoint, preferably of one 
stroke subtype only (e.g., ischemic stroke); d) Repeat measures utilizing standardized 
measurement methods and instruments obtained at regular intervals over at least a two-year 
period; e) the possibility of obtaining multiple stroke endpoints for each participant (i.e., no 
right-censoring at first recurrent event). 
For several reasons, the VISP clinical trial population was chosen as the source 
population for this study. First, a prospective study design reduces the potential bias in self-
reported risk factor information, satisfying the first characteristic listed above; in addition, 
since VISP was a clinical trial, the level of data quality and standardization of data collection 
methods was very high, ensuring good quality data. Second, all potential participants had to 
have a CT/MRI- and neurologist-ascertained and classified stroke to be enrolled (condition 
(b)).  Third, diagnostically ascertained and verified ischemic stroke was the only subtype of 
stroke studied in VISP – using a single stroke subtype enhances stroke risk prediction by 
avoiding the admixture of the differing effects of risk factors found with different stroke 
subtypes (per the third characteristic). Fourth, VISP obtained standardized repeat measures of 
risk factor profile information and changes in risk factors at six-month intervals for up to two 
years after the eligibility stroke, which was necessary for updating stroke risk predictions (the 
fourth characteristic). Finally, participants were eligible to continue taking part in VISP after 
having a recurrent stroke(s) which allows updating and extension of recurrent stroke risk 
prediction to additional recurrent strokes and satisfies the final characteristic of the desired 
study population.  
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A brief description of the study population follows: VISP was a trial of secondary 
prevention of stroke using high- and low-dose vitamins. The 3680 randomized participants in 
the VISP study were divided into two groups – a “low-dose” group (1853 individuals) and a 
“high-dose” group (1827 individuals). Both groups received multivitamins containing the 
reference intakes recommended by the US Food and Drug Administration – the low-dose 
multivitamin contained 200μg of pyridoxine (vitamin B6), 6 μg of cyanocobalamin (vitamin 
B12), and 20 μg of folic acid and the high-dose multivitamin contained 25 mg of pyridoxine, 
0.4 mg of cyanocobalamin, and 2.5 mg of folic acid; the multivitamins were 
indistinguishable in scent, color, or taste.  
The eligibility criteria for the VISP study and profiles of the treatment groups have 
been described previously. (9, 8)  VISP participants were followed at three-month intervals for 
up to two years.  The official schedule and type of follow-up visits was as follows:  clinic 
visits at one month, six months, twelve months, eighteen months, and twenty-four months 
after the randomization visit, and telephone visits at three, nine, fifteen, and twenty-one 
months post-randomization.  Clinics were allowed to vary the follow-up schedule if it 
facilitated obtaining clinic visit information; e.g., clinics with “snow birds” (participants in 
northern clinics who were accustomed to vacation in warmer climates during the winter) 
could conduct a clinic visit shortly before the participant was supposed to leave and obtain 
follow-up information by telephone visit while the patient was on vacation, thus resulting in 
two adjacent clinic visits followed by a telephone visit. A description of the VISP 
population’s characteristics at baseline and during the two-year follow-up appears in Tables 
2.1 and 2.2. 
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Exclusions 
Participants from the Glasgow, Scotland, clinic were excluded (46 participants, 190 
observations) due to differences in treatment modalities and exposures.(97-99) Literature 
research 100and clinical input suggested the exclusion from the analyses of those participants 
who were on heparin at baseline visit or at a follow-up visit (36 participants, 313 
observations) due to concerns that such individuals were significantly less healthy than other 
participants.  Non-clinical follow-up visits and follow-up visits outside the standard specified 
VISP time frame were excluded (17140 observations, 0 participants) and duplicate follow-up 
visits were removed (172 observations, 0 participants). Other exclusions, such as participants 
with multiple recurrent strokes, those with no follow-up visits or no visits beyond the six-
month follow-up visit, were considered (Table 2.8); of these, only “those with no follow-up 
visits” was considered (but resulted in no exclusions as such had already been excluded) and 
recurrent strokes after the first were censored to avoid bias in statistical estimates..  For 
Chapter III, those with irremediable missing data (678 observations, 279 participants) were 
excluded, leaving 3404 participants with 14142 observations (Table 3.1).  For Chapter IV, 
both analysis datasets – change over six months and change over twelve months – were 
restricted to those with a baseline and a twelve month visit (N=2791), then those with 
irremediable missing data (N=52 for baseline to six months, N=41 for baseline to twelve 
months) were excluded, leaving 2739 participants in the baseline to six months dataset (Table 
4.2), 2750 participants in the baseline to twelve months dataset (Table 4.3). 
Time points used in the analyses 
Two different approaches were used for the analysis for Chapter III and those for Chapter IV.  
For the first, only telephone contacts (visits at 3, 9, 15, and 21 months) were excluded from 
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the analysis dataset (part of the 17140 observations excluded above), since they did not 
contain clinically-obtained data such as blood pressure, etc. For the latter two analyses, only 
a single observation was retained for use in the statistical models: either an observation 
detailing the changes between baseline and six months (for change-over-six-months analysis) 
or an observation including the changes between baseline and twelve months (for change-
over-twelve months).   
Questionnaire and physical measurement data available from VISP 
 
Blood pressure   
Blood pressure was assessed at the baseline visit and follow-up clinic visits by 
following a standardized protocol and a random zero sphygmomanometer – systolic and 
diastolic blood pressures were each measured twice, five minutes apart.  (For purposes of 
data recording and data analysis, if two sets of values are available, the average of the two 
was used; if only one set was obtained, it was taken as the blood pressure.)   
Obese/overweight status 
Weight was recorded to the nearest pound, rounding down if the participant’s weight 
was between pound marks. Height was measured to the nearest inch; if the height was 
between inch marks, it was rounded down to the nearest whole inch. For the purposes of this 
study, height and weight were converted into metric units and BMI (height in meters divided 
by squared weight in kilograms) was used as a measure of weight for the Chapter III analysis 
and as part of the change in adherence to guidelines analysis in Chapter IV. BMI was also 
used in preliminary analyses to categorize participants into normoweight, overweight, or 
obese status based on WHO guidelines 
(http://apps.who.int/bmi/index.jsp?introPage=intro_3.html).  
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Cholesterol (total, HDL, LDL), triglycerides and homocyst(e)ine 
Cholesterol and triglyceride levels were recorded from a lipid profile obtained within 
120 days of the baseline, twelve-month, and twenty-four month visits. Since VISP’s main 
focus was control of homocyst(e)ine,  blood was drawn at each clinic visit (screening visit, 
baseline visit, and each clinic followup visit) and sent to the VISP Central Laboratory for 
assessment of homocyst(e)ine, vitamin B12, and folate levels to ensure that these analytes 
were measured using the same methods by the same personnel. (The exact blood analyses 
performed varied with the follow-up visit – homocyst(e)ine at each clinical follow-up visit; B 
vitamin and folate analyses were only performed at the six-month and eighteen-month 
follow-up visits.)  
Medications  
At the randomization visit and at follow-up visits, participants were asked to bring in 
medications and supplements that they were currently taking; these were recorded in the 
Medication Survey Form.  Subsequent to the conclusion of VISP, a pharmacist at UNC-CH 
coded this medication information into a systematic classification system. Two caveats to the 
use of this data exist: the first is that participants did not necessarily bring all of their 
medications to clinic for recording, and the second is that some medications taken on a short-
term basis while in hospital may not have been recorded at clinic visits.  However, both risk-
factor-independent medications and those related to medical conditions such as hypertension 
or diabetes were identified for analysis using this system.  
Medical history  
At the baseline visit and each clinic follow-up visit, a medical history was obtained 
using the standard form (Medical History and Exam for baseline, Medical Follow-Up for 
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follow-up visits) and a standardized protocol by nurses trained in data collection and forms 
administration.  The medical history included (but was not limited to) information on 
hypertension, diabetes, myocardial infarction, atrial fibrillation, congestive heart failure, 
chest pain, and history of coronary angioplasty or coronary artery bypass graft surgery.  
Information on tobacco use (ever versus never, current) was also obtained, including number 
of cigarettes per day for current cigarette smokers.  Participants were also asked how many 
strokes they had had including the VISP eligibility stroke.  At follow-up visits, participants 
were asked about recent hospital visits, newly diagnosed heart disease (e.g., heart attack, 
congestive heart disease, valvular heart disease, arrhythmias, etc.), recent surgical operations 
(heart bypass surgery, angioplasty, stent, endarterectomy, etc.), other newly diagnosed 
medical conditions (hypertension, cancer, diabetes, high cholesterol, anemia, etc.), current 
smoking status, dietary information (type of special diet), and estrogen or progestin use 
(women).  
Initial (first) stroke severity 
The Barthel Stroke, MMSE, and NIHSS instruments were available at the baseline 
visit and follow-up visits and were used to assess the severity of the sequelae of the first 
stroke (as well as recurrent strokes) on multiple dimensions - the Barthel for functional 
effects, the Mini-Mental for cognitive effects, and the NIHSS for neurologic outcome and 
degree of recovery.  These forms were also used to assess changes in functional status during 
the two years subsequent to the first stroke.  
Outcome data  
 
VISP had one primary event type – recurrent ischemic stroke – and two secondary 
events, coronary endpoints (fatal coronary heart disease, myocardial infarction, resuscitation 
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for cardiac collapse, coronary bypass surgery or angioplasty) and deaths. The three event 
types were processed using standardized methods and reviewed by external reviewers.  
The focus of the current project, however, was limited to recurrent ischemic stroke, 
for several reasons.  First, VISP was primarily intended as a stroke secondary prevention 
study; consequently, its design – including methods for follow-up and assessment of 
potential events, data collection forms, as well as patients recruited – were all intended to 
maximize efficiency and effectiveness of studying the effect of its intended intervention on 
recurrent stroke.  The other outcomes were added later and were of secondary importance to 
the study.  Second, the quality of the outcome data is strongest for stroke outcome data – the 
assessment and review methods were the most detailed and the review process was the most 
stringent of the three different VISP event types (more detail is given on the stroke review 
process in the next section).  Third, since each VISP participant was required to have had a 
stroke to be eligible for the study, and since the etiology of coronary outcome or death may 
be affected by a prior stroke (as opposed to, for coronary cases, a prior cardiac event), using 
the stroke outcome helped to reduce potential confounding due to different etiological 
processes.   
Assessment of stroke events 
 
Potential stroke events were detected using a combination of methods.  The primary 
method was the administration to each participant at each follow-up visit of an FSS form and 
an NIHSS form. Upon entry of either of these forms into the VISP DMS, the system would 
process the diagnostic information through a standardized algorithm and inform the user 
whether the symptoms matched those of a potential ischemic stroke (for the FSS) or whether 
there had been an one or more point increase in the NIHSS for certain questions. (In certain 
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circumstances where the NIHSS did not show an increase but the FSS was “positive”, a CT 
or MRI scan was obtained for use in the review process.) In addition, to increase the number 
of potential events, hospitalization records were obtained if they met certain criteria 
(discharge diagnoses, either stroke-related ICD-9 [431-434, 436] or –10 [I60-I64] codes, 
stroke-related textual diagnoses, or responses to questions on the hospitalization abstraction 
data entry form) for potential stroke events.  Finally, because some strokes resulted in 
fatalities and so could not be diagnosed by post-potential-event use of the FSS or NIHSS 
forms, data was obtained by abstracting death-related hospitalization records, death 
certificates, coroner’s reports, informant interview forms, physician questionnaire forms, and 
data from FSS or NIHSS forms within 30 days prior to the fatal potential event.  
This information was obtained by trained nurses at local field centers and processed 
into electronic data collection forms and sent to the DCC.  In addition, local staff forwarded 
copies of paper materials not amenable to data processing (clinical notes, death certificates, 
coroner’s notes) to the DCC for use in the review process. 
The local field center neurologist in combination with two external reviewers (both 
neurologists) performed the first stage of review for potential stroke events.  If two or more 
of the reviewers agreed that the event was or was not a stroke, their diagnosis was recorded 
and the review process considered complete.  If, however, one of the reviewers requested 
additional review, or if the initial reviewers could not arrive at a consensus, a paper review of 
the case by five external reviewers was conducted; if a majority of these reviewers agreed on 
a diagnosis, their diagnosis was recorded.  In most cases, review ended at either the first 
stage or at this second stage of review.  However, in some cases, the five external reviewers 
were not able to come to a consensus or wished to do additional review of the case.  In such 
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instances, either a conference call or a meeting was convened so that the reviewers could 
discuss their diagnoses and come to an agreement.  In very rare instances, when the 
reviewers were still unable to reach a verdict, the chair of the review committee decided the 
diagnosis of the potential event.  
Statistical Methods and Data Analysis  
 
General description of the analysis plan 
Figure 2.1 shows the general outline of the analytic plan for this study. The plan was 
highly iterative since each step depended on the results of the preceding step. This diagram 
does not show the treatment of individual risk factor model components since it is an 
overview of the process. The analytic plan is described in detail on the following pages.  
Choice of model for Research Questions 1, 2, and 3 
Research Questions 1, 2, and 3, while they all involve repeat measures of risk factors, 
use repeat measures in slightly different ways: Research Question 1 examines the general 
nature of the association between risk factors and recurrent stroke risk in the VISP cohort and 
accordingly uses all available risk factor profiles.  Research Questions 2 and 3 are more 
focused, examining the association between changes in risk factors over specific time periods 
and recurrent stroke risk.  Accordingly, although all three questions are best answered using a 
form of survival analysis, the exact form is different.  For Research Questions 2 and 3, the 
best form of survival analysis is the basic Cox proportional hazards model; however, for 
Research Question 1 and Specific Aim 1, after consultation with experienced researchers 
regarding the best approach to developing a predictive equation for recurrent stroke using the 
VISP cohort (risk factor profiles obtained at six-month intervals for up to two years), it was 
determined that the “counting process” or “proportional intensity” approach (an extended 
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Cox proportional hazards model using the “counting process” data structure, also known as 
the Andersen-Gill model) was the most appropriate and effective method of analysis. 
General description of the “counting process” model 
The following text is heavily adapted from Appendix 2 of Hosmer and Lemeshow 101 
and is included primarily for those readers who may not be familiar with this approach: 
In the counting process approach, subjects are followed from the time of enrollment 
in a study until an event occurs – the event-free survival time from initial enrollment to the 
occurrence of the event is also called the follow-up time, and can be denoted by a random 
variable (X).  A second random variable (Z) can be used to track time from initial enrollment 
to the end of observation (which may be after the occurrence of one or more events). The 
data collected for a subject consists of the actual time of observation (T) for any given 
subject (the minimum value of X or Z) and an indicator variable (C) which indicates whether 
T equals X (C=1) or T equals Z (C=0).  
There are three principal time-dependent functions in the counting process model.  
The first of these is the counting process itself (how many events occurred), which can be 
represented as: 
N(t) = I(T ≤ t, C=1)  (where t is a given point in time in follow-up) 
where I is an indicator function which equals 1 if the argument is true and 0 otherwise.  This 
process “counts” (hence the name) whether an event occurs at time t by shifting from a value 
of 0 to a value of 1; the value remains at 1 for the remainder of the interval of observation.  
(If no event occurs, of course, the value remains at 0 for the entire observation period.) The 
second function is the at-risk process, represented as 
 Y(t)=I(T ≥ t) 
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(where I is an indicator function as previously described) and indicates whether a subject is 
still being followed (at risk for an event) at t. If follow-up ends due to censoring or the 
occurrence of an event, the value of this function changes from 1 to 0. The third function, the 
intensity process, is represented by: 
 λ(t)dt=Y(t)h(t)dt, where h(t)dt = Pr(t ≤ T < t + dt, C=1 | T ≥ t) 
and h(t) is the hazard function for survival time. The intensity process can be viewed as the 
“expected number of events at time t”, since it is effectively the mathematical product of the 
number at risk, Y(t), and the risk of an event at t, h(t). 
As a subject is followed over time, many conditional probabilities of an event are 
accumulated, in a manner similar to a Kaplan-Meier estimate of survival probability.  The 
total expected number of events up to time t is calculated by integrating the intensity process 
over time to obtain the cumulative intensity process.  Consequently, the counting process 
approach yields two important numbers: the observed number of events at time t (from the 
counting process itself) and the expected number of events at time t (from the cumulative 
intensity process).   
The difference of these two numbers is the error component for the counting process 
model, a quantity similar to a residual, which, with certain assumptions, meets the definition 
of a “martingale.”  (A “martingale” is a process consisting of a sequence of random variables 
at different discrete points in time in which the conditional expected value of the next 
observation, given all of the past observations, is equal to the last observation.) As with the 
residuals for most regression models, the mean of the counting process martingale residual is 
zero, and it serves the same purpose as do residuals in other regression models, namely, as a 
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part of the evaluation of the goodness-of-fit of the model (including assumptions concerning 
the nature of the covariates and the shape of the outcome-independent variable association).  
Rationale for using the “counting process” model 
Although an argument could be made that the counting process model approach is not 
entirely appropriate for analysis of recurrent stroke events since it does not differentiate 
between the first recurrent event, the second recurrent event, etc., the counter to this is that 
the risk factors for recurrent stroke have been established to be the same as those for an 
initial stroke (albeit with some controversy), and are often of similar magnitude. 2 In 
addition, the “counting process” model does offer several advantages for this analysis.  First, 
such a model allows for the “clustered” nature of recurrent event analysis. Second, this 
modeling approach can incorporate multiple recurrent events (e.g., a second recurrent stroke, 
a third, and so on) in the one model; this is a more efficient use of the data in comparison 
with the use of separate models for each recurrent event. Third (related to the previous 
advantage), interaction indicator variables can be included in the model to determine whether 
the risk factor effects vary depending on whether the event is the first, second, or third (etc.) 
recurrent event.  Lastly, and perhaps foremost (according to Hosmer and Lemeshow), is that 
formulating a survival analysis model as a “counting process” model allows the use of 
martingale theory to prove the validity of many of the distributional elements of the model fit 
and assessment statistics.  
However, as with all regression methods, this model could be affected by the amount 
of missing data or the degree of intervariable correlation present in the data. In addition, an 
assessment of intravariable correlation over time was performed in order to determine the 
likely power available to the study.  Consequently, some preliminary assessments were 
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conducted to assess whether intervariable or intravariable correlations might be a threat to the 
stability of the models used in the analysis for Specific Aim 1, as well as to determine 
potential problems with missing data and to evaluate the variables being considered for 
inclusion in the models.  Risk factors may show strong correlations and may therefore cause 
problems for the analytic models; two variables highly correlated with each other should not 
be retained in the model unless they both contribute significantly to predictiveness or 
discriminatory ability. 
Assessment of intervariable correlations as potential threat to model 
To assess the degree of intervariable correlations at different time points, Pearson 
correlations (for continuous variables) and Kendall’s τ (for categorical variables) were 
estimated.  As can be seen in Tables 2.3 and 2.4, the degree of correlation between variables 
ranges from very weak (<0.001, triglycerides with systolic blood pressure at baseline) to 
moderate (0.464, systolic and diastolic blood pressure at baseline) to strong (0.829, LDL and 
total cholesterol at twelve months).  Obviously, some variables such as LDL cholesterol, 
HDL cholesterol, triglycerides, and total cholesterol are implicitly associated with one 
another, thus might be included in statistical models albeit with some trepidation.  
Assessment of intravariable correlations as potential threat to model 
To assess the degree of intravariable correlations between time points, Pearson’s r 
and Kendall’s τ were estimated; the results appear in Tables 2.5, 2.6 and 2.7.  The degree of 
correlation may be less significant here, as the counting process model is considered to be 
able to handle intravariable correlations; however, if a variable is highly correlated across 
different time points, the lower differentiation could have reduced the power of the study to 
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detect differences in outcomes.  Consequently, knowing something of the intravariable 
correlations was considered useful in selecting risk factors to be included in analytic models. 
The results of this assessment suggest that the inter- and intra-correlations of risk 
factors in the VISP study dataset were not of much concern, since the counting-process 
model can handle such and since the risk factors which show the highest degree of inter-
correlation are those which reasonably could be expected to show such.  Since these risk 
factors, to some extent, overlap one another, they were not all be included in any analytic 
model created for this project, and so did not affect the outcome.  
Missing data and data quality control methods 
VISP utilized quality controls incorporated into its data entry system; these controls 
were used to detect values out of normal ranges (e.g., cholesterol, triglycerides, etc.), 
incorrectly followed skip patterns, and inconsistent responses.  In addition, VISP performed 
standardized data checks on a monthly basis on certain important components of data entered 
by local clinics and followed-up with those clinics if data errors were not corrected in a 
timely manner.   Standard monthly reports included assessment of the completeness of data 
entry forms and other data quality-related items, although there was no enforcement of a 
minimum standard of completeness nor were the tables in these reports used to produce data 
quality control checks. 
Missing data: However, even given the higher data quality standards of a clinical trial, some 
data will inevitably be missing.  VISP’s standard data check procedures did not include some 
of the data elements to be used by this study; consequently, a preliminary assessment of the 
amount of missing data was conducted.  Table 2.9 shows the amount of missing data for the 
items shown in Table 2.1. 
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After preliminary assessments of patterns of missing data by age, race, gender, and 
stroke outcome (shown in Tables A.1, A.2, A.3, A.4, and A.5), although the patterns could 
not be categorized as “missing completely at random”, no significant and meaningful 
patterns of missingness were detected.  Accordingly, missing data was handled through one 
of three mechanisms:  1) Replacement by an earlier measurement if available and 
appropriate; 2) substitution using the average of chronologically-adjacent values (for 
continuous variables); 3) substitution of chronologically-adjacent values if the preceding 
value and the subsequent value were identical (for categorical variables); or, 4) (last resort) 
removal of the observation from the analysis.  
Other data quality issues: Laboratory re-analyses of blood factors such as cholesterol and 
triglycerides were not conducted since the repeatability of blood analysis is fairly high. (102, 
103) Individual participant continuous variables such as height, weight, cholesterol, blood 
pressure, triglycerides, folate, Vitamin B12, and homocysteine were checked for values 
beyond the individual’s mean +/- 1 SD.  Values falling above this range were set to the 
individual mean + 1SD; values falling below this range were set to the individual mean – 
1SD.  Missing or anomalous values at follow-up visits for time-invariant items such as 
gender or race/ethnicity were set to the baseline values.   
Specific variable definitions of risk factors 
This section describes how risk factor variables were defined for data analysis. 
Aspirin use: Participants brought their medications to clinic visits and the details of those 
medications were recorded by trained field center personnel on the Medication Survey form.  
Aspirin use was defined using the Medication Survey form data as the presence of 
medication code values “641000” (Salicylates) or “641099” (Salicylate combinations).  
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Aspirin use adherence: Aspirin use was considered – per medical guidelines 104 – to be 
mandatory for stroke survivors; accordingly, adherence was defined as the presence of 
aspirin in the participant’s Medication Survey Form data (see above) and non-adherence was 
defined as the absence of aspirin in the Medication Survey Form data. 
Atrial fibrillation status: Atrial fibrillation was defined as the presence of atrial fibrillation on 
an electrocardiogram as reported by trained field center medical personnel on the VISP ECG 
form. 
BMI: Height in inches and weight in pounds were measured by trained field center 
personnel. BMI was defined as height (meters)/squared weight (kg), using the source height 
and weight data.  
BMI adherence: Adherence to guidelines was defined using WHO standards 
(http://apps.who.int/bmi/index.jsp?introPage=intro_3.html) – if BMI was greater than or 
equal to 25.0, the participant was non-adherent; if BMI was less than 25.0, the participant 
was adherent to guidelines. 
Chronic kidney disease stage: Chronic kidney disease stage was defined using eGFR 
(calculated using the MDRD equation and serum creatinine) – Stage 1 if eGFR was greater 
than or equal to 90 ml/min/1.73m2, Stage 2 if eGFR was greater than or equal to 60 and less 
than 90 ml/min/1.73m2, Stage 3 if eGFR was greater than or equal to 30 and less than 60 
ml/min/1.73m2, and Stage 4 if eGFR was greater than or equal to 0 and less than 30 
ml/min/1.73m2. 
Combined dementia, deficit, dependency and disability status: Psychoneurological data was 
obtained by trained field center staff using the NIHSS, the MMSE, the Barthel Index, and the 
RSS.  The combined status was defined using the pooled impairment level reported from 
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NIHSS, the MMSE, the Barthel Index, and the RSS. “No impairment” was defined as an 
NIHSS score of between 0 and 5, an MMSE score greater than or equal to 27, a Barthel 
Index score of 20, and an RSS score of 0.  “Mild impairment” was defined as the presence of 
one or more of the following (and none more severe): NIHSS score between 6 and 13, 
MMSE score between 18 and 26, Barthel Index score of between 10 and 20, and RSS score 
of 1 or 2.  “Moderate impairment” (the highest level) was defined as the presence of either of 
the following: an MMSE score of between 0 and 12 or an RSS score of 4 or 5.  
Combined deficit and disability status: This status was defined using the NIHSS and the RSS 
form scores – an NIHSS score of between 0 and 5 and an RSS score of 0 was defined as 
“none”, an NIHSS score of between 6 and 13 or an RSS score of 1 or 2 was defined as 
“mild”, an NIHSS score of 14 or greater or an RSS score of 3 was defined as “moderate”, 
and an RSS score of 4 or 5 was defined as “severe.” 
Combined dementia and dependency status: This status was defined using the pooled 
information provided by the MMSE and the Barthel Index.  “None” was defined as an 
MMSE score of 27 or greater and a Barthel Index score of 20; “mild” was defined as either 
an MMSE score of between 18 and 26 or a Barthel Index score of between 10 and 20; 
“moderate” was defined as either an MMSE score between 12 and 18 or a Barthel Index 
score between 0 and 10; “severe” was defined as an MMSE score of between 0 and 12. 
Dementia status (mild, moderate, severe, any): Dementia was classified using categories 
based on the MMSE score – “no dementia” was defined as an MMSE score of 27 or greater, 
“mild dementia” was defined as an MMSE score of between 18 and 26, “moderate”dementia 
was defined to be present if the MMSE score was between 12 and 18, and “severe” dementia 
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was defined as an MMSE score of between 0 and 12. “Any” dementia was defined as an 
MMSE score of less than 26. 
Dependency status (mild, moderate, any): Dependency was categorized using the Barthel 
Index –a Barthel Index score of 20 defined the category of “no dependency”, a score between 
10 and 20 was defined as “mild dependency”, and a score of less than 10 was classified as 
“moderate dependency.”  
Diabetes status: Diabetes was determined to be present based on either self-report from the 
Medical History and Exam or Medical Follow-Up or the presence of anti-diabetic 
medications (code values “270000” (Antidiabetic), “271000” (Insulin), “271010” (Mixed 
insulin), “271020” (Beef insulin), “272030” (Pork insulin), “271040” (Human insulin), 
“272000” (Sulfonylureas), “272099” (Sulfonylurea combinations), “272500” (Biguanides), 
“272800” (Meglitinides), or “273000” (Diabetic other)) in the Medication Survey form. As a 
chronic condition, diabetes once diagnosed was determined always to be present – i.e., if a 
participant was classified as diabetic at baseline but subsequently self-reported as non-
diabetic, their classification status remained “diabetic”.  Similarly, if a participant self-
reported as “non-diabetic” but diabetic medications were present in the Medication Survey 
Form the participant’s status was defined as “diabetic.”  
Anti-diabetic medication use: Anti-diabetic medication use was defined as the presence of  
medication code values “270000” (Antidiabetic), “271000” (Insulin), “271010” (Mixed 
insulin), “271020” (Beef insulin), “272030” (Pork insulin), “271040” (Human insulin), 
“272000” (Sulfonylureas), “272099” (Sulfonylurea combinations), “272500” (Biguanides), 
“272800” (Meglitinides), or “273000” (Diabetic other) in the Medication Survey form. 
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Diabetes and anti-diabetic medication use: Diabetes status and anti-diabetic medication use 
were combined into a single status for purposes of analysis as follows:  if the participant self-
reported as being diabetic but no anti-diabetic medications were found in the Medication 
Survey Form, the status was defined as “diabetic without medications”; if the participant self-
reported as “diabetic” or anti-diabetic medications were found, the status was classified as 
“diabetic with medications”; if the participant reported their status as “non-diabetic” and no 
anti-diabetic medications were found, the status was defined as “non-diabetic”; finally, if the 
participant reported their status as “non-diabetic” but anti-diabetic medications were found, 
the participant was classified as “diabetic with medications”. 
Diabetes and anti-diabetic medication use adherence: Anti-diabetic medication was 
considered to be required if the participant was classified as diabetic.  Accordingly, if a 
participant was diabetic but no anti-diabetic medications were found in the Medication 
Survey Form, the participant was considered to be “non-adherent”, whereas if a participant 
was diabetic and anti-diabetic medications were found in the Medication Survey Form, the 
classification was “adherent”.  Lastly, if the participant was categorized as “non-diabetic” 
then the absence of anti-diabetic medications was defined as “adherent”.  
Disability status (mild, moderate, severe, any): Disability status was defined using the RSS 
score. “No” disability was categorized as an RSS score of 0, “mild” disability was defined as 
an RSS score of 1 or 2, “moderate” disability was classified as an RSS score of 3, and 
“severe” disability was defined as an RSS score of 4 or 5.  
Endarterectomy status: Endarterectomy status was based on participant self-reported status in 
the Medical History and Exam or Medical Follow-Up forms; if the participant reported that 
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either the right carotid artery, the left carotid artery, or both carotid arteries had been 
operated on, the participant was considered to have had an endarterectomy. 
Glomerular filtration rate (MDRD, estimated): Glomerular filtration rate was calculated 
using the MDRD equation and serum creatinine at baseline. 
Hypertension: A participant was considered to be hypertensive if measured systolic blood 
pressure was 140 mmHg or greater or measured diastolic blood pressure was 90 mmHg or 
greater or blood-pressure-lowering medications were found (codes “360000” 
(Antihypertensive), “361000” (ACE inhibitors), “361500” (Angiotensin II receptor blockers), 
“362000” (Adrenolytic antihypertensives), “362010” (Adrenolytics – central), “362020” 
(Adrenolytics – peripheral), “362030” (Reserpine), “363000” (Alpha blockers), “364000” 
(Vasodilators), “364010” (Fluoroquinolone vasodilators), “365000” (Antihypertensive – 
MAOIs), “366000” (Miscellaneous antihypertensives), “369900” (Antihypertensive 
combinations), “369910” (Reserpine combinations), “369915” (Calcium channel blocker and 
ACE inhibitor combinations), “369918” (ACE inhibitor and diuretic combinations), 
“369920” (Beta blocker combinations), “369940” (Angiotensin II receptor blocker and 
diuretic combinations), “369950” (Antiadrenergic (central) and diuretic combinations), 
“369955” (Alpha blocker and diuretic combinations), “370000” (Diuretics)).   As with 
diabetes, hypertension was considered to be a chronic condition and thus always present once 
diagnosed.  Participants initially classified as hypertensive who subsequently self-reported as 
“non-hypertensive” were categorized as hypertensive, and participants who self-reported as 
“non-hypertensive” but whose Medication Survey forms indicated the presence of blood-
pressure-lowering medications were also classified as hypertensive. 
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Blood-pressure-lowering medication use: Blood-pressure-lowering medication use was 
defined as the presence in the Medication Survey form of medication codes “360000” 
(Antihypertensive), “361000” (ACE inhibitors), “361500” (Angiotensin II receptor blockers), 
“362000” (Adrenolytic antihypertensives), “362010” (Adrenolytics – central), “362020” 
(Adrenolytics – peripheral), “362030” (Reserpine), “363000” (Alpha blockers), “364000” 
(Vasodilators), “364010” (Fluoroquinolone vasodilators), “365000” (Antihypertensive – 
MAOIs), “366000” (Miscellaneous antihypertensives), “369900” (Antihypertensive 
combinations), “369910” (Reserpine combinations), “369915” (Calcium channel blocker and 
ACE inhibitor combinations), “369918” (ACE inhibitor and diuretic combinations), 
“369920” (Beta blocker combinations), “369940” (Angiotensin II receptor blocker and 
diuretic combinations), “369950” (Antiadrenergic (central) and diuretic combinations), 
“369955” (Alpha blocker and diuretic combinations), “370000” (Diuretics). 
Hypertensive status and blood-pressure-lowering medication use: Hypertensive status and 
blood-pressure-lowering medication use were combined into a single status for purposes of 
analysis as follows:  if the participant met the criteria for being hypertensive but no blood-
pressure-lowering medications were found in the Medication Survey Form, the status was 
defined as “hypertensive without medications”; if the participant was classified via blood 
pressure as “hypertensive” and blood-pressure-lowering medications were found, the status 
was categorized as “hypertensive with medications”; if the participant was found to be “non-
hypertensive” and no blood-pressure-lowering medications were found, the status was 
defined as “non-hypertensive”; finally, if the participant’s blood pressure was normotensive 
but blood-pressure-lowering medications were found, the participant was classified as 
“hypertensive with medications”. 
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Hypertensive status and blood-pressure-lowering medication use adherence: Blood-pressure-
lowering medication was considered to be required if the participant was classified as 
hypertensive.  Accordingly, if a participant was classified as hypertensive but no blood-
pressure-lowering medications were found in the Medication Survey Form, the participant 
was considered to be “non-adherent”, whereas if a participant was hypertensive and blood-
pressure-lowering medications were found in the Medication Survey Form, the classification 
was “adherent”.  Lastly, if the participant was categorized as “non-hypertensive” then the 
absence of blood-pressure-lowering medications was defined as “adherent”. 
Hyperlipidemic status: A participant was classified as hyperlipidemic if total cholesterol was 
200 mg/dL or greater or lipid-lowering medications were present (codes “390000” 
(Antihyperlipidemic), “391000” (Bile sequestrants), “392000” (Fibrates), “394000” (HMG-
CoA reductase inhibitors (statins)), or “394099” (Antiplatelet and hypocholesterolemic 
agents)).   As with hypertension, hyperlipidemia was considered to be a chronic condition 
and thus always present once diagnosed.  Participants initially classified as hyperlipidemic 
who subsequently failed to meet the criteria were categorized as hyperlipidemic, and 
participants whose cholesterol was less than 200 mg/dL but whose Medication Survey forms 
indicated the presence of lipid-lowering medications were also classified as hyperlipidemic. 
Lipid-lowering medication use: Lipid-lowering medication use was defined as the presence 
in the Medication Survey Form of codes “390000” (Antihyperlipidemic), “391000” (Bile 
sequestrants), “392000” (Fibrates), “394000” (HMG-CoA reductase inhibitors (statins)), or 
“394099” (Antiplatelet and hypocholesterolemic agents). 
Hyperlipidemic status and lipid-lowering medication use: Hyperlipidemic status and lipid-
lowering medication use were combined into a single status for purposes of analysis as 
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follows:  if the participant was classified by cholesterol level as hyperlipidemic but no lipid-
lowering medications were found in the Medication Survey Form, the status was defined as 
“hyperlipidemic without medications”; if the participant was found to be “hyperlipidemic” 
and lipid-lowering medications were found, the status was classified as “hyperlipidemic with 
medications”; if the participant’s cholesterol was less than 200 and no lipid-lowering 
medications were found, the status was defined as “non-hyperlipidemic”; finally, if the 
participant’s cholesterol was less than 200 mg/dL but lipid-lowering medications were found, 
the participant was classified as “hyperlipidemic with medications”. 
Hyperlipidemic and lipid-lowering medication use adherence: Lipid-lowering medication 
was considered to be required if the participant was classified as hyperlipidemic.  
Consequently, if a participant was classified as hyperlipidemic but no lipid-lowering 
medications were found in the Medication Survey Form, the participant was considered to be 
“non-adherent”, whereas if a participant was hyperlipidemic and lipid-lowering medications 
were found in the Medication Survey Form, the classification was “adherent”.  Lastly, if the 
participant was categorized as “non-hyperlipidemic” then the absence of lipid-lowering 
medications was defined as “adherent”. 
Neurologic deficit status (mild, moderate, any): Neurologic deficit was defined using the 
NIHSS score.  If the participant’s NIHSS score was between 0 and 5, the participant was 
classified as having no deficit; a score between 6 and 13 was defined as “mild” neurologic 
deficit; lastly, if the score was 14 or greater, the participant was categorized as having a 
“moderate” neurologic deficit.  
Obesity and overweight status: Following the WHO criteria 
(http://apps.who.int/bmi/index.jsp?introPage=intro_3.html), overweight was defined as a 
55
 
BMI of between 25 and less than 30 kg/m2; obesity was defined as a BMI of 30 kg/m2 or 
greater.  
Rose angina status: Rose angina information was obtained by interviewing the participant 
using a standard Rose Angina Questionnaire.  Specifically, a participant was determined to 
have Rose angina if they had chest pain when they walked uphill or in a hurry or when they 
walked on the level, the pain was relieved within 10 minutes or less if they stopped or slowed 
down, and the pain was located in the sternum (upper, middle, or lower) or the left anterior 
chest or the left arm. 
Smoking status: Smoking status was self-reported by participants during interviews by 
trained field center staff using the Medical History and Exam (baseline) or Medical Follow-
Up (follow-up visits) forms.  Participants were categorized as “past” cigarette smokers 
(“Yes” or “No”) if they had ever smoked but did not currently and as “current” cigarette 
smokers if they still smoked (“Yes”) or “No” if they didn’t currently smoke.  
Preliminary power analyses for ability to achieve research goals 
 
A preliminary power analysis was conducted to determine whether the work had a 
low probability of success in detecting differences between groups and whether the VISP 
cohort provided a large enough sample size.  The selection of variables to be included in the 
analyses was based on a combination of an estimation of the intervariable correlations from 
the VISP cohort data – variables that are highly correlated should not be included in the same 
model – and each risk factor’s known role in stroke etiology.   
Power calculations were performed using univariate Cox proportional hazard models 
to obtain time-specific hazard function estimates and the simulation capabilities of the 
Nquery software.  Power was estimated as the percentage of “desired” results obtained out of 
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the number of simulations conducted, e.g., if out of 1000 simulations 800 yielded the desired 
result, the power estimate was 80%.  For simplicity and to obtain a more conservative 
estimate of power, the “change” in risk factors was estimated comparing follow-up clinic 
visit values to the baseline (randomization) visit value rather than the (possibly more 
sophisticated) comparison of each visit’s value to the previous visit’s value; the latter was 
considered too complex for easy assessment.  For all models used in the simulations, a 
common exponential dropout rate of approximately 1.2% per six-month follow-up period 
was used – this resulted in a cumulative dropout rate of 4.8%, which was close to the actual 
total dropout rate for the VISP study.  
The first power calculation utilized obesity status, the covariate considered to have 
the weakest association with stroke risk and thus yielding the lowest estimate of statistical 
power. Using obesity status at randomization visit, and using change from randomization 
visit for subsequent clinic visits (six month visit, twelve month visit, and eighteen month 
visit), simulations of estimated effects using Nquery (1000 simulations, α=0.05, two-sided 
test, using estimated hazards as shown in Table 2.10) yielded a 57% power to detect a 
difference between those who were obese at the randomization visit or became obese at 
subsequent visits and those who were non-obese at the randomization visit or became non-
obese at subsequent visits.  This estimate was, as expected, the lowest of the three calculated 
estimates.  
A different approach was used to estimate power for the comparison of diabetics to 
nondiabetics: The models were constructed comparing those who were diabetic at baseline 
(by self-report) to those who were not diabetic at baseline; followup visit models compared 
those whose status had not changed to those who became diabetic since the previous clinic 
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visit (generally speaking individuals remain diabetic once so diagnosed).  Although the 
resulting power estimate of 99% was very high and perhaps not-entirely-useful due to the 
source of the diabetic status classification, this estimate was also useful in setting the upper 
boundary for the power estimates.  Table 2.11 shows the estimated hazards and other data 
used in the calculations.  Note that the hazard for those who became diabetic did not change 
during the follow-up period – this was in part because only very few became diabetic during 
follow-up and none of these had a stroke. 
Since hypertensive status is very similar to diabetic status – once diagnosed, the status 
does not generally revert to “non-hypertensive” – the same approach used for estimating 
power based on diabetic status was used for hypertension power estimates. The estimated 
power for detecting a difference in stroke risk, comparing those who were hypertensive at 
baseline) or became hypertensive over time (compared to non-hypertensives at baseline or 
those whose status remained the same) was approximately 69%. Table 2.12 shows the 
changes in hazards for those who were hypertensive at baseline (or became hypertensive 
during followup) compared with those who were non-hypertensive at baseline (or whose 
status remained unchanged during followup).  As with diabetes, relatively few individuals 
became hypertensive during their time in VISP, and none had strokes during followup. 
In summary, although these are relatively crude power estimates, because they are 
also likely to be conservative estimates (based as they are on univariate models using crude 
comparisons), they suggest that the sample size available from the VISP study provided 
adequate power for detecting differences between those who are (or become) positive for a 
risk factor and those who are not (or convert to being negative).   
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Research Question 1 Analysis  
 
 All three research questions and the one specific aim were addressed using the same 
analyses.  Consequently, the description of the analysis approaches will be described under 
Research Question 1 and not repeated in other sections. 
Research Question 1: Which risk factors influence risk of recurrent ischemic stroke in 
the VISP population? 
Analysis: To address this research question, crude unadjusted univariate IRRs and 
stroke rates were calculated and models were constructed using two slightly different 
approaches. The IRRs were used to assess the effect of risk factors on recurrent stroke risk as 
well as to determine potential confounders (if the effect differed from the adjusted results). 
The first of these methods – which also addressed Specific Aim 1 – used an 
Andersen-Gill variant of the Cox proportional hazards model.  Two sets of variable types 
were developed, one restricted to standardly-measured clinical risk factors, the other 
including psychoneurological elements such as the MMSE, NIHSS, RSS, and the Barthel 
Index (list shown in Table 3.7).  Model development followed an ordered stochastic process 
that tested different combinations of risk factors:  risk factors were incorporated randomly 
into a model provided a similar risk factor was not already present or the total number of risk 
factors had not been reached.  The test model was then run and the BIC and the GB χ2 
calculated.  Two model development sequences were run; one, named “clinical”, included 
strictly standard clinic risk factors, the other, named “psychoneurological”, included both 
clinical and psychoneurological elements. After removal of models with duplicate risk factor 
combinations, the clinical sequence included 3940 models and the psychoneurological 
sequence included 4449 models. Models were then eliminated from further consideration if 
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they (a) were not in the lowest 10% of BIC values and (b) were not in the highest 10% of GB 
χ2 p-values.  The final lists of models from the clinical and “both” sequences were then 
reviewed for plausibility, discrimination and predictiveness, selecting one final model from 
each sequence.   
The second method used to address Research Question 1 used a basic Cox 
proportional hazards model examining the effects of changes in (a) medication and (b) risk 
factor adherence assessed over (i) the six months following the initial stroke or (ii) the twelve 
months following the initial stroke.   Medications and risk factors whose adherence was 
included in the models were standard clinical risk elements – aspirin use, anti-diabetic 
medication use, blood-pressure-lowering medication use, lipid-lowering medication use, 
BMI, cigarette smoking, SBP and TC – and adherence was assessed between either baseline 
and the six month follow-up visit or baseline and the twelve month follow-up visit. 
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TABLES AND FIGURES 
 
Table 2.1. VISP patient characteristics at baseline (first stroke)  
 
Characteristic Baseline 
N 1 % or  
mean (SD) 
Number of participants 3680 N/A 
Type of visit: 
Clinic 
Phone 
 
3680 
0 
 
100.0 
0.0 
Age (years) 3680 66.3 (11) 
Minimum (years):  35 
Maximum (years): 100 
Gender   
Men 2301 62.5 
Women 1379 37.5 
Race/ethnicity 
Black 
Other 
White 
 
545 
210 
2925 
 
14.8 
5.7 
79.5 
Smoking status 
Current smoker 
Past smoker (quit prior to 
study start) 
New smoker 
Quit smoking 
Never/non-smoker 
 
621 
1823 
 
N/A 
N/A 
1234 
 
16.9 
49.5 
 
N/A 
N/A 
33.5 
Weight (kg)  
Total 
Men 
Women 
 
3675 
2298 
1377 
 
81.2 (18) 
85.7 (17) 
73.7 (17) 
BMI (kg/m2)  2 
Total 
Men 
Women 
 
3643 
2279 
1364 
 
28.3 (6) 
28.1 (5) 
28.6 (6) 
Obesity status (BMI ≥30 kg/m2)  
Currently obese 
Newly obese 
Formerly obese 
Never/non-obese 
 
1123 
N/A 
N/A 
2520 
 
30.5 
N/A 
N/A 
68.5 
Blood pressure, mmHg 
Overall 
Systolic 
Diastolic 
Men 
Systolic 
Diastolic 
Women 
Systolic 
Diastolic 
 
 
3680 
3680 
 
2301 
1379 
 
2301 
1379 
 
 
140.8 (19) 
77.9 (10) 
 
140.1 (19) 
78.6 (10) 
 
142.0 (19) 
76.8 (10) 
Cholesterol level, mg/dl 
Total cholesterol 
HDL cholesterol 
LDL cholesterol 
 
3530 
3440 
3309 
 
201.9 (47) 
45.4 (16) 
122.5 (40) 
Triglyceride level, mg/dl 3417 174.7 (154) 
MMSE score 
Mean (SD) 
≥2 pt. decrease 3 
 
 
3648 
N/A 
 
 
26.9 (3) 
N/A 
NIHSS Score 
Mean (SD) 
Score distribution 
0-5 
6-13 
≥14 
 
3680 
 
3513 
163 
4 
 
1.7 (2) 
 
95.5 
4.4 
0.1 
61
 
Characteristic Baseline 
N 1 % or  
mean (SD) 
Barthel Index Score 
Mean (SD) 
Score distribution 
0-18 
≥ 19 
 
3674 
 
439 
3235 
 
19.4 (1) 
 
11.9 
88.1 
RSS 
Mean (SD) 
0 
1 
2 
3 
4 
5 
 
3680 
754 
1585 
904 
437 
0 
0 
 
1.3 (1) 
20.5 
43.1 
24.6 
11.9 
0.0 
0.0 
Medical conditions 
Hypertensive 
Yes – history 
Yes – new 
No 
Diabetic 
Yes – history 
Yes – new  
No 
 
 
2711 
N/A 
962 
 
1072 
N/A 
2606 
 
 
73.8 
N/A 
26.1 
 
29.1 
N/A 
70.8 
Medical conditions (ctd.) 
Heart condition or 
operation 4 
 
Yes – history 
Yes – new 
No 
 
Stroke prior to qualifying 
stroke 
Carotid endarterectomy 
Angina (from the Rose 
questionnaire) 
 
 
 
 
894 
N/A 
2786 
 
 
856 
 
247 
 
275 
 
 
 
 
 
24.2 
N/A 
75.7 
 
 
23.3 
 
6.7 
 
7.5 
1 Number of participants with data on characteristic of interest. 
2 Since duration of VISP follow-up was less than 2 years and study participants were all adults, height was replaced by 
baseline height if follow-up height measurement was not obtained and baseline height was available. 
3 Since previous visit. 
4 Includes myocardial infarction, congestive heart failure, coronary angioplasty, or coronary artery bypass graft surgery 
 
Table 2.2. VISP patient characteristics at follow-up visits 
 
Characteristic Six month visit Twelve month visit Eighteen month 
visit 
Twenty-four month 
visit 
N1 % or  
mean 
(SD) 
N % or  
mean (SD) 
N % or  
mean (SD) 
N % or  
mean 
(SD) 
Number of participants 3488 N/A 3366 N/A 3257 N/A 2856 N/A 
Type of visit: 
Clinic 
Phone 
 
3311 
165 
 
95.2 
4.7 
 
3148 
215 
 
93.5 
6.4 
 
2945 
301 
 
90.4 
9.2 
 
2670 
185 
 
93.5 
6.5 
Age (years) 3487 66.9 (11) 3365 67.3 (11) 3256 67.8 (11) 2856 68.3 (11) 
Minimum 
(years):  
35 36 36 37 
Maximum 
(years): 
101 101 97 98 
Gender         
Men 2164 62.0 2098 62.3 2024 62.1 1764 61.8 
Women 1324 38.0 1268 37.7 1233 37.9 1092 38.2 
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Characteristic Six month visit Twelve month visit Eighteen month 
visit 
Twenty-four month 
visit 
N1 % or  
mean 
(SD) 
N % or  
mean (SD) 
N % or  
mean (SD) 
N % or  
mean 
(SD) 
Race/ethnicity 
Black 
Other 
White 
 
491 
192 
2805 
 
14.1 
5.5 
80.4 
 
461 
179 
2726 
 
13.7 
5.3 
81.0 
 
450 
173 
2634 
 
13.8 
5.3 
80.9 
 
380 
147 
2329 
 
13.3 
5.2 
81.6 
Smoking status 
Current smoker 
Past smoker 
(quit prior to 
study start) 
New smoker 
Quit smoking 
Never/non-
smoker 
 
478 
N/A 
 
100 
99 
2809 
 
13.7 
N/A 
 
2.9 
2.8 
80.5 
 
465 
N/A 
 
70 
81 
2713 
 
13.8 
N/A 
 
2.1 
2.4 
80.6 
 
448 
N/A 
 
56 
64 
2624 
 
13.8 
N/A 
 
1.7 
2.0 
80.6 
 
379 
N/A 
 
43 
57 
2278 
 
13.3 
N/A 
 
1.5 
2.0 
79.7 
Weight (kg)  
Total 
Men 
Women 
 
3210 
1989 
1221 
 
81.5 (18) 
86.3 (17) 
73.8 (17) 
 
2829 
1894 
1155 
 
82.0 (18) 
86.4 (17) 
74.5 (17) 
 
2851 
1765 
1086 
 
82.1 (18) 
86.6 (18) 
74.8 (17) 
 
2590 
1599 
991 
 
82.1 (18.4) 
86.5 (17.6) 
74.9 (17.5) 
BMI (kg/m2)  2 
Total 
Men 
Women 
 
3202 
1982 
1220 
 
28.4 (6) 
28.3 (5) 
28.7 (6) 
 
3046 
1891 
1155 
 
28.5 (6) 
28.3 (5) 
29.0 (6) 
 
2845 
1760 
1085 
 
28.6 (6) 
28.4 (5) 
29.1 (7) 
 
2587 
1597 
990 
 
28.6 (6) 
28.3 (5) 
29.2 (7) 
Obesity status (BMI ≥30 
kg/m2)  
Currently obese 
Newly obese 
Formerly obese 
Never/non-
obese 
 
870 
152 
126 
2054 
 
24.9 
4.4 
3.6 
58.9 
 
874 
139 
101 
1932 
 
26.0 
4.1 
3.0 
57.4 
 
850 
109 
92 
1794 
 
26.1 
3.4 
2.8 
55.1 
 
770 
101 
85 
1631 
 
27.0 
3.5 
3.0 
57.1 
Blood pressure, mmHg 
Overall 
Systolic 
Diastolic 
Men 
Systolic 
Diastolic 
Women 
Systolic 
Diastolic 
 
 
3293 
3292 
 
2045 
2044 
 
1248 
1248 
 
 
140.7 (20) 
78.1 (11) 
 
139.6 (19) 
78.8 (11) 
 
142.4 (21) 
76.9 (11) 
 
 
3123 
3121 
 
1943 
1943 
 
1180 
1178 
 
 
140.2 (20) 
77.6 (11) 
 
139.4 (120) 
78.2 (11) 
 
141.4 (21) 
76.5 (11) 
 
 
29292
928 
 
1822 
1822 
 
1107 
1106 
 
 
139.0 (19) 
77.3 (11) 
 
138.4 (19) 
77.9 (11) 
 
140.0 (20) 
76.3 (12) 
 
 
2650 
2647 
 
1641 
1641 
 
1009 
1006 
 
 
138.9 (20) 
76.9 (11) 
 
138.1 (19) 
77.3 (11) 
 
140.3 (20) 
76.0 (11) 
Cholesterol level, mg/dl 
Total 
cholesterol 
HDL 
cholesterol 
LDL 
cholesterol 
 
N/A 
N/A 
N/A 
 
N/A 
N/A 
N/A 
 
2753 
2735 
2555 
 
193.9 (42) 
48.5 (16) 
112.0 (35) 
 
N/A 
N/A 
N/A 
 
N/A 
N/A 
N/A 
 
2359 
2342 
2202 
 
190.4 (42) 
48.8 (20) 
109.0 (35) 
Triglyceride level, mg/dl N/A N/A 2687 171.9 
(104.4) 
N/A N/A 2311 168.2 
(99.3) 
MMSE score 
Mean (SD) 
≥2 pt. decrease 
3 
 
 
N/A 
N/A 
 
 
N/A 
N/A 
 
 
3098 
564 
 
 
27.3 (3) 
18.1 
 
 
N/A 
N/A 
 
 
N/A 
N/A 
 
 
2638 
530 
 
 
27.3 (4) 
20.0 
NIHSS Score 
Mean (SD) 
Score 
distribution 
0-5 
6-13 
≥14 
 
3322 
 
3254 
66 
2 
 
1.0 (2) 
 
98.0 
2.0 
0.1 
 
3146 
 
3088 
56 
2 
 
0.9 (2) 
 
98.2 
1.8 
0.1 
 
2953 
 
2913 
38 
2 
 
0.8 (1) 
 
98.6 
1.3 
0.1 
 
2669 
 
2624 
39 
6 
 
0.8 (2) 
 
98.3 
1.5 
.2 
Barthel Index Score 
Mean (SD) 
Score 
distribution 
0-18 
≥ 19 
 
3325 
 
283 
3042 
 
19.6 (1) 
 
8.5 
91.5 
 
3147 
 
243 
2904 
 
19.6 (2) 
 
7.7 
92.3 
 
2969 
 
236 
2733 
 
19.6 (1) 
 
7.9 
92.1 
 
2688 
 
252 
2436 
 
19.4 (2) 
 
9.4 
90.6 
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Characteristic Six month visit Twelve month visit Eighteen month 
visit 
Twenty-four month 
visit 
N1 % or  
mean 
(SD) 
N % or  
mean (SD) 
N % or  
mean (SD) 
N % or  
mean 
(SD) 
RSS 
Mean (SD) 
0 
1 
2 
3 
4 
5 
 
3327 
1043 
1389 
633 
233 
26 
3 
 
1.0 (1) 
29.9 
39.8 
18.2 
6.7 
0.8 
0.1 
 
3153 
1106 
1254 
543 
206 
42 
2 
 
1.0 (1) 
32.8 
37.2 
16.1 
6.1 
1.3 
0.1 
 
2975 
1097 
1136 
484 
224 
32 
2 
 
1.0 (1) 
33.7 
34.9 
14.9 
6.9 
1.0 
0.1 
 
2689 
1025 
957 
452 
210 
38 
7 
 
1.0 (1) 
35.9 
33.5 
15.8 
7.4 
1.3 
0.3 
Medical conditions 
Hypertensive 
Yes – 
history 
Yes – new 
No 
Diabetic 
Yes – 
history 
Yes – new  
No 
 
 
2568 
20 
899 
 
1004 
8 
2474 
 
 
73.6 
0.6 
25.8 
 
28.8 
0.2 
70.9 
 
 
2453 
12 
902 
 
953 
15 
2398 
 
 
72.8 
0.4 
26.8 
 
28.3 
0.5 
71.2 
 
 
2352 
14 
892 
 
914 
11 
2330 
 
 
72.2 
0.4 
27.4 
 
28.1 
0.3 
71.5 
 
 
2014 
7 
835 
 
776 
13 
2067 
 
 
70.5 
0.3 
29.2 
 
27.2 
0.5 
72.4 
Medical conditions (ctd.) 
Heart condition 
or 
operation4 
 
Yes – 
history 
Yes – new 
No 
 
Stroke prior to 
qualifying 
stroke 
Carotid 
endarterect
omy 
Angina (from 
the Rose 
questionnai
re) 
 
 
 
 
828 
20 
2640 
 
 
N/A 
 
23 
 
N/A 
 
 
 
 
23.7 
0.6 
75.7 
 
 
N/A 
 
0.7 
 
N/A 
 
 
 
 
783 
20 
2563 
 
 
N/A 
 
7 
 
97 
 
 
 
 
23.3 
0.6 
76.1 
 
 
N/A 
 
0.2 
 
2.9 
 
 
 
 
744 
19 
2495 
 
 
N/A 
 
6 
 
N/A 
 
 
 
 
22.8 
0.6 
76.6 
 
 
N/A 
 
0.2 
 
N/A 
 
 
 
 
631 
23 
2202 
 
 
N/A 
 
3 
 
72 
 
 
 
 
22.1 
0.8 
77.1 
 
 
N/A 
 
0.1 
 
2.5 
 
1 Number of participants with data on characteristic of interest. 
2 Since duration of VISP follow-up was less than 2 years and study participants were all adults, height was replaced by 
baseline height if follow-up height measurement was not obtained and baseline height was available. 
3 Since previous visit. 
4 Includes myocardial infarction, congestive heart failure, coronary angioplasty, or coronary artery bypass graft surgery 
Table 2.3. Correlations (Pearson’s r)1 between different risk factors (with continuous 
values) at different time points during VISP cohort follow-up 
Time point Variable Age BMI SBP DBP TC HDL LDL TRIG 
Baseline Age 1.00        
BMI -0.211 1.00       
SBP 0.160 0.061 1.00      
DBP -0.177 0.108 0.464 1.00     
TC -0.069 0.046 0.055 0.050 1.00    
HDL 0.100 -0.127 0.173 0.015 0.206 1.00   
LDL -0.043 0.007 0.055 0.058 0.775 0.046 1.00  
TRIG  -0.116 0.147 -0.000 -0.007 0.385 -0.160 0.007 1.00 
Six months Age 1.00        
BMI -0.223 1.00       
SBP  0.154 0.100 1.00      
DBP  -0.157 0.116 0.519 1.00     
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Time point Variable Age BMI SBP DBP TC HDL LDL TRIG 
TC  N/A N/A N/A N/A 1.00    
HDL  N/A N/A N/A N/A N/A 1.00   
LDL  N/A N/A N/A N/A N/A N/A 1.00  
TRIG  N/A N/A N/A N/A N/A N/A N/A 1.00 
Twelve months Age 1.00        
BMI -0.236 1.00       
SBP  0.131 0.057 1.00      
DBP  -0.165 0.076 0.493 1.00     
TC  -0.029 0.037 0.125 0.112 1.00    
HDL  0.075 -0.166 0.020 0.017 0.215 1.00   
LDL  -0.013 0.022 0.109 0.120 0.829 0.017 1.00  
TRIG  -0.108 0.166 0.029 0.120 0.322 -0.309 0.038 1.00 
Eighteen months Age 1.00        
BMI -0.241 1.00       
SBP  0.122 0.068 1.00      
DBP  -0.182 0.125 0.488 1.00     
TC  N/A N/A N/A N/A 1.00    
HDL  N/A N/A N/A N/A N/A 1.00   
LDL  N/A N/A N/A N/A N/A N/A 1.00  
TRIG  N/A N/A N/A N/A N/A N/A N/A 1.00 
Twenty-four 
months 
Age 1.00        
BMI -0.246 1.00       
SBP  0.126 0.062 1.00      
DBP  -0.210 0.127 0.485 1.00     
TC  -0.026 -0.010 0.107 0.115 1.00    
HDL  0.074 -0.114 0.015 -0.013 0.204 1.00   
LDL  -0.044 -0.025 0.074 0.115 0.822 0.039 1.00  
TRIG  -0.110 0.180 0.049 0.072 0.301 -0.265 0.017 1.00 
 
1 Upper half of correlation table not shown to simplify presentation. 
 
Table 2.4. Correlations (Kendall’s τ) between categorical risk factors (coded as “Yes” 
or “No”) at different time points during VISP cohort follow-up1 
 
Time point Variable Smoker  HTN Diabetes CHD 2 Obese  
Baseline Smoker 1.00 (+)    
HTN -0.054 1.00    
Diabetes  -0.059 0.126 1.00   
CHD  -0.034 0.043 0.126 1.00  
Obese -0.066 0.110 0.180 0.036 1.00 
Six months Smoker  1.00     
HTN  -0.058 1.00    
Diabetes -0.055 0.121 1.00   
CHD  -0.023 0.043 0.125 1.00  
Obese -0.064 0.110 0.194 0.040 1.00 
Twelve months Smoker  1.00     
HTN  -0.081 1.00    
Diabetes -0.050 0.138 1.00   
CHD  -0.029 0.040 0.129 1.00  
Obese -0.070 0.101 0.181 0.029 1.00 
Eighteen months Smoker  1.00     
HTN  -0.080 1.00    
Diabetes -0.063 0.141 1.00   
CHD  -0.011 0.045 0.133 1.00  
Obese -0.074 0.106 0.189 0.031 1.00 
Twenty-four Smoker  1.00     
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Time point Variable Smoker  HTN Diabetes CHD 2 Obese  
months HTN  -0.094 1.00    
Diabetes -0.072 0.156 1.00   
CHD  -0.015 0.054 0.139 1.00  
Obese -0.054 0.121 0.188 0.038 1.00 
1 Upper half of correlation table not shown to simplify presentation. 
2 CHD = myocardial infarction, congestive heart failure, coronary angioplasty, or coronary artery bypass graft surgery 
 
Table 2.5. Correlations (Pearson’s r) within continuous risk factors measured at twelve-
month intervals during VISP cohort follow-up 
 
Variable Time point Baseline Six months Twenty-four months 
Total cholesterol Baseline 1.00   
Twelve months 0.455 1.00  
Twenty-four months 0.389 0.585 1.00 
HDL cholesterol Baseline 1.00   
Twelve months 0.632 1.00  
Twenty-four months 0.461 0.566 1.00 
LDL cholesterol Baseline 1.00   
Twelve months 0.381 1.00  
Twenty-four months 0.324 0.544 1.00 
Triglycerides Baseline 1.00   
Twelve months 0.577 1.00  
Twenty-four months 0.485 0.610 1.00 
 
Table 2.6. Correlations (Pearson’s r) within continuous risk factors measured at six-
month intervals during VISP cohort follow-up 
 
Variable Time point Baseline Six 
months 
Twelve 
months 
Eighteen 
months 
Twenty-four 
months 
Systolic 
blood 
pressure 
Baseline 1.00     
Six months 0.492 1.00    
Twelve months 0.423 0.517 1.00   
Eighteen months 0.361 0.457 0.524 1.00  
Twenty-four months 0.393 0.423 0.460 0.527 1.00 
Diastolic 
blood 
pressure 
Baseline 1.00     
Six months 0.395 1.00    
Twelve months 0.355 0.399 1.00   
Eighteen months 0.344 0.392 0.441 1.00  
Twenty-four months 0.355 0.324 0.370 0.421 1.00 
BMI Baseline 1.00     
Six months 0.905 1.00    
Twelve months 0.869 0.886 1.00   
Eighteen months 0.849 0.849 0.903 1.00  
Twenty-four months 0.843 0.844 0.892 0.914 1.00 
 
Table 2.7. Correlations (Kendall’s τ) within categorical risk factors (coded as “Yes” or 
“No”) measured at different time points during VISP cohort follow-up 
 
Variable Time point Baseline Six 
months 
Twelve 
months 
Eighteen 
months 
Twenty-four 
months 
Smoker Baseline 1.00 (+)    
Six months 0.785 1.00    
Twelve months 0.721 0.820 1.00   
Eighteen months 0.724 0.797 0.834 1.00  
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Variable Time point Baseline Six 
months 
Twelve 
months 
Eighteen 
months 
Twenty-four 
months 
Twenty-four months 0.692 0.768 0.786 0.844 1.00 
HTN Baseline 1.00     
Six months 0.978 1.00    
Twelve months 0.958 0.945 1.00   
Eighteen months 0.947 0.938 0.953 1.00  
Twenty-four months 0.934 0.925 0.941 0.952 1.00 
Diabetic  Baseline 1.00     
Six months 0.982 1.00    
Twelve months 0.966 0.964 1.00   
Eighteen months 0.960 0.958 0.958 1.00  
Twenty-four months 0.970 0.965 0.964 0.964 1.00 
CHD 1 Baseline 1.00     
Six months 0.974 1.00    
Twelve months 0.969 0.960 1.00   
Eighteen months 0.962 0.951 0.950 1.00  
Twenty-four months 0.957 0.946 0.945 0.952 1.00 
Obese  Baseline 1.00     
Six months 0.797 1.00    
Twelve months 0.750 0.793 1.00   
Eighteen months 0.721 0.747 0.818 1.00  
Twenty-four months 0.695 0.725 0.774 0.813 1.00 
1 CHD= myocardial infarction, congestive heart failure, coronary angioplasty, or coronary artery bypass graft surgery 
 
Table 2.8. List of exclusions considered for this study together with numbers of 
participants or observations removed by the exclusion (in order of exclusion listing) 
 
Exclusion 
group 
Exclusion description  
(details and reasons for exclusion) 
Exclusion 
performed? 
(Yes/No) 
Number of 
individuals 
excluded 
(Chapter III, 
Chapter IV) 
Number of 
observations 
excluded 
(Chapter III, 
Chapter IV) 
Glasgow 
clinic 
Remove individuals from the Glasgow, 
Scotland, clinic due to different 
exposures and different treatment 
modalities  
Yes 46 
46 
190 
190 
Heparin 
users 
Exclude individuals with medical 
therapeutic codes: 831000 (heparins), 
e.g., Caprin, heparin; 831010 (low 
molecular weight heparins);  reason:  
all such individuals in the VISP dataset 
showed moderate to severe disability, 
were likely in a hospital or other care 
facility, and likely had more serious 
medical conditions than other first-ever 
stroke survivors 
Yes 36 
36 
313 
313 
No 
followup 
Individuals without data beyond the 
baseline visit; reason: change in risk 
parameters cannot be estimated without 
at least two time points 
Yes  0 
 
0 
Insufficient 
followup 
Individuals without data beyond the 
six-month visit; reason: analysis goal 
for Chapter III required more than two 
time points 
No Not 
applicable 
Not applicable 
Multiple Exclude individuals with multiple No Not Not applicable 
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Exclusion 
group 
Exclusion description  
(details and reasons for exclusion) 
Exclusion 
performed? 
(Yes/No) 
Number of 
individuals 
excluded 
(Chapter III, 
Chapter IV) 
Number of 
observations 
excluded 
(Chapter III, 
Chapter IV) 
recurrent 
strokes 
recurrent strokes; reason: such 
individuals likely to be different from 
participants with only one recurrent 
stroke (more sick, different exposures, 
different risk factor profiles, etc.) 
applicable 
 
Table 2.9. Missing data (number and percent) in the VISP cohort dataset 
 
Characteristic Baseline Six month visit Twelve month 
visit 
Eighteen 
month visit 
Twenty-four 
month visit 
N 1 %  N %  N % N % N % 
Number of participants 3680 N/A 3488 N/A 3366 N/A 3257 N/A 2856 N/A 
Type of visit:  0 0.0 1 0.0 5 0.1 12 0.4 2 0.1 
Smoking status:  2 0.1 2 0.1 39 1.2 65 2.0 100 3.5 
Weight (kg)  5 0.1 278 8.0 317 10.1 406 12.5 266 9.3 
Body mass index (kg/m2)  2 37 1.0 286 8.2 320 9.5 412 12.6 269 9.4 
Obesity status (BMI ≥30 kg/m2)  37 1.0 286 8.2 322 9.6 413 12.7 270 9.5 
Blood pressure, mmHg 
Systolic 
Diastolic 
 
0 
0 
 
0.0 
0.0 
 
195 
196 
 
5.6 
5.6 
 
243 
245 
 
7.2 
7.3 
 
328 
329 
 
10.1 
10.1 
 
206 
209 
 
7.2 
7.3 
Cholesterol level, mg/dl 
Total cholesterol 
HDL cholesterol 
LDL cholesterol 
 
150 
240 
371 
 
4.1 
6.5 
10.1 
 
N/A 
N/A 
N/A 
 
N/A 
N/A 
N/A 
 
615 
633 
813 
 
18.3 
18.8 
24.1 
 
N/A 
N/A 
N/A 
 
N/A 
N/A 
N/A 
 
498 
515 
655 
 
17.4 
18.0 
22.9 
Triglyceride level, mg/dl 263 7.1 N/A N/A 681 20.2 N/A N/A 546 19.1 
MMSE score 32 0.9 N/A N/A 270 8.0 N/A N/A 219 7.7 
NIHSS Score 0 0.0 166 4.8 222 6.7 305 9.5 188 6.7 
Barthel Index Score 6 0.2 163 4.7 221 6.6 289 8.9 169 5.9 
RSS score 0 0.0 161 4.6 215 6.4 283 8.7 168 5.9 
Medical conditions 
Hypertensive 
Diabetic 
 
1 
2 
 
0.0 
0.1 
 
1 
2 
 
0.0 
0.1 
 
1 
2 
 
0.0 
0.1 
 
0 
3 
 
0.0 
0.1 
 
1 
1 
 
0.0 
0.0 
Medical conditions (ctd.) 
Heart condition or 
operation 3 
 
Stroke prior to 
qualifying stroke 
Carotid 
endarterectomy 
Angina (from the 
Rose 
questionnaire) 
 
 
0 
 
856 
 
1 
 
5 
 
 
 
 
0.0 
 
23.3 
 
0.0 
 
0.1 
 
 
0 
 
N/A 
 
1 
 
N/A 
 
 
 
0.0 
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N/A 
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N/A 
 
0.1 
 
N/A 
 
 
 
1 
 
N/A 
 
1 
 
169 
 
 
 
 
0.0 
 
N/A 
 
0.0 
 
5.9 
 
 
1 Number of participants with data on characteristic of interest. 
2 Since duration of VISP follow-up was less than 2 years and study participants were all adults, height was replaced by 
baseline height if follow-up height measurement was not obtained and baseline height was available. 
3 Includes myocardial infarction, congestive heart failure, coronary angioplasty, or coronary artery bypass graft surgery 
 
Table 2.10. Estimates of hazards for obese (or becoming obese) and non-obese (or 
becoming non-obese), by time period 
 
Item Baseline 6-month 
visit 
12-month 
visit 
18-month 
visit 
24-month 
visit 
Accrual (%) 100 0 0 0 0 
Obese exposed hazard rate 0.000 0.0390 0.0918 0.1238 0.1397 
Non-obese exposed hazard rate 0.000 0.0280 0.0709 0.1128 0.1330 
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Item Baseline 6-month 
visit 
12-month 
visit 
18-month 
visit 
24-month 
visit 
Obese expected surviving 100.00 96.175 87.739 77.524 67.417 
Non-obese expected surviving 100.00 97.239 90.586 80.922 70.842 
Common exp. dropout rate 0.000 0.0120 0.0240 0.0360 0.048 
 
Table 2.11. Estimates of hazards for diabetics versus non-diabetics (baseline) and those 
who became diabetics versus those whose status did not change (followup) 
 
Item Baseline 6-month 
visit 
12-month 
visit 
18-month 
visit 
24-month 
visit 
Accrual (%) 100 0 0 0 0 
Diabetic/became exp. hazard rate 0.000 0.0358 0.0358 0.0358 0.0358 
Diabetic/constant exp. hazard rate 0.000 0.0294 0.0837 0.1167 0.1327 
Diabetic/became expect. surviving 100.000 96.483 93.090 89.817 86.658 
Diabetic/constant expect. 
surviving 
100.000 97.103 89.306 79.469 69.596 
Common exp. dropout rate 0.000 0.0120 0.0240 0.0360 0.048 
 
Table 2.12. Estimates of hazards for hypertensives versus non-hypertensives (baseline) 
and those who became hypertensives versus those whose status did not change 
(followup) 
 
Item Baseline 6-month 
visit 
12-month 
visit 
18-month 
visit 
24-month 
visit 
Accrual (%) 100 0 0 0 0 
H’tnsive/became exp. hazard rate 0.000 0.0319 0.1320 0.1320 0.1320 
H’tnsive/constant exp. hazard rate 0.000 0.0295 0.0835 0.1164 0.1323 
H’tnsive/became expect. surviving 100.000 98.860 84.886 74.392 65.196 
H’tnsive/constant expect. 
surviving 
100.000 97.096 89.321 79.507 69.651 
Common exp. dropout rate 0.000 0.0120 0.0240 0.0360 0.048 
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Figure 2.1. Schematic of analysis plan for Specific Aim 1 
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CHAPTER III: PREDICTING RECURRENT STROKE USING 
REPEATED MEASURES OF RISK FACTORS 
 
Introduction  
 
Recurrent stroke carries with it a greater risk of disabling or fatal aftereffects (1, 2, 3) 
and poor quality of life compared to first-ever stroke. 1  Mortality from first-ever strokes has 
decreased, 10 thereby increasing  the number of those at risk for recurrent stroke as well as 
higher morbidity and health care costs. (1, 11) Secondary stroke prevention has been successful 
in controlled trials but less so in the general population 4 although improvements in this could 
be realized through optimizing the management of risk factors following a stroke. (5,6,7)   
Most current available stroke risk prediction equations do not incorporate repeat 
measures or information collected after the first stroke.  The development and calibration of a 
prediction equation that incorporates information on longitudinal changes in stroke risk 
factor profiles could contribute to options for reduction in the risk of stroke recurrence. The 
objective of this study was to examine whether the risk of stroke recurrence can be predicted 
effectively from changes in a patient’s risk factor profile observed at six-monthly intervals 
over the course of two years.  
Methods 
 
Population 
We analyzed data from the VISP trial, a study of persons with an ischemic stroke 
from September 1996 through May 2003. VISP’s methods and results have been described 
previously. (8, 9) Demographic, clinical and laboratory data were collected at baseline, with 
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follow-up data obtained at 6, 12, 18 and 24 months. For this analysis, those on heparin (n= 
36, observations=313), those from the Glasgow clinic (n= 46, observations=190), and those 
with irremediable missing data (n=279, observations=678) were excluded, leaving 3404 
participants with 14142 observations (Table 3.1).  
Variables included in the models 
We conducted literature searches to identify variables extant in the VISP data 
associated with stroke risk or present in stroke clinical care guidelines 105 and selected 20 
candidate elements, shown in Table 3.1.  
Some variables, such as diabetes, cigarette smoking, endarterectomy status, and 
number of prior strokes, were obtained by self-report.  Trained study staff assessed dementia 
using the MMSE, dependency using the Barthel Stroke Questionnaire, and disability using 
the RSS.  Blood pressure was obtained using the average of two seated readings using a 
random zero sphygmomanometer.  Atrial fibrillation was determined from ECGs performed 
at the baseline, twelve-month, and twenty-four month visit.  Medication use was determined 
using medication containers brought to clinic by participants.  Circulating levels of 
homocysteine were assessed from sera using the VISP central laboratory; (8, 9) cholesterol and 
triglyceride levels were assessed from sera at local laboratories at each study site.  
We calculated BMI as weight (kg)/height (m2). Dementia was defined as an MMSE  
score of less than 27, dependency as a Barthel Stroke score less than 20 and disability as a 
RSS value of 1 or more.  We created indicator variables combining medication use with 
diabetic status.  In order to ensure that all variables were on similar scales, we standardized 
continuous variables such as age, BMI, blood pressure, HDL cholesterol and total cholesterol 
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level, by dividing an individual’s value at a given time point by the cohort SD (Table 3.2) at 
the baseline visit.   
Missing data and data with extreme values 
We substituted for missing values such as height either baseline values, 
chronologically adjacent binary or categorical measures, or the average of chronologically 
adjacent continuous variable values.  We substituted the average of chronologically adjacent 
values for HDL and total cholesterol at the 6-month and 18-month visits. The results of 
substitution can be seen in Table 3.3. The remaining 279 participants (7.6% of the cohort) 
with missing data were omitted from these analyses.   
 We trimmed extreme values to an individual’s overall mean +/- one SD, resulting in 
trimmed values for some 2684 (18.98%) observations; the results of trimming can be seen in 
Table 3.4. 
Statistical Analysis 
Crude unadjusted univariate IRRs and stroke rates were calculated to assess the effect 
of risk factors on recurrent stroke risk as well as to determine potential confounders (if the 
effect differed from the adjusted results); the results are shown in Tables 3.5 and 3.6. 
Breslow-Day tests for EMM were run using baseline data. 
An Andersen-Gill variant of the Cox proportional hazards model was used to explore 
the association between changes in risk factors and recurrent stroke outcome.  This model 
structure reduces the possibility of intra-subject correlations while allowing the incorporation 
of time-dependent covariates thereby including changes in risk factors in the proportional 
hazards analysis through the use of time-period-specific risk sets. 106 All analyses reported 
used time-to-first recurrent stroke due to low statistical power for an analysis of multiple 
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recurrent events; 46 strokes which occurred after follow-up ended for the participant or 
which occurred in the absence of clinic visits were censored.  
Models were constructed using an ordered stochastic method; one set of models (“C” 
models) included only standard clinically available variables (and a few, such as 
homocysteine, that are not usually obtained at clinic visits), the other set (“PN” models) 
added psychoneurological elements (e.g., Barthel and RSS scores). Table 3.7 shows variable 
classification and the model(s) in which they were included.  The BIC was used to rank all 
models within a set; the models with the lowest BIC were further evaluated for goodness-of-
fit using the GB χ2 and for discrimination using AUC.  Models with the highest GB p-value 
and highest AUC values were then examined to select one PN model and one C model.   
Sensitivity analyses were conducted by comparing the hazard ratios and 95% CI 
produced using the dataset with imputed values to those produced using the dataset without 
imputed values.   The models were then validated following the method of Iasonos et. al. 107 
using 200 samples of participants drawn randomly with replacement. PHA violation 
assessments were performed using standard score tests. All analyses were conducted using 
SAS version 9.1 (Cary, NC). 
Results 
 
Population Description 
VISP randomized a total of 3680 ischemic stroke patients of which 3404 (92.5%) 
were included in these analyses. Mean and median ages (at baseline visit) were 66.5 and 67.3 
years, respectively; 37% were female, 20% African American or other ancestry.  Most 
participants (75%, Table 3.8) completed two years of follow-up; the average length of 
follow-up (including time from screening to randomization) was 692.4 days (SD 191.4).  
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There were a total of 229 first recurrent ischemic strokes among the 3324 participants 
(6.9%).   
Unadjusted results 
Tables 3.5 and 3.6 show the unadjusted univariate IRRs and stroke rates. Individuals 
whose change in dependency or disability status went from negative to positive or those with 
no change in status compared to individuals who lost dependency or disability showed 
significantly higher IRRs in both year 1 and year 2. Those without change in total or HDL 
cholesterol (compared with those whose total cholesterol levels decreased or HDL 
cholesterol increased) in year 1 had higher IRRs for recurrent stroke.  These results paralleled 
the adjusted results; accordingly, none of these were treated as potential confounders. 
Table A.7 shows the results of the Breslow-Day tests for EMM; nonwhite race 
showed significant and clinically plausible potential for EMM for the clinical model, 
accordingly the clinical model results are presented stratified by race. 
Model assessment 
The C model predicted recurrent stroke risk well (whites: χ2 33.13, p=0.0045; 
nonwhites: χ2 28.74, p=0.0174) as did the PN model (χ2 105.45, p<0.0001). The GB 
goodness-of fit statistic indicated that both models provided adequate fit (C, whites: χ2 8.33, 
p=0.5017; C, nonwhites: χ2 8.36, p=0.4985; PN: χ2 4.5, p=0.8757). Both models also showed 
moderate ability to discriminate between individuals who experienced a recurrent stroke and 
those who did not, the PN model slightly better (AUC=0.687) than the C model (overall: 
AUC=0.613).  
Bootstrap validation indicated that the models were reasonably robust.  For the C 
model, the overall bias-corrected AUC estimate was 0.634 and the 95% CI was (0.601, 
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0.662)) which included the full dataset’s point estimate of 0.613; the stratified bootstrap 
AUC estimates were 0.637 (95%CI (0.604, .669)) for whites and 0.750 (95%CI (0.694, 
0.803)) for nonwhites, respectively.  The PN model’s bias-corrected AUC was 0.695 (95% 
CI (0.662, 0.725)), again including the full dataset’s point estimate of 0.687.  The PHA 
violation assessment results (Tables A.8, A.9, A.10 and A.11) showed no significant 
deviations for any risk factors included in either the clinical or psychoneurological models.  
Model results 
In the C model, the adjusted hazard ratio for a recurrent stroke was higher (Table 3.9) 
for whites with untreated Type 2 diabetes or higher homocysteine levels and for nonwhites 
with more pre-baseline strokes; total cholesterol and aspirin (in nonwhites) showed the 
opposite effect.  In the PN model, those participants with any dependency had a nearly three-
fold higher risk of a recurrent stroke than those without.  Those with any disability also had a 
higher risk of recurrent stroke.  
Sensitivity analysis 
Sensitivity analysis indicated that removal of substituted values resulted in some 
changes in model results for some risk factors.  For Model C in nonwhites, the hazard ratio 
(95%CI) for aspirin use went from 0.50 (0.28, 0.90) to 0.66 (0.18, 2.37), for total cholesterol 
from 0.58 (0.41, 0.83) to 0.72 (034, 1.52) and for number of prior strokes from 1.18 (1.08, 
1.29) to 1.27 (0.97, 1.67).  For Model C in whites, the hazard ratio (95% CI) for 
homocysteine went from 1.17 (1. 04, 1.32) to 1.33 (1.00, 1.79).  For Model PN, removal of 
substituted values resulted in minor and nonsignificant changes in model estimates.  
 
 
76
 
Discussion 
 
We developed and calibrated two models using repeat measurements of readily 
available risk and healthy behavior variables obtained at six-month intervals over a two-year 
time period to estimate the effect of differences between time-point-specific risk factor 
values on recurrent stroke risk. We found that those at a significantly higher risk of recurrent 
stroke included whites with untreated Type 2 diabetes or high homocysteine levels, 
nonwhites with strokes prior to the VISP eligibility stroke, as well as individuals with any 
dependency or any disability; those at a lower risk of recurrent stroke included nonwhites 
with aspirin use.    
Other models have been developed to predict recurrent stroke risk, such as the SPI–I 
and –II 51 which use risk factor information at the time of the first stroke.  The Lehigh Valley 
Recurrent Stroke Study used a single average of four measures of systolic blood pressure 
(obtained over a four-year period) dichotomized into >=140 mmHg and <140mmHg. 52  The 
current study differs from these two preceding efforts by including the actual repeat 
measurements of risk factor data in the analysis.  Such data, used in a score system similar to 
that of  Charlesworth, 108  may be used by healthcare providers and their patients to target the 
risk factor in their stroke patients which yields the greatest reduction in predicted recurrent 
stroke risk, or, alternatively, to estimate the effect on risk of the most easily modified risk 
factor.  For example, a healthcare provider could estimate the patient’s risk of recurrent 
stroke using the patient’s risk factor profile at the time of initial stroke twice – once without 
changes, once with one or more changes - to show the patient the effect on their risk.  
Similarly, the patient could choose either to modify a single risk factor with a large estimated 
effect on risk or several each with a smaller effect, based on their personal preferences.  
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There are several limitations to this study.  Clinical trial inclusion criteria, such as 
those used in VISP, may have resulted in a cohort slightly different from the general stroke 
survivor population (allowing for roughly 7.5% refusals and 4.2% other reasons).  
Participants in a clinical trial are often more healthy than nonparticipants, more aware of the 
need to modify health behaviors, and interact more with medical personnel than does the 
general population. 109  VISP participant vitamin adherence 110 may confirm this – 6% or 
fewer consistently had adherence less than 75% - and use of lipid-lowering medications 
increased over time (unlike the medication adherence seen in other studies with more brief 
interaction). 111 Some variables included in the models, such as diabetes and current cigarette 
smoking status, were based on self-report data, which can contain errors not found in 
clinically-measured and verified data.  The average number of cigarettes smoked per day was 
2 at both the baseline and last follow-up visit, suggesting that cigarette smokers were not 
very different from non-smokers and that not much change in smoking habits had in fact 
occurred. There were relatively few nonwhites in the VISP population cohort, thus it is 
unknown to what degree our results apply to nonwhite stroke survivors; further, some 23.3% 
of the VISP study population had had one or more strokes prior to the VISP eligibility stroke, 
which could reduce their comparability to the general stroke population. 112  However, the 
hazard ratio and confidence interval for stroke prior to the index stroke, while significant in 
nonwhites, were close to 1.00, suggesting that this did not significantly alter recurrent stroke 
risk. In addition, the relatively small degree of change in risk factors such as BMI suggest 
that on average VISP participants were not so different from the general stroke population. 39 
Lastly, with regard to the sensitivity analysis results for Model C for whites for 
homocysteine, the effect of removing observations with substituted values was not as great 
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(0.04 difference in the lower limit of the confidence interval, easily within the changes seen 
in other point estimates or confidence limits of 0.05 or less); for nonwhites, on the other 
hand, aspirin and total cholesterol were substituted at a higher proportion (compared to 
whites) than were other variables. These results suggest the need for further research in these 
areas.   
The use of the VISP study cohort also provided several strengths.  As a clinical trial 
of stroke, all participants were required to have at least one verified ischemic stroke to be 
included in the cohort; in addition, clinical trial standards ensured higher standards of 
exposure data verification and (especially) outcome assessment, a more complete and 
carefully obtained array of information collected as part of the test of the study hypothesis, 
reduction of possible recall bias, standardized training of study personnel to ensure minimal 
variation in data collection, and the repeat measures of risk factor data obtained using the 
same standards at the same time intervals. VISP also provided a high degree of completed 
follow-up visits (more than 75% of participants completed all visits). In short, the VISP 
cohort was chosen to maximize internal validity over external validity.   
In conclusion, we developed and calibrated two statistical models for predicting 
recurrent stroke based on changes in risk factors and healthy behaviors.  The clinical model 
uses measurements readily available in clinical settings; the psychoneurological model 
requires investment of more time, training, and effort in collecting non-standard information, 
but returns a more accurate prediction.  Such models may be used to develop score systems 
which utilize changes in risk factors (individual response and adherence patterns) to target 
specific risk factors so that clinical management of stroke can be optimized. Efforts now 
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underway to implement complex secondary stroke prevention programs 109 may also be aided 
by the results of this study.  
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TABLES 
 
Table 3.1.  Description of study population at each time point 
Variable Baseline 6 months 12 months 18 months 24 months 
Number of participants 3324 2991 2852 2412 2563
Age in years (mean (SD)) 66.52 (10.77) 67.10 (10.69) 67.82 (10.59) 67.93 (10.66) 68.38 (10.63)
Male gender (n (%)) 2084 (62.70) 1876 (62.72) 1782 (62.48) 1510(62.60) 1585 (61.84)
Nonwhite ancestry (n (%)) 675 (20.31) 576 (19.26) 541 (18.97) 447 (18.53) 468 (18.26)
Any dependency (n (%)) 726 (21.84) 505 (16.88) 433 (15.18) 386 (16.00) 401 (15.65)
Any disability (n (%)) 2650 (79.72) 2073 (69.31) 1871 (65.60) 1529 (63.39) 1600 (62.43)
BMI [kg/m2] (mean (SD)) 28.31 (5.64) 28.40 (5.66) 28.44 (5.56) 28.53 (5.60) 28.61 (5.76)
HDL [mmol/L] (mean (SD)) 1.17 (0.38) 1.19 (0.38) 1.23 (0.44) 1.23 (0.44) 1.24 (0.47)
TC [mmol/L] (mean (SD)) 5.16 (1.17) 5.09 (1.05) 4.97 (1.07) 4.93 (1.00) 4.90 (1.05)
Lipid-lowering med use (n (%)) 1466 (44.10) 1473 (49.25) 1462 (51.26) 1305 (54.10) 1471 (57.39)
Homocysteine [μmol/L] (mean 
(SD)) 
97.37 (32.72) 84.87 (29.39) 84.63 (30.53) 83.17 (31.06) 84.22 (30.48)
Systolic blood pressure (mmHg) 140.7 (18.37) 140.5 (19.03) 140.3 (18.99) 139.1 (18.65) 138.6 (18.81)
Blood-pressure-lowering med use 
(n (%)) 
1612 (48.50) 1607 (53.73) 1557 (54.59) 1321 (54.77) 1495 (58.33)
Current cigarette smoker (n (%)) 544 (16.37) 491 (16.42) 461 (16.16) 389 (16.13) 397 (15.49)
Diabetic w/ meds (n (%)) 821 (24.70) 743 (24.84) 723 (25.35) 606 (25.12) 656 (25.60)
Diabetic w/o meds (n (%)) 155 (4.66) 145 (4.85) 143 (5.01) 119 (4.93) 126 (4.92)
Atrial fibrillation (ECG) (n (%)) 8 (0.24) 40 (1.34) 35 (1.23) 26 (1.08) 35 (1.37)
Aspirin use (n (%)) 2026 (60.95) 1769 (59.14) 1683 (59.01) 1454 (60.28) 1524 (59.46)
Past cigarette smoker (n (%)) 1657 (49.85) (N/A) (N/A) (N/A) (N/A)
Number of prior strokes  (n (%)) (N/A) (N/A) (N/A) (N/A)
0 2549 (76.68)  
1 557 (16.76)  
>=2 218 (6.56)  
 
Table 3.2. Cohort baseline standard deviations for continuous variables 
 
Variable Standard 
deviation 
Age (years) 10.79
BMI (kg/m2) 5.63
HDL (mmol/L) 0.39
TC (mmol/L) 1.18
Systolic blood pressure (mmHg) 18.36
Homocyst(e)ine (μmol/L) 33.51
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Table 3.3. Minimum and maximum counts of substituted risk factor values, by age, 
race, gender, and stroke outcome  
 
 
Group Level Risk factor with 
smallest count 
N (%) Risk factor with 
largest count 
N (%) 
Age < median BMI 2 (0.03) HDL cholesterol 391 (5.53)
 >= median Current smoker 1 (0.01) HDL cholesterol 400 (5.66)
Stroke No Current smoker 3 (0.02) HDL cholesterol 762 (5.69)
 Yes Current smoker 1 (0.13) Any dependency 36 (4.82)
Gender Female Diabetic w/meds 1 (0.02) HDL cholesterol 321 (6.05)
 Male Current smoker 3 (0.03) HDL cholesterol 470 (5.32)
Race White Current smoker 1 (0.01) HDL cholesterol 596 (5.21)
 Nonwhite BMI 1 (0.04) HDL cholesterol 195 (7.2)
 
 
 
Table 3.4. Frequencies of trimmed values, by interval variable 
 
Variable Trim status N (%) 
Vitamin B12 Not trimmed 14056 (99.39)
 Trimmed to mean +/- 1SD 86 (0.61)
Diastolic blood pressure Not trimmed 13933 (98.52)
 Trimmed to mean +/- 1SD 209 (1.48)
Folate Not trimmed 14092 (99.65)
 Trimmed to mean +/- 1SD 50 (0.35)
HDL cholesterol Not trimmed 14069 (99.48)
 Trimmed to mean +/- 1SD 73 (0.52)
Height  Not trimmed 12316 (87.09)
 Trimmed to mean +/- 1SD 6 (0.04)
 Re-set to mode of participant 1587 (11.22)
 Set to baseline height 233 (1.65)
LDL cholesterol Not trimmed 14064 (99.45)
 Trimmed to mean +/- 1SD 78 (0.55)
Systolic blood pressure Not trimmed 13947 (98.62)
 Trimmed to mean +/- 1SD 195 (1.38)
Homocyst(e)ine) Not trimmed 13940 (98.57)
 Trimmed to mean +/- 1SD 202 (1.43)
Total cholesterol Not trimmed 14072 (99.51)
 Trimmed to mean +/- 1SD 70 (0.49)
Triglyceride Not trimmed 14080 (99.56)
 Trimmed to mean +/- 1SD 62 (0.44)
Weight Not trimmed 13990 (98.93)
 Trimmed to mean +/- 1SD 152 (1.07)
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Table 3.5. Incidence of recurrent stroke in year one of follow-up (per 100 person-years) 
by change in risk factors  
 
Variable Change 
Year 1 - 
Strokes 
Year 1 - follow-up 
time (days) 
Year 1 - 
stroke 
rate (per 
100 py) 
Year 1 - 
incidence rate 
ratio (95% CI) 
Any dependency - to + 17 195.86 8.68 2.12 (1.27, 3.53)
Any dependency No change 109 2666.03 4.09 2.62 (1.07, 6.42)
Any dependency + to - 5 320.63 1.56  
Any disability - to + 9 151.66 5.93 1.28 (0.65, 2.52)
Any disability No change 112 2415.74 4.64 2.85 (1.49, 5.44)
Any disability + to - 10 615.12 1.63  
Body mass index [kg/m2] - to + 2 257.69 0.78 0.19 (0.05, 0.77)
Body mass index [kg/m2] No change 115 2772.24 4.15 0.45 (0.26, 0.78)
Body mass index [kg/m2] + to - 14 152.59 9.17  
Homocyst(e)ine [umol/L] - to + 11 330.06 3.33 0.7 (0.37, 1.31) 
Homocyst(e)ine [umol/L] No change 80 1692.73 4.73 1.37 (0.94, 2) 
Homocyst(e)ine [umol/L] + to - 40 1159.73 3.45  
HDL cholesterol [mg/dl] - to + 17 695.37 2.44 0.49 (0.29, 0.82)
HDL cholesterol [mg/dl] No change 109 2183.00 4.99 3.04 (1.24, 7.45)
HDL cholesterol [mg/dl] + to - 5 304.15 1.64  
Total cholesterol [mg/dl] - to + 10 515.83 1.94 0.35 (0.18, 0.67)
Total cholesterol [mg/dl] No change 100 1779.25 5.62 2.37 (1.48, 3.79)
Total cholesterol [mg/dl] + to - 21 887.45 2.37  
Lipid-lowering med use - to + 13 500.72 2.60 0.59 (0.33, 1.05)
Lipid-lowering med use No change 111 2537.97 4.37 0.9 (0.42, 1.93) 
Lipid-lowering med use + to - 7 143.83 4.87  
Systolic blood pressure [mmHg] - to + 33 868.64 3.80 0.78 (0.51, 1.19)
Systolic blood pressure [mmHg] No change 62 1277.49 4.85 1.4 (0.93, 2.11) 
Systolic blood pressure [mmHg] + to - 36 1036.39 3.47  
Blood pressure lowering med use - to + 14 422.37 3.31 0.83 (0.48, 1.45)
Blood pressure lowering med use No change 105 2618.42 4.01 0.47 (0.26, 0.85)
Blood pressure lowering med use + to - 12 141.73 8.47  
Current cigarette smoker - to + 2 111.54 1.79 0.45 (0.11, 1.82)
Current cigarette smoker No change 118 2939.41 4.01 0.48 (0.26, 0.89)
Current cigarette smoker + to - 11 131.57 8.36  
Diabetic w/ meds - to + 2 89.27 2.24 0.55 (0.14, 2.22)
Diabetic w/ meds No change 125 3048.68 4.10 0.46 (0.17, 1.24)
Diabetic w/ meds + to - 4 44.57 8.97  
Diabetic w/o meds - to + 5 66.48 7.52 1.85 (0.76, 4.52)
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Variable Change 
Year 1 - 
Strokes 
Year 1 - follow-up 
time (days) 
Year 1 - 
stroke 
rate (per 
100 py) 
Year 1 - 
incidence rate 
ratio (95% CI) 
Diabetic w/o meds No change 125 3071.73 4.07 1.8 (0.25, 12.88)
Diabetic w/o meds + to - 1 44.32 2.26  
Atrial fibrillation [ECG] - to + 2 33.57 5.96 1.45 (0.36, 5.86)
Atrial fibrillation [ECG] No change 129 3146.95 4.10 . (., .) 
Atrial fibrillation [ECG] + to - . 2.00 .  
Aspirin use - to + 21 329.57 6.37 1.98 (1.22, 3.2) 
Aspirin use No change 79 2457.15 3.22 0.41 (0.27, 0.62)
Aspirin use + to - 31 395.81 7.83  
 
Table 3.6. Incidence of recurrent stroke in year two of follow-up (per 100 person-years) 
by change in risk factors  
 
Variable Change 
Year 2 - 
Strokes 
Year 2 - 
follow-up 
time (days) 
Year 2 - 
stroke 
rate (per 
100 py) 
Year 2 - 
incidence rate 
ratio (95% CI) 
Any dependency - to + 22 185.76 11.84 3.6 (2.25, 5.75) 
Any dependency No change 85 2585.80 3.29 1 (0.53, 1.87) 
Any dependency + to - 11 335.77 3.28  
Any disability - to + 11 148.24 7.42 1.73 (0.93, 3.23) 
Any disability No change 99 2314.91 4.28 3.45 (1.68, 7.09) 
Any disability + to - 8 644.18 1.24  
Body mass index [kg/m2] - to + 7 267.23 2.62 0.68 (0.32, 1.46) 
Body mass index [kg/m2] No change 104 2688.92 3.87 0.84 (0.39, 1.81) 
Body mass index [kg/m2] + to - 7 151.18 4.63  
Homocyst(e)ine [umol/L] - to + 18 335.37 5.37 1.27 (0.75, 2.14) 
Homocyst(e)ine [umol/L] No change 67 1584.31 4.23 1.52 (1, 2.31) 
Homocyst(e)ine [umol/L] + to - 33 1187.66 2.78  
HDL cholesterol [mg/dl] - to + 19 719.39 2.64 0.68 (0.41, 1.12) 
HDL cholesterol [mg/dl] No change 81 2075.80 3.90 0.68 (0.41, 1.13) 
HDL cholesterol [mg/dl] + to - 18 312.14 5.77  
Total cholesterol [mg/dl] - to + 21 527.20 3.98 1 (0.61, 1.63) 
Total cholesterol [mg/dl] No change 66 1664.02 3.97 1.17 (0.76, 1.79) 
Total cholesterol [mg/dl] + to - 31 916.11 3.38  
Lipid-lowering med use - to + 14 517.11 2.71 0.67 (0.38, 1.17) 
Lipid-lowering med use No change 100 2454.04 4.07 1.38 (0.51, 3.75) 
Lipid-lowering med use + to - 4 136.18 2.94  
Systolic blood pressure [mmHg] - to + 38 869.26 4.37 1.54 (0.97, 2.45) 
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Variable Change 
Year 2 - 
Strokes 
Year 2 - 
follow-up 
time (days) 
Year 2 - 
stroke 
rate (per 
100 py) 
Year 2 - 
incidence rate 
ratio (95% CI) 
Systolic blood pressure [mmHg] No change 34 1203.37 2.83 0.64 (0.41, 1) 
Systolic blood pressure [mmHg] + to - 46 1034.70 4.45  
Blood pressure lowering med use - to + 17 433.62 3.92 1.02 (0.61, 1.71) 
Blood pressure lowering med use No change 97 2535.74 3.83 1.32 (0.49, 3.59) 
Blood pressure lowering med use + to - 4 137.97 2.90  
Current cigarette smoker - to + 2 117.29 1.71 0.45 (0.11, 1.82) 
Current cigarette smoker No change 109 2869.87 3.80 0.65 (0.3, 1.4) 
Current cigarette smoker + to - 7 120.17 5.83  
Diabetic w/ meds - to + 7 89.21 7.85 2.14 (1, 4.6) 
Diabetic w/ meds No change 109 2976.07 3.66 0.77 (0.19, 3.12) 
Diabetic w/ meds + to - 2 42.05 4.76  
Diabetic w/o meds - to + 2 64.90 3.08 0.85 (0.21, 3.44) 
Diabetic w/o meds No change 109 2999.69 3.63 0.22 (0.1, 0.47) 
Diabetic w/o meds + to - 7 42.74 16.38  
Atrial fibrillation [ECG] - to + 1 33.85 2.95 0.77 (0.11, 5.51) 
Atrial fibrillation [ECG] No change 117 3071.92 3.81 . (., .) 
Atrial fibrillation [ECG] + to - . 1.56 .  
Aspirin use - to + 14 329.34 4.25 1.31 (0.74, 2.31) 
Aspirin use No change 78 2398.36 3.25 0.47 (0.3, 0.73) 
Aspirin use + to - 26 379.63 6.85  
 
Table 3.7. List of variables considered in clinical (C) models, psychoneurological (PN) 
models, or both (B) 
 
Variable Classification Model(s) in 
which included 
((C), (PN), 
or (B)) 
Lipid-lowering medication use (C) (B) 
Blood-pressure-lowering medication use (C) (B) 
Any neurological deficit (PN) (PN) 
Any dementia (PN) (PN) 
Any dependency (PN) (PN) 
Any disability (PN) (PN) 
Aspirin use (C) (B) 
Body mass index (C) (B) 
Obesity, overweight status (C) (B) 
Serum creatinine (C) (B) 
Current cigarette smoker (C) (B) 
Vitamin B12 (C) (B) 
85
 
Variable Classification Model(s) in 
which included 
((C), (PN), 
or (B)) 
Diastolic blood pressure (C) (B) 
Atrial fibrillation on ECG (C) (B) 
Diabetes status and medication use (C) (B) 
Endarterectomy status (C) (B) 
Serum folate  (C) (B) 
HDL cholesterol (C) (B) 
Homocyst(e)ine (C) (B) 
Hyperlipidemic status and medication use (C) (B) 
Hypertensive status and medication use (C) (B) 
LDL cholesterol (C) (B) 
Past cigarette smoker (C) (B) 
Rose angina (C) (B) 
Systolic blood pressure (C) (B) 
Systolic blood pressure and medication use (C) (B) 
Total cholesterol (C) (B) 
Total cholesterol and medication use (C) (B) 
Serum triglycerides (C) (B) 
Number of prior strokes (C) (B) 
Mild, moderate, or severe dementia 
(categorical) 
(PN) (PN) 
Mild or moderate dependency (categorical) (PN) (PN) 
Mild, moderate, or severe disability (PN) (PN) 
Mild or moderate neurological deficit (PN) (PN) 
 
Table 3.8. Last clinic visit per participant 
 
Clinic visit N (%) 
Twenty-four month visit 2563 (75.29)
Eighteen-month visit 322 (9.46)
Twelve-month visit 191 (5.61)
Six-month visit 189 (5.55)
Baseline 139 (4.08)
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Table 3.9.  Hazard ratios(*) for recurrent stroke based on risk factors assessed at 
baseline and at six-month intervals  
Variable Clinical Model Psycho-Neurological 
Model 
 
Whites 
Hazard Ratio 
(95% CI) 
Nonwhites 
Hazard Ratio 
(95% CI) 
 
Hazard Ratio  
(95% CI) 
Non-changing items  
(assessed only at baseline): 
Male gender 0.86 (0.62, 1.18) 1.08 (0.58, 2.02) 0.95 (0.72, 1.25)
Nonwhite ancestry (Not included)† (Not included) 1.04 (0.75, 1.44)
Past cigarette smoker 0.80 (0.59, 1.08) 1.06 (0.58, 1.93) (Not included) 
Number of prior strokes  1.08 (0.99, 1.19) 1.18 (1.08, 1.29) (Not included)
Items measured at  
baseline and follow-up visits: 
Age (per 10.79 SDU‡) 1.05 (0.88, 1.24) 1.12 (0.82, 1.53) 1.03 (0.90, 1.18)
Any dependency (Not included) (Not included) 2.95 (2.23, 3.88)
Any disability  (Not included) (Not included) 2.39 (1.62, 3.51)
BMI (per 5.63 SDU) 1.03 (0.88, 1.21) 0.97 (0.73, 1.29) 1.00 (0.88, 1.14)
HDL cholesterol (per 39.41 SDU) (Not included) (Not included) 0.97 (0.84, 1.12)
Total cholesterol (per 46.04 SDU) 1.07 (0.91, 1.26) 0.58 (0.41, 0.83) (Not included)
Lipid-lowering med use 0.85 (0.63,1.14) 1.01 (0.56, 1.81) (Not included)
Systolic blood pressure (per 18.36 SDU) 0.97 (0.85, 1.12) 1.10 (0.84, 1.43) (Not included)
Blood-pressure-lowering med use 1.12 (0.82, 1.52) 1.20 (0.65, 2.24) (Not included)
Current cigarette smoker 0.62 (0.37, 1.03) 0.94 (0.43, 2.07) (Not included)
Diabetic w/ meds 1.17 (0.82, 1.68) 0.97 (0.51, 1.82) (Not included)
Diabetic w/o meds 2.42 (1.46, 3.99) 1.15 (0.39, 3.39) (Not included)
Atrial fibrillation (ECG) 1.25 (0.39, 3.95) 1.95 (0.24, 15.74) (Not included)
Aspirin use 0.85 (0.63, 1.14) 0.50 (0.28, 0.90) (Not included)
Homocysteine (per 4.53 SDU) 1.17 (1.04, 1.32) 1.11 (0.89, 1.39) (Not included)
(*) For items that incorporate change, the hazard ratios shown represent the proportionate change in stroke rate due to a unit 
change in the respective covariate in each six-month time period. 
† Not included in model. 
‡ Age, BMI, HDL cholesterol, homocysteine level and systolic blood pressure were standardized by dividing the value for 
an individual at a given time point by the standard deviation of the population at the baseline visit.  
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CHAPTER IV: CHANGES IN ADHERENCE TO MEDICATIONS 
AND RISK FACTOR LEVELS AND THE RISK OF STROKE RECURRENCE 
  
Introduction  
 
Recurrent stroke carries with it a greater risk of disabling or fatal aftereffects (1, 2, 3) 
and poor quality of life compared to first-ever stroke. 1  Mortality from first-ever strokes has 
decreased, 10 thereby increasing  the number of those at risk for recurrent stroke as well as 
morbidity and health care costs. (1, 11) Secondary stroke prevention has been successful in 
controlled trials but less so in the general population. (4, 113)  It has been suggested that 
improvements could come about through improving adherence to stroke care guidelines. (5,6,7)   
However, there have been relatively few studies of changes in adherence to stroke 
care guidelines  (39,111, 114) and most of these have not examined the effects on recurrent stroke 
risk of post-stroke changes in guideline adherence or were focused on one aspect of guideline 
adherence. 115 Consequently, examining the results of changes in adherence to guidelines, 
either in terms of medication use or continuous risk factor variables such as systolic blood 
pressure or total cholesterol, might contribute to improvements in focus of secondary stroke 
prevention. The objective of this study was to examine the effect of changes in medication or 
continuous factor (e.g., SBP, TC) adherence over a six- or twelve-month period after 
ischemic stroke on the risk of stroke recurrence.  
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Methods 
 
Population 
We analyzed data from the VISP trial.  The VISP subjects were identified by 
neurologists as having experienced an ischemic stroke from September 1996 through May 
2003. VISP’s methods and results have been described previously. (8, 9) We selected a subset 
of the demographic, clinical and laboratory variables collected at the baseline, six-month and 
twelve-month follow-up visits. We excluded those on heparin (n=36) and those from the 
Glasgow clinic (n=46); the latter exclusion was due to the likelihood of different exposures at 
the Glasgow clinic and the small sample size (1.3% of total cohort).  We constructed two 
separate datasets to analyze change in adherence, one using data between the baseline and 
six-month follow-up visit (Base6), the other using data between the baseline and twelve-
month follow-up visit (Base12). Both datasets were restricted to those participants with both 
a baseline and twelve-month visit (N=2791); this cohort of participants was 37.1% female 
and 18.3% African-American or other ancestry. After excluding participants with 
irremediable missing data, 2739 participants remained in the Base6 dataset and 2750 
participants remained in the Base12 dataset.  For the Base6 dataset, mean and median ages at 
six month visit were 66.9 and 67.8 years, respectively; for the Base12 dataset, mean and 
median ages at twelve-month visit were 67.8 and 69.1 years.   There were a total of 132 first 
recurrent ischemic strokes among the 2739 participants (4.8%) when censoring was applied 
to strokes within the first six months (Base6 dataset) and 77 first recurrent ischemic strokes 
among the 2750 participants (2.8%) when censoring was applied to strokes within the first 
twelve months (Base12 dataset).  The difference in the counts of recurrent strokes is due to 
the necessity of censoring strokes between the time points used for assessing change in 
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adherence, e.g., for the Base6 dataset, strokes occurring between the baseline visit and the six 
month visit were censored, whereas for the Base12 dataset, strokes occurring between the 
baseline visit and the twelve month visit were censored.  As the latter time period is six 
months greater than the former, more strokes were censored in the Base12 dataset. 
 
Variables included in the models 
We conducted literature searches to identify variables extant in the VISP data 
associated with stroke risk or present in stroke clinical care guidelines. 105  The 10 candidate 
elements selected for further evaluation (beyond age, race, and gender) included the 
following clinically-relevant factors: aspirin use; BMI; cigarette smoking status; systolic 
blood pressure; total cholesterol; diabetic status; hypertensive status; and lipid-lowering, 
blood-pressure-lowering and anti-diabetic medication use.  
Some variables, such as diabetic status and cigarette smoking, were obtained by self-
report.  Blood pressure was obtained using the average of two seated readings using a 
random-zero sphygmomanometer.  Medication use was determined using medication 
containers brought to clinic visits by participants.  Cholesterol levels were assessed using 
local lab reports.   
We defined an undesirable SBP level as a measured value greater than or equal to 
120mmHg; an undesirable TC level was defined as 200mg/dl or greater. BMI was calculated 
as weight (kg)/height (m2) and an undesirable level for BMI was defined as 25 kg/m2 or 
higher.  We constructed categorical indicator variables to measure changes in adherence to 
medication use guidelines and to risk factor guidelines. Table 4.1 shows the coding for 
medication adherence variables such as diabetes, blood pressure lowering, or lipid-lowering.  
For continuous variables such as BMI, systolic blood pressure, or total cholesterol, the 
90
 
reference level was “maintained desirable levels” (e.g., a BMI of less than 25 kg/m2); other 
categorical levels (in increasing order of perceived risk) included “changing from an 
undesirable level to a desirable level” (e.g., a BMI of 25 kg/m2 or greater moving to a BMI of 
less than 25), “changing from a desirable level to an undesirable level” (a BMI of less than 
25 kg/m2 to a BMI of 25 kg/m2 or greater), or staying at an undesirable level.  Table 4.2 
shows the levels of time-point-specific status and change together with counts of participants 
and recurrent strokes in each category for the Base6 dataset; Table 4.3 shows the same counts 
and levels for the Base12 dataset. 
Missing data and data with extreme values  
VISP conducted routine data quality control measures for most but not all data 
collected.  We therefore substituted for missing values prior to creating the Base6 and 
Base12 datasets using either baseline values (e.g., for height), chronologically adjacent 
measures (for binary or categorical variables), or the average of chronologically adjacent 
values (for continuous variables).  We also substituted the average of chronologically 
adjacent values for total cholesterol at the 6-month visit. The results of substitution can be 
seen in Tables 4.4 (Base6 dataset) and 4.5 (Base12 dataset). The remaining missing data 
could not be remedied without multiple imputation for 52 individuals (1.9%) in the Base6 
dataset and 41 individuals (1.5%) in the Base12 dataset; as these constituted less than 5% of 
the Base6 and Base12 cohorts, we therefore omitted these subjects from these analyses.  We 
trimmed extreme values to an individual’s overall mean +/- one SD, resulting in trimmed 
values for some 2684 (18.98%) observations; the results of trimming can be seen in Tables 
4.6 and 4.7. In order to ensure that all variables were on similar scales, we standardized age 
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by dividing an individual’s value at a given time point by the cohort SD (10.54) at the 
baseline visit. 
Statistical Analysis 
Crude unadjusted univariate IRRs and stroke rates were calculated to assess the effect 
of risk factors on recurrent stroke risk as well as to determine potential confounders (if the 
effect differed from the adjusted results). Breslow-Day tests for EMM were run using 
baseline data. 
After developing the initial predictor variable coding, it was determined that there 
were too many parameters for the number of events in the dataset.  Preliminary analysis 
suggested that total cholesterol and systolic blood pressure and the respective medications 
were highly correlated, as expected; a high level of correlation could be a threat to model 
stability if both sets of predictor variables were in the model simultaneously.  We thought to 
exclude the continuous risk factors but found that total cholesterol and systolic blood 
pressure contributed to model predictiveness and discrimination.  Although there were 
multiple ways in which the models could be split (biology, relevance to recurrent stroke, data 
quality, etc.), to keep a desirable count of events per model parameter, 116 we decided to 
construct separate medication adherence (use of aspirin, anti-diabetic medications, blood-
pressure-lowering medications, and lipid-lowering medications) and continuous variable 
(systolic blood pressure, total cholesterol) adherence models.  
Sensitivity analyses were conducted by running the models without the observations 
for which we had substituted items with missing data and comparing the hazard ratios and 
95% confidence intervals (95% CI) produced using the dataset with imputed values to those 
produced using the dataset without imputed values.   The models were then validated 
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following the method of Iasonos et. al. 107 using 200 samples of participants drawn randomly 
with replacement. PHA violation assessments were performed using standard score tests. All 
analyses were conducted using SAS version 9.1 (Cary, NC). 
Results 
 
Assessment of medication and continuous variable adherence and change in adherence  
Tables 4.2 and 4.3 show the levels of adherence to medication use guidelines and 
continuous variable guidelines among VISP participants.  Over 1600 (60%) used aspirin, 
approximately 2300 (83%) were non-smokers, and relatively few (140 (5%)) never used 
needed anti-diabetic medication. In terms of adherence to other guidelines, VISP participants 
were more heterogeneous: more than 1900 (72%) had a BMI of 25 kg/m2 or more, roughly 
800 (30%) never used needed blood-pressure-lowering medications, and approximately 800 
(30%) never used lipid-lowering medications. Positive change in adherence (becoming 
adherent) was nearly exactly balanced in the Base6 and Base12 datasets by equal numbers of 
those who had once been in adherence but who stopped adhering to guidelines.  
Unadjusted results 
Tables 4.8 (baseline to six months) and 4.9 (baseline to twelve months) show the 
unadjusted crude recurrent stroke incident rate ratios and stroke rates.   In Table 4.8, being of 
nonwhite race was associated with an elevated IRR (IRR 1.56, 95%CI (1.06, 2.30)), as was 
not using needed blood-pressure-lowering medications at baseline (IRR 1.89, 95%CI (1.15, 
3.10)), using needed anti-DM medications (1.56 (1.07, 2.28)) or not using needed anti-DM 
medications at baseline (3.43 (1.97, 5.97)). Stopping or never using anti-DM medications 
also showed an elevated IRR (3.11 (1.87, 5.18)).  For the baseline-to-twelve months analysis 
(Table 4.9), similar to the results shown in Table 4.8, not using needed blood-pressure-
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lowering medications at baseline was associated with an elevated IRR (3.51 (1.65, 7.46)). 
Participants of nonwhite race showed an increased IRR (1.98 (1.22, 3.23)) as did aspirin use 
at baseline (1.68 (1.02, 2.77)), having a baseline BMI greater than or equal to the median 
(1.59 (1.01, 2.51)), or having a baseline SBP greater than or equal to the median (2.03 (1.26, 
3.27)); contrary to Table 4.8, however, starting use of anti-DM medications showed an 
elevated IRR (3.57 (1.12, 11.34)).  The results for stopping or never using anti-DM 
medications between baseline and six months and starting anti-DM medications between 
baseline and twelve months closely approximated the adjusted results, so these risk factors 
were not treated as potential confounders. 
Model assessment 
Preliminary checks for EMM detected no clinically-significant and statistically-
significant Breslow-Day results (Tables A.13 and A.14); accordingly, no models were 
stratified due to EMM. A check of PHA violations using score tests (Tables A.15, A.16, 
A.17, A.18, A.19, A.20, A.21, and A.22) and plots of scaled Schoenfeld residuals indicated 
that “stopping or never used aspirin” in the Base6 medication adherence model was 
associated with a violation of the PHA.  We investigated further and found 101 individuals 
(Table A.23) for whom the model did not fit well; these participants had considerably more 
recurrent strokes (Table A.23, 45% versus 5% for the overall cohort) and more of them 
started using blood-pressure-lowering medications between baseline and six months (10% 
versus 5% of the overall cohort).  Several options for resolving this were considered, 
including removal of the observations, partitioning the time axis (censoring the events after 
the time at which the violation occurred), using a different modeling approach such as an 
accelerated failure time or additive hazards model, programming time-dependent covariates, 
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and stratification. 106  Removal of the 101 observations would have removed 45 of the 132 
recurrent strokes; partitioning the time axis would have removed the same strokes; using a 
different modeling approach was undesirable due to the relative infrequency of utilization of 
the alternative approaches; programming time-dependent covariates caused technical and 
implementation difficulties; consequently, we stratified the Base6 medication adherence 
model by aspirin use and did the same for the Base12 medication adherence model for 
consistency.  
Likelihood ratio statistics indicated that only two models – baseline to six months 
medication (stopped or never used aspirin) and baseline to twelve months continuous 
varialble adherence – predicted recurrent stroke risk well – the χ2 statistics for the models (by 
stratum for the medication adherence models) were as follows:  baseline to six months, 
medication adherence (used or started aspirin), 15.536 (p=0.3425); baseline to six months, 
medication adherence (stopped or never used aspirin), 32.059 (p=0.0039); baseline to six 
months, continuous variable adherence, 17.415 (p=0.2347); baseline to twelve months, 
medication adherence (used or started aspirin), 22.037 (p=0.0779); baseline to twelve 
months, medication adherence (stopped or never used aspirin), 22.227 (p=0.0741); baseline 
to twelve months, continuous variable adherence, 30.005 (p=0.0076).  All models provided 
adequate fit by GB goodness-of-fit statistics.  AUC statistics showed that the models 
provided approximately the same level of discrimination; by model and stratum:  baseline to 
six months, medication adherence (used or started aspirin), 0.6291; baseline to six months, 
medication adherence (stopped or never used aspirin), 0.6839; baseline to six months, 
continuous variable adherence, 0.6042; baseline to twelve months, medication adherence 
(used or started aspirin), 0.6835; baseline to twelve months, medication adherence (stopped 
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or never used aspirin), 0.7399; baseline to twelve months, continuous variable adherence, 
0.6752. Bootstrap validation showed that the models were fairly robust: the baseline to six 
months medication adherence model’s (used or started aspirin) bias-corrected AUC statistic 
was .6719 (95% CI: 0.6125, 0.7294, full dataset AUC 0.6291); the baseline to six months 
medication adherence model’s (stopped or never used aspirin) bias-corrected AUC statistic 
was 0.7313 (95% CI: 0.6641, 0.7918, full dataset AUC 0.6839); the baseline to six months 
continuous risk factor adherence model’s bias-corrected AUC statistic was 0.6344 (95% CI: 
0.5924, 0.6732, full dataset AUC 0.6042); the baseline to twelve month medication 
adherence model’s (started or used aspirin) AUC statistic was 0.7250 (95% CI: 0.6629, 
0.7857, full dataset AUC 0.6835); the baseline to twelve month medication adherence 
model’s (stopped or never used aspirin) AUC statistic was 0.8005 (95% CI: 0.7304, 0.8643, 
full dataset AUC 0.7399); and the baseline to twelve month continuous risk factor adherence 
model’s bias-corrected AUC statistic was 0.7082 (95% CI: 0.6490, 0.7558, full dataset AUC 
0.6752).  
Model results 
The results of the adjusted analyses are shown in Tables 4.10 (baseline to six month 
medication adherence), 4.11 (baseline to twelve month medication adherence) and 4.12 
(continuous variable adherence).  Those who stopped taking aspirin between time points or 
who never took aspirin often showed higher if nonsignificant adjusted hazard ratios.  
However, anti-diabetic medication use – between baseline and six months, for aspirin non-
users, stopping use or never using anti-diabetic medications showed a hazard ratio of 5.12 
(2.55, 10.27), and between baseline and twelve months, starting anti-diabetic medications 
had approximately the same HR (5.04 (1.11, 22.92)).  Other risk factors were associated with 
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a higher risk of recurrent stroke: age for those using aspirin or starting aspirin in both 
baseline to six and baseline to twelve months; nonwhite ancestry for those using or starting 
use of aspirin between baseline and twelve months (HR 2.41 (1.30, 4.50)), and maintaining a 
BMI of greater than or equal to 25 kg/m2 between baseline and twelve months in those 
stopping use or never using aspirin (HR 4.41 (1.02, 18.95)). For the continuous variable 
adherence models, for both time periods, only age and nonwhite ancestry showed statistically 
significant hazard ratios.   
Although removal of substituted values did not change any results for the baseline to 
twelve months medication adherence or continuous variable adherence models, in the 
baseline to six months adherence models the sensitivity analysis results showed slightly more 
significant changes.  In the baseline to six months medication adherence model (started or 
used aspirin), the hazard ratio (95% CI) for age changed from 1.29 (1.01, 1.66) to 1.19 (0.90, 
1.56) and that for nonwhite ancestry changed from 1.60 (0.95, 2.69) to 2.02 (1.15, 3.53).  In 
the baseline to six months continuous risk factor adherence model, the estimate for age 
shifted from 1.23 (1.02, 1.49) to 1.11 (0.90, 1.37). 
Discussion 
 
We examined the data from the VISP cohort to determine whether adherence to 
clinical stroke care guidelines over a six-month or twelve-month period influenced the risk of 
recurrent stroke.  We found that for those not taking or stopping the use of aspirin not using 
anti-diabetes medication was associated with a statistically significant risk of recurrent 
stroke. For those not taking or stopping use of aspirin between baseline and twelve months 
maintaining a BMI greater than or equal to 25 kg/m2 also was associated with a statistically 
significant risk of recurrent stroke. Among those using or starting aspirin use between 
97
 
baseline and twelve months, nonwhite participants were also at significantly higher risk of 
recurrent stroke. 
Some of our results invite discussion and consideration of alternative explanations.  
For example, several factors – including starting blood-pressure-lowering, lipid-lowering, or 
anti-diabetic medications, stopping cigarette smoking, or reducing BMI from 25 kg/m2 or 
greater to under 25 kg/m2 –showed non-significant but elevated hazard ratios; this may be 
due to the presence of the associated conditions at or before the time point of assessment and 
not the pure effect of improving adherence to guidelines. We did code the medication 
change-in-adherence indicator variables so that newly diagnosed diabetes, hyperlipidemia, or 
hypertension was incorporated together with change(s) in medication usage, however, such 
coding cannot take into account the severity of the condition, does not measure the duration 
between diagnosis and start of medication usage and, as an effectively “intent-to-treat” 
measure does not incorporate actual medication consumption.  Similarly, removing a risk 
factor such as elevated BMI or cigarette smoking may be associated with risk at least 
temporarily beyond the point at which the risk factor is removed.  Lastly, the finding that 
nonwhite participants who started aspirin or maintained aspirin use between baseline and 
twelve months were at an increased risk of recurrent stroke seems contrary to the findings in 
Chapter III – while likely due to the effect of a relatively small nonwhite cohort in the VISP 
study, this result, taken together with recent reports that aggressive medical therapy is 
preferable to other forms of stroke prevention,(117, 118) may suggest further research into time-
period-specific effects of aspirin use in nonwhite stroke survivors.   
There are several limitations to this study.  VISP’s randomization criteria may have 
resulted in a cohort slightly different from the general stroke survivor population (allowing 
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for roughly 7.5% refusals and 4.2% other reasons), as evidenced by the fact that only 
3680/6900 (60%) of screened participants were randomized.  In addition, some 23.3% of the 
VISP study population had had one or more strokes prior to the VISP eligibility stroke, 
which could reduce their comparability to the general stroke population. 112Participants in a 
clinical trial are often more healthy than nonparticipants and more aware of the need to 
modify lifestyle and other behaviors, possibly reinforced by the higher degree of interaction 
(compared with the general population) 109 with medical personnel required for endpoint 
ascertainment.  An assessment of VISP participant vitamin adherence 110 may confirm this – 
6% or fewer consistently had adherence less than 75%, and use of lipid-lowering and blood-
pressure-lowering medications increased over time. Further, VISP did provide “best available 
medical and surgical management to prevent recurrent stroke, which included risk factor 
control education, and, usually, administration of aspirin, 325 mg/d;”9 VISP’s protocol (as 
described on its Stroke Trials Registry web page) specified that risk factor control education 
should be provided for vascular risk factors including: blood pressure, high LDL cholesterol, 
low HDL cholesterol, diabetes, and smoking 
(http://www.strokecenter.org/trials/TrialDetail.aspx?tid=37). There were relatively few 
nonwhites in the VISP population cohort; consequently, it is not clear whether our results can 
be generalized to the nonwhite stroke survivor population.  However, the relatively small 
degree of change in risk factors such as BMI seen in Table 4.2 suggest that on average VISP 
participants, with regard to exposure, were not so different from the general stroke 
population 39 or that clinicians’ ability to achieve greater degrees of change required more 
than six months (possibly confirmed by the slightly larger changes in risk factors between 
baseline and the twelve month clinic visit). Our ability to detect a significant difference in 
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recurrent stroke risk between levels of change assessed over six months may have been 
limited by the relatively small degree and relatively balanced nature of the changes seen in 
Tables 4.2 and 4.3 for both the six-month and twelve-month periods; however, VISP only 
had clinic visits at six month intervals, and we therefore chose the six- and twelve-month 
intervals to minimize the number of strokes needing to be censored and to maximize the risk 
of stroke (per the results seen by Hardiee and colleagues). 31  “At-risk” intervals of six or 
twelve months and VISP’s standard two years of follow-up may not have corresponded with 
the latency periods of improvements in medication or risk factor adherence, thus reducing the 
chances of observing the greatest effect on recurrent stroke risk. Lastly, an assessment of 
univariate post-hoc statistical power (Table 4.13) suggests that on average we had a 53% 
power for medication adherence factors (other than anti-diabetic medications) and a 61% 
power for continuous risk adherence factors to detect a significant difference in recurrent 
stroke risk. 
The use of the VISP study cohort also provided several strengths.  As a clinical trial 
of stroke, all participants were required to have at least one verified ischemic stroke to be 
included in the cohort; in addition, clinical trial standards ensured higher standards of 
exposure data verification and (especially) outcome assessment, a more complete and 
carefully collected array of information collected as part of the test of the study hypothesis, 
reduction of possible recall bias, standardized training of study personnel to ensure minimal 
variation in data collection, and the repeat measures of risk factor data obtained using the 
same standards at the same time intervals. VISP also provided a high degree of completed 
follow-up visits (more than 75% of participants completed all follow-up visits and 88.8% of 
participants had both a baseline and six-month visit). The choice of study population was 
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therefore essentially a trade-off between internal and external validity; the VISP cohort was 
chosen to maximize internal validity.   
In conclusion, we found that lack of adherence to medication guidelines, particularly 
for aspirin and anti-diabetic medications, maintaining a BMI greater than or equal to 25 
kg/m2, or being of nonwhite ancestry (for those using or starting aspirin use over the year 
following stroke) was associated with a statistically significant risk of recurrent stroke. Our 
inability to detect significant differences for improvements in adherence for other 
medications or for continuous risk factor adherence (such as systolic blood pressure or total 
cholesterol) may have resulted from the relatively small numbers of uncensored recurrent 
strokes and a lack of statistical power, but perhaps these results may provide suggestions for 
further research into recurrent stroke reduction.   
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TABLES 
Table 4.1. Definitions of medication adherence variables (except aspirin) 
Condition 
status at 
baseline 
(present, 
not 
present) 
Medication 
status at 
baseline 
(present, not 
present) 
Condition 
status at 
follow-up 
visit 
(present, 
not 
present) 
Medication 
status at 
follow-up 
visit (present, 
not present) 
Adherence variable code and 
status 
Not present Not applicable Not present Not applicable 0 (Not needed) 
Present Present Present Present 0 (Used medication , both visits) 
Present Present Present Not present 2 (Stopped use  between visits) 
Present Not present Present Present 1 (Started use between visits) 
Present Not present Present Not present 2 (Never used) 
Not present Not present Present Present 0 (Used medication at follow-up) 
Not present Not present Present Not present 2 (Didn’t use at follow-up) 
Table 4.2.  Description of study population (N=2739), risk factors, and change in risk 
factors at or between baseline and six-month visits, with counts of recurrent stroke 
Risk factor Risk factor level Baseline 
Stroke=N
(N (%)
or 
mean  
(SD)) 
Baseline 
Stroke=Y
(N (%)
or 
mean  
(SD)) 
Six 
months 
Stroke=N
(N (%)
or 
mean  
(SD)) 
Six 
months 
Stroke=Y 
(N (%) 
or 
mean  
(SD)) 
Change, 
baseline 
to six 
months 
Stroke=N 
(N (%)) 
Change,
baseline
to six 
months
Stroke=Y
(N (%)) 
Age (years)  66 (10.7) 68 (10.8) 67 (10.7) 69 (10.8)  
Nonwhite race No 2103 (81) 97 (73)   
 Yes 504 (19) 35 (27)   
Male gender No 981 (38) 52 (39)   
 Yes 1626 (62) 80 (61)   
Aspirin use Not using 1013 (39) 49 (37) 1067 (41) 52 (39)  
 Using 1594 (61) 83 (63) 1540 (59) 80 (61)  
 Maintained use 
between time points 
 1358 (52) 73 (55)
 Started using between 
time points 
 182 (7) 7 (5)
 Stopped using 
between time points 
or never used 
 1067 (41) 52 (39)
BMI (kg/m2) < 25 737 (28) 32 (24) 737 (28) 32 (24)  
 >=25 1870 (72) 100 (76) 1870 (72) 100 (76)  
 Stayed <25  656 (25) 29 (22)
 Change >=25 to <25  81 (3) 3 (2)
 Change <25 to >=25  81 (3) 3 (2)
 Stayed >=25  1789 (69) 97 (73)
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Risk factor Risk factor level Baseline 
Stroke=N
(N (%)
or 
mean  
(SD)) 
Baseline 
Stroke=Y
(N (%)
or 
mean  
(SD)) 
Six 
months 
Stroke=N
(N (%)
or 
mean  
(SD)) 
Six 
months 
Stroke=Y 
(N (%) 
or 
mean  
(SD)) 
Change, 
baseline 
to six 
months 
Stroke=N 
(N (%)) 
Change,
baseline
to six 
months
Stroke=Y
(N (%)) 
Current cigarette 
smoker 
Not using 2163 (83) 114 (86) 2168 (83) 115 (87)  
 Using 444 (17) 18 (14) 439 (17) 17 (13)  
 Did not use at either 
time point 
 2090 (80) 111 (84)
 Stopped using 
between time points 
 78 (3) 4 (3)
 Started using between 
time points or kept 
using 
 439 (17) 17 (13)
Anti-diabetic med 
use 
Need/not using 105 (4) 15 (11) 117 (4) 17 (13)  
 Need/using 647 (25) 41 (31) 650 (25) 41 (31)  
 Not needed 1855 (71) 76 (58) 1840 (71) 74 (56)  
 Maintained use 
between time points 
 2461 (94) 114 (86)
 Started using between 
time points 
 29 (1) 1 (1)
 Stopped using 
between time points 
or never used 
 117 (4) 17 (13)
Blood-pressure-
lowering med use 
Need/not using 636 (24) 42 (32) 781 (30) 39 (30)  
 Need/using 1254 (48) 65 (49) 1390 (53) 78 (59)  
 Not needed 717 (28) 25 (19) 436 (17) 15 (11)  
 Maintained use 
between time points 
 1695 (65) 83 (63)
 Started using between 
time points 
 131 (5) 10 (8)
 Stopped using 
between time points 
or never used 
 781 (30) 39 (30)
Lipid-lowering 
med use 
Need/not using 723 (28) 38 (29) 740 (28) 41 (31)  
 Need/using 1154 (44) 57 (43) 1282 (49) 62 (47)  
 Not needed 730 (28) 37 (28) 585 (22) 29 (22)  
 Maintained use 
between time points 
 1715 (66) 88 (67)
 Started using between 
time points 
 152 (6) 3 (2)
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Risk factor Risk factor level Baseline 
Stroke=N
(N (%)
or 
mean  
(SD)) 
Baseline 
Stroke=Y
(N (%)
or 
mean  
(SD)) 
Six 
months 
Stroke=N
(N (%)
or 
mean  
(SD)) 
Six 
months 
Stroke=Y 
(N (%) 
or 
mean  
(SD)) 
Change, 
baseline 
to six 
months 
Stroke=N 
(N (%)) 
Change,
baseline
to six 
months
Stroke=Y
(N (%)) 
 Stopped using 
between time points 
or never used 
 740 (28) 41 (31)
SBP (mmHg) <120 314 (12) 17 (13) 307 (12) 10 (8)  
 >=120 2293 (88) 115 (87) 2300 (88) 122 (92)  
 Stayed <120  113 (4) 5 (4)
 Change >=120 to 
<120 
 194 (7) 5 (4)
 Change <120 to 
>=120 
 201 (8) 12 (9)
 Stayed >=120  2099 (81) 110 (83)
TC (mg/dl) <200 1331 (51) 60 (45) 1409 (54) 69 (52)  
 >=200 1276 (49) 72 (55) 1198 (46) 63 (48)  
 Stayed <200  1207 (46) 56 (42)
 Change >=200 to 
<200 
 202 (8) 13 (10)
 Change <200 to 
>=200 
 124 (5) 4 (3)
 Stayed >=200  1074 (41) 59 (45)
 
Table 4.3.  Description of study population (N=2750), risk factors, and change in risk 
factors at or between baseline and twelve-month visits, with counts of recurrent 
stroke 
Risk factor Risk factor level Baseline 
Stroke=N
(N (%)
or 
mean  
(SD)) 
Baseline 
Stroke=Y
(N (%)
or 
mean 
 (SD)) 
Twelve
months
Stroke=N
(N (%)
or 
mean 
 (SD)) 
Twelve 
months 
Stroke=Y 
(N (%) 
or 
mean 
 (SD)) 
Change, 
baseline 
to twelve 
months 
Stroke=N 
(N (%)) 
Change,
baseline
to twelve
months 
Stroke=Y
(N (%)) 
Age (years)  67 (10.6) 70 (9.4) 68 (10.6) 71 (9.4)  
Nonwhite race No 2192 (82) 54 (70)   
 Yes 481 (18) 23 (30)   
Male gender No 990 (37) 31 (40)   
 Yes 1683 (63) 46 (60)   
Aspirin use Not using 1046 (39) 21 (27) 1106 (41) 26 (34)  
 Using 1627 (61) 56 (73) 1567 (59) 51 (66)  
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Risk factor Risk factor level Baseline 
Stroke=N
(N (%)
or 
mean  
(SD)) 
Baseline 
Stroke=Y
(N (%)
or 
mean 
 (SD)) 
Twelve
months
Stroke=N
(N (%)
or 
mean 
 (SD)) 
Twelve 
months 
Stroke=Y 
(N (%) 
or 
mean 
 (SD)) 
Change, 
baseline 
to twelve 
months 
Stroke=N 
(N (%)) 
Change,
baseline
to twelve
months 
Stroke=Y
(N (%)) 
 Maintained use 
between time points 
 1331 (50) 47 (61)
 Started using between 
time points 
 236 (9) 4 (5)
 Stopped using 
between time points 
or never used 
 1106 (41) 26 (34)
BMI (kg/m2) < 25 755 (28) 16 (21) 758 (28) 16 (21)  
 >=25 1918 (72) 61 (79) 1915 (72) 61 (79)  
 Stayed <25  645 (24) 14 (18)
 Change >=25 to <25  113 (4) 2 (3)
 Change <25 to >=25  110 (4) 2 (3)
 Stayed >=25  1805 (68) 59 (77)
Current cigarette 
smoker 
Not using 2236 (84) 69 (90) 2235 (84) 68 (88)  
 Using 437 (16) 8 (10) 438 (16) 9 (12)  
 Did not use at either 
time point 
 2140 (80) 66 (86)
 Stopped using 
between time points 
 95 (4) 2 (3)
 Started using between 
time points or kept 
using 
 438 (16) 9 (12)
Anti-diabetic med 
use 
Need/not using 112 (4) 6 (8) 135 (5) 5 (6)  
 Need/using 662 (25) 22 (29) 677 (25) 23 (30)  
 Not needed 1899 (71) 49 (64) 1861 (70) 49 (64)  
 Maintained use 
between time points 
 2511 (94) 69 (90)
 Started using between 
time points 
 27 (1) 3 (4)
 Stopped using 
between time points 
or never used 
 135 (5) 5 (6)
Blood-pressure-
lowering med use 
Need/not using 642 (24) 27 (35) 877 (33) 29 (38)  
 Need/using 1296 (48) 41 (53) 1451 (54) 47 (61)  
 Not needed 735 (27) 9 (12) 345 (13) 1 (1)  
 Maintained use 
between time points 
 1642 (61) 41 (53)
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Risk factor Risk factor level Baseline 
Stroke=N
(N (%)
or 
mean  
(SD)) 
Baseline 
Stroke=Y
(N (%)
or 
mean 
 (SD)) 
Twelve
months
Stroke=N
(N (%)
or 
mean 
 (SD)) 
Twelve 
months 
Stroke=Y 
(N (%) 
or 
mean 
 (SD)) 
Change, 
baseline 
to twelve 
months 
Stroke=N 
(N (%)) 
Change,
baseline
to twelve
months 
Stroke=Y
(N (%)) 
 Started using between 
time points 
 154 (6) 7 (9)
 Stopped using 
between time points 
or never used 
 877 (33) 29 (38)
Lipid-lowering 
med use 
Need/not using 752 (28) 26 (34) 828 (31) 23 (30)  
 Need/using 1164 (44) 30 (39) 1361 (51) 39 (51)  
 Not needed 757 (28) 21 (27) 484 (18) 15 (19)  
 Maintained use 
between time points 
 1635 (61) 47 (61)
 Started using between 
time points 
 210 (8) 7 (9)
 Stopped using 
between time points 
or never used 
 828 (31) 23 (30)
SBP (mmHg) <120 313 (12) 8 (10) 326 (12) 4 (5)  
 >=120 2360 (88) 69 (90) 2347 (88) 73 (95)  
 Stayed <120  115 (4) 1 (1)
 Change >=120 to 
<120 
 211 (8) 3 (4)
 Change <120 to 
>=120 
 198 (7) 7 (9)
 Stayed >=120  2149 (80) 66 (86)
TC (mg/dl) <200 1376 (51) 34 (44) 1589 (59) 44 (57)  
 >=200 1297 (49) 43 (56) 1084 (41) 33 (43)  
 Stayed <200  1096 (41) 29 (38)
 Change >=200 to 
<200 
 493 (18) 15 (19)
 Change <200 to 
>=200 
 280 (10) 5 (6)
 Stayed >=200  804 (30) 28 (36)
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Table 4.4. Minimum and maximum counts of substituted risk factor values, by age, 
race, gender, and stroke outcome, for baseline-to-six-months dataset  
 
Group Level Risk factor with smallest count N (%) Risk factor with largest count N (%) 
Age at 6 
months  
< median Current cig smoker baseline 1 (0.07) BP lowering med use 6 month 43 (3.13)
 >= median Current cig smoker baseline 1 (0.07) BP lowering med use 6 month 66 (4.83)
Stroke No Current cig smoker baseline 2 (0.08) BP lowering med use 6 month 101 (4)
 Yes Anti-DM med use baseline 1 (0.47) BP lowering med use 6 month 12 (5.58)
Gender Female Current cig smoker baseline 1 (0.1) BP lowering med use 6 month 52 (5.03)
 Male BMI baseline 1 (0.06) BP lowering med use 6 month 57 (3.34)
Race White Current cig smoker 6 month 1 (0.05) BP lowering med use 6 month 94 (4.27)
 Nonwhite Current cig smoker 6 month 1 (0.19) BP lowering med use 6 month 23 (4.27)
 
Table 4.5. Minimum and maximum counts of substituted risk factor values, by age, 
race, gender, and stroke outcome, for baseline-to-twelve-months dataset  
 
Group Level 
Risk factor with smallest 
count N (%) Risk factor with largest count N (%) 
Age at 12 
months 
< median Current cig smoker baseline 1 (0.07) BP lowering med use 12 month 45 (3.26)
 >= median Current cig smoker baseline 1 (0.07) BP lowering med use 12 month 60 (4.38)
Stroke No Current cig smoker 12 month 1 (0.04) BP lowering med use 12 month 94 (3.69)
 Yes Anti-DM med use baseline 1 (0.49) BP lowering med use 12 month 11 (5.39)
Gender Female Current cig smoker baseline 1 (0.1) BP lowering med use 12 month 37 (3.62)
 Male Current cig smoker baseline 1 (0.06) BP lowering med use 12 month 68 (3.93)
Race White Current cig smoker baseline 2 (0.09) BP lowering med use 12 month 77 (3.43)
 Nonwhite Anti-DM med use baseline 1 (0.2) BP lowering med use 12 month 28 (5.56)
 
Table 4.6. Frequencies of trimmed values, by interval variable, baseline to six months 
 
Variable Trim status Baseline (N (%)) Six months (N (%)) 
Weight [kg] Trimmed to mean – 1SD 19 (0.69) 13 (0.47)
Weight [kg] Not trimmed 2712 (99.01) 2712 (99.01)
Weight [kg] Trimmed to mean + 1SD 8 (0.29) 14 (0.51)
Total cholesterol [mg/dl] Trimmed to mean – 1SD 11 (0.4) 0 (0.00)
Total cholesterol [mg/dl] Not trimmed 2719 (99.27) 2739 (100)
Total cholesterol [mg/dl] Trimmed to mean + 1SD 9 (0.33) 0 (0.00)
Systolic BP [mmHg] Trimmed to mean – 1SD 13 (0.47) 18 (0.66)
Systolic BP [mmHg] Not trimmed 2706 (98.8) 2697 (98.47)
Systolic BP [mmHg] Trimmed to mean + 1SD 20 (0.73) 24 (0.88)
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Table 4.7. Frequencies of trimmed values, by interval variable, baseline to twelve 
months 
 
Variable Trim status Baseline (N (%)) Twelve months (N (%)) 
Weight [kg] Trimmed to mean – 1SD 22 (0.8) 19 (0.69)
Weight [kg] Not trimmed 2717 (98.8) 2718 (98.84)
Weight [kg] Trimmed to mean + 1SD 11 (0.4) 13 (0.47)
Total cholesterol [mg/dl] Trimmed to mean – 1SD 13 (0.47) 11 (0.4)
Total cholesterol [mg/dl] Not trimmed 2728 (99.2) 2726 (99.13)
Total cholesterol [mg/dl] Trimmed to mean + 1SD 9 (0.33) 13 (0.47)
Systolic BP [mmHg] Trimmed to mean – 1SD 14 (0.51) 18 (0.65)
Systolic BP [mmHg] Not trimmed 2716 (98.76) 2711 (98.58)
Systolic BP [mmHg] Trimmed to mean + 1SD 20 (0.73) 21 (0.76)
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Table 4.8. Incidence of recurrent stroke (per 100 person-years) by baseline risk factor 
levels and change in risk factors between baseline and six months (for analysis results 
shown in Tables 4.10 and 4.12) 
 
Variable 
Change 
or 
level Strokes
Follow-up time
(years) 
Stroke rate 
(per 100 py) 
Incidence rate
ratio (95% CI) 
Male gender Yes 80 2196.46 3.64 0.93 (0.66, 1.32)
 No 52 1322.84 3.93 
Nonwhite race Yes 35 660.95 5.30 1.56 (1.06, 2.30)
 No 97 2858.35 3.39 
Aspirin use at baseline Yes 83 2171.87 3.82 1.05 (0.74, 1.49)
 No 49 1347.43 3.64 
Aspirin use change Started using 7 244.62 2.86 0.73 (0.34, 1.59)
 Used at both time points 73 1863.46 3.92 
 Stopped use/never used 52 1411.22 3.68 0.94 (0.66, 1.34)
 Used at both time points 73 1863.46 3.92 
BMI at baseline >= 
median 
Yes 73 1745.10 4.18 1.26 (0.89, 1.78)
 No 59 1774.20 3.33 
Change in BMI Change >=25 to <25 3 109.17 2.75 0.84 (0.26, 2.76)
 Stayed <25 29 885.53 3.27 
 Change <25 to >=25 3 106.25 2.82 0.86 (0.26, 2.82)
 Stayed <25 29 885.53 3.27 
 Stayed >=25 97 2418.35 4.01 1.23 (0.81, 1.86)
 Stayed <25 29 885.53 3.27 
Current cigarette 
smoker at baseline 
Yes 18 585.25 3.08 0.79 (0.48, 1.30)
 No 114 2934.05 3.89 
Change in smoking Stopped using 4 101.03 3.96 1.01 (0.37, 2.74)
 Did not use at either time 
point 
111 2831.93 3.92 
 Started using/kept using 17 586.34 2.90 0.74 (0.44, 1.23)
 Did not use at either time 
point 
111 2831.93 3.92 
Blood-pressure-
lowering med use at 
baseline 
Needed and used 65 1653.78 3.93 1.55 (0.98, 2.46)
 Not needed 25 988.35 2.53 
 Needed/not used 42 877.17 4.79 1.89 (1.15, 3.10)
 Not needed 25 988.35 2.53 
Blood-pressure-
lowering med use 
change 
Med needed - started using 10 176.92 5.65 1.54 (0.80, 2.97)
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Variable 
Change 
or 
level Strokes
Follow-up time
(years) 
Stroke rate 
(per 100 py) 
Incidence rate
ratio (95% CI) 
 Med needed/used or not 
needed 
83 2268.51 3.66 
 Med needed - stopped 
use/never used 
39 1073.86 3.63 0.99 (0.68, 1.45)
 Med needed/used or not 
needed 
83 2268.51 3.66 
Anti-DM med use at 
baseline 
Needed and used 41 866.05 4.73 1.56 (1.07, 2.28)
 Not needed 76 2509.01 3.03 
 Needed/not used 15 144.24 10.40 3.43 (1.97, 5.97)
 Not needed 76 2509.01 3.03 
Anti-DM med use 
change 
Med needed - started using 1 38.06 2.63 0.77 (0.11, 5.51)
 Med needed/used or not 
needed 
114 3321.75 3.43 
 Med needed - stopped 
use/never used 
17 159.49 10.66 3.11 (1.87, 5.18)
 Med needed/used or not 
needed 
114 3321.75 3.43 
Lipid-lowering med use 
at baseline 
Needed and used 57 1542.52 3.70 0.98 (0.65, 1.48)
 Not needed 37 979.30 3.78 
 Needed/not used 38 997.47 3.81 1.01 (0.64, 1.59)
 Not needed 37 979.30 3.78 
Change in lipid-
lowering med use 
Med needed - started using 3 208.23 1.44 0.38 (0.12, 1.20)
 Med needed/used or not 
needed 
88 2300.97 3.82 
 Med needed - stopped 
use/never used 
41 1010.10 4.06 1.06 (0.73, 1.54)
 Med needed/used or not 
needed 
88 2300.97 3.82 
SBP [mmHg] at 
baseline >= median 
Yes 74 1802.03 4.11 1.22 (0.87, 1.72)
 No 58 1717.27 3.38 
Change in SBP Change >=120 to <120 5 258.88 1.93 0.56 (0.16, 1.93)
 Stayed <120 5 144.37 3.46 
 Change <120 to >=120 12 268.51 4.47 1.29 (0.45, 3.66)
 Stayed <120 5 144.37 3.46 
 Stayed >=120 110 2847.54 3.86 1.12 (0.46, 2.74)
 Stayed <120 5 144.37 3.46 
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Variable 
Change 
or 
level Strokes
Follow-up time
(years) 
Stroke rate 
(per 100 py) 
Incidence rate
ratio (95% CI) 
TC [mgdl] at baseline 
>= median 
Yes 75 1795.83 4.18 1.26 (0.89, 1.78)
 No 57 1723.47 3.31 
Change in TC Change >=200 to <200 13 277.84 4.68 1.34 (0.73, 2.45)
 Stayed <200 56 1606.13 3.49 
 Change <200 to >=200 4 164.99 2.42 0.69 (0.25, 1.90)
 Stayed <200 56 1606.13 3.49 
 Stayed >=200 59 1470.33 4.01 1.15 (0.80, 1.66)
 Stayed <200 56 1606.13 3.49 
 
Table 4.9. Incidence of recurrent stroke (per 100 person-years) by baseline risk factor 
levels and change in risk factors between baseline and twelve months (for analysis 
results shown in Table 4.11 and 4.12)  
 
Variable 
Change 
or 
level Strokes
Follow-up time
(years) 
Stroke rate 
(per 100 py) 
Incidence rate
ratio (95% CI) 
Male gender Yes 46 1464.84 3.14 0.87 (0.55, 1.37)
 No 31 859.62 3.61 
Nonwhite race Yes 23 411.13 5.59 1.98 (1.22, 3.23)
 No 54 1913.33 2.82 
Aspirin use at baseline Yes 56 1427.79 3.92 1.68 (1.02, 2.77)
 No 21 896.68 2.34 
Aspirin use change Started using 4 204.53 1.96 0.49 (0.18, 1.36)
 Used at both time points 47 1181.76 3.98 
 Stopped use/never used 26 938.18 2.77 0.70 (0.43, 1.13)
 Used at both time points 47 1181.76 3.98 
BMI at baseline >= 
median 
Yes 47 1154.10 4.07 1.59 (1.01, 2.51)
 No 30 1170.36 2.56 
Change in BMI Change >=25 to <25 2 100.26 1.99 0.80 (0.18, 3.52)
 Stayed <25 14 563.30 2.49 
 Change <25 to >=25 2 95.13 2.10 0.84 (0.19, 3.70)
 Stayed <25 14 563.30 2.49 
 Stayed >=25 59 1565.77 3.77 1.51 (0.84, 2.70)
 Stayed <25 14 563.30 2.49 
Current cigarette 
smoker at baseline 
Yes 8 376.06 2.13 0.60 (0.29, 1.25)
 No 69 1948.40 3.54 
Change in smoking Stopped using 2 81.73 2.45 0.69 (0.17, 2.82)
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Variable 
Change 
or 
level Strokes
Follow-up time
(years) 
Stroke rate 
(per 100 py) 
Incidence rate
ratio (95% CI) 
 Did not use at either time 
point 
66 1863.39 3.54 
 Started using/kept using 9 379.35 2.37 0.67 (0.33, 1.34)
 Did not use at either time 
point 
66 1863.39 3.54 
Blood-pressure-
lowering med use at 
baseline 
Needed and used 41 1098.11 3.73 2.74 (1.33, 5.64)
 Not needed 9 659.79 1.36 
 Needed/not used 27 566.56 4.77 3.51 (1.65, 7.46)
 Not needed 9 659.79 1.36 
Blood-pressure-
lowering med use 
change 
Med needed - started using 7 132.99 5.26 1.80 (0.81, 4.01)
 Med needed/used or not 
needed 
41 1406.47 2.92 
 Med needed - stopped 
use/never used 
29 785.01 3.69 1.26 (0.78, 2.03)
 Med needed/used or not 
needed 
41 1406.47 2.92 
Anti-DM med use at 
baseline 
Needed and used 22 572.26 3.84 1.30 (0.79, 2.15)
 Not needed 49 1653.46 2.96 
 Needed/not used 6 98.74 6.08 2.05 (0.88, 4.79)
 Not needed 49 1653.46 2.96 
Anti-DM med use 
change 
Med needed - started using 3 26.60 11.28 3.57 (1.12, 11.34)
 Med needed/used or not 
needed 
69 2184.70 3.16 
 Med needed - stopped 
use/never used 
5 113.17 4.42 1.40 (0.56, 3.47)
 Med needed/used or not 
needed 
69 2184.70 3.16 
Lipid-lowering med use 
at baseline 
Needed and used 30 997.31 3.01 0.94 (0.54, 1.64)
 Not needed 21 658.26 3.19 
 Needed/not used 26 668.90 3.89 1.22 (0.69, 2.17)
 Not needed 21 658.26 3.19 
Change in lipid-
lowering med use 
Med needed - started using 7 188.90 3.71 1.12 (0.51, 2.48)
 Med needed/used or not 
needed 
47 1415.09 3.32 
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Variable 
Change 
or 
level Strokes
Follow-up time
(years) 
Stroke rate 
(per 100 py) 
Incidence rate
ratio (95% CI) 
 Med needed - stopped 
use/never used 
23 720.47 3.19 0.96 (0.58, 1.58)
 Med needed/used or not 
needed 
47 1415.09 3.32 
SBP [mmHg] at 
baseline >= median 
Yes 52 1175.12 4.43 2.03 (1.26, 3.27)
 No 25 1149.35 2.18 
Change in SBP Change >=120 to <120 3 176.19 1.70 1.63 (0.17, 15.67)
 Stayed <120 1 96.54 1.04 
 Change <120 to >=120 7 167.73 4.17 4.01 (0.49, 32.59)
 Stayed <120 1 96.54 1.04 
 Stayed >=120 66 1884.00 3.50 3.37 (0.47, 24.28)
 Stayed <120 1 96.54 1.04 .
TC [mgdl] at baseline 
>= median 
Yes 44 1177.85 3.74 1.30 (0.83, 2.04)
 No 33 1146.61 2.88 .
Change in TC Change >=200 to <200 15 435.37 3.45 1.11 (0.60, 2.07)
 Stayed <200 29 936.29 3.10 .
 Change <200 to >=200 5 240.12 2.08 0.67 (0.26, 1.73)
 Stayed <200 29 936.29 3.10 .
 Stayed >=200 28 712.68 3.93 1.27 (0.76, 2.13)
 Stayed <200 29 936.29 3.10 .
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Table 4.10. Adjusted hazard ratios and 95% CI for change in medication adherence 
assessed over the first six months post-stroke, stratified by aspirin use 
 
Risk factor Level Used aspirin at 
both time 
points or 
started between 
time points 
HR (95% CI) 
Stopped aspirin 
use between time 
points or never 
used 
HR (95% CI) 
Age at end of period 
(per 10.54 SDU‡) 
(Not applicable) 1.29 (1.01, 1.66) 1.13 (0.84, 1.53)
Male gender (Not applicable) 1.20 (0.75, 1.91) 0.75 (0.43, 1.30)
Nonwhite ancestry (Not applicable) 1.60 (0.95, 2.69) 1.39 (0.74, 2.61)
Anti-diabetic 
medication use 
Started using between time points 1.18 (0.16, 8.59) 0.00 (0.00, 0.00)
 Stopped using between time points/never used 1.64 (0.71, 3.80) 5.12 (2.55, 10.27)
Lipid-lowering 
medication use 
Started using between time points 0.68 (0.21, 2.21) 0.00 (0.00, 0.00)
 Stopped using between time points/never used 1.04 (0.64, 1.69) 1.10 (0.60, 2.01)
Blood-pressure-
lowering medication 
use 
Started using between time points 1.35 (0.54, 3.40) 2.15 (0.83, 5.57)
 Stopped using between time points/never used 0.95 (0.58, 1.54) 0.94 (0.49, 1.78)
BMI (kg/m2) Changed from >=25 to < 25 between time 
points 
0.37 (0.05, 2.80) 1.62 (0.35, 7.46)
 Changed from <25 to >= 25 between time 
points 
0.78 (0.18, 3.36) 0.94 (0.12, 7.45)
 Stayed >=25 between time points 1.18 (0.70, 2.00) 1.22 (0.60, 2.51)
Current cigarette 
smoker 
Stopped using between time points 0.53 (0.07, 3.87) 1.90 (0.56, 6.43)
 Started or kept using between time points  0.55 (0.26, 1.16) 1.31 (0.61, 2.82)
‡ Age was standardized by dividing the value for an individual at a given time point by the standard deviation of the 
population at the baseline visit. 
 
Table 4.11. Adjusted hazard ratios and 95% CI for change in medication adherence 
assessed over the first twelve months post-stroke, stratified by aspirin use 
 
Risk factor Level Used aspirin at 
both time points 
or started 
between time 
points 
HR (95% CI) 
Stopped use of 
aspirin between 
time points or 
never used 
HR (95% CI) 
Age at end of period (per 
10.54 SDU‡) 
(Not applicable) 1.63 (1.18, 2.25) 1.52 (0.96, 2.40)
Male gender (Not applicable) 1.25 (0.70, 2.26) 0.63 (0.28, 1.40)
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Risk factor Level Used aspirin at 
both time points 
or started 
between time 
points 
HR (95% CI) 
Stopped use of 
aspirin between 
time points or 
never used 
HR (95% CI) 
Nonwhite ancestry (Not applicable) 2.41 (1.30, 4.50) 1.83 (0.74, 4.52)
Anti-diabetic medication use Started using between time points 1.71 (0.23, 12.58) 5.04 (1.11, 22.92)
 Stopped using between time 
points/never used 
1.13 (0.35, 3.68) 1.74 (0.40, 7.49)
Lipid-lowering medication 
use 
Started using between time points 1.52 (0.63, 3.69) 0.56 (0.07, 4.29)
 Stopped using between time 
points/never used 
0.90 (0.48, 1.68) 1.00 (0.42, 2.39)
Blood-pressure-lowering 
medication use 
Started using between time points 1.52 (0.53, 4.36) 2.58 (0.71, 9.33)
 Stopped using between time 
points/never used 
1.14 (0.63, 2.06) 1.55 (0.66, 3.64)
BMI (kg/m2) Changed from >=25 to < 25 between 
time points 
0.39 (0.05, 2.98) 4.28 (0.38, 47.70)
 Changed from <25 to >= 25 between 
time points 
0.98 (0.22, 4.40) 0.00 (0.00, 0.00)
 Stayed >=25 between time points 1.22 (0.62, 2.40) 4.41 (1.02, 18.95)
Current cigarette smoker Stopped using between time points 0.00 (0.00, 0.00) 2.19 (0.46, 10.46)
 Started or kept using between time 
points  
0.77 (0.32, 1.85) 1.20 (0.33, 4.34)
‡ Age was standardized by dividing the value for an individual at a given time point by the standard deviation of the 
population at the baseline visit. 
 
 
Table 4.12. Adjusted hazard ratios and 95% CI for change in adherence to systolic 
blood pressure and total cholesterol guidelines assessed over the first six months post-
stroke and over the first twelve months post-stroke 
 
Risk factor Level Baseline to six 
months 
HR (95% CI) 
Baseline to 
twelve months 
HR (95% CI) 
Age at end of period (per 
10.54 SDU‡) 
(Not applicable) 1.23 (1.02, 1.49) 1.61 (1.23, 2.10)
Male gender (Not applicable) 1.02 (0.71, 1.46) 1.01 (0.64, 1.62)
Nonwhite ancestry (Not applicable) 1.70 (1.14, 2.53) 2.35 (1.42, 3.89)
BMI (kg/m2) Changed from >=25 to < 25 between time 
points 
0.85 (0.26, 2.79) 0.84 (0.19, 3.70)
 Changed from <25 to >= 25 between time 
points 
0.87 (0.26, 2.85) 0.88 (0.20, 3.87)
 Stayed >=25 between time points 1.24 (0.81, 1.89) 1.65 (0.91, 3.00)
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Risk factor Level Baseline to six 
months 
HR (95% CI) 
Baseline to 
twelve months 
HR (95% CI) 
Current cigarette smoker Stopped using between time points 1.10 (0.40, 3.03) 0.86 (0.21, 3.57)
 Started or kept using between time points 0.81 (0.48, 1.37) 0.90 (0.44, 1.84)
SBP (mmHg) Changed from >=120 to <120 between 
time points 
0.52 (0.15, 1.79) 1.42 (0.15, 13.66)
 Changed from <120 to >=120 between 
time points 
1.15 (0.40, 3.29) 3.49 (0.43, 28.44)
 Stayed >=120 between time points 0.93 (0.38, 2.31) 2.51 (0.35, 18.13)
TC (mg/dl) Changed from >=200 to <200 between 
time points 
1.40 (0.77, 2.57) 1.22 (0.65, 2.28)
 Changed from <200 to >=200 between 
time points 
0.71 (0.26, 1.95) 0.71 (0.28, 1.85)
 Stayed >=200 between time points 1.18 (0.81, 1.71) 1.29 (0.76, 2.20)
‡ Age was standardized by dividing the value for an individual at a given time point by the standard deviation of the 
population at the baseline visit. 
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Table 4.13. Statistical power results (α set to 0.05, two-sided) for models shown in 
Tables 4.10, 4.11, and 4.12 (maximum power (less than 1.00)=0.86, minimum=0.05) 
 
Stratification 
Level Risk Factor 
Reference 
level 
Count 
Level 
of 
interest
Count 
Accrual
time 
Follow- 
up 
time 
Total
time 
HR 
(95% CI) Power
Baseline to six 
months 
medication 
adherence 
model - started 
or kept using 
aspirin  
BMI  >=25 to < 25 413 57 257 539 796 0.37 (0.05, 2.80) 0.999
BMI  <25 to >= 25 413 53 257 543 800 0.78 (0.18, 3.36) 0.246
BMI  >=25 to >=25 413 1097 257 539 796 1.18 (0.70, 2.00) 0.972
Current cig smoker, 
stopped using 
1290 45 256 539 795 0.53 (0.07, 3.87) 0.830
Current cig smoker, 
started/kept using 
1290 285 256 541 797 0.55 (0.26, 1.16) 1.000
Anti-DM med use, 
started using 
1529 15 262 542 804 1.18 (0.16, 8.59) 0.074
Anti-DM med use, 
stopped 
using/never used 
1529 76 256 539 795 1.64 (0.71, 3.80) 0.847
Blood-pressure-
lowering med use, 
started using 
1033 79 255 539 794 1.35 (0.54, 3.40) 0.464
Blood-pressure-
lowering med use, 
stopped 
using/never used 
1033 508 255 541 796 0.95 (0.58, 1.54) 0.129
Lipid-lowering 
med use  started 
using 
1043 94 255 541 796 0.68 (0.21, 2.21) 0.742
Lipid-lowering 
med use  stopped 
using/never used 
1043 483 255 540 795 1.04 (0.64, 1.69) 0.094
Baseline to six 
months 
medication 
adherence 
model – 
stopped using 
or never used 
aspirin 
BMI  >=25 to < 25 272 27 261 543 804 1.62 (0.35, 7.46) 0.411
BMI  <25 to >= 25 272 31 253 536 789 0.94 (0.12, 7.45) 0.057
BMI  >=25 to >=25 272 789 251 540 791 1.22 (0.60, 2.51) 0.976
Current cig smoker, 
stopped using 
911 37 251 541 792 1.90 (0.56, 6.43) 0.759
Current cig smoker, 
started/kept using 
911 171 251 539 790 1.31 (0.61, 2.82) 0.698
Anti-DM med use, 
started using 
1046 15 251 542 793 0.00 (0.00, .) 1.000
Anti-DM med use, 
stopped 
using/never used 
1046 58 251 539 790 5.12 (2.55, 
10.27) 
1.000
Blood-pressure-
lowering med use, 
started using 
745 62 251 539 790 2.15 (0.83, 5.57) 0.982
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Stratification 
Level Risk Factor 
Reference 
level 
Count 
Level 
of 
interest
Count 
Accrual
time 
Follow- 
up 
time 
Total
time 
HR 
(95% CI) Power
Blood-pressure-
lowering med use, 
stopped 
using/never used 
745 312 252 539 791 0.94 (0.49, 1.78) 0.121
Lipid-lowering 
med use  started 
using 
760 61 253 542 795 0.00 (0.00, .) 1.000
Lipid-lowering 
med use  stopped 
using/never used 
760 298 258 540 798 1.10 (0.60, 2.01) 0.213
Baseline to six 
months, 
continuous 
risk factor 
change model 
BMI  >=25 to < 25 685 84 256 538 794 0.85 (0.26, 2.79) 0.183
BMI  <25 to >= 25 685 84 254 541 795 0.87 (0.26, 2.85) 0.147
BMI  >=25 to >=25 685 1886 253 539 792 1.24 (0.81, 1.89) 1.000
Current cig smoker, 
stopped using 
2201 82 254 539 793 1.10 (0.40, 3.03) 0.094
Current cig smoker, 
started/kept using 
2201 456 254 540 794 0.81 (0.48, 1.37) 0.887
Systolic BP, >=120 
to <120 
118 199 256 541 797 0.52 (0.15, 1.79) 1.000
Systolic BP, <120 
to >=120 
118 213 251 540 791 1.15 (0.40, 3.29) 0.302
Systolic BP, >=120 
to >=120 
118 2209 253 539 792 0.93 (0.38, 2.31) 0.674
Total cholesterol  
>=200 to <200 
1263 215 255 539 794 1.40 (0.77, 2.57) 0.932
Total cholesterol  
<200 to >=200 
1263 128 255 542 797 0.71 (0.26, 1.95) 0.774
Total cholesterol  
>=200 to >=200 
1263 1133 255 541 796 1.18 (0.81, 1.71) 0.976
Baseline to 
twelve months 
medication 
adherence 
model - started 
or kept using 
aspirin  
BMI  >=25 to <25 390 76 441 358 799 0.39 (0.05, 2.98) 1.000
BMI  <25 to >=25 390 68 441 361 802 0.98 (0.22, 4.40) 0.052
BMI  >=25 to >=25 390 1084 437 358 795 1.22 (0.62, 2.40) 0.996
Current cig smoker 
, stopped using 
1283 55 438 358 796 0.00 (0.00, .) 1.000
Current cig smoker 
, started/kept using 
1283 280 438 358 796 0.77 (0.32, 1.85) 0.867
Anti-DM med use , 
started using 
1520 15 446 360 806 1.71 (0.23, 
12.58) 
0.299
Anti-DM med use , 
stopped 
using/never used 
1520 83 444 358 802 1.13 (0.35, 3.68) 0.123
Blood-pressure-
lowering med use , 
started using 
981 94 438 357 795 1.52 (0.53, 4.36) 0.806
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Stratification 
Level Risk Factor 
Reference 
level 
Count 
Level 
of 
interest
Count 
Accrual
time 
Follow- 
up 
time 
Total
time 
HR 
(95% CI) Power
Blood-pressure-
lowering med use , 
stopped 
using/never used 
981 543 438 359 797 1.14 (0.63, 2.06) 0.578
Lipid-lowering 
med use  started 
using 
960 132 437 357 794 1.52 (0.63, 3.69) 0.917
Lipid-lowering 
med use  stopped 
using/never used 
960 526 439 359 798 0.90 (0.48, 1.68) 0.400
Baseline to 
twelve months 
medication 
adherence 
model – 
stopped using 
or never used 
aspirin 
BMI  >=25 to <25 269 39 453 358 811 4.28 (0.38, 
47.70) 
1.000
BMI  <25 to >=25 269 44 444 359 803 0.00 (0.00, .) 1.000
BMI  >=25 to >=25 269 780 433 357 790 4.41 (1.02, 
18.95) 
1.000
Current cig smoker 
, stopped using 
923 42 436 362 798 2.19 (0.46, 
10.46) 
0.926
Current cig smoker 
, started/kept using 
923 167 436 357 793 1.20 (0.33, 4.34) 0.383
Anti-DM med use , 
started using 
1060 15 451 357 808 5.04 (1.11, 
22.92) 
0.948
Anti-DM med use , 
stopped 
using/never used 
1060 57 441 357 798 1.74 (0.40, 7.49) 0.820
Blood-pressure-
lowering med use , 
started using 
702 67 439 357 796 2.58 (0.71, 9.33) 0.999
Blood-pressure-
lowering med use , 
stopped 
using/never used 
702 363 433 360 793 1.55 (0.66, 3.64) 1.000
Lipid-lowering 
med use  started 
using 
722 85 441 359 800 0.56 (0.07, 4.29) 0.957
Lipid-lowering 
med use  stopped 
using/never used 
722 325 436 359 795 1.00 (0.42, 2.39) 0.050
Baseline to six 
months, 
continuous 
risk factor 
change model 
BMI  >=25 to <25 659 115 442 358 800 0.84 (0.19, 3.70) 0.261
BMI  <25 to >=25 659 112 442 360 802 0.88 (0.20, 3.87) 0.159
BMI  >=25 to >=25 659 1864 435 358 793 1.65 (0.91, 3.00) 1.000
Current cig   
smoker , stopped 
using 
2206 97 437 358 795 0.86 (0.21, 3.57) 0.182
Current cig   
smoker , 
started/kept using 
2206 447 437 358 795 0.90 (0.44, 1.84) 0.350
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Stratification 
Level Risk Factor 
Reference 
level 
Count 
Level 
of 
interest
Count 
Accrual
time 
Follow- 
up 
time 
Total
time 
HR 
(95% CI) Power
Systolic BP , 
>=120 to <120 
116 214 435 358 793 1.42 (0.15, 
13.66) 
0.948
Systolic BP , <120 
to >=120 
116 205 431 358 789 3.49 (0.43, 
28.44) 
1.000
Systolic BP , 
>=120 to >=120 
116 2215 437 358 795 2.51 (0.35, 
18.13) 
1.000
Total cholesterol 
>=200 to <200 
1125 508 439 358 797 1.22 (0.65, 2.28) 0.884
Total cholesterol 
<200 to >=200 
1125 285 439 358 797 0.71 (0.28, 1.85) 0.982
Total cholesterol 
>=200 to >=200 
1125 832 439 359 798 1.29 (0.76, 2.20) 0.999
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CHAPTER V: DISCUSSION 
 
Recapitulation of overall study aims, findings, and degree to which the goals of the 
doctoral research have been met 
 
Overall Research Questions and Study Aims (from Chapter I) 
This project posed the following three research questions and specific aims: 
 Question 1: Which risk factors influence risk of recurrent ischemic stroke in the VISP 
population? 
 Question 2: Do short-term changes (e.g., six-month) in risk factors after an ischemic 
stroke influence the risk of recurrent ischemic stroke?  
 Question 3: Can repeat assessments of risk factors improve the estimation of risk of 
an ischemic stroke? 
Specific Aim 1 (Research Questions 1 and 2): Develop a robust, well-fit prediction 
equation for recurrent ischemic stroke (using the Andersen-Gill form of the Cox proportional 
hazards approach) which incorporates known invariant risk factors (gender, race/ethnicity, 
age), modifiable risk factors measured at the time of the first stroke and at followup visits 
(e.g., obesity, smoking status, medication use), the sequelae of the first stroke (assessed by 
Rankin, Barthel and Mini-Mental data), and stroke status (first-ever, multiple previous 
strokes). 
Specific Aim 2 (Research Question 3): Develop a “scoring system” based on the validated 
prediction equation which can be used by clinical personnel to optimize patient counseling 
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and care by determining the likely outcomes of differential risk reduction strategies and 
targeting those risk factors which have a larger impact on recurrent stroke risk. 
Study findings 
Specific Aim 1 results 
 
Specific Aim 1 – the creation of a robust well-fit prediction model for recurrent 
ischemic stroke – was accomplished by the development of the models shown in Table 3.9.  
These models – both the clinical and psychoneurological versions – used the Andersen-Gill 
variant of the Cox proportional hazards model and incorporated both non-varying and 
modifiable risk factors.  Clinical data assessed at the time of the first stroke, as well as the 
psychoneurological effects of that stroke, were included together with assessments of risk 
factors at follow-up visits over the course of up to two years after the first stroke.   
Research Question 1 results 
 The results shown in Table 3.9 indicate that both standard clinical stroke risk factors 
such as prior stroke in nonwhite participants and untreated diabetes mellitus in white 
participants (as well as the less-standard homocysteine levels in white participants) together 
with standard preventive factors such as aspirin use in nonwhite participants were associated 
with, respectively, increased and decreased recurrent stroke risk in the VISP cohort.  Less 
expected but perhaps more intriguing was the determination that psychological dependency 
and neurological disability also were related to an increase in the risk of a recurrent stroke.  
Research Question 2 Results 
 
Although most changes in risk factors over the six-month or twelve-month period 
following the first stroke (shown in Tables 4.8, 4.9, 4.10 and 4.11) were not influential with 
respect to recurrent stroke risk, there was one significant exception emerging from the 
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adjusted results: stopping the use of anti-diabetic medications (or never using such 
medications) was strongly associated with an increased risk of recurrent stroke.  Ceasing the 
use of aspirin or never using aspirin, although not linked in the same way to recurrent stroke 
risk, appeared to influence slightly the effects of changes in adherence to other medications; 
the effects of ceasing or never using lipid-lowering medications or starting the use of blood-
pressure-lowering medications were different (if non-significantly) between those who used 
aspirin and those who did not.    
Research Question 3 Results  
 
 It is difficult to say unequivocally that repeat measurements of risk factors or changes 
in adherence to medication and continuous risk factor guidelines improved the estimation of 
recurrent stroke risk, given the nearly-balanced nature of change seen in Tables 4.1 and 4.2.  
More directly, the models shown in Table 3.9, if converted into a risk prediction score system 
such as that developed by Charlesworth and colleagues, 108 can be used to estimate possible 
increases or decreases in recurrent stroke risk based on desired levels of risk factors at future 
time points, thereby increasing the optimization of stroke risk.  
Degree to which the goals of the doctoral research have been met 
 All of the doctoral research goals – except the development of the score system 
(Specific Aim 2) – have been met.  Specific Aim 1 – the construction of a robust well-fit 
model – was addressed in Chapter III and Chapter IV; four models were developed, the first 
two were Andersen-Gill variants of the Cox proportional hazards model, including the full 
VISP cohort and multiple observations per participant; the third and fourth, in Chapter IV, 
were standard Cox proportional hazards models restricted to the participants with a baseline 
and a twelve-month follow-up visit.  The first two models had adequate fit, provided good 
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predictiveness of recurrent stroke risk, showed moderate ability to discriminate between 
individuals who went on to experience a recurrent stroke and those who did not, and were 
reasonably robust (as indicated by bootstrap validation).  The third and fourth models – both 
standard Cox proportional hazards models – assessed the effect on recurrent stroke of 
improvements in medication adherence (third) and continuous variable adherence (fourth); 
both predicted stroke recurrence moderately well, were reasonably well-fit and robust, and 
discriminated reasonably well, the medication adherence model performing slightly better 
than the continuous variable model in all three areas. Although the fourth model did not yield 
results indicating the effect on recurrent stroke risk of improving adherence to systolic blood 
pressure or total cholesterol guidelines, the third model did reveal that, perhaps expectedly, 
those not in compliance with post-stroke aspirin use guidelines were at a greater risk of 
recurrent stroke if they also did not comply with anti-diabetic medication use guidelines or 
maintained a BMI of 25 kg/m2 or higher.   This model also hinted at the effects of non-
compliance with other medication guidelines when individuals did not adhere to aspirin 
guidelines.  
 As part of the model development which addressed Specific Aim 1, results were 
generated that addressed Research Questions 1, 2, and 3.  Research Question 1 was addressed 
by all four developed models: in the VISP cohort, untreated Type 2 diabetes, higher 
homocysteine levels, more pre-baseline strokes, any dependency or disability, and being of 
nonwhite ancestry were associated with an increased risk of recurrent stroke, whereas total 
cholesterol (for nonwhites) was associated with a decreased risk of recurrent stroke; lack of 
compliance with aspirin use guidelines was associated with a greater risk of recurrent stroke 
(particularly in the first year post-stroke in nonwhite participants), but, paradoxically, was 
124
 
also associated with a decreased recurrent stroke risk in nonwhites over the entire two year 
VISP follow-up time period.  
Answering Research Question 2, lack of adherence to anti-diabetic medication use 
guidelines, in those not taking or stopping the use of aspirin, appeared to increase the risk of 
recurrent stroke; similarly, not bringing BMI to below 25kg/m2 in those not taking or 
stopping aspirin use, resulted in a statistically significant risk of recurrent stroke.  Adherence 
to other medication guidelines or to continuous risk factor guidelines, e.g., those for systolic 
blood pressure or total cholesterol, did not appear, in these analyses, to affect recurrent stroke 
risk.    
Research Question 3 was also answered by the latter results – in the VISP cohort, 
repeat assessments of risk factors did not lead directly to an optimization of recurrent stroke 
outcome but a lack of adherence to medication use guidelines did result in the reverse effect.  
Medication adherence did improve slightly in some areas, and could therefore be considered 
to have been enhanced due to the structure of the clinical trial’s follow-up protocol (of which 
repeat assessments of risk factors were a part), however, this did not result in an 
improvement in recurrent stroke outcome. 
The sole doctoral research goal which has not been addressed was Specific Aim 2 – 
the construction of a score system to implement the models developed in Chapter III.  This 
goal was to have been the target of the effort described in Chapter IV, however, that effort 
became moot given the suboptimal prediction and classification properties of the risk 
prediction equation in this population, and the small degree of risk factor change observed 
over the period of follow-up.  
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Study Strengths 
Validity and utility of the analysis approach 
 Although several analytic approaches could have been used to address the research 
questions and specific aims of this study, the choice of a Cox proportional hazards model and 
of the Andersen-Gill variant of the Cox model offers some advantages that strengthen the 
analysis.  One of these is the relative ease of incorporating time-dependent covariates into the 
model (useful for assessing the effects of repeat measures on recurrent stroke risk); per 
Therneau, 106 “the most common form of time-dependent covariates is a repeated 
measurement on a subject or a change in the subject’s treatment, [both of which] are 
straightforward in [the counting process formulation of the Cox model].”  A second 
advantage is the Andersen-Gill model’s handling of the correlations of repeat measurements; 
since the “internal computations for a Cox model have a term for each unique…event time” 
and a given term’s calculations are limited to the observations that are at risk for each event 
time, any given internal sum will involve effectively a set of independent observations; 
similarly, the use of repeated intervals for each subject, in the Andersen-Gill formulation, are 
effectively a mechanism for selecting the correct values for the subject for each “at-risk” 
interval. Multiple measurements are similarly easily incorporated since each at-risk interval 
can be broken into smaller time units as necessary. Although not utilized by this study due to 
a lack of sample size and power, the counting-process approach also is the simplest under 
which to formulate and construct a multiple-events analysis (albeit with strong assumptions) 
and the model formulation treats multiple events as time-ordered (unlike other marginal 
model approaches), a desirable approach. Hosmer and Lemeshow 101 point out that the Cox 
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model also produces effect estimates that can be interpreted as a ratio of risks, similar to a 
relative risk. 
 The approaches used in Chapters III and IV to select factors to include in the models 
also provide strengths to the analysis approach.  In Chapter III, the focus was solely on 
determining whether repeat measurements of risk factors could be used to predict recurrent 
stroke risk; the use of an ordered stochastic process (thereby not relying on pre-conceptions 
of which factors would be strongly predictive) allowed the selection of a strong model 
through the testing of many factor combinations and assessing the results using the BIC, GB 
goodness-of-fit, and AUC statistics.  In contrast, the use in Chapter IV of specific clinically-
accepted risk factors, clinical post-stroke adherence guidelines and change towards or away 
from those guidelines as the foundation of the models intended to address whether short-term 
changes in risk factors influenced recurrent stroke risk provided those models with two 
strengths:  1) It provided clinically-relevant measures of the effect on recurrent stroke risk of 
desirable changes in risk factors and 2) it offered an assessment of the effects of improving 
risk factor profiles in accordance with standard post-stroke care guidelines. 
Novelty of the analysis approach 
So far as can be determined, this is the first attempt at predicting recurrent stroke risk 
using repeat measures of stroke risk factors; other studies, such as Stroke Prognostic  
Instrument I and Stroke Prognostic Instrument II 51 and the Lehigh Valley Recurrent Stroke 
Study, either used risk factor information obtained at the time of the first stroke or used a 
single averaged risk factor value. 52  The current study differs from these two preceding 
efforts by including the actual repeat measurements of risk factor data in the analysis.  
Similarly, although other studies have examined the association of sociodemographic 
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categorization on lifestyle changes after stroke,39 the ability of healthcare providers to 
improve adherence to clinical stroke prevention guidelines 119 or to treat extant risk factors 
after stroke,120 or the effect of individualized patient profile provision via data management 
systems on healthcare providers’ ability to conform with national guidelines,43 or the 
influence of methods of post-stroke care on improvements in adherence,121 only one other 
study by Redfern et. al. 109 is beginning to evaluate the effects of improving adherence to 
post-stroke care guidelines, and this study has not yet published the results of its trial of 
“individualized secondary prevention packages for patients, carers and health professionals”.  
However, Redfern’s study limited its efforts to three time points – within 10 weeks, 3 
months, and 6 months post-stroke – whereas the current work examined the results of 
improving adherence over a twelve-month period post-stroke.  
Sample size and source of population 
The choice of the VISP cohort as the population source for this study also provided 
analytic advantages in terms of geographic diversity and sample size.  VISP drew its 
participants from 53 clinics in the United States and Canada (the Glasgow, Scotland, clinic 
was excluded from these analyses), which provided a geographically-diverse cohort thus 
avoiding the possible problems with regional differences in stroke prevalence. (15, 97)  The 
VISP study also provided a reasonably large pool of randomized participants (N=3680) with 
multiple follow-up visits (up to 4) per participant, which was an essential element for this 
study.  Although VISP’s race/ethnic composition was not as diverse as might have been 
desired (only 20% were of African-American or other ancestry), women comprised roughly 
37% of the cohort, and the cohort included individuals between the ages of 35 and 89 years. 
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Data available from the VISP cohort 
The data collected by the VISP study provided several strengths to this work.  
Clinical trial standards ensured higher standards of exposure data verification and 
(especially) outcome assessment.  As a clinical trial of stroke, VISP obtained a wide variety 
of data as part of the test of the study hypothesis, including psychoneurological (Barthel, 
RSS, MMSE, and Rankin), neurological symptoms (reflexes, temperature, vibration, and 
sensation), diet information, and standard stroke risk factor information, providing the data 
necessary for predicting recurrent stroke and for assessing the effects of changes in risk 
factors or compliance with medication and other guidelines on stroke risk. VISP used 
standardized training of study personnel to ensure minimal variation in data collection and 
the study protocol helped ensure collection of clinic data at standard follow-up time intervals. 
Prospective data collection helped reduce possible recall bias.   
Outcomes 
 Another area in which the use of the VISP population provided strengths was the 
outcome; since VISP was a clinical trial of stroke, classification and diagnosis of stroke 
symptoms was critically important.  VISP used standard validated stroke symptoms forms to 
classify the likely cause of symptoms into TIA, vertebrobasilar strokes, carotid strokes, or 
ischemic strokes.  In addition, stroke neurologists, in a three- or four-stage process, reviewed 
the symptoms together with any necessary ancillary information (e.g., hospitalization 
information, death certificate information) to correctly classify the symptoms as “not a 
stroke” or “ischemic stroke.”  The care and precision used in this process reduced the 
possibility that stroke symptoms might actually result from, e.g., TIA, thus helping to ensure 
129
 
that a mixing of condition-specific risk factors (confounding) would not occur 122 and the 
models’ ability to discriminate would not be diminished. (123, 124) 
Study Limitations 
 
VISP cohort dataset 
At the same time, the use of the VISP cohort may have imposed some limitations on this 
work.  Clinical trial inclusion criteria, such as those used in VISP, may have resulted in a 
cohort slightly different from the general stroke survivor population (allowing for roughly 
7.5% refusals and 4.2% other reasons).  Selection bias – in the form of the “healthy 
volunteer” – can occur in clinical trials, increasing the proportion of participants (compared 
to nonparticipants or those who leave a study early on) who are more healthy, more aware of 
the benefits of good diet and adherence to clinical care guidelines, and more able to 
participate for the full duration of follow-up. 109  However, although at first glance VISP’s 
participant vitamin adherence – 6% or fewer consistently had adherence less than 75% 110 – 
may suggest that this cohort was generally healthier than the general stroke survivor 
population, Table 2.1 indicates that at baseline 74% of the cohort was hypertensive, 29% 
were diabetic, the average BMI was 28 kg/m2, and over 60% had an RSS score greater than 
or equal to 1. The use of lipid-lowering medications increased over time, which is different 
from medication adherence seen in other studies with less interaction, 111 but this may also be 
due to an increasing prevalence of hypercholesterolemia in the cohort. Most exposures 
considered in this work were clinically- or laboratory-measured, but some, such as cigarette 
smoking status (and, in part, diabetes status), were based on self-report, thus potentially 
introducing some elements of information bias.  The relatively smaller proportion of 
nonwhite participants in the VISP cohort limits our ability to generalize our results to the 
130
 
general stroke survivor population through exposure differences 125as well as differences in 
stroke experience. 126  In addition, approximately one-quarter of the VISP cohort had had one 
or more strokes previous to the baseline stroke, thus may have been different from the other 
75% of the VISP cohort (127, 128) as well as the general stroke survivor population. 112  
However, the hazard ratio and confidence interval for prior stroke – significant in nonwhites 
but close to 1.00 – suggest that this likely did not measurably alter recurrent stroke risk. In 
addition, although VISP provided “best available medical and surgical management to 
prevent recurrent stroke, which included risk factor control education [for vascular risk 
factors such as BP, high LDL cholesterol, low HDL cholesterol, diabetes and smoking], and, 
usually, administration of aspirin, 325 mg/d,” 9 the relatively small degree of change in risk 
factors such as SBP, TC, and BMI suggest that on average the differences between the VISP 
cohort and the general stroke survivor population were not that large. 39  One last area in 
which the use of the VISP cohort may have restricted the ability to detect meaningful 
differences concerns the exclusion during the randomization stage of those who did not 
adhere to the vitamin protocol (http://www.strokecenter.org/trials/TrialDetail.aspx?tid=37) – 
this may have removed more individuals who in general did not adhere to post-stroke care 
guidelines, potentially balancing the numbers of those in adherence and those not in 
adherence to post-stroke guidelines and thus rendering the cohort less representative of stroke 
survivors in general.39  
Exposure misclassification 
 Although all VISP participants had at least one stroke prior to randomization, thus 
diminishing the possibility of differential information bias (specifically recall bias) between 
those with a stroke and those without, nondifferential exposure misclassification is still a 
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possibility.  Table 5.1 shows the method of data collection of the various factors considered 
or included in these analyses; most were measured (via standardized interview or specimen 
collection), but stroke history, smoking status, and, to some extent, diabetes status were 
obtained by self-report.  All information was obtained prospectively without regard to stroke 
status or exposure by clinical staff trained in a standard fashion, however, this does not 
preclude the possibility of inaccurate reporting of exposure status thus leading to potential 
nondifferential misclassification.  The result of such misclassification of exposure (per 
Rothman, 129 page 127) is a likely bias towards the null, given that any misclassification was 
independent by risk factor. However, since the exposure(s) had more than two categories 
there is a chance that bias could have been away from the null. 
Time periods of exposure assessment 
 VISP’s follow-up protocol included clinic visits at six, twelve, eighteen and twenty-
four months.  This restricted the time points at which risk factors were measured and the 
number of changes in risk factors or adherence to stroke prevention guidelines that could be 
assessed.   The time points used in the Chapter IV analysis were even further restricted due to 
the necessity of censoring events which occurred between the clinic visits used to assess 
change, e.g., a stroke had to be censored if it occurred before a change was assessed. The 
combination of two years of follow-up, a restriction on the number of time points of 
measurement, the latency periods of improvements in medication adherence or continuous 
risk factor adherence and the relatively small degree and very balanced nature of the changes 
seen in Table 4.2 likely limited the ability to detect a significant difference in recurrent stroke 
risk in the model results shown in Tables 3.8, 4.10, 4.11, and 4.12.   
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Sample size considerations 
 Although VISP recruited slightly over the number calculated to yield adequate power 
(http://www.strokecenter.org/trials/TrialDetail.aspx?tid=37), and Table 3.7 indicates that the 
majority (75%) had all four follow-up clinical visits, there were two areas in which the VISP 
cohort did not provide an adequate sample size: nonwhite participants (20% of the VISP 
cohort were nonwhite) and recurrent strokes (fewer than 6.9% of participants had a recurrent 
stroke).  The first imposed limits on the generalizability of the results to the nonwhite stroke 
survivor population; the second created difficulties for formulating the statistical models in 
Chapter IV, since, per the “10 events per parameter” or even the “5 events per parameter” 
rule116 the counts of 132 (baseline to six months) and 77 (baseline to twelve months) 
recurrent strokes were insufficient given the parameter count of 14 for the medication 
adherence and continuous factor adherence models. 
Statistical power 
The issue of sample size brings up the related topic of statistical power.  For the analyses 
presented in Chapter III, a post-hoc univariate assessment of statistical power (Table A.12) 
suggests that there was adequate statistical power for most of the factors present in the 
clinical and psychoneurological models; however, some analytes, such as atrial fibrillation 
(in whites), current cigarette smoker (in nonwhites), and diabetic with medications (in 
nonwhites) were “underpowered.”  Similarly, for the analyses performed in Chapter IV, 
several of the medication adherence factors – e.g., started anti-diabetic medication use – and 
some of the continuous factor adherence variables – e.g, SBP (<120 to >=120mmHg, 
baseline to six months) – lacked sufficient power to detect a difference between groups 
(Table 4.13).  
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Future directions 
 
To our knowledge, this study was the first to attempt to predict recurrent stroke 
using repeated measures of risk factors or changes in adherence to secondary stroke 
prevention guidelines.  Given the increasing cost in terms of quality of life and health 
expenditures (1, 30) as well as the difficulties in secondary prevention, (4, 59, 130) more 
research is indicated to determine the effects of improving adherence to secondary 
prevention guidelines through following patients over time after a first, and hopefully 
single stroke. 
 A study designed to examine the research questions posed by this study would 
include participants in the study without regard to their adherence status – as part of the 
randomization of participants, VISP excluded those not adhering to the study vitamin 
protocol, which may have “tipped” the balance of adherers and non-adherers more towards 
the adhering side, thus diminishing statistical power. Including non-adherers – or more 
precisely not excluding such individuals – would include individuals “at risk” of 
improvements in adherence, make the study population more representative of stroke 
survivors, provide more variations of adherence, and improve statistical power. 
 Such a study would also include more information on the study participants prior to 
the initial stroke, on the post-stroke medical care provided to participants (both acute and 
long-term, together with the type of care provided), family histories of stroke, physical 
activity engaged in by participants, and supportive care provided by family members (or, 
alternatively, the degree of isolation or social support possessed by the participant).  
Additional desirable information includes risk factors present before the first stroke, the 
levels of depression and stress experienced by the survivor both before and after the 
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stroke, the level of impaired cognition present in the participant (together with the degree 
of inability to self-care), and access to medical care. Information on post-stroke medical 
care might enable resolution of potentially paradoxical results where participants 
otherwise indistinguishable in terms of risk factor profiles experience different recurrent 
stroke outcomes.  Physical activity was not measured by the VISP study, but exercise has 
been found to reduce cardiovascular risk, 131 specifically the risk of stroke; (65, 66, 132, 133) 
assessing duration, frequency and type of work- and leisure-related physical activity would 
allow for estimates of the effect of exercise in the context of adherence to medication and 
other risk factor guidelines. Last but certainly not least, information on care and support 
provided by family members and other caregivers would (similar to post-stroke medical 
care) help resolve differences in stroke outcome for otherwise similar participants134 as 
well as provide information on the effects of support in the context of risk factor profiles. 
 A third area in which the study would differ from the VISP cohort is measurement 
of medication adherence. VISP’s data on medications other than the study vitamin did not 
include pill counts nor information on periods of non-adherence for specific medications 
(e.g., possibly due to medication interactions or adjustment of dosage), and was obtained 
only at six-month intervals.   In order to study the effects of medication adherence and 
changes in medication adherence on recurrent stroke risk, medication compliance should 
be measured in terms of pill counts.   Pill counts are vulnerable to manipulation, e.g., 
participants emptying the bottles into the trash, but are a more precise measurement of 
adherence and enable checks on consistency between measurements.  Including 
information on periods of non-adherence would refine the estimation of exposure time 
which in turn would improve risk estimates.  A further refinement of this, if possible, 
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would be checks of hospital and pharmacy records for determination of periodicity and 
frequency of medication refills for further assessment of medication adherence. Monthly 
assessments of medication usage would provide a measurement of medication usage more 
in keeping with standard prescription refill practice as well as a more precise measurement 
of changes in medication adherence.  (Weekly assessments, while desirable from a 
statistical perspective, would prove difficult and expensive from a clinical standpoint.) 
 On a related front, the study would include assessment of changes in risk factors 
such as weight and blood pressure and changes in severity of conditions such as diabetes 
on a more-frequent basis than VISP’s six-month intervals. Doing so would reduce the 
imprecision in estimates of when a change took place, when a condition was diagnosed, or 
when treatment of a condition began, and thus would improve statistical precision as well 
as estimates of associated stroke risk.  Ideally, a weekly assessment of risk factor levels 
obtained via interview would be performed by trained clinic staff in order to ensure a more 
consistent and standardized measurement, however, if such were deemed too expensive, a 
web-based assessment completed by participants could be substituted, provided that 
adequate quality control checks and periodic consistency checks were implemented.   
Other physically measured risk factors, such as cholesterol, triglycerides, and glucose, 
might be measured on a biweekly or monthly basis to avoid drawing too much blood from 
participants while providing more frequent assessments of these analytes.   
 A fifth area in which a study designed to examine the effect of adherence to post-
stroke care guidelines would differ from the VISP cohort is sample size; this applies in 
terms of the number of recurrent strokes, the number of exposed and unexposed 
individuals (related both to adherence and changes in adherence) as well as in relationship 
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to the parameters of the categorization of change in risk factor levels.  Addressing the first 
and last of these, one of the weaknesses of the current study was the number of recurrent 
strokes, which was borderline acceptable for the analyses in Chapter III but not sufficient 
for the analyses in Chapter IV.  Although Vittinghoff and colleagues116 state that five 
events per parameter can be sufficient for adequate model stability, this study found that 
this rule did not assure good model performance for the analyses in Chapter IV (only two 
of six models performed well) even after recoding adherence indicator variables to reduce 
the number of model parameters.  If the original coding had been preserved and the same 
models had been run, 330 recurrent strokes would have been necessary to satisfy the “10 
events per parameter” rule for the medication adherence models and 210 recurrent strokes 
for the interval factor adherence models.  Fortunately, addressing the second issue above 
(increasing the numbers of exposed and unexposed individuals) should also remedy the 
first and the last.  Table 5.2 shows the variety of crude sample size estimates based on the 
results of the Chapter IV models; the lowest plausible estimate (given the difficulties with 
the VISP cohort of 3680), which is based on SBP model results, is 3995, the highest 
estimate, which is based on a change in BMI over twelve months from less than 25 kg/m2 
to greater than/equal to 25 kg/m2, is 51493.  However, while more precise estimates are 
highly desirable to avoid either an underpowered or overly expensive study, the conclusion 
drawn from these calculations is clear enough:  a larger study composed of a wider variety 
of participants with differing backgrounds and adherence to post-stroke guidelines will 
help to improve the statistical power and precision of the models described here (or their 
successors). 
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 Further work in predicting recurrent stroke may aid neurologists and other health 
care professionals in formulating better approaches for stroke survivors to reduce their 
recurrent stroke risk, in providing better care for their patients, and reducing the morbidity 
and fiscal costs associated with recurrent stroke.  
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TABLES 
Table 5.1. Method of data collection for factors considered or included in the analyses 
 
Risk factor Method of data collection 
(self-report, measured) 
Gender Self-report and measured 
Age Self-report 
Weight, height (BMI) Measured 
Aspirin use Measured 
Diabetes Self-report and measured 
Anti-diabetes medication use (*) Measured 
Blood pressure Measured 
Blood-pressure-lowering medication use Measured 
Cholesterol level Measured 
Lipid-lowering medication use Measured 
Triglyceride level Measured 
Creatinine level Measured 
Cyanocobalamin Measured 
Folate level Measured 
Atrial fibrillation (ECG) Measured 
Homocyst(e)ine Measured 
Stroke history Self-report 
Severity of first stroke Measured 
MMSE (dementia) Measured 
Barthel (dependency) Measured 
RSS (disability) Measured 
NIHSS (deficit) Measured 
Smoking status Self-report 
Rose angina status Measured 
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Table 5.2. List of sample size estimates (alpha set to 0.05, power set to 90%, two-sided), 
based on Chapter IV models 
 
Risk Factor 
Stratification 
Level 
Time 
period 
VISP
Ref
Count
VISP
Level
Count
Total
time 
HR 
(95% CI) 
 
Power
Est.  
N 
in 
each
group
Anti-DM med use (red 
alt), started using 
Started aspirin Baseline to 
six months 
1529 15 804 1.18 (0.16, 8.59) 0.900 772
Anti-DM med use (red 
alt), started using 
Started aspirin Baseline to 
twelve 
months 
1520 15 806 1.71 (0.23, 12.58) 0.900 77
Anti-DM med use (red 
alt), started using 
Stopped/no 
aspirin 
Baseline to 
six months 
1046 15 793 0.00 (0.00, .) 0.934 5
Anti-DM med use (red 
alt), started using 
Stopped/no 
aspirin 
Baseline to 
twelve 
months 
1060 15 808 5.04 (1.11, 22.92) 0.915 13
Anti-DM med use (red 
alt), stopped using/never 
used 
Started aspirin Baseline to 
six months 
1529 76 795 1.64 (0.71, 3.80) 0.901 90
Anti-DM med use (red 
alt), stopped using/never 
used 
Started aspirin Baseline to 
twelve 
months 
1520 83 802 1.13 (0.35, 3.68) 0.900 1411
Anti-DM med use (red 
alt), stopped using/never 
used 
Stopped/no 
aspirin 
Baseline to 
six months 
1046 58 790 5.12 (2.55, 10.27) 0.918 13
Anti-DM med use (red 
alt), stopped using/never 
used 
Stopped/no 
aspirin 
Baseline to 
twelve 
months 
1060 57 798 1.74 (0.40, 7.49) 0.903 73
BMI (red alt) <25 to >= 
25 
Interval Baseline to 
six months 
685 84 795 0.87 (0.26, 2.85) 0.900 1088
BMI (red alt) <25 to >= 
25 
Started aspirin Baseline to 
six months 
413 53 800 0.78 (0.18, 3.36) 0.901 345
BMI (red alt) <25 to >= 
25 
Stopped/no 
aspirin 
Baseline to 
six months 
272 31 789 0.94 (0.12, 7.45) 0.900 5493
BMI (red alt) <25 to 
>=25 
Interval Baseline to 
twelve 
months 
659 112 802 0.88 (0.20, 3.87) 0.900 1290
BMI (red alt) <25 to 
>=25 
Started aspirin Baseline to 
twelve 
months 
390 68 802 0.98 (0.22, 4.40) 0.900 51493
BMI (red alt) <25 to 
>=25 
Stopped/no 
aspirin 
Baseline to 
twelve 
months 
269 44 803 0.00 (0.00, .) 0.934 5
BMI (red alt) >=25 to < 
25 
Interval Baseline to 
six months 
685 84 794 0.85 (0.26, 2.79) 0.900 800
BMI (red alt) >=25 to < 
25 
Started aspirin Baseline to 
six months 
413 57 796 0.37 (0.05, 2.80) 0.905 25
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Risk Factor 
Stratification 
Level 
Time 
period 
VISP
Ref
Count
VISP
Level
Count
Total
time 
HR 
(95% CI) 
 
Power
Est.  
N 
in 
each
group
BMI (red alt) >=25 to < 
25 
Stopped/no 
aspirin 
Baseline to 
six months 
272 27 804 1.62 (0.35, 7.46) 0.902 95
BMI (red alt) >=25 to 
<25 
Interval Baseline to 
twelve 
months 
659 115 800 0.84 (0.19, 3.70) 0.900 696
BMI (red alt) >=25 to 
<25 
Started aspirin Baseline to 
twelve 
months 
390 76 799 0.39 (0.05, 2.98) 0.910 28
BMI (red alt) >=25 to 
<25 
Stopped/no 
aspirin 
Baseline to 
twelve 
months 
269 39 811 4.28 (0.38, 47.70) 0.918 15
BMI (red alt) >=25 to 
>=25 
Interval Baseline to 
six months 
685 1886 792 1.24 (0.81, 1.89) 0.901 459
BMI (red alt) >=25 to 
>=25 
Interval Baseline to 
twelve 
months 
659 1864 793 1.65 (0.91, 3.00) 0.901 88
BMI (red alt) >=25 to 
>=25 
Started aspirin Baseline to 
six months 
413 1097 796 1.18 (0.70, 2.00) 0.900 772
BMI (red alt) >=25 to 
>=25 
Started aspirin Baseline to 
twelve 
months 
390 1084 795 1.22 (0.62, 2.40) 0.900 536
BMI (red alt) >=25 to 
>=25 
Stopped/no 
aspirin 
Baseline to 
six months 
272 789 791 1.22 (0.60, 2.51) 0.900 536
BMI (red alt) >=25 to 
>=25 
Stopped/no 
aspirin 
Baseline to 
twelve 
months 
269 780 790 4.41 (1.02, 18.95) 0.907 14
Blood-pressure-
lowering med use (red 
alt), started using 
Started aspirin Baseline to 
six months 
1033 79 794 1.35 (0.54, 3.40) 0.901 238
Blood-pressure-
lowering med use (red 
alt), started using 
Started aspirin Baseline to 
twelve 
months 
981 94 795 1.52 (0.53, 4.36) 0.901 124
Blood-pressure-
lowering med use (red 
alt), started using 
Stopped/no 
aspirin 
Baseline to 
six months 
745 62 790 2.15 (0.83, 5.57) 0.902 40
Blood-pressure-
lowering med use (red 
alt), started using 
Stopped/no 
aspirin 
Baseline to 
twelve 
months 
702 67 796 2.58 (0.71, 9.33) 0.908 28
Blood-pressure-
lowering med use (red 
alt), stopped using/never 
used 
Started aspirin Baseline to 
six months 
1033 508 796 0.95 (0.58, 1.54) 0.900 7992
Blood-pressure-
lowering med use (red 
alt), stopped using/never 
used 
Started aspirin Baseline to 
twelve 
months 
981 543 797 1.14 (0.63, 2.06) 0.900 1229
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Risk Factor 
Stratification 
Level 
Time 
period 
VISP
Ref
Count
VISP
Level
Count
Total
time 
HR 
(95% CI) 
 
Power
Est.  
N 
in 
each
group
Blood-pressure-
lowering med use (red 
alt), stopped using/never 
used 
Stopped/no 
aspirin 
Baseline to 
six months 
745 312 791 0.94 (0.49, 1.78) 0.900 5493
Blood-pressure-
lowering med use (red 
alt), stopped using/never 
used 
Stopped/no 
aspirin 
Baseline to 
twelve 
months 
702 363 793 1.55 (0.66, 3.64) 0.902 114
Current cig smoker (red 
alt), started/kept using 
Interval Baseline to 
six months 
2201 456 794 0.81 (0.48, 1.37) 0.901 478
Current cig smoker (red 
alt), started/kept using 
Interval Baseline to 
twelve 
months 
2206 447 795 0.90 (0.44, 1.84) 0.900 1898
Current cig smoker (red 
alt), started/kept using 
Started aspirin Baseline to 
six months 
1290 285 797 0.55 (0.26, 1.16) 0.903 63
Current cig smoker (red 
alt), started/kept using 
Started aspirin Baseline to 
twelve 
months 
1283 280 796 0.77 (0.32, 1.85) 0.900 312
Current cig smoker (red 
alt), started/kept using 
Stopped/no 
aspirin 
Baseline to 
six months 
911 171 790 1.31 (0.61, 2.82) 0.901 293
Current cig smoker (red 
alt), started/kept using 
Stopped/no 
aspirin 
Baseline to 
twelve 
months 
923 167 793 1.20 (0.33, 4.34) 0.900 637
Current cig smoker (red 
alt), stopped using 
Interval Baseline to 
six months 
2201 82 793 1.10 (0.40, 3.03) 0.900 2318
Current cig smoker (red 
alt), stopped using 
Interval Baseline to 
twelve 
months 
2206 97 795 0.86 (0.21, 3.57) 0.900 928
Current cig smoker (red 
alt), stopped using 
Started aspirin Baseline to 
six months 
1290 45 795 0.53 (0.07, 3.87) 0.902 56
Current cig smoker (red 
alt), stopped using 
Started aspirin Baseline to 
twelve 
months 
1283 55 796 0.00 (0.00, .) 0.934 5
Current cig smoker (red 
alt), stopped using 
Stopped/no 
aspirin 
Baseline to 
six months 
911 37 792 1.90 (0.56, 6.43) 0.901 55
Current cig smoker (red 
alt), stopped using 
Stopped/no 
aspirin 
Baseline to 
twelve 
months 
923 42 798 2.19 (0.46, 10.46) 0.907 39
Lipid-lowering med use 
(red alt) started using 
Started aspirin Baseline to 
six months 
1043 94 796 0.68 (0.21, 2.21) 0.902 146
Lipid-lowering med use 
(red alt) started using 
Started aspirin Baseline to 
twelve 
months 
960 132 794 1.52 (0.63, 3.69) 0.901 124
Lipid-lowering med use 
(red alt) started using 
Stopped/no 
aspirin 
Baseline to 
six months 
760 61 795 0.00 (0.00, .) 0.934 5
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Risk Factor 
Stratification 
Level 
Time 
period 
VISP
Ref
Count
VISP
Level
Count
Total
time 
HR 
(95% CI) 
 
Power
Est.  
N 
in 
each
group
Lipid-lowering med use 
(red alt) started using 
Stopped/no 
aspirin 
Baseline to 
twelve 
months 
722 85 800 0.56 (0.07, 4.29) 0.904 67
Lipid-lowering med use 
(red alt) stopped 
using/never used 
Started aspirin Baseline to 
six months 
1043 483 795 1.04 (0.64, 1.69) 0.900 13666
Lipid-lowering med use 
(red alt) stopped 
using/never used 
Started aspirin Baseline to 
twelve 
months 
960 526 798 0.90 (0.48, 1.68) 0.900 1898
Lipid-lowering med use 
(red alt) stopped 
using/never used 
Stopped/no 
aspirin 
Baseline to 
six months 
760 298 798 1.10 (0.60, 2.01) 0.900 2318
Lipid-lowering med use 
(red alt) stopped 
using/never used 
Stopped/no 
aspirin 
Baseline to 
twelve 
months 
722 325 795 1.00 (0.42, 2.39) . .
Systolic BP (red alt), 
<120 to >=120 
Interval Baseline to 
six months 
118 213 791 1.15 (0.40, 3.29) 0.900 1080
Systolic BP (red alt), 
<120 to >=120 
Interval Baseline to 
twelve 
months 
116 205 789 3.49 (0.43, 28.44) 0.910 18 
Systolic BP (red alt), 
>=120 to <120 
Interval Baseline to 
six months 
118 199 797 0.52 (0.15, 1.79) 0.902 53 
Systolic BP (red alt), 
>=120 to <120 
Interval Baseline to 
twelve 
months 
116 214 793 1.42 (0.15, 13.66) 0.900 175 
Systolic BP (red alt), 
>=120 to >=120 
Interval Baseline to 
six months 
118 2209 792 0.93 (0.38, 2.31) 0.900 3995 
Systolic BP (red alt), 
>=120 to >=120 
Interval Baseline to 
twelve 
months 
116 2215 795 2.51 (0.35, 18.13) 0.904 29 
Total cholesterol (red 
alt) <200 to >=200 
Interval Baseline to 
six months 
1263 128 797 0.71 (0.26, 1.95) 0.900 183 
Total cholesterol (red 
alt) >=200 to <200 
Interval Baseline to 
six months 
1263 215 794 1.40 (0.77, 2.57) 0.901 190 
Total cholesterol (red 
alt) >=200 to >=200 
Interval Baseline to 
six months 
1263 1133 796 1.18 (0.81, 1.71) 0.900 772 
Total cholesterol (red) 
<200 to >=200 
Interval Baseline to 
twelve 
months 
1125 285 797 0.71 (0.28, 1.85) 0.900 183 
Total cholesterol (red) 
>=200 to <200 
Interval Baseline to 
twelve 
months 
1125 508 797 1.22 (0.65, 2.28) 0.900 536 
Total cholesterol (red) 
>=200 to >=200 
Interval Baseline to 
twelve 
months 
1125 832 798 1.29 (0.76, 2.20) 0.901 329 
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APPENDIX: Additional Tables and Figures 
 
Table A.1. Assessment of data missingness at baseline visit by age group, race, gender, 
stroke outcome (for analysis results shown in Table 3.9) 
 
Variable 
Stratifying 
variable Level 
Missing 
or Present
Baseline 
(N (%)) 
Baseline χ2 
p-value 
Lipid-lowering med use Age 3-5 Missing 5 (0.15) 0.3817
Lipid-lowering med use Age 3-5 Present 1364 (41.07) 0.3817
Lipid-lowering med use Age 6-8 Missing 4 (0.12) 0.3817
Lipid-lowering med use Age 6-8 Present 1948 (58.66) 0.3817
Lipid-lowering med use Nonwhite ancestry No Missing 3 (0.09) 0.0005
Lipid-lowering med use Nonwhite ancestry No Present 2646 (79.67) 0.0005
Lipid-lowering med use Nonwhite ancestry Yes Missing 6 (0.18) 0.0005
Lipid-lowering med use Nonwhite ancestry Yes Present 666 (20.05) 0.0005
Lipid-lowering med use Male gender No Missing 4 (0.12) 0.6576
Lipid-lowering med use Male gender No Present 1235 (37.19) 0.6576
Lipid-lowering med use Male gender Yes Missing 5 (0.15) 0.6576
Lipid-lowering med use Male gender Yes Present 2077 (62.54) 0.6576
Lipid-lowering med use Stroke outcome No Missing 9 (0.27) 0.9412
Lipid-lowering med use Stroke outcome No Present 3310 (99.67) 0.9412
Lipid-lowering med use Stroke outcome Yes Missing 0 (0.00) 0.9412
Lipid-lowering med use Stroke outcome Yes Present 2 (0.06) 0.9412
Blood-pressure-lowering med use Age 3-5 Missing 5 (0.15) 0.3817
Blood-pressure-lowering med use Age 3-5 Present 1364 (41.07) 0.3817
Blood-pressure-lowering med use Age 6-8 Missing 4 (0.12) 0.3817
Blood-pressure-lowering med use Age 6-8 Present 1948 (58.66) 0.3817
Blood-pressure-lowering med use Nonwhite ancestry No Missing 3 (0.09) 0.0005
Blood-pressure-lowering med use Nonwhite ancestry No Present 2646 (79.67) 0.0005
Blood-pressure-lowering med use Nonwhite ancestry Yes Missing 6 (0.18) 0.0005
Blood-pressure-lowering med use Nonwhite ancestry Yes Present 666 (20.05) 0.0005
Blood-pressure-lowering med use Male gender No Missing 4 (0.12) 0.6576
Blood-pressure-lowering med use Male gender No Present 1235 (37.19) 0.6576
Blood-pressure-lowering med use Male gender Yes Missing 5 (0.15) 0.6576
Blood-pressure-lowering med use Male gender Yes Present 2077 (62.54) 0.6576
Blood-pressure-lowering med use Stroke outcome No Missing 9 (0.27) 0.9412
Blood-pressure-lowering med use Stroke outcome No Present 3310 (99.67) 0.9412
Blood-pressure-lowering med use Stroke outcome Yes Missing 0 (0.00) 0.9412
Blood-pressure-lowering med use Stroke outcome Yes Present 2 (0.06) 0.9412
Any dependency Age 3-5 Missing 1 (0.03) 0.5096
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Variable 
Stratifying 
variable Level 
Missing 
or Present
Baseline 
(N (%)) 
Baseline χ2 
p-value 
Any dependency Age 3-5 Present 1368 (41.19) 0.5096
Any dependency Age 6-8 Missing 3 (0.09) 0.5096
Any dependency Age 6-8 Present 1949 (58.69) 0.5096
Any dependency Nonwhite ancestry No Missing 3 (0.09) 0.8124
Any dependency Nonwhite ancestry No Present 2646 (79.67) 0.8124
Any dependency Nonwhite ancestry Yes Missing 1 (0.03) 0.8124
Any dependency Nonwhite ancestry Yes Present 671 (20.20) 0.8124
Any dependency Male gender No Missing 3 (0.09) 0.1188
Any dependency Male gender No Present 1236 (37.22) 0.1188
Any dependency Male gender Yes Missing 1 (0.03) 0.1188
Any dependency Male gender Yes Present 2081 (62.66) 0.1188
Any dependency Stroke outcome No Missing 4 (0.12) 0.9608
Any dependency Stroke outcome No Present 3315 (99.82) 0.9608
Any dependency Stroke outcome Yes Missing 0 (0.00) 0.9608
Any dependency Stroke outcome Yes Present 2 (0.06) 0.9608
Any disability Age 3-5 Missing 0 (0.00) N/A
Any disability Age 3-5 Present 1369 (41.22) N/A
Any disability Age 6-8 Missing 0 (0.00) N/A
Any disability Age 6-8 Present 1952 (58.78) N/A
Any disability Nonwhite ancestry No Missing 0 (0.00) N/A
Any disability Nonwhite ancestry No Present 2649 (79.77) N/A
Any disability Nonwhite ancestry Yes Missing 0 (0.00) N/A
Any disability Nonwhite ancestry Yes Present 672 (20.23) N/A
Any disability Male gender No Missing 0 (0.00) N/A
Any disability Male gender No Present 1239 (37.31) N/A
Any disability Male gender Yes Missing 0 (0.00) N/A
Any disability Male gender Yes Present 2082 (62.69) N/A
Any disability Stroke outcome No Missing 0 (0.00) N/A
Any disability Stroke outcome No Present 3319 (99.94) N/A
Any disability Stroke outcome Yes Missing 0 (0.00) N/A
Any disability Stroke outcome Yes Present 2 (0.06) N/A
BMI Age 3-5 Missing 6 (0.18) 0.1051
BMI Age 3-5 Present 1363 (41.04) 0.1051
BMI Age 6-8 Missing 18 (0.54) 0.1051
BMI Age 6-8 Present 1934 (58.24) 0.1051
BMI Nonwhite ancestry No Missing 22 (0.66) 0.1452
BMI Nonwhite ancestry No Present 2627 (79.10) 0.1452
BMI Nonwhite ancestry Yes Missing 2 (0.06) 0.1452
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Variable 
Stratifying 
variable Level 
Missing 
or Present
Baseline 
(N (%)) 
Baseline χ2 
p-value 
BMI Nonwhite ancestry Yes Present 670 (20.17) 0.1452
BMI Male gender No Missing 11 (0.33) 0.3861
BMI Male gender No Present 1228 (36.98) 0.3861
BMI Male gender Yes Missing 13 (0.39) 0.3861
BMI Male gender Yes Present 2069 (62.30) 0.3861
BMI Stroke outcome No Missing 24 (0.72) 0.9039
BMI Stroke outcome No Present 3295 (99.22) 0.9039
BMI Stroke outcome Yes Missing 0 (0.00) 0.9039
BMI Stroke outcome Yes Present 2 (0.06) 0.9039
Current cigarette smoker Age 3-5 Missing 0 (0.00) N/A
Current cigarette smoker Age 3-5 Present 1369 (41.22) N/A
Current cigarette smoker Age 6-8 Missing 0 (0.00) N/A
Current cigarette smoker Age 6-8 Present 1952 (58.78) N/A
Current cigarette smoker Nonwhite ancestry No Missing 0 (0.00) N/A
Current cigarette smoker Nonwhite ancestry No Present 2649 (79.77) N/A
Current cigarette smoker Nonwhite ancestry Yes Missing 0 (0.00) N/A
Current cigarette smoker Nonwhite ancestry Yes Present 672 (20.23) N/A
Current cigarette smoker Male gender No Missing 0 (0.00) N/A
Current cigarette smoker Male gender No Present 1239 (37.31) N/A
Current cigarette smoker Male gender Yes Missing 0 (0.00) N/A
Current cigarette smoker Male gender Yes Present 2082 (62.69) N/A
Current cigarette smoker Stroke outcome No Missing 0 (0.00) N/A
Current cigarette smoker Stroke outcome No Present 3319 (99.94) N/A
Current cigarette smoker Stroke outcome Yes Missing 0 (0.00) N/A
Current cigarette smoker Stroke outcome Yes Present 2 (0.06) N/A
HDL cholesterol Age 3-5 Missing 38 (1.14) 0.4556
HDL cholesterol Age 3-5 Present 1331 (40.08) 0.4556
HDL cholesterol Age 6-8 Missing 63 (1.90) 0.4556
HDL cholesterol Age 6-8 Present 1889 (56.88) 0.4556
HDL cholesterol Nonwhite ancestry No Missing 80 (2.41) 0.8874
HDL cholesterol Nonwhite ancestry No Present 2569 (77.36) 0.8874
HDL cholesterol Nonwhite ancestry Yes Missing 21 (0.63) 0.8874
HDL cholesterol Nonwhite ancestry Yes Present 651 (19.60) 0.8874
HDL cholesterol Male gender No Missing 28 (0.84) 0.0431
HDL cholesterol Male gender No Present 1211 (36.46) 0.0431
HDL cholesterol Male gender Yes Missing 73 (2.20) 0.0431
HDL cholesterol Male gender Yes Present 2009 (60.49) 0.0431
HDL cholesterol Stroke outcome No Missing 101 (3.04) 0.8022
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Variable 
Stratifying 
variable Level 
Missing 
or Present
Baseline 
(N (%)) 
Baseline χ2 
p-value 
HDL cholesterol Stroke outcome No Present 3218 (96.90) 0.8022
HDL cholesterol Stroke outcome Yes Missing 0 (0.00) 0.8022
HDL cholesterol Stroke outcome Yes Present 2 (0.06) 0.8022
Nondiabetic w/meds Age 3-5 Missing 5 (0.15) 0.3817
Nondiabetic w/meds Age 3-5 Present 1364 (41.07) 0.3817
Nondiabetic w/meds Age 6-8 Missing 4 (0.12) 0.3817
Nondiabetic w/meds Age 6-8 Present 1948 (58.66) 0.3817
Nondiabetic w/meds Nonwhite ancestry No Missing 3 (0.09) 0.0005
Nondiabetic w/meds Nonwhite ancestry No Present 2646 (79.67) 0.0005
Nondiabetic w/meds Nonwhite ancestry Yes Missing 6 (0.18) 0.0005
Nondiabetic w/meds Nonwhite ancestry Yes Present 666 (20.05) 0.0005
Nondiabetic w/meds Male gender No Missing 4 (0.12) 0.6576
Nondiabetic w/meds Male gender No Present 1235 (37.19) 0.6576
Nondiabetic w/meds Male gender Yes Missing 5 (0.15) 0.6576
Nondiabetic w/meds Male gender Yes Present 2077 (62.54) 0.6576
Nondiabetic w/meds Stroke outcome No Missing 9 (0.27) 0.9412
Nondiabetic w/meds Stroke outcome No Present 3310 (99.67) 0.9412
Nondiabetic w/meds Stroke outcome Yes Missing 0 (0.00) 0.9412
Nondiabetic w/meds Stroke outcome Yes Present 2 (0.06) 0.9412
Diabetic w/o meds Age 3-5 Missing 5 (0.15) 0.3817
Diabetic w/o meds Age 3-5 Present 1364 (41.07) 0.3817
Diabetic w/o meds Age 6-8 Missing 4 (0.12) 0.3817
Diabetic w/o meds Age 6-8 Present 1948 (58.66) 0.3817
Diabetic w/o meds Nonwhite ancestry No Missing 3 (0.09) 0.0005
Diabetic w/o meds Nonwhite ancestry No Present 2646 (79.67) 0.0005
Diabetic w/o meds Nonwhite ancestry Yes Missing 6 (0.18) 0.0005
Diabetic w/o meds Nonwhite ancestry Yes Present 666 (20.05) 0.0005
Diabetic w/o meds Male gender No Missing 4 (0.12) 0.6576
Diabetic w/o meds Male gender No Present 1235 (37.19) 0.6576
Diabetic w/o meds Male gender Yes Missing 5 (0.15) 0.6576
Diabetic w/o meds Male gender Yes Present 2077 (62.54) 0.6576
Diabetic w/o meds Stroke outcome No Missing 9 (0.27) 0.9412
Diabetic w/o meds Stroke outcome No Present 3310 (99.67) 0.9412
Diabetic w/o meds Stroke outcome Yes Missing 0 (0.00) 0.9412
Diabetic w/o meds Stroke outcome Yes Present 2 (0.06) 0.9412
Diabetic w/ meds Age 3-5 Missing 5 (0.15) 0.3817
Diabetic w/ meds Age 3-5 Present 1364 (41.07) 0.3817
Diabetic w/ meds Age 6-8 Missing 4 (0.12) 0.3817
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Variable 
Stratifying 
variable Level 
Missing 
or Present
Baseline 
(N (%)) 
Baseline χ2 
p-value 
Diabetic w/ meds Age 6-8 Present 1948 (58.66) 0.3817
Diabetic w/ meds Nonwhite ancestry No Missing 3 (0.09) 0.0005
Diabetic w/ meds Nonwhite ancestry No Present 2646 (79.67) 0.0005
Diabetic w/ meds Nonwhite ancestry Yes Missing 6 (0.18) 0.0005
Diabetic w/ meds Nonwhite ancestry Yes Present 666 (20.05) 0.0005
Diabetic w/ meds Male gender No Missing 4 (0.12) 0.6576
Diabetic w/ meds Male gender No Present 1235 (37.19) 0.6576
Diabetic w/ meds Male gender Yes Missing 5 (0.15) 0.6576
Diabetic w/ meds Male gender Yes Present 2077 (62.54) 0.6576
Diabetic w/ meds Stroke outcome No Missing 9 (0.27) 0.9412
Diabetic w/ meds Stroke outcome No Present 3310 (99.67) 0.9412
Diabetic w/ meds Stroke outcome Yes Missing 0 (0.00) 0.9412
Diabetic w/ meds Stroke outcome Yes Present 2 (0.06) 0.9412
Atrial fibrillation Age 3-5 Missing 0 (0.00) N/A
Atrial fibrillation Age 3-5 Present 1369 (41.22) N/A
Atrial fibrillation Age 6-8 Missing 0 (0.00) N/A
Atrial fibrillation Age 6-8 Present 1952 (58.78) N/A
Atrial fibrillation Nonwhite ancestry No Missing 0 (0.00) N/A
Atrial fibrillation Nonwhite ancestry No Present 2649 (79.77) N/A
Atrial fibrillation Nonwhite ancestry Yes Missing 0 (0.00) N/A
Atrial fibrillation Nonwhite ancestry Yes Present 672 (20.23) N/A
Atrial fibrillation Male gender No Missing 0 (0.00) N/A
Atrial fibrillation Male gender No Present 1239 (37.31) N/A
Atrial fibrillation Male gender Yes Missing 0 (0.00) N/A
Atrial fibrillation Male gender Yes Present 2082 (62.69) N/A
Atrial fibrillation Stroke outcome No Missing 0 (0.00) N/A
Atrial fibrillation Stroke outcome No Present 3319 (99.94) N/A
Atrial fibrillation Stroke outcome Yes Missing 0 (0.00) N/A
Atrial fibrillation Stroke outcome Yes Present 2 (0.06) N/A
Aspirin use Age 3-5 Missing 5 (0.15) 0.3817
Aspirin use Age 3-5 Present 1364 (41.07) 0.3817
Aspirin use Age 6-8 Missing 4 (0.12) 0.3817
Aspirin use Age 6-8 Present 1948 (58.66) 0.3817
Aspirin use Nonwhite ancestry No Missing 3 (0.09) 0.0005
Aspirin use Nonwhite ancestry No Present 2646 (79.67) 0.0005
Aspirin use Nonwhite ancestry Yes Missing 6 (0.18) 0.0005
Aspirin use Nonwhite ancestry Yes Present 666 (20.05) 0.0005
Aspirin use Male gender No Missing 4 (0.12) 0.6576
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Variable 
Stratifying 
variable Level 
Missing 
or Present
Baseline 
(N (%)) 
Baseline χ2 
p-value 
Aspirin use Male gender No Present 1235 (37.19) 0.6576
Aspirin use Male gender Yes Missing 5 (0.15) 0.6576
Aspirin use Male gender Yes Present 2077 (62.54) 0.6576
Aspirin use Stroke outcome No Missing 9 (0.27) 0.9412
Aspirin use Stroke outcome No Present 3310 (99.67) 0.9412
Aspirin use Stroke outcome Yes Missing 0 (0.00) 0.9412
Aspirin use Stroke outcome Yes Present 2 (0.06) 0.9412
Systolic BP Age 3-5 Missing 0 (0.00) N/A
Systolic BP Age 3-5 Present 1369 (41.22) N/A
Systolic BP Age 6-8 Missing 0 (0.00) N/A
Systolic BP Age 6-8 Present 1952 (58.78) N/A
Systolic BP Nonwhite ancestry No Missing 0 (0.00) N/A
Systolic BP Nonwhite ancestry No Present 2649 (79.77) N/A
Systolic BP Nonwhite ancestry Yes Missing 0 (0.00) N/A
Systolic BP Nonwhite ancestry Yes Present 672 (20.23) N/A
Systolic BP Male gender No Missing 0 (0.00) N/A
Systolic BP Male gender No Present 1239 (37.31) N/A
Systolic BP Male gender Yes Missing 0 (0.00) N/A
Systolic BP Male gender Yes Present 2082 (62.69) N/A
Systolic BP Stroke outcome No Missing 0 (0.00) N/A
Systolic BP Stroke outcome No Present 3319 (99.94) N/A
Systolic BP Stroke outcome Yes Missing 0 (0.00) N/A
Systolic BP Stroke outcome Yes Present 2 (0.06) N/A
Homocysteine Age 3-5 Missing 10 (0.30) 0.3779
Homocysteine Age 3-5 Present 1359 (40.92) 0.3779
Homocysteine Age 6-8 Missing 20 (0.60) 0.3779
Homocysteine Age 6-8 Present 1932 (58.18) 0.3779
Homocysteine Nonwhite ancestry No Missing 22 (0.66) 0.3784
Homocysteine Nonwhite ancestry No Present 2627 (79.10) 0.3784
Homocysteine Nonwhite ancestry Yes Missing 8 (0.24) 0.3784
Homocysteine Nonwhite ancestry Yes Present 664 (19.99) 0.3784
Homocysteine Male gender No Missing 15 (0.45) 0.1488
Homocysteine Male gender No Present 1224 (36.86) 0.1488
Homocysteine Male gender Yes Missing 15 (0.45) 0.1488
Homocysteine Male gender Yes Present 2067 (62.24) 0.1488
Homocysteine Stroke outcome No Missing 30 (0.90) 0.8926
Homocysteine Stroke outcome No Present 3289 (99.04) 0.8926
Homocysteine Stroke outcome Yes Missing 0 (0.00) 0.8926
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Variable 
Stratifying 
variable Level 
Missing 
or Present
Baseline 
(N (%)) 
Baseline χ2 
p-value 
Homocysteine Stroke outcome Yes Present 2 (0.06) 0.8926
Total cholesterol Age 3-5 Missing 29 (0.87) 0.5746
Total cholesterol Age 3-5 Present 1340 (40.35) 0.5746
Total cholesterol Age 6-8 Missing 36 (1.08) 0.5746
Total cholesterol Age 6-8 Present 1916 (57.69) 0.5746
Total cholesterol Nonwhite ancestry No Missing 44 (1.32) 0.0144
Total cholesterol Nonwhite ancestry No Present 2605 (78.44) 0.0144
Total cholesterol Nonwhite ancestry Yes Missing 21 (0.63) 0.0144
Total cholesterol Nonwhite ancestry Yes Present 651 (19.60) 0.0144
Total cholesterol Male gender No Missing 17 (0.51) 0.0604
Total cholesterol Male gender No Present 1222 (36.80) 0.0604
Total cholesterol Male gender Yes Missing 48 (1.45) 0.0604
Total cholesterol Male gender Yes Present 2034 (61.25) 0.0604
Total cholesterol Stroke outcome No Missing 65 (1.96) 0.8416
Total cholesterol Stroke outcome No Present 3254 (97.98) 0.8416
Total cholesterol Stroke outcome Yes Missing 0 (0.00) 0.8416
Total cholesterol Stroke outcome Yes Present 2 (0.06) 0.8416
 
Table A.2. Assessment of data missingness at six month visit by age group, race, gender, 
stroke outcome (for analysis results shown in Table 3.9) 
 
Variable 
Stratifying 
variable Level 
Missing 
or Present
6 mos. 
(N (%)) 
6 mos. χ2 
p-value 
Lipid-lowering med use Age 3-5 Missing 69 (2.31) 0.8483
Lipid-lowering med use Age 3-5 Present 1052 (35.24) 0.8483
Lipid-lowering med use Age 6-8 Missing 118 (3.95) 0.8483
Lipid-lowering med use Age 6-8 Present 1746 (58.49) 0.8483
Lipid-lowering med use Nonwhite ancestry No Missing 148 (4.96) 0.5517
Lipid-lowering med use Nonwhite ancestry No Present 2264 (75.85) 0.5517
Lipid-lowering med use Nonwhite ancestry Yes Missing 39 (1.31) 0.5517
Lipid-lowering med use Nonwhite ancestry Yes Present 534 (17.89) 0.5517
Lipid-lowering med use Male gender No Missing 81 (2.71) 0.0782
Lipid-lowering med use Male gender No Present 1032 (34.57) 0.0782
Lipid-lowering med use Male gender Yes Missing 106 (3.55) 0.0782
Lipid-lowering med use Male gender Yes Present 1766 (59.16) 0.0782
Lipid-lowering med use Stroke outcome No Missing 178 (5.96) 0.0808
Lipid-lowering med use Stroke outcome No Present 2724 (91.26) 0.0808
Lipid-lowering med use Stroke outcome Yes Missing 9 (0.30) 0.0808
Lipid-lowering med use Stroke outcome Yes Present 74 (2.48) 0.0808
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Variable 
Stratifying 
variable Level 
Missing 
or Present
6 mos. 
(N (%)) 
6 mos. χ2 
p-value 
Blood-pressure-lowering med use Age 3-5 Missing 69 (2.31) 0.8483
Blood-pressure-lowering med use Age 3-5 Present 1052 (35.24) 0.8483
Blood-pressure-lowering med use Age 6-8 Missing 118 (3.95) 0.8483
Blood-pressure-lowering med use Age 6-8 Present 1746 (58.49) 0.8483
Blood-pressure-lowering med use Nonwhite ancestry No Missing 148 (4.96) 0.5517
Blood-pressure-lowering med use Nonwhite ancestry No Present 2264 (75.85) 0.5517
Blood-pressure-lowering med use Nonwhite ancestry Yes Missing 39 (1.31) 0.5517
Blood-pressure-lowering med use Nonwhite ancestry Yes Present 534 (17.89) 0.5517
Blood-pressure-lowering med use Male gender No Missing 81 (2.71) 0.0782
Blood-pressure-lowering med use Male gender No Present 1032 (34.57) 0.0782
Blood-pressure-lowering med use Male gender Yes Missing 106 (3.55) 0.0782
Blood-pressure-lowering med use Male gender Yes Present 1766 (59.16) 0.0782
Blood-pressure-lowering med use Stroke outcome No Missing 178 (5.96) 0.0808
Blood-pressure-lowering med use Stroke outcome No Present 2724 (91.26) 0.0808
Blood-pressure-lowering med use Stroke outcome Yes Missing 9 (0.30) 0.0808
Blood-pressure-lowering med use Stroke outcome Yes Present 74 (2.48) 0.0808
Any dependency Age 3-5 Missing 63 (2.11) 0.7052
Any dependency Age 3-5 Present 1058 (35.44) 0.7052
Any dependency Age 6-8 Missing 111 (3.72) 0.7052
Any dependency Age 6-8 Present 1753 (58.73) 0.7052
Any dependency Nonwhite ancestry No Missing 140 (4.69) 0.9054
Any dependency Nonwhite ancestry No Present 2272 (76.11) 0.9054
Any dependency Nonwhite ancestry Yes Missing 34 (1.14) 0.9054
Any dependency Nonwhite ancestry Yes Present 539 (18.06) 0.9054
Any dependency Male gender No Missing 75 (2.51) 0.1020
Any dependency Male gender No Present 1038 (34.77) 0.1020
Any dependency Male gender Yes Missing 99 (3.32) 0.1020
Any dependency Male gender Yes Present 1773 (59.40) 0.1020
Any dependency Stroke outcome No Missing 166 (5.56) 0.1330
Any dependency Stroke outcome No Present 2736 (91.66) 0.1330
Any dependency Stroke outcome Yes Missing 8 (0.27) 0.1330
Any dependency Stroke outcome Yes Present 75 (2.51) 0.1330
Any disability Age 3-5 Missing 63 (2.11) 0.7960
Any disability Age 3-5 Present 1058 (35.44) 0.7960
Any disability Age 6-8 Missing 109 (3.65) 0.7960
Any disability Age 6-8 Present 1755 (58.79) 0.7960
Any disability Nonwhite ancestry No Missing 138 (4.62) 0.8446
Any disability Nonwhite ancestry No Present 2274 (76.18) 0.8446
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Variable 
Stratifying 
variable Level 
Missing 
or Present
6 mos. 
(N (%)) 
6 mos. χ2 
p-value 
Any disability Nonwhite ancestry Yes Missing 34 (1.14) 0.8446
Any disability Nonwhite ancestry Yes Present 539 (18.06) 0.8446
Any disability Male gender No Missing 75 (2.51) 0.0775
Any disability Male gender No Present 1038 (34.77) 0.0775
Any disability Male gender Yes Missing 97 (3.25) 0.0775
Any disability Male gender Yes Present 1775 (59.46) 0.0775
Any disability Stroke outcome No Missing 164 (5.49) 0.1243
Any disability Stroke outcome No Present 2738 (91.73) 0.1243
Any disability Stroke outcome Yes Missing 8 (0.27) 0.1243
Any disability Stroke outcome Yes Present 75 (2.51) 0.1243
BMI Age 3-5 Missing 143 (4.79) 0.0725
BMI Age 3-5 Present 978 (32.76) 0.0725
BMI Age 6-8 Missing 282 (9.45) 0.0725
BMI Age 6-8 Present 1582 (53.00) 0.0725
BMI Nonwhite ancestry No Missing 356 (11.93) 0.0942
BMI Nonwhite ancestry No Present 2056 (68.88) 0.0942
BMI Nonwhite ancestry Yes Missing 69 (2.31) 0.0942
BMI Nonwhite ancestry Yes Present 504 (16.88) 0.0942
BMI Male gender No Missing 146 (4.89) 0.1769
BMI Male gender No Present 967 (32.40) 0.1769
BMI Male gender Yes Missing 279 (9.35) 0.1769
BMI Male gender Yes Present 1593 (53.37) 0.1769
BMI Stroke outcome No Missing 408 (13.67) 0.0987
BMI Stroke outcome No Present 2494 (83.55) 0.0987
BMI Stroke outcome Yes Missing 17 (0.57) 0.0987
BMI Stroke outcome Yes Present 66 (2.21) 0.0987
Current cigarette smoker Age 3-5 Missing 2 (0.07) 0.0681
Current cigarette smoker Age 3-5 Present 1119 (37.49) 0.0681
Current cigarette smoker Age 6-8 Missing 0 (0.00) 0.0681
Current cigarette smoker Age 6-8 Present 1864 (62.45) 0.0681
Current cigarette smoker Nonwhite ancestry No Missing 1 (0.03) 0.2685
Current cigarette smoker Nonwhite ancestry No Present 2411 (80.77) 0.2685
Current cigarette smoker Nonwhite ancestry Yes Missing 1 (0.03) 0.2685
Current cigarette smoker Nonwhite ancestry Yes Present 572 (19.16) 0.2685
Current cigarette smoker Male gender No Missing 0 (0.00) 0.2753
Current cigarette smoker Male gender No Present 1113 (37.29) 0.2753
Current cigarette smoker Male gender Yes Missing 2 (0.07) 0.2753
Current cigarette smoker Male gender Yes Present 1870 (62.65) 0.2753
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Variable 
Stratifying 
variable Level 
Missing 
or Present
6 mos. 
(N (%)) 
6 mos. χ2 
p-value 
Current cigarette smoker Stroke outcome No Missing 2 (0.07) 0.8109
Current cigarette smoker Stroke outcome No Present 2900 (97.15) 0.8109
Current cigarette smoker Stroke outcome Yes Missing 0 (0.00) 0.8109
Current cigarette smoker Stroke outcome Yes Present 83 (2.78) 0.8109
HDL cholesterol Age 3-5 Missing 1120 (37.52) 0.2902
HDL cholesterol Age 3-5 Present 1 (0.03) 0.2902
HDL cholesterol Age 6-8 Missing 1859 (62.28) 0.2902
HDL cholesterol Age 6-8 Present 5 (0.17) 0.2902
HDL cholesterol Nonwhite ancestry No Missing 2407 (80.64) 0.8749
HDL cholesterol Nonwhite ancestry No Present 5 (0.17) 0.8749
HDL cholesterol Nonwhite ancestry Yes Missing 572 (19.16) 0.8749
HDL cholesterol Nonwhite ancestry Yes Present 1 (0.03) 0.8749
HDL cholesterol Male gender No Missing 1110 (37.19) 0.5192
HDL cholesterol Male gender No Present 3 (0.10) 0.5192
HDL cholesterol Male gender Yes Missing 1869 (62.61) 0.5192
HDL cholesterol Male gender Yes Present 3 (0.10) 0.5192
HDL cholesterol Stroke outcome No Missing 2897 (97.05) 0.0384
HDL cholesterol Stroke outcome No Present 5 (0.17) 0.0384
HDL cholesterol Stroke outcome Yes Missing 82 (2.75) 0.0384
HDL cholesterol Stroke outcome Yes Present 1 (0.03) 0.0384
Nondiabetic w/meds Age 3-5 Missing 69 (2.31) 0.8483
Nondiabetic w/meds Age 3-5 Present 1052 (35.24) 0.8483
Nondiabetic w/meds Age 6-8 Missing 118 (3.95) 0.8483
Nondiabetic w/meds Age 6-8 Present 1746 (58.49) 0.8483
Nondiabetic w/meds Nonwhite ancestry No Missing 148 (4.96) 0.5517
Nondiabetic w/meds Nonwhite ancestry No Present 2264 (75.85) 0.5517
Nondiabetic w/meds Nonwhite ancestry Yes Missing 39 (1.31) 0.5517
Nondiabetic w/meds Nonwhite ancestry Yes Present 534 (17.89) 0.5517
Nondiabetic w/meds Male gender No Missing 81 (2.71) 0.0782
Nondiabetic w/meds Male gender No Present 1032 (34.57) 0.0782
Nondiabetic w/meds Male gender Yes Missing 106 (3.55) 0.0782
Nondiabetic w/meds Male gender Yes Present 1766 (59.16) 0.0782
Nondiabetic w/meds Stroke outcome No Missing 178 (5.96) 0.0808
Nondiabetic w/meds Stroke outcome No Present 2724 (91.26) 0.0808
Nondiabetic w/meds Stroke outcome Yes Missing 9 (0.30) 0.0808
Nondiabetic w/meds Stroke outcome Yes Present 74 (2.48) 0.0808
Diabetic w/o meds Age 3-5 Missing 69 (2.31) 0.8483
Diabetic w/o meds Age 3-5 Present 1052 (35.24) 0.8483
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Variable 
Stratifying 
variable Level 
Missing 
or Present
6 mos. 
(N (%)) 
6 mos. χ2 
p-value 
Diabetic w/o meds Age 6-8 Missing 118 (3.95) 0.8483
Diabetic w/o meds Age 6-8 Present 1746 (58.49) 0.8483
Diabetic w/o meds Nonwhite ancestry No Missing 148 (4.96) 0.5517
Diabetic w/o meds Nonwhite ancestry No Present 2264 (75.85) 0.5517
Diabetic w/o meds Nonwhite ancestry Yes Missing 39 (1.31) 0.5517
Diabetic w/o meds Nonwhite ancestry Yes Present 534 (17.89) 0.5517
Diabetic w/o meds Male gender No Missing 81 (2.71) 0.0782
Diabetic w/o meds Male gender No Present 1032 (34.57) 0.0782
Diabetic w/o meds Male gender Yes Missing 106 (3.55) 0.0782
Diabetic w/o meds Male gender Yes Present 1766 (59.16) 0.0782
Diabetic w/o meds Stroke outcome No Missing 178 (5.96) 0.0808
Diabetic w/o meds Stroke outcome No Present 2724 (91.26) 0.0808
Diabetic w/o meds Stroke outcome Yes Missing 9 (0.30) 0.0808
Diabetic w/o meds Stroke outcome Yes Present 74 (2.48) 0.0808
Diabetic w/ meds Age 3-5 Missing 69 (2.31) 0.8483
Diabetic w/ meds Age 3-5 Present 1052 (35.24) 0.8483
Diabetic w/ meds Age 6-8 Missing 118 (3.95) 0.8483
Diabetic w/ meds Age 6-8 Present 1746 (58.49) 0.8483
Diabetic w/ meds Nonwhite ancestry No Missing 148 (4.96) 0.5517
Diabetic w/ meds Nonwhite ancestry No Present 2264 (75.85) 0.5517
Diabetic w/ meds Nonwhite ancestry Yes Missing 39 (1.31) 0.5517
Diabetic w/ meds Nonwhite ancestry Yes Present 534 (17.89) 0.5517
Diabetic w/ meds Male gender No Missing 81 (2.71) 0.0782
Diabetic w/ meds Male gender No Present 1032 (34.57) 0.0782
Diabetic w/ meds Male gender Yes Missing 106 (3.55) 0.0782
Diabetic w/ meds Male gender Yes Present 1766 (59.16) 0.0782
Diabetic w/ meds Stroke outcome No Missing 178 (5.96) 0.0808
Diabetic w/ meds Stroke outcome No Present 2724 (91.26) 0.0808
Diabetic w/ meds Stroke outcome Yes Missing 9 (0.30) 0.0808
Diabetic w/ meds Stroke outcome Yes Present 74 (2.48) 0.0808
Atrial fibrillation Age 3-5 Missing 53 (1.78) 0.0445
Atrial fibrillation Age 3-5 Present 1068 (35.78) 0.0445
Atrial fibrillation Age 6-8 Missing 61 (2.04) 0.0445
Atrial fibrillation Age 6-8 Present 1803 (60.40) 0.0445
Atrial fibrillation Nonwhite ancestry No Missing 76 (2.55) 0.0001
Atrial fibrillation Nonwhite ancestry No Present 2336 (78.26) 0.0001
Atrial fibrillation Nonwhite ancestry Yes Missing 38 (1.27) 0.0001
Atrial fibrillation Nonwhite ancestry Yes Present 535 (17.92) 0.0001
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Variable 
Stratifying 
variable Level 
Missing 
or Present
6 mos. 
(N (%)) 
6 mos. χ2 
p-value 
Atrial fibrillation Male gender No Missing 40 (1.34) 0.6206
Atrial fibrillation Male gender No Present 1073 (35.95) 0.6206
Atrial fibrillation Male gender Yes Missing 74 (2.48) 0.6206
Atrial fibrillation Male gender Yes Present 1798 (60.23) 0.6206
Atrial fibrillation Stroke outcome No Missing 106 (3.55) 0.0050
Atrial fibrillation Stroke outcome No Present 2796 (93.67) 0.0050
Atrial fibrillation Stroke outcome Yes Missing 8 (0.27) 0.0050
Atrial fibrillation Stroke outcome Yes Present 75 (2.51) 0.0050
Aspirin use Age 3-5 Missing 69 (2.31) 0.8483
Aspirin use Age 3-5 Present 1052 (35.24) 0.8483
Aspirin use Age 6-8 Missing 118 (3.95) 0.8483
Aspirin use Age 6-8 Present 1746 (58.49) 0.8483
Aspirin use Nonwhite ancestry No Missing 148 (4.96) 0.5517
Aspirin use Nonwhite ancestry No Present 2264 (75.85) 0.5517
Aspirin use Nonwhite ancestry Yes Missing 39 (1.31) 0.5517
Aspirin use Nonwhite ancestry Yes Present 534 (17.89) 0.5517
Aspirin use Male gender No Missing 81 (2.71) 0.0782
Aspirin use Male gender No Present 1032 (34.57) 0.0782
Aspirin use Male gender Yes Missing 106 (3.55) 0.0782
Aspirin use Male gender Yes Present 1766 (59.16) 0.0782
Aspirin use Stroke outcome No Missing 178 (5.96) 0.0808
Aspirin use Stroke outcome No Present 2724 (91.26) 0.0808
Aspirin use Stroke outcome Yes Missing 9 (0.30) 0.0808
Aspirin use Stroke outcome Yes Present 74 (2.48) 0.0808
Systolic BP Age 3-5 Missing 71 (2.38) 0.5716
Systolic BP Age 3-5 Present 1050 (35.18) 0.5716
Systolic BP Age 6-8 Missing 128 (4.29) 0.5716
Systolic BP Age 6-8 Present 1736 (58.16) 0.5716
Systolic BP Nonwhite ancestry No Missing 161 (5.39) 0.9703
Systolic BP Nonwhite ancestry No Present 2251 (75.41) 0.9703
Systolic BP Nonwhite ancestry Yes Missing 38 (1.27) 0.9703
Systolic BP Nonwhite ancestry Yes Present 535 (17.92) 0.9703
Systolic BP Male gender No Missing 82 (2.75) 0.2366
Systolic BP Male gender No Present 1031 (34.54) 0.2366
Systolic BP Male gender Yes Missing 117 (3.92) 0.2366
Systolic BP Male gender Yes Present 1755 (58.79) 0.2366
Systolic BP Stroke outcome No Missing 190 (6.37) 0.1218
Systolic BP Stroke outcome No Present 2712 (90.85) 0.1218
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Variable 
Stratifying 
variable Level 
Missing 
or Present
6 mos. 
(N (%)) 
6 mos. χ2 
p-value 
Systolic BP Stroke outcome Yes Missing 9 (0.30) 0.1218
Systolic BP Stroke outcome Yes Present 74 (2.48) 0.1218
Homocysteine Age 3-5 Missing 96 (3.22) 0.9047
Homocysteine Age 3-5 Present 1025 (34.34) 0.9047
Homocysteine Age 6-8 Missing 162 (5.43) 0.9047
Homocysteine Age 6-8 Present 1702 (57.02) 0.9047
Homocysteine Nonwhite ancestry No Missing 211 (7.07) 0.6762
Homocysteine Nonwhite ancestry No Present 2201 (73.74) 0.6762
Homocysteine Nonwhite ancestry Yes Missing 47 (1.57) 0.6762
Homocysteine Nonwhite ancestry Yes Present 526 (17.62) 0.6762
Homocysteine Male gender No Missing 109 (3.65) 0.0847
Homocysteine Male gender No Present 1004 (33.63) 0.0847
Homocysteine Male gender Yes Missing 149 (4.99) 0.0847
Homocysteine Male gender Yes Present 1723 (57.72) 0.0847
Homocysteine Stroke outcome No Missing 247 (8.27) 0.1296
Homocysteine Stroke outcome No Present 2655 (88.94) 0.1296
Homocysteine Stroke outcome Yes Missing 11 (0.37) 0.1296
Homocysteine Stroke outcome Yes Present 72 (2.41) 0.1296
Total cholesterol Age 3-5 Missing 1120 (37.52) 0.2902
Total cholesterol Age 3-5 Present 1 (0.03) 0.2902
Total cholesterol Age 6-8 Missing 1859 (62.28) 0.2902
Total cholesterol Age 6-8 Present 5 (0.17) 0.2902
Total cholesterol Nonwhite ancestry No Missing 2407 (80.64) 0.8749
Total cholesterol Nonwhite ancestry No Present 5 (0.17) 0.8749
Total cholesterol Nonwhite ancestry Yes Missing 572 (19.16) 0.8749
Total cholesterol Nonwhite ancestry Yes Present 1 (0.03) 0.8749
Total cholesterol Male gender No Missing 1110 (37.19) 0.5192
Total cholesterol Male gender No Present 3 (0.10) 0.5192
Total cholesterol Male gender Yes Missing 1869 (62.61) 0.5192
Total cholesterol Male gender Yes Present 3 (0.10) 0.5192
Total cholesterol Stroke outcome No Missing 2897 (97.05) 0.0384
Total cholesterol Stroke outcome No Present 5 (0.17) 0.0384
Total cholesterol Stroke outcome Yes Missing 82 (2.75) 0.0384
Total cholesterol Stroke outcome Yes Present 1 (0.03) 0.0384
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Table A.3. Assessment of data missingness at twelve-month visit by age group, race, 
gender, stroke outcome (for analysis results shown in Table 3.9) 
 
Variable 
Stratifying 
variable Level 
Missing 
or Present
12 mos. 
(N (%)) 
12 mos. χ2 
p-value 
Lipid-lowering med use Age 3-5 Missing 74 (2.60) 0.7544
Lipid-lowering med use Age 3-5 Present 887 (31.17) 0.7544
Lipid-lowering med use Age 6-8 Missing 139 (4.88) 0.7544
Lipid-lowering med use Age 6-8 Present 1746 (61.35) 0.7544
Lipid-lowering med use Nonwhite ancestry No Missing 163 (5.73) 0.0765
Lipid-lowering med use Nonwhite ancestry No Present 2145 (75.37) 0.0765
Lipid-lowering med use Nonwhite ancestry Yes Missing 50 (1.76) 0.0765
Lipid-lowering med use Nonwhite ancestry Yes Present 488 (17.15) 0.0765
Lipid-lowering med use Male gender No Missing 86 (3.02) 0.3719
Lipid-lowering med use Male gender No Present 982 (34.50) 0.3719
Lipid-lowering med use Male gender Yes Missing 127 (4.46) 0.3719
Lipid-lowering med use Male gender Yes Present 1651 (58.01) 0.3719
Lipid-lowering med use Stroke outcome No Missing 205 (7.20) 0.2198
Lipid-lowering med use Stroke outcome No Present 2570 (90.30) 0.2198
Lipid-lowering med use Stroke outcome Yes Missing 8 (0.28) 0.2198
Lipid-lowering med use Stroke outcome Yes Present 63 (2.21) 0.2198
Blood-pressure-lowering med use Age 3-5 Missing 74 (2.60) 0.7544
Blood-pressure-lowering med use Age 3-5 Present 887 (31.17) 0.7544
Blood-pressure-lowering med use Age 6-8 Missing 139 (4.88) 0.7544
Blood-pressure-lowering med use Age 6-8 Present 1746 (61.35) 0.7544
Blood-pressure-lowering med use Nonwhite ancestry No Missing 163 (5.73) 0.0765
Blood-pressure-lowering med use Nonwhite ancestry No Present 2145 (75.37) 0.0765
Blood-pressure-lowering med use Nonwhite ancestry Yes Missing 50 (1.76) 0.0765
Blood-pressure-lowering med use Nonwhite ancestry Yes Present 488 (17.15) 0.0765
Blood-pressure-lowering med use Male gender No Missing 86 (3.02) 0.3719
Blood-pressure-lowering med use Male gender No Present 982 (34.50) 0.3719
Blood-pressure-lowering med use Male gender Yes Missing 127 (4.46) 0.3719
Blood-pressure-lowering med use Male gender Yes Present 1651 (58.01) 0.3719
Blood-pressure-lowering med use Stroke outcome No Missing 205 (7.20) 0.2198
Blood-pressure-lowering med use Stroke outcome No Present 2570 (90.30) 0.2198
Blood-pressure-lowering med use Stroke outcome Yes Missing 8 (0.28) 0.2198
Blood-pressure-lowering med use Stroke outcome Yes Present 63 (2.21) 0.2198
Any dependency Age 3-5 Missing 76 (2.67) 0.4722
Any dependency Age 3-5 Present 885 (31.10) 0.4722
Any dependency Age 6-8 Missing 135 (4.74) 0.4722
Any dependency Age 6-8 Present 1750 (61.49) 0.4722
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Variable 
Stratifying 
variable Level 
Missing 
or Present
12 mos. 
(N (%)) 
12 mos. χ2 
p-value 
Any dependency Nonwhite ancestry No Missing 160 (5.62) 0.0423
Any dependency Nonwhite ancestry No Present 2148 (75.47) 0.0423
Any dependency Nonwhite ancestry Yes Missing 51 (1.79) 0.0423
Any dependency Nonwhite ancestry Yes Present 487 (17.11) 0.0423
Any dependency Male gender No Missing 85 (2.99) 0.3898
Any dependency Male gender No Present 983 (34.54) 0.3898
Any dependency Male gender Yes Missing 126 (4.43) 0.3898
Any dependency Male gender Yes Present 1652 (58.05) 0.3898
Any dependency Stroke outcome No Missing 203 (7.13) 0.2094
Any dependency Stroke outcome No Present 2572 (90.37) 0.2094
Any dependency Stroke outcome Yes Missing 8 (0.28) 0.2094
Any dependency Stroke outcome Yes Present 63 (2.21) 0.2094
Any disability Age 3-5 Missing 73 (2.57) 0.5624
Any disability Age 3-5 Present 888 (31.20) 0.5624
Any disability Age 6-8 Missing 132 (4.64) 0.5624
Any disability Age 6-8 Present 1753 (61.60) 0.5624
Any disability Nonwhite ancestry No Missing 156 (5.48) 0.0578
Any disability Nonwhite ancestry No Present 2152 (75.61) 0.0578
Any disability Nonwhite ancestry Yes Missing 49 (1.72) 0.0578
Any disability Nonwhite ancestry Yes Present 489 (17.18) 0.0578
Any disability Male gender No Missing 82 (2.88) 0.4477
Any disability Male gender No Present 986 (34.65) 0.4477
Any disability Male gender Yes Missing 123 (4.32) 0.4477
Any disability Male gender Yes Present 1655 (58.15) 0.4477
Any disability Stroke outcome No Missing 197 (6.92) 0.1798
Any disability Stroke outcome No Present 2578 (90.58) 0.1798
Any disability Stroke outcome Yes Missing 8 (0.28) 0.1798
Any disability Stroke outcome Yes Present 63 (2.21) 0.1798
BMI Age 3-5 Missing 130 (4.57) 0.3796
BMI Age 3-5 Present 831 (29.20) 0.3796
BMI Age 6-8 Missing 278 (9.77) 0.3796
BMI Age 6-8 Present 1607 (56.47) 0.3796
BMI Nonwhite ancestry No Missing 338 (11.88) 0.3302
BMI Nonwhite ancestry No Present 1970 (69.22) 0.3302
BMI Nonwhite ancestry Yes Missing 70 (2.46) 0.3302
BMI Nonwhite ancestry Yes Present 468 (16.44) 0.3302
BMI Male gender No Missing 137 (4.81) 0.0752
BMI Male gender No Present 931 (32.71) 0.0752
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Variable 
Stratifying 
variable Level 
Missing 
or Present
12 mos. 
(N (%)) 
12 mos. χ2 
p-value 
BMI Male gender Yes Missing 271 (9.52) 0.0752
BMI Male gender Yes Present 1507 (52.95) 0.0752
BMI Stroke outcome No Missing 393 (13.81) 0.0982
BMI Stroke outcome No Present 2382 (83.70) 0.0982
BMI Stroke outcome Yes Missing 15 (0.53) 0.0982
BMI Stroke outcome Yes Present 56 (1.97) 0.0982
Current cigarette smoker Age 3-5 Missing 2 (0.07) 0.2280
Current cigarette smoker Age 3-5 Present 959 (33.70) 0.2280
Current cigarette smoker Age 6-8 Missing 1 (0.04) 0.2280
Current cigarette smoker Age 6-8 Present 1884 (66.20) 0.2280
Current cigarette smoker Nonwhite ancestry No Missing 1 (0.04) 0.0345
Current cigarette smoker Nonwhite ancestry No Present 2307 (81.06) 0.0345
Current cigarette smoker Nonwhite ancestry Yes Missing 2 (0.07) 0.0345
Current cigarette smoker Nonwhite ancestry Yes Present 536 (18.83) 0.0345
Current cigarette smoker Male gender No Missing 1 (0.04) 0.8807
Current cigarette smoker Male gender No Present 1067 (37.49) 0.8807
Current cigarette smoker Male gender Yes Missing 2 (0.07) 0.8807
Current cigarette smoker Male gender Yes Present 1776 (62.40) 0.8807
Current cigarette smoker Stroke outcome No Missing 3 (0.11) 0.7816
Current cigarette smoker Stroke outcome No Present 2772 (97.40) 0.7816
Current cigarette smoker Stroke outcome Yes Missing 0 (0.00) 0.7816
Current cigarette smoker Stroke outcome Yes Present 71 (2.49) 0.7816
HDL cholesterol Age 3-5 Missing 167 (5.87) 0.5054
HDL cholesterol Age 3-5 Present 794 (27.90) 0.5054
HDL cholesterol Age 6-8 Missing 309 (10.86) 0.5054
HDL cholesterol Age 6-8 Present 1576 (55.38) 0.5054
HDL cholesterol Nonwhite ancestry No Missing 367 (12.90) 0.0147
HDL cholesterol Nonwhite ancestry No Present 1941 (68.20) 0.0147
HDL cholesterol Nonwhite ancestry Yes Missing 109 (3.83) 0.0147
HDL cholesterol Nonwhite ancestry Yes Present 429 (15.07) 0.0147
HDL cholesterol Male gender No Missing 185 (6.50) 0.5084
HDL cholesterol Male gender No Present 883 (31.03) 0.5084
HDL cholesterol Male gender Yes Missing 291 (10.22) 0.5084
HDL cholesterol Male gender Yes Present 1487 (52.25) 0.5084
HDL cholesterol Stroke outcome No Missing 462 (16.23) 0.4937
HDL cholesterol Stroke outcome No Present 2313 (81.27) 0.4937
HDL cholesterol Stroke outcome Yes Missing 14 (0.49) 0.4937
HDL cholesterol Stroke outcome Yes Present 57 (2.00) 0.4937
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Variable 
Stratifying 
variable Level 
Missing 
or Present
12 mos. 
(N (%)) 
12 mos. χ2 
p-value 
Nondiabetic w/meds Age 3-5 Missing 74 (2.60) 0.7544
Nondiabetic w/meds Age 3-5 Present 887 (31.17) 0.7544
Nondiabetic w/meds Age 6-8 Missing 139 (4.88) 0.7544
Nondiabetic w/meds Age 6-8 Present 1746 (61.35) 0.7544
Nondiabetic w/meds Nonwhite ancestry No Missing 163 (5.73) 0.0765
Nondiabetic w/meds Nonwhite ancestry No Present 2145 (75.37) 0.0765
Nondiabetic w/meds Nonwhite ancestry Yes Missing 50 (1.76) 0.0765
Nondiabetic w/meds Nonwhite ancestry Yes Present 488 (17.15) 0.0765
Nondiabetic w/meds Male gender No Missing 86 (3.02) 0.3719
Nondiabetic w/meds Male gender No Present 982 (34.50) 0.3719
Nondiabetic w/meds Male gender Yes Missing 127 (4.46) 0.3719
Nondiabetic w/meds Male gender Yes Present 1651 (58.01) 0.3719
Nondiabetic w/meds Stroke outcome No Missing 205 (7.20) 0.2198
Nondiabetic w/meds Stroke outcome No Present 2570 (90.30) 0.2198
Nondiabetic w/meds Stroke outcome Yes Missing 8 (0.28) 0.2198
Nondiabetic w/meds Stroke outcome Yes Present 63 (2.21) 0.2198
Diabetic w/o meds Age 3-5 Missing 74 (2.60) 0.7544
Diabetic w/o meds Age 3-5 Present 887 (31.17) 0.7544
Diabetic w/o meds Age 6-8 Missing 139 (4.88) 0.7544
Diabetic w/o meds Age 6-8 Present 1746 (61.35) 0.7544
Diabetic w/o meds Nonwhite ancestry No Missing 163 (5.73) 0.0765
Diabetic w/o meds Nonwhite ancestry No Present 2145 (75.37) 0.0765
Diabetic w/o meds Nonwhite ancestry Yes Missing 50 (1.76) 0.0765
Diabetic w/o meds Nonwhite ancestry Yes Present 488 (17.15) 0.0765
Diabetic w/o meds Male gender No Missing 86 (3.02) 0.3719
Diabetic w/o meds Male gender No Present 982 (34.50) 0.3719
Diabetic w/o meds Male gender Yes Missing 127 (4.46) 0.3719
Diabetic w/o meds Male gender Yes Present 1651 (58.01) 0.3719
Diabetic w/o meds Stroke outcome No Missing 205 (7.20) 0.2198
Diabetic w/o meds Stroke outcome No Present 2570 (90.30) 0.2198
Diabetic w/o meds Stroke outcome Yes Missing 8 (0.28) 0.2198
Diabetic w/o meds Stroke outcome Yes Present 63 (2.21) 0.2198
Diabetic w/ meds Age 3-5 Missing 74 (2.60) 0.7544
Diabetic w/ meds Age 3-5 Present 887 (31.17) 0.7544
Diabetic w/ meds Age 6-8 Missing 139 (4.88) 0.7544
Diabetic w/ meds Age 6-8 Present 1746 (61.35) 0.7544
Diabetic w/ meds Nonwhite ancestry No Missing 163 (5.73) 0.0765
Diabetic w/ meds Nonwhite ancestry No Present 2145 (75.37) 0.0765
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Variable 
Stratifying 
variable Level 
Missing 
or Present
12 mos. 
(N (%)) 
12 mos. χ2 
p-value 
Diabetic w/ meds Nonwhite ancestry Yes Missing 50 (1.76) 0.0765
Diabetic w/ meds Nonwhite ancestry Yes Present 488 (17.15) 0.0765
Diabetic w/ meds Male gender No Missing 86 (3.02) 0.3719
Diabetic w/ meds Male gender No Present 982 (34.50) 0.3719
Diabetic w/ meds Male gender Yes Missing 127 (4.46) 0.3719
Diabetic w/ meds Male gender Yes Present 1651 (58.01) 0.3719
Diabetic w/ meds Stroke outcome No Missing 205 (7.20) 0.2198
Diabetic w/ meds Stroke outcome No Present 2570 (90.30) 0.2198
Diabetic w/ meds Stroke outcome Yes Missing 8 (0.28) 0.2198
Diabetic w/ meds Stroke outcome Yes Present 63 (2.21) 0.2198
Atrial fibrillation Age 3-5 Missing 12 (0.42) 0.6119
Atrial fibrillation Age 3-5 Present 949 (33.35) 0.6119
Atrial fibrillation Age 6-8 Missing 28 (0.98) 0.6119
Atrial fibrillation Age 6-8 Present 1857 (65.25) 0.6119
Atrial fibrillation Nonwhite ancestry No Missing 27 (0.95) 0.0270
Atrial fibrillation Nonwhite ancestry No Present 2281 (80.15) 0.0270
Atrial fibrillation Nonwhite ancestry Yes Missing 13 (0.46) 0.0270
Atrial fibrillation Nonwhite ancestry Yes Present 525 (18.45) 0.0270
Atrial fibrillation Male gender No Missing 10 (0.35) 0.0994
Atrial fibrillation Male gender No Present 1058 (37.17) 0.0994
Atrial fibrillation Male gender Yes Missing 30 (1.05) 0.0994
Atrial fibrillation Male gender Yes Present 1748 (61.42) 0.0994
Atrial fibrillation Stroke outcome No Missing 35 (1.23) <0.0001
Atrial fibrillation Stroke outcome No Present 2740 (96.28) <0.0001
Atrial fibrillation Stroke outcome Yes Missing 5 (0.18) <0.0001
Atrial fibrillation Stroke outcome Yes Present 66 (2.32) <0.0001
Aspirin use Age 3-5 Missing 74 (2.60) 0.7544
Aspirin use Age 3-5 Present 887 (31.17) 0.7544
Aspirin use Age 6-8 Missing 139 (4.88) 0.7544
Aspirin use Age 6-8 Present 1746 (61.35) 0.7544
Aspirin use Nonwhite ancestry No Missing 163 (5.73) 0.0765
Aspirin use Nonwhite ancestry No Present 2145 (75.37) 0.0765
Aspirin use Nonwhite ancestry Yes Missing 50 (1.76) 0.0765
Aspirin use Nonwhite ancestry Yes Present 488 (17.15) 0.0765
Aspirin use Male gender No Missing 86 (3.02) 0.3719
Aspirin use Male gender No Present 982 (34.50) 0.3719
Aspirin use Male gender Yes Missing 127 (4.46) 0.3719
Aspirin use Male gender Yes Present 1651 (58.01) 0.3719
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Variable 
Stratifying 
variable Level 
Missing 
or Present
12 mos. 
(N (%)) 
12 mos. χ2 
p-value 
Aspirin use Stroke outcome No Missing 205 (7.20) 0.2198
Aspirin use Stroke outcome No Present 2570 (90.30) 0.2198
Aspirin use Stroke outcome Yes Missing 8 (0.28) 0.2198
Aspirin use Stroke outcome Yes Present 63 (2.21) 0.2198
Systolic BP Age 3-5 Missing 76 (2.67) 0.9177
Systolic BP Age 3-5 Present 885 (31.10) 0.9177
Systolic BP Age 6-8 Missing 147 (5.17) 0.9177
Systolic BP Age 6-8 Present 1738 (61.07) 0.9177
Systolic BP Nonwhite ancestry No Missing 169 (5.94) 0.0348
Systolic BP Nonwhite ancestry No Present 2139 (75.16) 0.0348
Systolic BP Nonwhite ancestry Yes Missing 54 (1.90) 0.0348
Systolic BP Nonwhite ancestry Yes Present 484 (17.01) 0.0348
Systolic BP Male gender No Missing 88 (3.09) 0.5341
Systolic BP Male gender No Present 980 (34.43) 0.5341
Systolic BP Male gender Yes Missing 135 (4.74) 0.5341
Systolic BP Male gender Yes Present 1643 (57.73) 0.5341
Systolic BP Stroke outcome No Missing 213 (7.48) 0.0472
Systolic BP Stroke outcome No Present 2562 (90.02) 0.0472
Systolic BP Stroke outcome Yes Missing 10 (0.35) 0.0472
Systolic BP Stroke outcome Yes Present 61 (2.14) 0.0472
Homocysteine Age 3-5 Missing 94 (3.30) 0.6678
Homocysteine Age 3-5 Present 867 (30.46) 0.6678
Homocysteine Age 6-8 Missing 175 (6.15) 0.6678
Homocysteine Age 6-8 Present 1710 (60.08) 0.6678
Homocysteine Nonwhite ancestry No Missing 208 (7.31) 0.0967
Homocysteine Nonwhite ancestry No Present 2100 (73.79) 0.0967
Homocysteine Nonwhite ancestry Yes Missing 61 (2.14) 0.0967
Homocysteine Nonwhite ancestry Yes Present 477 (16.76) 0.0967
Homocysteine Male gender No Missing 103 (3.62) 0.7858
Homocysteine Male gender No Present 965 (33.91) 0.7858
Homocysteine Male gender Yes Missing 166 (5.83) 0.7858
Homocysteine Male gender Yes Present 1612 (56.64) 0.7858
Homocysteine Stroke outcome No Missing 256 (9.00) 0.0098
Homocysteine Stroke outcome No Present 2519 (88.51) 0.0098
Homocysteine Stroke outcome Yes Missing 13 (0.46) 0.0098
Homocysteine Stroke outcome Yes Present 58 (2.04) 0.0098
Total cholesterol Age 3-5 Missing 164 (5.76) 0.4107
Total cholesterol Age 3-5 Present 797 (28.00) 0.4107
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Variable 
Stratifying 
variable Level 
Missing 
or Present
12 mos. 
(N (%)) 
12 mos. χ2 
p-value 
Total cholesterol Age 6-8 Missing 299 (10.51) 0.4107
Total cholesterol Age 6-8 Present 1586 (55.73) 0.4107
Total cholesterol Nonwhite ancestry No Missing 353 (12.40) 0.0036
Total cholesterol Nonwhite ancestry No Present 1955 (68.69) 0.0036
Total cholesterol Nonwhite ancestry Yes Missing 110 (3.87) 0.0036
Total cholesterol Nonwhite ancestry Yes Present 428 (15.04) 0.0036
Total cholesterol Male gender No Missing 182 (6.39) 0.3867
Total cholesterol Male gender No Present 886 (31.13) 0.3867
Total cholesterol Male gender Yes Missing 281 (9.87) 0.3867
Total cholesterol Male gender Yes Present 1497 (52.60) 0.3867
Total cholesterol Stroke outcome No Missing 449 (15.78) 0.4251
Total cholesterol Stroke outcome No Present 2326 (81.73) 0.4251
Total cholesterol Stroke outcome Yes Missing 14 (0.49) 0.4251
Total cholesterol Stroke outcome Yes Present 57 (2.00) 0.4251
 
Table A.4. Assessment of data missingness at eighteen-month visit by age group, race, 
gender, stroke outcome (for analysis results shown in Table 3.9) 
 
Variable 
Stratifying 
variable Level 
Missing 
or Present
18 mos. 
(N (%)) 
18 mos. χ2 
p-value 
Lipid-lowering med use Age 3-5 Missing 81 (3.37) 0.7483
Lipid-lowering med use Age 3-5 Present 757 (31.46) 0.7483
Lipid-lowering med use Age 6-8 Missing 158 (6.57) 0.7483
Lipid-lowering med use Age 6-8 Present 1410 (58.60) 0.7483
Lipid-lowering med use Nonwhite ancestry No Missing 191 (7.94) 0.4937
Lipid-lowering med use Nonwhite ancestry No Present 1771 (73.61) 0.4937
Lipid-lowering med use Nonwhite ancestry Yes Missing 48 (2.00) 0.4937
Lipid-lowering med use Nonwhite ancestry Yes Present 396 (16.46) 0.4937
Lipid-lowering med use Male gender No Missing 95 (3.95) 0.4303
Lipid-lowering med use Male gender No Present 805 (33.46) 0.4303
Lipid-lowering med use Male gender Yes Missing 144 (5.99) 0.4303
Lipid-lowering med use Male gender Yes Present 1362 (56.61) 0.4303
Lipid-lowering med use Stroke outcome No Missing 236 (9.81) 0.4347
Lipid-lowering med use Stroke outcome No Present 2124 (88.28) 0.4347
Lipid-lowering med use Stroke outcome Yes Missing 3 (0.12) 0.4347
Lipid-lowering med use Stroke outcome Yes Present 43 (1.79) 0.4347
Blood-pressure-lowering med use Age 3-5 Missing 81 (3.37) 0.7483
Blood-pressure-lowering med use Age 3-5 Present 757 (31.46) 0.7483
Blood-pressure-lowering med use Age 6-8 Missing 158 (6.57) 0.7483
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Variable 
Stratifying 
variable Level 
Missing 
or Present
18 mos. 
(N (%)) 
18 mos. χ2 
p-value 
Blood-pressure-lowering med use Age 6-8 Present 1410 (58.60) 0.7483
Blood-pressure-lowering med use Nonwhite ancestry No Missing 191 (7.94) 0.4937
Blood-pressure-lowering med use Nonwhite ancestry No Present 1771 (73.61) 0.4937
Blood-pressure-lowering med use Nonwhite ancestry Yes Missing 48 (2.00) 0.4937
Blood-pressure-lowering med use Nonwhite ancestry Yes Present 396 (16.46) 0.4937
Blood-pressure-lowering med use Male gender No Missing 95 (3.95) 0.4303
Blood-pressure-lowering med use Male gender No Present 805 (33.46) 0.4303
Blood-pressure-lowering med use Male gender Yes Missing 144 (5.99) 0.4303
Blood-pressure-lowering med use Male gender Yes Present 1362 (56.61) 0.4303
Blood-pressure-lowering med use Stroke outcome No Missing 236 (9.81) 0.4347
Blood-pressure-lowering med use Stroke outcome No Present 2124 (88.28) 0.4347
Blood-pressure-lowering med use Stroke outcome Yes Missing 3 (0.12) 0.4347
Blood-pressure-lowering med use Stroke outcome Yes Present 43 (1.79) 0.4347
Any dependency Age 3-5 Missing 81 (3.37) 0.6400
Any dependency Age 3-5 Present 757 (31.46) 0.6400
Any dependency Age 6-8 Missing 161 (6.69) 0.6400
Any dependency Age 6-8 Present 1407 (58.48) 0.6400
Any dependency Nonwhite ancestry No Missing 194 (8.06) 0.5593
Any dependency Nonwhite ancestry No Present 1768 (73.48) 0.5593
Any dependency Nonwhite ancestry Yes Missing 48 (2.00) 0.5593
Any dependency Nonwhite ancestry Yes Present 396 (16.46) 0.5593
Any dependency Male gender No Missing 95 (3.95) 0.5306
Any dependency Male gender No Present 805 (33.46) 0.5306
Any dependency Male gender Yes Missing 147 (6.11) 0.5306
Any dependency Male gender Yes Present 1359 (56.48) 0.5306
Any dependency Stroke outcome No Missing 239 (9.93) 0.4207
Any dependency Stroke outcome No Present 2121 (88.15) 0.4207
Any dependency Stroke outcome Yes Missing 3 (0.12) 0.4207
Any dependency Stroke outcome Yes Present 43 (1.79) 0.4207
Any disability Age 3-5 Missing 81 (3.37) 0.7860
Any disability Age 3-5 Present 757 (31.46) 0.7860
Any disability Age 6-8 Missing 157 (6.53) 0.7860
Any disability Age 6-8 Present 1411 (58.65) 0.7860
Any disability Nonwhite ancestry No Missing 189 (7.86) 0.3712
Any disability Nonwhite ancestry No Present 1773 (73.69) 0.3712
Any disability Nonwhite ancestry Yes Missing 49 (2.04) 0.3712
Any disability Nonwhite ancestry Yes Present 395 (16.42) 0.3712
Any disability Male gender No Missing 92 (3.82) 0.6749
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Variable 
Stratifying 
variable Level 
Missing 
or Present
18 mos. 
(N (%)) 
18 mos. χ2 
p-value 
Any disability Male gender No Present 808 (33.58) 0.6749
Any disability Male gender Yes Missing 146 (6.07) 0.6749
Any disability Male gender Yes Present 1360 (56.53) 0.6749
Any disability Stroke outcome No Missing 235 (9.77) 0.4395
Any disability Stroke outcome No Present 2125 (88.32) 0.4395
Any disability Stroke outcome Yes Missing 3 (0.12) 0.4395
Any disability Stroke outcome Yes Present 43 (1.79) 0.4395
BMI Age 3-5 Missing 141 (5.86) 0.1873
BMI Age 3-5 Present 697 (28.97) 0.1873
BMI Age 6-8 Missing 298 (12.39) 0.1873
BMI Age 6-8 Present 1270 (52.78) 0.1873
BMI Nonwhite ancestry No Missing 364 (15.13) 0.4133
BMI Nonwhite ancestry No Present 1598 (66.42) 0.4133
BMI Nonwhite ancestry Yes Missing 75 (3.12) 0.4133
BMI Nonwhite ancestry Yes Present 369 (15.34) 0.4133
BMI Male gender No Missing 161 (6.69) 0.7258
BMI Male gender No Present 739 (30.71) 0.7258
BMI Male gender Yes Missing 278 (11.55) 0.7258
BMI Male gender Yes Present 1228 (51.04) 0.7258
BMI Stroke outcome No Missing 434 (18.04) 0.1909
BMI Stroke outcome No Present 1926 (80.05) 0.1909
BMI Stroke outcome Yes Missing 5 (0.21) 0.1909
BMI Stroke outcome Yes Present 41 (1.70) 0.1909
Current cigarette smoker Age 3-5 Missing 1 (0.04) 0.6524
Current cigarette smoker Age 3-5 Present 837 (34.79) 0.6524
Current cigarette smoker Age 6-8 Missing 1 (0.04) 0.6524
Current cigarette smoker Age 6-8 Present 1567 (65.13) 0.6524
Current cigarette smoker Nonwhite ancestry No Missing 2 (0.08) 0.5009
Current cigarette smoker Nonwhite ancestry No Present 1960 (81.46) 0.5009
Current cigarette smoker Nonwhite ancestry Yes Missing 0 (0.00) 0.5009
Current cigarette smoker Nonwhite ancestry Yes Present 444 (18.45) 0.5009
Current cigarette smoker Male gender No Missing 1 (0.04) 0.7127
Current cigarette smoker Male gender No Present 899 (37.36) 0.7127
Current cigarette smoker Male gender Yes Missing 1 (0.04) 0.7127
Current cigarette smoker Male gender Yes Present 1505 (62.55) 0.7127
Current cigarette smoker Stroke outcome No Missing 2 (0.08) 0.8434
Current cigarette smoker Stroke outcome No Present 2358 (98.00) 0.8434
Current cigarette smoker Stroke outcome Yes Missing 0 (0.00) 0.8434
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Variable 
Stratifying 
variable Level 
Missing 
or Present
18 mos. 
(N (%)) 
18 mos. χ2 
p-value 
Current cigarette smoker Stroke outcome Yes Present 46 (1.91) 0.8434
HDL cholesterol Age 3-5 Missing 834 (34.66) 0.9148
HDL cholesterol Age 3-5 Present 4 (0.17) 0.9148
HDL cholesterol Age 6-8 Missing 1561 (64.88) 0.9148
HDL cholesterol Age 6-8 Present 7 (0.29) 0.9148
HDL cholesterol Nonwhite ancestry No Missing 1952 (81.13) 0.4224
HDL cholesterol Nonwhite ancestry No Present 10 (0.42) 0.4224
HDL cholesterol Nonwhite ancestry Yes Missing 443 (18.41) 0.4224
HDL cholesterol Nonwhite ancestry Yes Present 1 (0.04) 0.4224
HDL cholesterol Male gender No Missing 896 (37.24) 0.9429
HDL cholesterol Male gender No Present 4 (0.17) 0.9429
HDL cholesterol Male gender Yes Missing 1499 (62.30) 0.9429
HDL cholesterol Male gender Yes Present 7 (0.29) 0.9429
HDL cholesterol Stroke outcome No Missing 2350 (97.67) 0.0814
HDL cholesterol Stroke outcome No Present 10 (0.42) 0.0814
HDL cholesterol Stroke outcome Yes Missing 45 (1.87) 0.0814
HDL cholesterol Stroke outcome Yes Present 1 (0.04) 0.0814
Nondiabetic w/meds Age 3-5 Missing 82 (3.41) 0.8203
Nondiabetic w/meds Age 3-5 Present 756 (31.42) 0.8203
Nondiabetic w/meds Age 6-8 Missing 158 (6.57) 0.8203
Nondiabetic w/meds Age 6-8 Present 1410 (58.60) 0.8203
Nondiabetic w/meds Nonwhite ancestry No Missing 191 (7.94) 0.4087
Nondiabetic w/meds Nonwhite ancestry No Present 1771 (73.61) 0.4087
Nondiabetic w/meds Nonwhite ancestry Yes Missing 49 (2.04) 0.4087
Nondiabetic w/meds Nonwhite ancestry Yes Present 395 (16.42) 0.4087
Nondiabetic w/meds Male gender No Missing 96 (3.99) 0.3815
Nondiabetic w/meds Male gender No Present 804 (33.42) 0.3815
Nondiabetic w/meds Male gender Yes Missing 144 (5.99) 0.3815
Nondiabetic w/meds Male gender Yes Present 1362 (56.61) 0.3815
Nondiabetic w/meds Stroke outcome No Missing 237 (9.85) 0.4300
Nondiabetic w/meds Stroke outcome No Present 2123 (88.24) 0.4300
Nondiabetic w/meds Stroke outcome Yes Missing 3 (0.12) 0.4300
Nondiabetic w/meds Stroke outcome Yes Present 43 (1.79) 0.4300
Diabetic w/o meds Age 3-5 Missing 82 (3.41) 0.8203
Diabetic w/o meds Age 3-5 Present 756 (31.42) 0.8203
Diabetic w/o meds Age 6-8 Missing 158 (6.57) 0.8203
Diabetic w/o meds Age 6-8 Present 1410 (58.60) 0.8203
Diabetic w/o meds Nonwhite ancestry No Missing 191 (7.94) 0.4087
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Variable 
Stratifying 
variable Level 
Missing 
or Present
18 mos. 
(N (%)) 
18 mos. χ2 
p-value 
Diabetic w/o meds Nonwhite ancestry No Present 1771 (73.61) 0.4087
Diabetic w/o meds Nonwhite ancestry Yes Missing 49 (2.04) 0.4087
Diabetic w/o meds Nonwhite ancestry Yes Present 395 (16.42) 0.4087
Diabetic w/o meds Male gender No Missing 96 (3.99) 0.3815
Diabetic w/o meds Male gender No Present 804 (33.42) 0.3815
Diabetic w/o meds Male gender Yes Missing 144 (5.99) 0.3815
Diabetic w/o meds Male gender Yes Present 1362 (56.61) 0.3815
Diabetic w/o meds Stroke outcome No Missing 237 (9.85) 0.4300
Diabetic w/o meds Stroke outcome No Present 2123 (88.24) 0.4300
Diabetic w/o meds Stroke outcome Yes Missing 3 (0.12) 0.4300
Diabetic w/o meds Stroke outcome Yes Present 43 (1.79) 0.4300
Diabetic w/ meds Age 3-5 Missing 82 (3.41) 0.8203
Diabetic w/ meds Age 3-5 Present 756 (31.42) 0.8203
Diabetic w/ meds Age 6-8 Missing 158 (6.57) 0.8203
Diabetic w/ meds Age 6-8 Present 1410 (58.60) 0.8203
Diabetic w/ meds Nonwhite ancestry No Missing 191 (7.94) 0.4087
Diabetic w/ meds Nonwhite ancestry No Present 1771 (73.61) 0.4087
Diabetic w/ meds Nonwhite ancestry Yes Missing 49 (2.04) 0.4087
Diabetic w/ meds Nonwhite ancestry Yes Present 395 (16.42) 0.4087
Diabetic w/ meds Male gender No Missing 96 (3.99) 0.3815
Diabetic w/ meds Male gender No Present 804 (33.42) 0.3815
Diabetic w/ meds Male gender Yes Missing 144 (5.99) 0.3815
Diabetic w/ meds Male gender Yes Present 1362 (56.61) 0.3815
Diabetic w/ meds Stroke outcome No Missing 237 (9.85) 0.4300
Diabetic w/ meds Stroke outcome No Present 2123 (88.24) 0.4300
Diabetic w/ meds Stroke outcome Yes Missing 3 (0.12) 0.4300
Diabetic w/ meds Stroke outcome Yes Present 43 (1.79) 0.4300
Atrial fibrillation Age 3-5 Missing 96 (3.99) 0.8390
Atrial fibrillation Age 3-5 Present 742 (30.84) 0.8390
Atrial fibrillation Age 6-8 Missing 184 (7.65) 0.8390
Atrial fibrillation Age 6-8 Present 1384 (57.52) 0.8390
Atrial fibrillation Nonwhite ancestry No Missing 216 (8.98) 0.0433
Atrial fibrillation Nonwhite ancestry No Present 1746 (72.57) 0.0433
Atrial fibrillation Nonwhite ancestry Yes Missing 64 (2.66) 0.0433
Atrial fibrillation Nonwhite ancestry Yes Present 380 (15.79) 0.0433
Atrial fibrillation Male gender No Missing 90 (3.74) 0.0528
Atrial fibrillation Male gender No Present 810 (33.67) 0.0528
Atrial fibrillation Male gender Yes Missing 190 (7.90) 0.0528
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Variable 
Stratifying 
variable Level 
Missing 
or Present
18 mos. 
(N (%)) 
18 mos. χ2 
p-value 
Atrial fibrillation Male gender Yes Present 1316 (54.70) 0.0528
Atrial fibrillation Stroke outcome No Missing 273 (11.35) 0.4446
Atrial fibrillation Stroke outcome No Present 2087 (86.74) 0.4446
Atrial fibrillation Stroke outcome Yes Missing 7 (0.29) 0.4446
Atrial fibrillation Stroke outcome Yes Present 39 (1.62) 0.4446
Aspirin use Age 3-5 Missing 81 (3.37) 0.7483
Aspirin use Age 3-5 Present 757 (31.46) 0.7483
Aspirin use Age 6-8 Missing 158 (6.57) 0.7483
Aspirin use Age 6-8 Present 1410 (58.60) 0.7483
Aspirin use Nonwhite ancestry No Missing 191 (7.94) 0.4937
Aspirin use Nonwhite ancestry No Present 1771 (73.61) 0.4937
Aspirin use Nonwhite ancestry Yes Missing 48 (2.00) 0.4937
Aspirin use Nonwhite ancestry Yes Present 396 (16.46) 0.4937
Aspirin use Male gender No Missing 95 (3.95) 0.4303
Aspirin use Male gender No Present 805 (33.46) 0.4303
Aspirin use Male gender Yes Missing 144 (5.99) 0.4303
Aspirin use Male gender Yes Present 1362 (56.61) 0.4303
Aspirin use Stroke outcome No Missing 236 (9.81) 0.4347
Aspirin use Stroke outcome No Present 2124 (88.28) 0.4347
Aspirin use Stroke outcome Yes Missing 3 (0.12) 0.4347
Aspirin use Stroke outcome Yes Present 43 (1.79) 0.4347
Systolic BP Age 3-5 Missing 83 (3.45) 0.6693
Systolic BP Age 3-5 Present 755 (31.38) 0.6693
Systolic BP Age 6-8 Missing 164 (6.82) 0.6693
Systolic BP Age 6-8 Present 1404 (58.35) 0.6693
Systolic BP Nonwhite ancestry No Missing 197 (8.19) 0.4442
Systolic BP Nonwhite ancestry No Present 1765 (73.36) 0.4442
Systolic BP Nonwhite ancestry Yes Missing 50 (2.08) 0.4442
Systolic BP Nonwhite ancestry Yes Present 394 (16.38) 0.4442
Systolic BP Male gender No Missing 96 (3.99) 0.6167
Systolic BP Male gender No Present 804 (33.42) 0.6167
Systolic BP Male gender Yes Missing 151 (6.28) 0.6167
Systolic BP Male gender Yes Present 1355 (56.32) 0.6167
Systolic BP Stroke outcome No Missing 243 (10.10) 0.7231
Systolic BP Stroke outcome No Present 2117 (87.99) 0.7231
Systolic BP Stroke outcome Yes Missing 4 (0.17) 0.7231
Systolic BP Stroke outcome Yes Present 42 (1.75) 0.7231
Homocysteine Age 3-5 Missing 100 (4.16) 0.6867
  
168
 
Variable 
Stratifying 
variable Level 
Missing 
or Present
18 mos. 
(N (%)) 
18 mos. χ2 
p-value 
Homocysteine Age 3-5 Present 738 (30.67) 0.6867
Homocysteine Age 6-8 Missing 196 (8.15) 0.6867
Homocysteine Age 6-8 Present 1372 (57.02) 0.6867
Homocysteine Nonwhite ancestry No Missing 230 (9.56) 0.0687
Homocysteine Nonwhite ancestry No Present 1732 (71.99) 0.0687
Homocysteine Nonwhite ancestry Yes Missing 66 (2.74) 0.0687
Homocysteine Nonwhite ancestry Yes Present 378 (15.71) 0.0687
Homocysteine Male gender No Missing 113 (4.70) 0.7703
Homocysteine Male gender No Present 787 (32.71) 0.7703
Homocysteine Male gender Yes Missing 183 (7.61) 0.7703
Homocysteine Male gender Yes Present 1323 (54.99) 0.7703
Homocysteine Stroke outcome No Missing 292 (12.14) 0.4521
Homocysteine Stroke outcome No Present 2068 (85.95) 0.4521
Homocysteine Stroke outcome Yes Missing 4 (0.17) 0.4521
Homocysteine Stroke outcome Yes Present 42 (1.75) 0.4521
Total cholesterol Age 3-5 Missing 834 (34.66) 0.9148
Total cholesterol Age 3-5 Present 4 (0.17) 0.9148
Total cholesterol Age 6-8 Missing 1561 (64.88) 0.9148
Total cholesterol Age 6-8 Present 7 (0.29) 0.9148
Total cholesterol Nonwhite ancestry No Missing 1952 (81.13) 0.4224
Total cholesterol Nonwhite ancestry No Present 10 (0.42) 0.4224
Total cholesterol Nonwhite ancestry Yes Missing 443 (18.41) 0.4224
Total cholesterol Nonwhite ancestry Yes Present 1 (0.04) 0.4224
Total cholesterol Male gender No Missing 896 (37.24) 0.9429
Total cholesterol Male gender No Present 4 (0.17) 0.9429
Total cholesterol Male gender Yes Missing 1499 (62.30) 0.9429
Total cholesterol Male gender Yes Present 7 (0.29) 0.9429
Total cholesterol Stroke outcome No Missing 2350 (97.67) 0.0814
Total cholesterol Stroke outcome No Present 10 (0.42) 0.0814
Total cholesterol Stroke outcome Yes Missing 45 (1.87) 0.0814
Total cholesterol Stroke outcome Yes Present 1 (0.04) 0.0814
 
Table A.5. Assessment of data missingness at twenty-four month visit by age group, 
race, gender, stroke outcome (for analysis results shown in Table 3.9) 
 
Variable 
Stratifying 
variable Level 
Missing 
or Present
24 mos. 
(N (%)) 
24 mos. χ2 
p-value 
Lipid-lowering med use Age 3-5 Missing 47 (1.84) 0.2316
Lipid-lowering med use Age 3-5 Present 780 (30.49) 0.2316
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Variable 
Stratifying 
variable Level 
Missing 
or Present
24 mos. 
(N (%)) 
24 mos. χ2 
p-value 
Lipid-lowering med use Age 6-8 Missing 120 (4.69) 0.2316
Lipid-lowering med use Age 6-8 Present 1611 (62.98) 0.2316
Lipid-lowering med use Nonwhite ancestry No Missing 128 (5.00) 0.0753
Lipid-lowering med use Nonwhite ancestry No Present 1964 (76.78) 0.0753
Lipid-lowering med use Nonwhite ancestry Yes Missing 39 (1.52) 0.0753
Lipid-lowering med use Nonwhite ancestry Yes Present 427 (16.69) 0.0753
Lipid-lowering med use Male gender No Missing 69 (2.70) 0.3842
Lipid-lowering med use Male gender No Present 907 (35.46) 0.3842
Lipid-lowering med use Male gender Yes Missing 98 (3.83) 0.3842
Lipid-lowering med use Male gender Yes Present 1484 (58.01) 0.3842
Lipid-lowering med use Stroke outcome No Missing 162 (6.33) 0.0188
Lipid-lowering med use Stroke outcome No Present 2367 (92.53) 0.0188
Lipid-lowering med use Stroke outcome Yes Missing 5 (0.20) 0.0188
Lipid-lowering med use Stroke outcome Yes Present 24 (0.94) 0.0188
Blood-pressure-lowering med use Age 3-5 Missing 47 (1.84) 0.2316
Blood-pressure-lowering med use Age 3-5 Present 780 (30.49) 0.2316
Blood-pressure-lowering med use Age 6-8 Missing 120 (4.69) 0.2316
Blood-pressure-lowering med use Age 6-8 Present 1611 (62.98) 0.2316
Blood-pressure-lowering med use Nonwhite ancestry No Missing 128 (5.00) 0.0753
Blood-pressure-lowering med use Nonwhite ancestry No Present 1964 (76.78) 0.0753
Blood-pressure-lowering med use Nonwhite ancestry Yes Missing 39 (1.52) 0.0753
Blood-pressure-lowering med use Nonwhite ancestry Yes Present 427 (16.69) 0.0753
Blood-pressure-lowering med use Male gender No Missing 69 (2.70) 0.3842
Blood-pressure-lowering med use Male gender No Present 907 (35.46) 0.3842
Blood-pressure-lowering med use Male gender Yes Missing 98 (3.83) 0.3842
Blood-pressure-lowering med use Male gender Yes Present 1484 (58.01) 0.3842
Blood-pressure-lowering med use Stroke outcome No Missing 162 (6.33) 0.0188
Blood-pressure-lowering med use Stroke outcome No Present 2367 (92.53) 0.0188
Blood-pressure-lowering med use Stroke outcome Yes Missing 5 (0.20) 0.0188
Blood-pressure-lowering med use Stroke outcome Yes Present 24 (0.94) 0.0188
Any dependency Age 3-5 Missing 46 (1.80) 0.2063
Any dependency Age 3-5 Present 781 (30.53) 0.2063
Any dependency Age 6-8 Missing 119 (4.65) 0.2063
Any dependency Age 6-8 Present 1612 (63.02) 0.2063
Any dependency Nonwhite ancestry No Missing 127 (4.96) 0.0977
Any dependency Nonwhite ancestry No Present 1965 (76.82) 0.0977
Any dependency Nonwhite ancestry Yes Missing 38 (1.49) 0.0977
Any dependency Nonwhite ancestry Yes Present 428 (16.73) 0.0977
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Variable 
Stratifying 
variable Level 
Missing 
or Present
24 mos. 
(N (%)) 
24 mos. χ2 
p-value 
Any dependency Male gender No Missing 67 (2.62) 0.5028
Any dependency Male gender No Present 909 (35.54) 0.5028
Any dependency Male gender Yes Missing 98 (3.83) 0.5028
Any dependency Male gender Yes Present 1484 (58.01) 0.5028
Any dependency Stroke outcome No Missing 160 (6.25) 0.0174
Any dependency Stroke outcome No Present 2369 (92.61) 0.0174
Any dependency Stroke outcome Yes Missing 5 (0.20) 0.0174
Any dependency Stroke outcome Yes Present 24 (0.94) 0.0174
Any disability Age 3-5 Missing 47 (1.84) 0.2316
Any disability Age 3-5 Present 780 (30.49) 0.2316
Any disability Age 6-8 Missing 120 (4.69) 0.2316
Any disability Age 6-8 Present 1611 (62.98) 0.2316
Any disability Nonwhite ancestry No Missing 128 (5.00) 0.0753
Any disability Nonwhite ancestry No Present 1964 (76.78) 0.0753
Any disability Nonwhite ancestry Yes Missing 39 (1.52) 0.0753
Any disability Nonwhite ancestry Yes Present 427 (16.69) 0.0753
Any disability Male gender No Missing 67 (2.62) 0.5887
Any disability Male gender No Present 909 (35.54) 0.5887
Any disability Male gender Yes Missing 100 (3.91) 0.5887
Any disability Male gender Yes Present 1482 (57.94) 0.5887
Any disability Stroke outcome No Missing 162 (6.33) 0.0188
Any disability Stroke outcome No Present 2367 (92.53) 0.0188
Any disability Stroke outcome Yes Missing 5 (0.20) 0.0188
Any disability Stroke outcome Yes Present 24 (0.94) 0.0188
BMI Age 3-5 Missing 100 (3.91) 0.1325
BMI Age 3-5 Present 727 (28.42) 0.1325
BMI Age 6-8 Missing 247 (9.66) 0.1325
BMI Age 6-8 Present 1484 (58.01) 0.1325
BMI Nonwhite ancestry No Missing 289 (11.30) 0.4354
BMI Nonwhite ancestry No Present 1803 (70.48) 0.4354
BMI Nonwhite ancestry Yes Missing 58 (2.27) 0.4354
BMI Nonwhite ancestry Yes Present 408 (15.95) 0.4354
BMI Male gender No Missing 138 (5.39) 0.5054
BMI Male gender No Present 838 (32.76) 0.5054
BMI Male gender Yes Missing 209 (8.17) 0.5054
BMI Male gender Yes Present 1373 (53.67) 0.5054
BMI Stroke outcome No Missing 340 (13.29) 0.0945
BMI Stroke outcome No Present 2189 (85.57) 0.0945
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Variable 
Stratifying 
variable Level 
Missing 
or Present
24 mos. 
(N (%)) 
24 mos. χ2 
p-value 
BMI Stroke outcome Yes Missing 7 (0.27) 0.0945
BMI Stroke outcome Yes Present 22 (0.86) 0.0945
Current cigarette smoker Age 3-5 Missing 0 (0.00) 0.3281
Current cigarette smoker Age 3-5 Present 827 (32.33) 0.3281
Current cigarette smoker Age 6-8 Missing 2 (0.08) 0.3281
Current cigarette smoker Age 6-8 Present 1729 (67.59) 0.3281
Current cigarette smoker Nonwhite ancestry No Missing 2 (0.08) 0.5043
Current cigarette smoker Nonwhite ancestry No Present 2090 (81.70) 0.5043
Current cigarette smoker Nonwhite ancestry Yes Missing 0 (0.00) 0.5043
Current cigarette smoker Nonwhite ancestry Yes Present 466 (18.22) 0.5043
Current cigarette smoker Male gender No Missing 0 (0.00) 0.2665
Current cigarette smoker Male gender No Present 976 (38.15) 0.2665
Current cigarette smoker Male gender Yes Missing 2 (0.08) 0.2665
Current cigarette smoker Male gender Yes Present 1580 (61.77) 0.2665
Current cigarette smoker Stroke outcome No Missing 2 (0.08) 0.8796
Current cigarette smoker Stroke outcome No Present 2527 (98.79) 0.8796
Current cigarette smoker Stroke outcome Yes Missing 0 (0.00) 0.8796
Current cigarette smoker Stroke outcome Yes Present 29 (1.13) 0.8796
HDL cholesterol Age 3-5 Missing 132 (5.16) 0.1256
HDL cholesterol Age 3-5 Present 695 (27.17) 0.1256
HDL cholesterol Age 6-8 Missing 319 (12.47) 0.1256
HDL cholesterol Age 6-8 Present 1412 (55.20) 0.1256
HDL cholesterol Nonwhite ancestry No Missing 348 (13.60) 0.0051
HDL cholesterol Nonwhite ancestry No Present 1744 (68.18) 0.0051
HDL cholesterol Nonwhite ancestry Yes Missing 103 (4.03) 0.0051
HDL cholesterol Nonwhite ancestry Yes Present 363 (14.19) 0.0051
HDL cholesterol Male gender No Missing 189 (7.39) 0.0707
HDL cholesterol Male gender No Present 787 (30.77) 0.0707
HDL cholesterol Male gender Yes Missing 262 (10.24) 0.0707
HDL cholesterol Male gender Yes Present 1320 (51.60) 0.0707
HDL cholesterol Stroke outcome No Missing 440 (17.20) 0.0039
HDL cholesterol Stroke outcome No Present 2089 (81.67) 0.0039
HDL cholesterol Stroke outcome Yes Missing 11 (0.43) 0.0039
HDL cholesterol Stroke outcome Yes Present 18 (0.70) 0.0039
Nondiabetic w/meds Age 3-5 Missing 51 (1.99) 0.1246
Nondiabetic w/meds Age 3-5 Present 776 (30.34) 0.1246
Nondiabetic w/meds Age 6-8 Missing 136 (5.32) 0.1246
Nondiabetic w/meds Age 6-8 Present 1595 (62.35) 0.1246
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Variable 
Stratifying 
variable Level 
Missing 
or Present
24 mos. 
(N (%)) 
24 mos. χ2 
p-value 
Nondiabetic w/meds Nonwhite ancestry No Missing 144 (5.63) 0.0788
Nondiabetic w/meds Nonwhite ancestry No Present 1948 (76.15) 0.0788
Nondiabetic w/meds Nonwhite ancestry Yes Missing 43 (1.68) 0.0788
Nondiabetic w/meds Nonwhite ancestry Yes Present 423 (16.54) 0.0788
Nondiabetic w/meds Male gender No Missing 78 (3.05) 0.2984
Nondiabetic w/meds Male gender No Present 898 (35.11) 0.2984
Nondiabetic w/meds Male gender Yes Missing 109 (4.26) 0.2984
Nondiabetic w/meds Male gender Yes Present 1473 (57.58) 0.2984
Nondiabetic w/meds Stroke outcome No Missing 182 (7.11) 0.0388
Nondiabetic w/meds Stroke outcome No Present 2347 (91.75) 0.0388
Nondiabetic w/meds Stroke outcome Yes Missing 5 (0.20) 0.0388
Nondiabetic w/meds Stroke outcome Yes Present 24 (0.94) 0.0388
Diabetic w/o meds Age 3-5 Missing 51 (1.99) 0.1246
Diabetic w/o meds Age 3-5 Present 776 (30.34) 0.1246
Diabetic w/o meds Age 6-8 Missing 136 (5.32) 0.1246
Diabetic w/o meds Age 6-8 Present 1595 (62.35) 0.1246
Diabetic w/o meds Nonwhite ancestry No Missing 144 (5.63) 0.0788
Diabetic w/o meds Nonwhite ancestry No Present 1948 (76.15) 0.0788
Diabetic w/o meds Nonwhite ancestry Yes Missing 43 (1.68) 0.0788
Diabetic w/o meds Nonwhite ancestry Yes Present 423 (16.54) 0.0788
Diabetic w/o meds Male gender No Missing 78 (3.05) 0.2984
Diabetic w/o meds Male gender No Present 898 (35.11) 0.2984
Diabetic w/o meds Male gender Yes Missing 109 (4.26) 0.2984
Diabetic w/o meds Male gender Yes Present 1473 (57.58) 0.2984
Diabetic w/o meds Stroke outcome No Missing 182 (7.11) 0.0388
Diabetic w/o meds Stroke outcome No Present 2347 (91.75) 0.0388
Diabetic w/o meds Stroke outcome Yes Missing 5 (0.20) 0.0388
Diabetic w/o meds Stroke outcome Yes Present 24 (0.94) 0.0388
Diabetic w/ meds Age 3-5 Missing 51 (1.99) 0.1246
Diabetic w/ meds Age 3-5 Present 776 (30.34) 0.1246
Diabetic w/ meds Age 6-8 Missing 136 (5.32) 0.1246
Diabetic w/ meds Age 6-8 Present 1595 (62.35) 0.1246
Diabetic w/ meds Nonwhite ancestry No Missing 144 (5.63) 0.0788
Diabetic w/ meds Nonwhite ancestry No Present 1948 (76.15) 0.0788
Diabetic w/ meds Nonwhite ancestry Yes Missing 43 (1.68) 0.0788
Diabetic w/ meds Nonwhite ancestry Yes Present 423 (16.54) 0.0788
Diabetic w/ meds Male gender No Missing 78 (3.05) 0.2984
Diabetic w/ meds Male gender No Present 898 (35.11) 0.2984
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Variable 
Stratifying 
variable Level 
Missing 
or Present
24 mos. 
(N (%)) 
24 mos. χ2 
p-value 
Diabetic w/ meds Male gender Yes Missing 109 (4.26) 0.2984
Diabetic w/ meds Male gender Yes Present 1473 (57.58) 0.2984
Diabetic w/ meds Stroke outcome No Missing 182 (7.11) 0.0388
Diabetic w/ meds Stroke outcome No Present 2347 (91.75) 0.0388
Diabetic w/ meds Stroke outcome Yes Missing 5 (0.20) 0.0388
Diabetic w/ meds Stroke outcome Yes Present 24 (0.94) 0.0388
Atrial fibrillation Age 3-5 Missing 76 (2.97) 0.1307
Atrial fibrillation Age 3-5 Present 751 (29.36) 0.1307
Atrial fibrillation Age 6-8 Missing 193 (7.54) 0.1307
Atrial fibrillation Age 6-8 Present 1538 (60.13) 0.1307
Atrial fibrillation Nonwhite ancestry No Missing 202 (7.90) 0.0027
Atrial fibrillation Nonwhite ancestry No Present 1890 (73.89) 0.0027
Atrial fibrillation Nonwhite ancestry Yes Missing 67 (2.62) 0.0027
Atrial fibrillation Nonwhite ancestry Yes Present 399 (15.60) 0.0027
Atrial fibrillation Male gender No Missing 115 (4.50) 0.1009
Atrial fibrillation Male gender No Present 861 (33.66) 0.1009
Atrial fibrillation Male gender Yes Missing 154 (6.02) 0.1009
Atrial fibrillation Male gender Yes Present 1428 (55.82) 0.1009
Atrial fibrillation Stroke outcome No Missing 261 (10.20) 0.0026
Atrial fibrillation Stroke outcome No Present 2268 (88.66) 0.0026
Atrial fibrillation Stroke outcome Yes Missing 8 (0.31) 0.0026
Atrial fibrillation Stroke outcome Yes Present 21 (0.82) 0.0026
Aspirin use Age 3-5 Missing 47 (1.84) 0.2316
Aspirin use Age 3-5 Present 780 (30.49) 0.2316
Aspirin use Age 6-8 Missing 120 (4.69) 0.2316
Aspirin use Age 6-8 Present 1611 (62.98) 0.2316
Aspirin use Nonwhite ancestry No Missing 128 (5.00) 0.0753
Aspirin use Nonwhite ancestry No Present 1964 (76.78) 0.0753
Aspirin use Nonwhite ancestry Yes Missing 39 (1.52) 0.0753
Aspirin use Nonwhite ancestry Yes Present 427 (16.69) 0.0753
Aspirin use Male gender No Missing 69 (2.70) 0.3842
Aspirin use Male gender No Present 907 (35.46) 0.3842
Aspirin use Male gender Yes Missing 98 (3.83) 0.3842
Aspirin use Male gender Yes Present 1484 (58.01) 0.3842
Aspirin use Stroke outcome No Missing 162 (6.33) 0.0188
Aspirin use Stroke outcome No Present 2367 (92.53) 0.0188
Aspirin use Stroke outcome Yes Missing 5 (0.20) 0.0188
Aspirin use Stroke outcome Yes Present 24 (0.94) 0.0188
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Variable 
Stratifying 
variable Level 
Missing 
or Present
24 mos. 
(N (%)) 
24 mos. χ2 
p-value 
Systolic BP Age 3-5 Missing 60 (2.35) 0.3285
Systolic BP Age 3-5 Present 767 (29.98) 0.3285
Systolic BP Age 6-8 Missing 145 (5.67) 0.3285
Systolic BP Age 6-8 Present 1586 (62.00) 0.3285
Systolic BP Nonwhite ancestry No Missing 160 (6.25) 0.1487
Systolic BP Nonwhite ancestry No Present 1932 (75.53) 0.1487
Systolic BP Nonwhite ancestry Yes Missing 45 (1.76) 0.1487
Systolic BP Nonwhite ancestry Yes Present 421 (16.46) 0.1487
Systolic BP Male gender No Missing 84 (3.28) 0.3860
Systolic BP Male gender No Present 892 (34.87) 0.3860
Systolic BP Male gender Yes Missing 121 (4.73) 0.3860
Systolic BP Male gender Yes Present 1461 (57.11) 0.3860
Systolic BP Stroke outcome No Missing 200 (7.82) 0.0657
Systolic BP Stroke outcome No Present 2329 (91.05) 0.0657
Systolic BP Stroke outcome Yes Missing 5 (0.20) 0.0657
Systolic BP Stroke outcome Yes Present 24 (0.94) 0.0657
Homocysteine Age 3-5 Missing 71 (2.78) 0.2565
Homocysteine Age 3-5 Present 756 (29.55) 0.2565
Homocysteine Age 6-8 Missing 173 (6.76) 0.2565
Homocysteine Age 6-8 Present 1558 (60.91) 0.2565
Homocysteine Nonwhite ancestry No Missing 191 (7.47) 0.1360
Homocysteine Nonwhite ancestry No Present 1901 (74.32) 0.1360
Homocysteine Nonwhite ancestry Yes Missing 53 (2.07) 0.1360
Homocysteine Nonwhite ancestry Yes Present 413 (16.15) 0.1360
Homocysteine Male gender No Missing 106 (4.14) 0.0738
Homocysteine Male gender No Present 870 (34.01) 0.0738
Homocysteine Male gender Yes Missing 138 (5.39) 0.0738
Homocysteine Male gender Yes Present 1444 (56.45) 0.0738
Homocysteine Stroke outcome No Missing 234 (9.15) <0.0001
Homocysteine Stroke outcome No Present 2295 (89.72) <0.0001
Homocysteine Stroke outcome Yes Missing 10 (0.39) <0.0001
Homocysteine Stroke outcome Yes Present 19 (0.74) <0.0001
Total cholesterol Age 3-5 Missing 129 (5.04) 0.1788
Total cholesterol Age 3-5 Present 698 (27.29) 0.1788
Total cholesterol Age 6-8 Missing 307 (12.00) 0.1788
Total cholesterol Age 6-8 Present 1424 (55.67) 0.1788
Total cholesterol Nonwhite ancestry No Missing 337 (13.17) 0.0077
Total cholesterol Nonwhite ancestry No Present 1755 (68.61) 0.0077
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Variable 
Stratifying 
variable Level 
Missing 
or Present
24 mos. 
(N (%)) 
24 mos. χ2 
p-value 
Total cholesterol Nonwhite ancestry Yes Missing 99 (3.87) 0.0077
Total cholesterol Nonwhite ancestry Yes Present 367 (14.35) 0.0077
Total cholesterol Male gender No Missing 185 (7.23) 0.0436
Total cholesterol Male gender No Present 791 (30.92) 0.0436
Total cholesterol Male gender Yes Missing 251 (9.81) 0.0436
Total cholesterol Male gender Yes Present 1331 (52.03) 0.0436
Total cholesterol Stroke outcome No Missing 425 (16.61) 0.0026
Total cholesterol Stroke outcome No Present 2104 (82.25) 0.0026
Total cholesterol Stroke outcome Yes Missing 11 (0.43) 0.0026
Total cholesterol Stroke outcome Yes Present 18 (0.70) 0.0026
 
Table A.6. Profile list of models selected based on BIC and GB χ2 p-values, sorted by 
GB χ2 p-value (for analysis results shown in Table 3.9) 
Model 
Number 
BIC 
value 
GB 
p-value 
Risk 
factors 
included 
6474 3580.15 0.8148 Age NonwhiteAncestry MaleGender SystolicBP DisabilityMildModSevRSS  
6011 3597.56 0.8231 Age NonwhiteAncestry MaleGender AntiHypertensiveMedUse AtrialFib 
SystolicBP DisabilityMildModSevRSS  
7135 3597.56 0.8231 Age NonwhiteAncestry MaleGender DisabilityMildModSevRSS 
SBPwithAntiHtnMeds AtrialFib  
3469 3597.56 0.8231 Age NonwhiteAncestry MaleGender SBPwithAntiHtnMeds 
DisabilityMildModSevRSS AtrialFib  
9096 3608.11 0.8330 Age NonwhiteAncestry MaleGender DiastolicBP DiabetesMgmtStatus 
DisabilityMildModSevRSS CurrentSmoker  
7136 3607.00 0.8347 Age NonwhiteAncestry MaleGender DisabilityMildModSevRSS 
SBPwithAntiHtnMeds AtrialFib RoseAngina  
1461 3609.72 0.8386 Age NonwhiteAncestry MaleGender DiastolicBP AnyDependency  
3059 3609.72 0.8386 Age NonwhiteAncestry MaleGender AnyDependency DiastolicBP  
1711 3596.16 0.8453 Age NonwhiteAncestry MaleGender DependencyMildModBAR VitaminB12 
AnyDisability  
3733 3604.54 0.8469 Age NonwhiteAncestry MaleGender DisabilityMildModSevRSS PastCigSmoker 
TotalChol wHyperLipidMeds CurrentSmoker  
4996 3590.13 0.8527 Age NonwhiteAncestry MaleGender DisabilityMildModSevRSS PastCigSmoker 
CurrentSmoker NumPriorStrokes  
10501 3613.93 0.8528 Age NonwhiteAncestry MaleGender AnyNeurolDeficit AnyDisability 
LDLCholesterol Creatinine  
3 3610.64 0.8546 Age NonwhiteAncestry MaleGender NumPriorStrokes Endarterectomy 
DependencyMildModBAR  
3400 3609.90 0.8548 Age NonwhiteAncestry MaleGender DependencyMildModBAR LDLCholesterol  
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Model 
Number 
BIC 
value 
GB 
p-value 
Risk 
factors 
included 
954 3611.47 0.8604 Age NonwhiteAncestry MaleGender AnyDependency SystolicBP  
11128 3611.47 0.8604 Age NonwhiteAncestry MaleGender SystolicBP AnyDependency  
2165 3609.52 0.8623 Age NonwhiteAncestry MaleGender AnyDependency Endarterectomy  
3194 3609.52 0.8623 Age NonwhiteAncestry MaleGender Endarterectomy AnyDependency  
2372 3576.92 0.8737 Age NonwhiteAncestry MaleGender AnyDependency AntiHypertensiveMedUse 
DisabilityMildModSevRSS  
1967 3607.32 0.8792 Age NonwhiteAncestry MaleGender HDLCholesterol SystolicBP VitaminB12 
DisabilityMildModSevRSS PastCigSmoker  
6043 3604.77 0.8804 Age NonwhiteAncestry MaleGender AnyDisability AnyNeurolDeficit Creatinine  
6411 3611.26 0.8835 Age NonwhiteAncestry MaleGender AnyDementia AnyNeurolDeficit 
AnyDisability TotalChol  
9337 3608.06 0.8927 Age NonwhiteAncestry MaleGender AnyNeurolDeficit SystolicBP AnyDependency 
AntiHyperLipidMeds Creatinine  
11581 3609.48 0.8997 Age NonwhiteAncestry MaleGender AnyDementia AnyDisability Homocysteine 
NeuroDeficitMildModNIH  
1970 3612.64 0.9012 Age NonwhiteAncestry MaleGender DisabilityMildModSevRSS NumPriorStrokes 
HyperlipidMgmtStatus PastCigSmoker  
2402 3606.13 0.9045 Age NonwhiteAncestry MaleGender AnyDisability NeuroDeficitMildModNIH 
AnyDementia  
5786 3606.13 0.9045 Age NonwhiteAncestry MaleGender NeuroDeficitMildModNIH AnyDementia 
AnyDisability  
8733 3589.58 0.9137 Age NonwhiteAncestry MaleGender SystolicBP RoseAngina 
DisabilityMildModSevRSS  
9648 3608.59 0.9204 Age NonwhiteAncestry MaleGender DiabetesMgmtStatus AspirinUse SystolicBP 
DisabilityMildModSevRSS  
8802 3613.74 0.9206 Age NonwhiteAncestry MaleGender NumPriorStrokes DiastolicBP BodyMassIndex 
AnyDependency NeuroDeficitMildModNIH AspirinUse  
9845 3612.45 0.9233 Age NonwhiteAncestry MaleGender AnyDisability DependencyMildModBAR 
NeuroDeficitMildModNIH PastCigSmoker AntiHypertensiveMedUse AnyDementia 
AtrialFib  
1966 3598.96 0.9238 Age NonwhiteAncestry MaleGender HDLCholesterol SystolicBP VitaminB12 
DisabilityMildModSevRSS  
4888 3576.91 0.9326 Age NonwhiteAncestry MaleGender AnyDependency NeuroDeficitMildModNIH 
AnyDisability  
3807 3605.13 0.9363 Age NonwhiteAncestry MaleGender SBPwithAntiHtnMeds 
DisabilityMildModSevRSS PastCigSmoker Triglycerides  
6816 3585.92 0.9424 Age NonwhiteAncestry MaleGender PastCigSmoker DisabilityMildModSevRSS 
Folate  
4069 3582.50 0.9459 Age NonwhiteAncestry MaleGender Folate DependencyMildModBAR 
DisabilityMildModSevRSS  
143 3596.13 0.9481 Age NonwhiteAncestry MaleGender HDLCholesterol AnyDisability 
DependencyMildModBAR  
1135 3587.19 0.9529 Age NonwhiteAncestry MaleGender AnyDementia LDLCholesterol 
DisabilityMildModSevRSS  
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Model 
Number 
BIC 
value 
GB 
p-value 
Risk 
factors 
included 
7536 3593.64 0.9630 Age NonwhiteAncestry MaleGender DisabilityMildModSevRSS AnyDementia 
AspirinUse LDLCholesterol  
9844 3603.65 0.9635 Age NonwhiteAncestry MaleGender AnyDisability DependencyMildModBAR 
NeuroDeficitMildModNIH PastCigSmoker AntiHypertensiveMedUse AnyDementia 
144 3605.65 0.9683 Age NonwhiteAncestry MaleGender HDLCholesterol AnyDisability 
DependencyMildModBAR TotalChol  
10283 3602.54 0.9809 Age NonwhiteAncestry MaleGender DisabilityMildModSevRSS VitaminB12 
BodyMassIndex Folate AspirinUse  
4781 3611.82 0.9860 Age NonwhiteAncestry MaleGender BodyMassIndex AnyDependency  
6191 3612.48 0.9904 Age NonwhiteAncestry MaleGender AtrialFib TotalChol DiabetesMgmtStatus 
AnyDisability AnyNeurolDeficit AnyDependency  
 
Table A.7. Significant Breslow-Day results (p<0.05) for assessment of EMM using 
baseline risk factors (for analysis results shown in Table 3.9) 
 
STRATIFYING 
VARIABLE LEVEL 
VARIABLE 
OF 
INTEREST LEVEL 
N 
STROKE 
(-) 
N 
STROKE 
(+) OR (95% CI) 
BRESLOW-
DAY  
χ2,DF,P 
Aspirin use Overall Current 
cigarette 
smoker 
Overall . . 1.07 (0.76, 1.5) 4.5674, 1, 0.0326 
Aspirin use No Current 
cigarette 
smoker 
Overall . . 1.66 (1, 2.77)  
Aspirin use No Current 
cigarette 
smoker 
No 1053 73   
Aspirin use No Current 
cigarette 
smoker 
Yes 182 21   
Aspirin use Yes Current 
cigarette 
smoker 
Overall . . 0.79 (0.5, 1.26)  
Aspirin use Yes Current 
cigarette 
smoker 
No 1581 137   
Aspirin use Yes Current 
cigarette 
smoker 
Yes 334 23   
Aspirin use Overall BMI (kg/m2) 
>= median 
Overall . . 1.21 (0.93, 1.56) 4.6724, 1, 0.0307 
Aspirin use No BMI (kg/m2) 
>= median 
Overall . . 0.84 (0.55, 1.27)  
Aspirin use No BMI (kg/m2) 
>= median 
No 615 51   
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE 
OF 
INTEREST LEVEL 
N 
STROKE 
(-) 
N 
STROKE 
(+) OR (95% CI) 
BRESLOW-
DAY  
χ2,DF,P 
Aspirin use No BMI (kg/m2) 
>= median 
Yes 620 43   
Aspirin use Yes BMI (kg/m2) 
>= median 
Overall . . 1.5 (1.08, 2.09)  
Aspirin use Yes BMI (kg/m2) 
>= median 
No 971 65   
Aspirin use Yes BMI (kg/m2) 
>= median 
Yes 944 95   
SBP (mmHg) >= 
median 
Overall Diabetic w/ 
meds 
Overall . . 1.12 (0.84, 1.5) 8.5494, 1, 0.0035 
SBP (mmHg) >= 
median 
No Diabetic w/ 
meds 
Overall . . 1.81 (1.19, 2.76)  
SBP (mmHg) >= 
median 
No Diabetic w/ 
meds 
No 1091 69   
SBP (mmHg) >= 
median 
No Diabetic w/ 
meds 
Yes 314 36   
SBP (mmHg) >= 
median 
Yes Diabetic w/ 
meds 
Overall . . 0.76 (0.51, 1.15)  
SBP (mmHg) >= 
median 
Yes Diabetic w/ 
meds 
No 1285 117   
SBP (mmHg) >= 
median 
Yes Diabetic w/ 
meds 
Yes 460 32   
SBP (mmHg) >= 
median 
Overall Anti-
hypertensive 
med use 
Overall . . 1.18 (0.91, 1.52) 4.7821, 1, 0.0288 
SBP (mmHg) >= 
median 
No Anti-
hypertensive 
med use 
Overall . . 1.63 (1.09, 2.42)  
SBP (mmHg) >= 
median 
No Anti-
hypertensive 
med use 
No 825 49   
SBP (mmHg) >= 
median 
No Anti-
hypertensive 
med use 
Yes 580 56   
SBP (mmHg) >= 
median 
Yes Anti-
hypertensive 
med use 
Overall . . 0.91 (0.65, 1.27)  
SBP (mmHg) >= 
median 
Yes Anti-
hypertensive 
med use 
No 803 72   
SBP (mmHg) >= 
median 
Yes Anti-
hypertensive 
med use 
Yes 942 77   
Total cholesterol 
(mg/dl) >= 
median 
Overall Diabetic w/o 
meds 
Overall . . 2.46 (1.57, 3.84) 5.2764, 1, 0.0216 
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE 
OF 
INTEREST LEVEL 
N 
STROKE 
(-) 
N 
STROKE 
(+) OR (95% CI) 
BRESLOW-
DAY  
χ2,DF,P 
Total cholesterol 
(mg/dl) >= 
median 
No Diabetic w/o 
meds 
Overall . . 1.27 (0.57, 2.82)  
Total cholesterol 
(mg/dl) >= 
median 
No Diabetic w/o 
meds 
No 1504 117   
Total cholesterol 
(mg/dl) >= 
median 
No Diabetic w/o 
meds 
Yes 71 7   
Total cholesterol 
(mg/dl) >= 
median 
Yes Diabetic w/o 
meds 
Overall . . 3.86 (2.21, 6.74)  
Total cholesterol 
(mg/dl) >= 
median 
Yes Diabetic w/o 
meds 
No 1512 112   
Total cholesterol 
(mg/dl) >= 
median 
Yes Diabetic w/o 
meds 
Yes 63 18   
Total cholesterol 
(mg/dl) >= 
median 
Overall Nonwhite 
ancestry 
Overall . . 1.2 (0.88, 1.62) 4.121, 1, 0.0424 
Total cholesterol 
(mg/dl) >= 
median 
No Nonwhite 
ancestry 
Overall . . 1.6 (1.07, 2.4)  
Total cholesterol 
(mg/dl) >= 
median 
No Nonwhite 
ancestry 
No 1245 87   
Total cholesterol 
(mg/dl) >= 
median 
No Nonwhite 
ancestry 
Yes 330 37   
Total cholesterol 
(mg/dl) >= 
median 
Yes Nonwhite 
ancestry 
Overall . . 0.84 (0.53, 1.36)  
Total cholesterol 
(mg/dl) >= 
median 
Yes Nonwhite 
ancestry 
No 1269 108   
Total cholesterol 
(mg/dl) >= 
median 
Yes Nonwhite 
ancestry 
Yes 306 22   
HDL (mg/dl) >= 
median 
Overall Anti-
hypertensive 
med use 
Overall . . 1.18 (0.91, 1.52) 10.9616, 1, 
0.0009 
HDL (mg/dl) >= 
median 
No Anti-
hypertensive 
med use 
Overall . . 1.84 (1.26, 2.69)  
HDL (mg/dl) >= 
median 
No Anti-
hypertensive 
med use 
No 767 44   
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE 
OF 
INTEREST LEVEL 
N 
STROKE 
(-) 
N 
STROKE 
(+) OR (95% CI) 
BRESLOW-
DAY  
χ2,DF,P 
HDL (mg/dl) >= 
median 
No Anti-
hypertensive 
med use 
Yes 785 83   
HDL (mg/dl) >= 
median 
Yes Anti-
hypertensive 
med use 
Overall . . 0.76 (0.52, 1.1)  
HDL (mg/dl) >= 
median 
Yes Anti-
hypertensive 
med use 
No 861 77   
HDL (mg/dl) >= 
median 
Yes Anti-
hypertensive 
med use 
Yes 737 50   
HDL (mg/dl) >= 
median 
Overall Nonwhite 
ancestry 
Overall . . 1.2 (0.88, 1.62) 6.1161, 1, 0.0134 
HDL (mg/dl) >= 
median 
No Nonwhite 
ancestry 
Overall . . 1.73 (1.15, 2.6)  
HDL (mg/dl) >= 
median 
No Nonwhite 
ancestry 
No 1263 91   
HDL (mg/dl) >= 
median 
No Nonwhite 
ancestry 
Yes 289 36   
HDL (mg/dl) >= 
median 
Yes Nonwhite 
ancestry 
Overall . . 0.8 (0.5, 1.27)  
HDL (mg/dl) >= 
median 
Yes Nonwhite 
ancestry 
No 1251 104   
HDL (mg/dl) >= 
median 
Yes Nonwhite 
ancestry 
Yes 347 23   
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Table A.8. Evaluation of possible PHA violations (for analysis results shown in Table 
3.9) – time and LOG(time) score tests for clinical model 
 
Covariate 
Time LOG (time) 
Rho χ2 df P Rho χ2 df P 
Age (years, standardized) 0.1217 3.6102 1 0.0574 0.0992 2.3975 1 0.1215
Nonwhite ancestry 0.1024 2.5266 1 0.1119 0.0888 1.8988 1 0.1682
Male gender 0.0171 0.0677 1 0.7947 0.0044 0.0044 1 0.9469
Lipid-lowering med use -0.0133 0.0421 1 0.8375 -0.0213 0.1076 1 0.7428
Blood-pressure-lowering med use 0.0928 1.9172 1 0.1662 0.1098 2.6868 1 0.1012
BMI (standardized) 0.0649 1.0548 1 0.3044 0.0551 0.7584 1 0.3838
Current cigarette smoker 0.0067 0.0102 1 0.9194 -0.0056 0.0072 1 0.9322
Diabetic w/o meds -0.0630 0.9405 1 0.3321 -0.0388 0.3558 1 0.5509
Diabetic w/ meds 0.0276 0.1721 1 0.6783 0.0444 0.4443 1 0.5051
Atrial fibrillation (ECG) -0.0199 0.0918 1 0.7619 -0.0417 0.4034 1 0.5253
Past cigarette smoker 0.0146 0.0495 1 0.8240 0.0256 0.1528 1 0.6959
Aspirin use 0.0292 0.2007 1 0.6541 0.0154 0.0560 1 0.8130
SBP (standardized) 0.0221 0.1349 1 0.7134 0.0245 0.1652 1 0.6844
Homocysteine (standardized) -0.0201 0.0421 1 0.8375 -0.0028 0.0008 1 0.9772
TC (standardized) 0.0580 0.9587 1 0.3275 0.0821 1.9194 1 0.1659
Number of prior strokes (standardized) -0.0147 0.0388 1 0.8438 -0.0229 0.0949 1 0.7580
Global test . 11.5312 16 0.7756 . 12.3934 16 0.7165
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Table A.9. Evaluation of possible PHA violations (for analysis results shown in Table 
3.9) –  rank(time) and Kaplan-Meier (time) score tests for clinical model 
 
Covariate 
RANK (time) Kaplan-Meier (time) 
Rho χ2 df P Rho χ2 df P 
Age (years, standardized) 0.1107 2.9863 1 0.0840 0.1228 3.6799 1 0.0551
Nonwhite ancestry 0.0966 2.2463 1 0.1339 0.0987 2.3464 1 0.1256
Male gender 0.0138 0.0444 1 0.8331 0.0207 0.0995 1 0.7524
Lipid-lowering med use -0.0223 0.1177 1 0.7315 -0.0117 0.0326 1 0.8568
Blood-pressure-lowering med use 0.0990 2.1832 1 0.1395 0.0891 1.7684 1 0.1836
BMI (standardized) 0.0605 0.9158 1 0.3386 0.0650 1.0556 1 0.3042
Current cigarette smoker 0.0035 0.0028 1 0.9579 0.0074 0.0125 1 0.9111
Diabetic w/o meds -0.0504 0.6009 1 0.4382 -0.0651 1.0020 1 0.3168
Diabetic w/ meds 0.0374 0.3155 1 0.5743 0.0228 0.1174 1 0.7319
Atrial fibrillation (ECG) -0.0344 0.2734 1 0.6011 -0.0136 0.0428 1 0.8361
Past cigarette smoker 0.0155 0.0557 1 0.8134 0.0142 0.0470 1 0.8284
Aspirin use 0.0227 0.1220 1 0.7269 0.0365 0.3138 1 0.5754
SBP (standardized) 0.0340 0.3186 1 0.5725 0.0116 0.0372 1 0.8472
Homocysteine (standardized) -0.0101 0.0106 1 0.9180 -0.0242 0.0607 1 0.8055
TC (standardized) 0.0692 1.3660 1 0.2425 0.0512 0.7461 1 0.3877
Number of prior strokes (standardized) -0.0217 0.0847 1 0.7711 -0.0122 0.0270 1 0.8696
Global test . 12.1728 16 0.7320 . 10.6374 16 0.8313
 
 
Table A.10. Evaluation of possible PHA violations (for analysis results shown in Table 
3.9) – time and LOG(time) score tests for psychoneurological model 
 
Covariate 
Time LOG (time) 
Rho χ2 df P Rho χ2 df P 
Age (years, standardized) 0.1095 2.7797 1 0.0955 0.0904 1.8955 1 0.1686
Nonwhite ancestry 0.1042 2.5647 1 0.1093 0.0911 1.9596 1 0.1616
Male gender 0.0251 0.1386 1 0.7097 0.0033 0.0024 1 0.9610
Any dependency (BAR) 0.0622 0.8857 1 0.3466 0.0412 0.3875 1 0.5336
Any disability (RSS) 0.0887 1.8123 1 0.1782 0.1324 4.0371 1 0.0445
BMI (standardized) 0.0851 1.6345 1 0.2011 0.0807 1.4718 1 0.2251
HDL cholesterol (standardized) 0.0396 0.3656 1 0.5454 0.0257 0.1538 1 0.6950
Global test . 10.7165 7 0.1515 . 10.9855 7 0.1393
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Table A.11. Evaluation of possible PHA violations (for analysis results shown in Table 
3.9) – rank(time) and Kaplan-Meier(time) score tests for psychoneurological model 
 
Covariate 
RANK (time) Kaplan-Meier (time) 
Rho χ2 df P Rho Χ2 df P 
Age (years, standardized) 0.1024 2.4315 1 0.1189 0.1065 2.6299 1 0.1049
Nonwhite ancestry 0.1013 2.4231 1 0.1196 0.0983 2.2840 1 0.1307
Male gender 0.0146 0.0474 1 0.8277 0.0333 0.2455 1 0.6202
Any dependency (BAR) 0.0455 0.4729 1 0.4917 0.0818 1.5316 1 0.2159
Any disability (RSS) 0.1107 2.8224 1 0.0930 0.0733 1.2352 1 0.2664
BMI (standardized) 0.0841 1.5983 1 0.2062 0.0817 1.5063 1 0.2197
HDL cholesterol (standardized) 0.0291 0.1978 1 0.6565 0.0434 0.4408 1 0.5068
Global test . 10.6487 7 0.1547 . 10.5136 7 0.1613
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Table A.12. Statistical power results (α set to 0.05, two-sided) for clinical and 
psychoneurological models (maximum power (less than 1.00)=0.85, minimum=0.1) 
 
Model Risk Factor 
Reference 
level 
Count 
Level 
of 
interest
Count 
Accrual
time 
Follow
- up
time 
Total 
time 
HR 
(95% CI) Power
Clinical - 
whites 
Male gender 4146 7289 413 413 826 0.86 (0.62, 1.18) 1.000
Current cigarette smoker 9735 1700 415 415 830 0.62 (0.37, 1.03) 1.000
Diabetic w/o meds 10948 487 420 420 840 2.42 (1.46, 3.99) 1.000
Diabetic w/ meds 8838 2597 418 418 836 1.17 (0.82, 1.68) 1.000
Atrial fibrillation (ECG) 11308 127 462 462 924 1.25 (0.39, 3.95) 0.425
Past cigarette smoker 5446 5989 413 413 826 0.80 (0.59, 1.08) 1.000
Aspirin use 4636 6799 414 414 828 0.85 (0.63, 1.14) 1.000
Number of prior strokes 
(standardized) 
9042 1740 414 414 828 1.08 (0.99, 1.19) 0.621
Clinical – 
nonwhites 
Male gender 1159 1548 408 408 816 1.08 (0.58, 2.02) 0.571
Current cigarette smoker 2125 582 405 405 810 0.94 (0.43, 2.07) 0.184
Diabetic w/o meds 2506 201 408 408 816 1.15 (0.39, 3.39) 0.288
Diabetic w/ meds 1755 952 405 405 810 0.97 (0.51, 1.82) 0.102
Atrial fibrillation (ECG) 2690 17 403 403 806 1.95 (0.24, 15.74) 0.465
Past cigarette smoker 1632 1075 405 405 810 1.06 (0.58, 1.93) 0.272
Aspirin use 1050 1657 404 404 808 0.50 (0.28, 0.90) 1.000
Number of prior strokes 
(standardized) 
1944 541 405 405 810 1.18 (1.08, 1.29) 0.775
Psychoneur
ological 
Nonwhite ancestry 11435 2707 413 413 826 1.04 (0.75, 1.44) 0.303
Male gender 5305 8837 411 411 822 0.95 (0.72, 1.25) 0.926
Any dependency (BAR) 11691 2451 415 415 830 2.95 (2.23, 3.88) 1.000
Any disability (RSS) 4419 9723 451 451 902 2.39 (1.62, 3.51) 1.000
 
Table A.13. Summary table of significant Breslow-Day results (p< 0.05) for assessment 
of EMM using baseline risk factors, six month risk factors and change in medication 
and risk factor adherence (for analysis results in Tables 4.10, 4.11, and 4.12) 
 
STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST 
 
LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Age at baseline 
>=60 years 
Overall Anti-DM med 
use at baseline 
Overall . . 1.29 (0.96, 1.72) 4.012, 1, 0.0452 
Age at baseline 
>=60 years 
No Anti-DM med 
use at baseline 
Overall . . 2.05 (1.2, 3.5)  
Age at baseline 
>=60 years 
No Anti-DM med 
use at baseline 
No 36 564   
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST 
 
LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Age at baseline 
>=60 years 
No Anti-DM med 
use at baseline 
Yes 25 191   
Age at baseline 
>=60 years 
Yes Anti-DM med 
use at baseline 
Overall . . 1.07 (0.75, 1.52)  
Age at baseline 
>=60 years 
Yes Anti-DM med 
use at baseline 
No 132 1564   
Age at baseline 
>=60 years 
Yes Anti-DM med 
use at baseline 
Yes 45 499   
Age at baseline 
>=60 years 
Overall Anti-DM med 
use at six mos.
Overall . . 1.17 (0.87, 1.57) 4.2431, 1, 0.0394
Age at baseline 
>=60 years 
No Anti-DM med 
use at six mos.
Overall . . 1.89 (1.1, 3.24)  
Age at baseline 
>=60 years 
No Anti-DM med 
use at six mos.
No 37 562   
Age at baseline 
>=60 years 
No Anti-DM med 
use at six mos.
Yes 24 193   
Age at baseline 
>=60 years 
Yes Anti-DM med 
use at six mos.
Overall . . 0.96 (0.67, 1.38)  
Age at baseline 
>=60 years 
Yes Anti-DM med 
use at six mos.
No 135 1558   
Age at baseline 
>=60 years 
Yes Anti-DM med 
use at six mos.
Yes 42 505   
Age at baseline 
>=60 years 
Overall Lipid-lowering 
med use at 
baseline 
Overall . . 0.98 (0.75, 1.28) 5.8761, 1, 0.0153
Age at baseline 
>=60 years 
No Lipid-lowering 
med use at 
baseline 
Overall . . 1.7 (1.01, 2.88)  
Age at baseline 
>=60 years 
No Lipid-lowering 
med use at 
baseline 
No 27 434   
Age at baseline 
>=60 years 
No Lipid-lowering 
med use at 
baseline 
Yes 34 321   
Age at baseline 
>=60 years 
Yes Lipid-lowering 
med use at 
baseline 
Overall . . 0.8 (0.59, 1.1)  
Age at baseline 
>=60 years 
Yes Lipid-lowering 
med use at 
baseline 
No 108 1149   
Age at baseline 
>=60 years 
Yes Lipid-lowering 
med use at 
baseline 
Yes 69 914   
Age at six mos. 
>= 60 years 
Overall Anti-DM med 
use at baseline 
Overall . . 1.29 (0.96, 1.72) 4.012, 1, 0.0452 
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST 
 
LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Age at six mos. 
>= 60 years 
No Anti-DM med 
use at baseline 
Overall . . 2.05 (1.2, 3.5)  
Age at six mos. 
>= 60 years 
No Anti-DM med 
use at baseline 
No 36 564   
Age at six mos. 
>= 60 years 
No Anti-DM med 
use at baseline 
Yes 25 191   
Age at six mos. 
>= 60 years 
Yes Anti-DM med 
use at baseline 
Overall . . 1.07 (0.75, 1.52)  
Age at six mos. 
>= 60 years 
Yes Anti-DM med 
use at baseline 
No 132 1564   
Age at six mos. 
>= 60 years 
Yes Anti-DM med 
use at baseline 
Yes 45 499   
Age at six mos. 
>= 60 years 
Overall Anti-DM med 
use at six mos.
Overall . . 1.17 (0.87, 1.57) 4.2431, 1, 0.0394
Age at six mos. 
>= 60 years 
No Anti-DM med 
use at six mos.
Overall . . 1.89 (1.1, 3.24)  
Age at six mos. 
>= 60 years 
No Anti-DM med 
use at six mos.
No 37 562   
Age at six mos. 
>= 60 years 
No Anti-DM med 
use at six mos.
Yes 24 193   
Age at six mos. 
>= 60 years 
Yes Anti-DM med 
use at six mos.
Overall . . 0.96 (0.67, 1.38)  
Age at six mos. 
>= 60 years 
Yes Anti-DM med 
use at six mos.
No 135 1558   
Age at six mos. 
>= 60 years 
Yes Anti-DM med 
use at six mos.
Yes 42 505   
Age at six mos. 
>= 60 years 
Overall Lipid-lowering 
med use at 
baseline 
Overall . . 0.98 (0.75, 1.28) 5.8761, 1, 0.0153
Age at six mos. 
>= 60 years 
No Lipid-lowering 
med use at 
baseline 
Overall . . 1.7 (1.01, 2.88)  
Age at six mos. 
>= 60 years 
No Lipid-lowering 
med use at 
baseline 
No 27 434   
Age at six mos. 
>= 60 years 
No Lipid-lowering 
med use at 
baseline 
Yes 34 321   
Age at six mos. 
>= 60 years 
Yes Lipid-lowering 
med use at 
baseline 
Overall . . 0.8 (0.59, 1.1)  
Age at six mos. 
>= 60 years 
Yes Lipid-lowering 
med use at 
baseline 
No 108 1149   
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST 
 
LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Age at six mos. 
>= 60 years 
Yes Lipid-lowering 
med use at 
baseline 
Yes 69 914   
Anti-DM med 
use at baseline 
Overall Baseline SBP 
>= median 
Overall . . 1.21 (0.93, 1.58) 10.1323, 1, 
0.0015 
Anti-DM med 
use at baseline 
No Baseline SBP 
>= median 
Overall . . 1.58 (1.14, 2.17)  
Anti-DM med 
use at baseline 
No Baseline SBP 
>= median 
No 67 1088   
Anti-DM med 
use at baseline 
No Baseline SBP 
>= median 
Yes 101 1040   
Anti-DM med 
use at baseline 
Yes Baseline SBP 
>= median 
Overall . . 0.61 (0.37, 1)  
Anti-DM med 
use at baseline 
Yes Baseline SBP 
>= median 
No 39 300   
Anti-DM med 
use at baseline 
Yes Baseline SBP 
>= median 
Yes 31 390   
Anti-DM med 
use at six mos. 
Overall BMI at six 
mos. >= 
median 
Overall . . 1.15 (0.88, 1.5) 3.8789, 1, 0.0489
Anti-DM med 
use at six mos. 
No BMI at six 
mos. >= 
median 
Overall . . 0.96 (0.7, 1.32)  
Anti-DM med 
use at six mos. 
No BMI at six 
mos. >= 
median 
No 96 1164   
Anti-DM med 
use at six mos. 
No BMI at six 
mos. >= 
median 
Yes 76 956   
Anti-DM med 
use at six mos. 
Yes BMI at six 
mos. >= 
median 
Overall . . 1.89 (1.04, 3.42)  
Anti-DM med 
use at six mos. 
Yes BMI at six 
mos. >= 
median 
No 15 249   
Anti-DM med 
use at six mos. 
Yes BMI at six 
mos. >= 
median 
Yes 51 449   
Anti-DM med 
use at six mos. 
Overall Aspirin use at 
six mos. 
Overall . . 0.98 (0.75, 1.28) 4.7197, 1, 0.0298
Anti-DM med 
use at six mos. 
No Aspirin use at 
six mos. 
Overall . . 1.2 (0.87, 1.65)  
Anti-DM med 
use at six mos. 
No Aspirin use at 
six mos. 
No 61 841   
Anti-DM med 
use at six mos. 
No Aspirin use at 
six mos. 
Yes 111 1279   
  
188
 
STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST 
 
LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Anti-DM med 
use at six mos. 
Yes Aspirin use at 
six mos. 
Overall . . 0.62 (0.37, 1.02)  
Anti-DM med 
use at six mos. 
Yes Aspirin use at 
six mos. 
No 37 307   
Anti-DM med 
use at six mos. 
Yes Aspirin use at 
six mos. 
Yes 29 391   
Anti-DM med 
use at six mos. 
Overall Baseline SBP 
>= median 
Overall . . 1.21 (0.93, 1.58) 6.1468, 1, 0.0132
Anti-DM med 
use at six mos. 
No Baseline SBP 
>= median 
Overall . . 1.47 (1.08, 2.02)  
Anti-DM med 
use at six mos. 
No Baseline SBP 
>= median 
No 72 1091   
Anti-DM med 
use at six mos. 
No Baseline SBP 
>= median 
Yes 100 1029   
Anti-DM med 
use at six mos. 
Yes Baseline SBP 
>= median 
Overall . . 0.7 (0.42, 1.16)  
Anti-DM med 
use at six mos. 
Yes Baseline SBP 
>= median 
No 34 297   
Anti-DM med 
use at six mos. 
Yes Baseline SBP 
>= median 
Yes 32 401   
Lipid-lowering 
med use at 
baseline 
Overall Baseline age 
>=median 
Overall . . 1.27 (0.98, 1.66) 4.3532, 1, 0.0369
Lipid-lowering 
med use at 
baseline 
No Baseline age 
>=median 
Overall . . 1.64 (1.14, 2.36)  
Lipid-lowering 
med use at 
baseline 
No Baseline age 
>=median 
No 51 790   
Lipid-lowering 
med use at 
baseline 
No Baseline age 
>=median 
Yes 84 793   
Lipid-lowering 
med use at 
baseline 
Yes Baseline age 
>=median 
Overall . . 0.92 (0.62, 1.38)  
Lipid-lowering 
med use at 
baseline 
Yes Baseline age 
>=median 
No 55 635   
Lipid-lowering 
med use at 
baseline 
Yes Baseline age 
>=median 
Yes 48 600   
Lipid-lowering 
med use at 
baseline 
Overall Six month age 
>=baseline 
Overall . . 1.27 (0.98, 1.66) 4.3532, 1, 0.0369
Lipid-lowering 
med use at 
baseline 
No Six month age 
>=baseline 
Overall . . 1.64 (1.14, 2.36)  
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST 
 
LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Lipid-lowering 
med use at 
baseline 
No Six month age 
>=baseline 
No 51 790   
Lipid-lowering 
med use at 
baseline 
No Six month age 
>=baseline 
Yes 84 793   
Lipid-lowering 
med use at 
baseline 
Yes Six month age 
>=baseline 
Overall . . 0.92 (0.62, 1.38)  
Lipid-lowering 
med use at 
baseline 
Yes Six month age 
>=baseline 
No 55 635   
Lipid-lowering 
med use at 
baseline 
Yes Six month age 
>=baseline 
Yes 48 600   
Change in lipid-
lowering med 
adherence 
Overall Aspirin use at 
baseline 
Overall . . 1.11 (0.85, 1.47) 18.4195, 3, 
0.0004 
Change in lipid-
lowering med 
adherence 
Adherent Aspirin use at 
baseline 
Overall . . 1.17 (0.84, 1.64)  
Change in lipid-
lowering med 
adherence 
Adherent Aspirin use at 
baseline 
No 58 753   
Change in lipid-
lowering med 
adherence 
Adherent Aspirin use at 
baseline 
Yes 100 1107   
Change in lipid-
lowering med 
adherence 
Started 
using 
Aspirin use at 
baseline 
Overall . . . (., .)  
Change in lipid-
lowering med 
adherence 
Started 
using 
Aspirin use at 
baseline 
No 0 61   
Change in lipid-
lowering med 
adherence 
Started 
using 
Aspirin use at 
baseline 
Yes 7 109   
Change in lipid-
lowering med 
adherence 
Stopped 
using 
Aspirin use at 
baseline 
Overall . . 0.15 (0.04, 0.49)  
Change in lipid-
lowering med 
adherence 
Stopped 
using 
Aspirin use at 
baseline 
No 11 50   
Change in lipid-
lowering med 
adherence 
Stopped 
using 
Aspirin use at 
baseline 
Yes 4 123   
Change in lipid-
lowering med 
adherence 
Never 
used 
Aspirin use at 
baseline 
Overall . . 1.4 (0.79, 2.5)  
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST 
 
LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Change in lipid-
lowering med 
adherence 
Never 
used 
Aspirin use at 
baseline 
No 18 238   
Change in lipid-
lowering med 
adherence 
Never 
used 
Aspirin use at 
baseline 
Yes 40 377   
Blood-pressure-
lowering med 
use at baseline 
Overall Baseline SBP 
>= median 
Overall . . 1.21 (0.93, 1.58) 5.7763, 1, 0.0162
Blood-pressure-
lowering med 
use at baseline 
No Baseline SBP 
>= median 
Overall . . 1.66 (1.13, 2.45)  
Blood-pressure-
lowering med 
use at baseline 
No Baseline SBP 
>= median 
No 49 808   
Blood-pressure-
lowering med 
use at baseline 
No Baseline SBP 
>= median 
Yes 65 644   
Blood-pressure-
lowering med 
use at baseline 
Yes Baseline SBP 
>= median 
Overall . . 0.87 (0.6, 1.25)  
Blood-pressure-
lowering med 
use at baseline 
Yes Baseline SBP 
>= median 
No 57 580   
Blood-pressure-
lowering med 
use at baseline 
Yes Baseline SBP 
>= median 
Yes 67 786   
Blood-pressure-
lowering med 
use at baseline 
Overall Six month 
SBP >=median
Overall . . 1.27 (0.97, 1.66) 4.25, 1, 0.0393 
Blood-pressure-
lowering med 
use at baseline 
No Six month 
SBP >=median
Overall . . 1.68 (1.14, 2.47)  
Blood-pressure-
lowering med 
use at baseline 
No Six month 
SBP >=median
No 47 785   
Blood-pressure-
lowering med 
use at baseline 
No Six month 
SBP >=median
Yes 67 667   
Blood-pressure-
lowering med 
use at baseline 
Yes Six month 
SBP >=median
Overall . . 0.96 (0.66, 1.39)  
Blood-pressure-
lowering med 
use at baseline 
Yes Six month 
SBP >=median
No 55 591   
Blood-pressure-
lowering med 
use at baseline 
Yes Six month 
SBP >=median
Yes 69 775   
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST 
 
LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Blood-pressure-
lowering med 
use at six mos. 
Overall Baseline SBP 
>= median 
Overall . . 1.21 (0.93, 1.58) 6.8162, 1, 0.009 
Blood-pressure-
lowering med 
use at six mos. 
No Baseline SBP 
>= median 
Overall . . 1.77 (1.18, 2.67)  
Blood-pressure-
lowering med 
use at six mos. 
No Baseline SBP 
>= median 
No 44 759   
Blood-pressure-
lowering med 
use at six mos. 
No Baseline SBP 
>= median 
Yes 57 554   
Blood-pressure-
lowering med 
use at six mos. 
Yes Baseline SBP 
>= median 
Overall . . 0.87 (0.61, 1.23)  
Blood-pressure-
lowering med 
use at six mos. 
Yes Baseline SBP 
>= median 
No 62 629   
Blood-pressure-
lowering med 
use at six mos. 
Yes Baseline SBP 
>= median 
Yes 75 876   
Blood-pressure-
lowering med 
use at six mos. 
Overall Six month 
SBP >=median
Overall . . 1.27 (0.97, 1.66) 5.9417, 1, 0.0148
Blood-pressure-
lowering med 
use at six mos. 
No Six month 
SBP >=median
Overall . . 1.84 (1.22, 2.78)  
Blood-pressure-
lowering med 
use at six mos. 
No Six month 
SBP >=median
No 40 718   
Blood-pressure-
lowering med 
use at six mos. 
No Six month 
SBP >=median
Yes 61 595   
Blood-pressure-
lowering med 
use at six mos. 
Yes Six month 
SBP >=median
Overall . . 0.94 (0.66, 1.34)  
Blood-pressure-
lowering med 
use at six mos. 
Yes Six month 
SBP >=median
No 62 658   
Blood-pressure-
lowering med 
use at six mos. 
Yes Six month 
SBP >=median
Yes 75 847   
Change in BMI 
adherence  
Overall Aspirin use at 
baseline 
Overall . . 1.11 (0.85, 1.47) 11.445, 5, 0.0432
Change in BMI 
adherence  
Stayed 
<25 
Aspirin use at 
baseline 
Overall . . 0.75 (0.44, 1.27)  
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST 
 
LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Change in BMI 
adherence  
Stayed 
<25 
Aspirin use at 
baseline 
No 28 269   
Change in BMI 
adherence  
Stayed 
<25 
Aspirin use at 
baseline 
Yes 33 422   
Change in BMI 
adherence  
>=25 to 
<25 
Aspirin use at 
baseline 
Overall . . 0.21 (0.05, 0.93)  
Change in BMI 
adherence  
>=25 to 
<25 
Aspirin use at 
baseline 
No 5 23   
Change in BMI 
adherence  
>=25 to 
<25 
Aspirin use at 
baseline 
Yes 3 67   
Change in BMI 
adherence  
<25 to 
>=25 
Aspirin use at 
baseline 
Overall . . 1.17 (0.2, 6.74)  
Change in BMI 
adherence  
<25 to 
>=25 
Aspirin use at 
baseline 
No 2 34   
Change in BMI 
adherence  
<25 to 
>=25 
Aspirin use at 
baseline 
Yes 4 58   
Change in BMI 
adherence  
>=25 to 
>=25, 
>=.25SD 
decr 
Aspirin use at 
baseline 
Overall . . 1.03 (0.57, 1.86)  
Change in BMI 
adherence  
>=25 to 
>=25, 
>=.25SD 
decr 
Aspirin use at 
baseline 
No 19 192   
Change in BMI 
adherence  
>=25 to 
>=25, 
>=.25SD 
decr 
Aspirin use at 
baseline 
Yes 33 324   
Change in BMI 
adherence  
>=25 to 
>=25, no 
change 
Aspirin use at 
baseline 
Overall . . 1.44 (0.82, 2.54)  
Change in BMI 
adherence  
>=25 to 
>=25, no 
change 
Aspirin use at 
baseline 
No 19 265   
Change in BMI 
adherence  
>=25 to 
>=25, no 
change 
Aspirin use at 
baseline 
Yes 41 396   
Change in BMI 
adherence  
>=25 to 
>=25, 
>=.25SD 
incr 
Aspirin use at 
baseline 
Overall . . 1.88 (1, 3.53)  
Change in BMI 
adherence  
>=25 to 
>=25, 
>=.25SD 
incr 
Aspirin use at 
baseline 
No 14 319   
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST 
 
LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Change in BMI 
adherence  
>=25 to 
>=25, 
>=.25SD 
incr 
Aspirin use at 
baseline 
Yes 37 449   
Change in BMI 
adherence  
Overall Baseline TC 
>= median 
Overall . . 1.12 (0.86, 1.46) 13.2789, 5, 
0.0209 
Change in BMI 
adherence  
Stayed 
<25 
Baseline TC 
>= median 
Overall . . 1.48 (0.87, 2.52)  
Change in BMI 
adherence  
Stayed 
<25 
Baseline TC 
>= median 
No 25 350   
Change in BMI 
adherence  
Stayed 
<25 
Baseline TC 
>= median 
Yes 36 341   
Change in BMI 
adherence  
>=25 to 
<25 
Baseline TC 
>= median 
Overall . . 0.16 (0.02, 1.38)  
Change in BMI 
adherence  
>=25 to 
<25 
Baseline TC 
>= median 
No 7 48   
Change in BMI 
adherence  
>=25 to 
<25 
Baseline TC 
>= median 
Yes 1 42   
Change in BMI 
adherence  
<25 to 
>=25 
Baseline TC 
>= median 
Overall . . 5.95 (0.67, 
52.97) 
 
Change in BMI 
adherence  
<25 to 
>=25 
Baseline TC 
>= median 
No 1 50   
Change in BMI 
adherence  
<25 to 
>=25 
Baseline TC 
>= median 
Yes 5 42   
Change in BMI 
adherence  
>=25 to 
>=25, 
>=.25SD 
decr 
Baseline TC 
>= median 
Overall . . 1.15 (0.65, 2.04)  
Change in BMI 
adherence  
>=25 to 
>=25, 
>=.25SD 
decr 
Baseline TC 
>= median 
No 23 246   
Change in BMI 
adherence  
>=25 to 
>=25, 
>=.25SD 
decr 
Baseline TC 
>= median 
Yes 29 270   
Change in BMI 
adherence  
>=25 to 
>=25, no 
change 
Baseline TC 
>= median 
Overall . . 1.46 (0.85, 2.52)  
Change in BMI 
adherence  
>=25 to 
>=25, no 
change 
Baseline TC 
>= median 
No 23 315   
Change in BMI 
adherence  
>=25 to 
>=25, no 
change 
Baseline TC 
>= median 
Yes 37 346   
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST 
 
LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Change in BMI 
adherence  
>=25 to 
>=25, 
>=.25SD 
incr 
Baseline TC 
>= median 
Overall . . 0.6 (0.34, 1.08)  
Change in BMI 
adherence  
>=25 to 
>=25, 
>=.25SD 
incr 
Baseline TC 
>= median 
No 31 371   
Change in BMI 
adherence  
>=25 to 
>=25, 
>=.25SD 
incr 
Baseline TC 
>= median 
Yes 20 397   
Change in BMI 
adherence  
Overall Six month TC 
>= median 
Overall . . 1 (0.77, 1.3) 11.2954, 5, 
0.0458 
Change in BMI 
adherence  
Stayed 
<25 
Six month TC 
>= median 
Overall . . 1.75 (1.02, 2.99)  
Change in BMI 
adherence  
Stayed 
<25 
Six month TC 
>= median 
No 23 355   
Change in BMI 
adherence  
Stayed 
<25 
Six month TC 
>= median 
Yes 38 336   
Change in BMI 
adherence  
>=25 to 
<25 
Six month TC 
>= median 
Overall . . 0.18 (0.02, 1.51)  
Change in BMI 
adherence  
>=25 to 
<25 
Six month TC 
>= median 
No 7 50   
Change in BMI 
adherence  
>=25 to 
<25 
Six month TC 
>= median 
Yes 1 40   
Change in BMI 
adherence  
<25 to 
>=25 
Six month TC 
>= median 
Overall . . 1 (0.19, 5.22)  
Change in BMI 
adherence  
<25 to 
>=25 
Six month TC 
>= median 
No 3 46   
Change in BMI 
adherence  
<25 to 
>=25 
Six month TC 
>= median 
Yes 3 46   
Change in BMI 
adherence  
>=25 to 
>=25, 
>=.25SD 
decr 
Six month TC 
>= median 
Overall . . 0.75 (0.42, 1.32)  
Change in BMI 
adherence  
>=25 to 
>=25, 
>=.25SD 
decr 
Six month TC 
>= median 
No 29 250   
Change in BMI 
adherence  
>=25 to 
>=25, 
>=.25SD 
decr 
Six month TC 
>= median 
Yes 23 266   
Change in BMI 
adherence  
>=25 to 
>=25, no 
change 
Six month TC 
>= median 
Overall . . 1.27 (0.75, 2.17)  
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST 
 
LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Change in BMI 
adherence  
>=25 to 
>=25, no 
change 
Six month TC 
>= median 
No 26 326   
Change in BMI 
adherence  
>=25 to 
>=25, no 
change 
Six month TC 
>= median 
Yes 34 335   
Change in BMI 
adherence  
>=25 to 
>=25, 
>=.25SD 
incr 
Six month TC 
>= median 
Overall . . 0.65 (0.36, 1.15)  
Change in BMI 
adherence  
>=25 to 
>=25, 
>=.25SD 
incr 
Six month TC 
>= median 
No 30 369   
Change in BMI 
adherence  
>=25 to 
>=25, 
>=.25SD 
incr 
Six month TC 
>= median 
Yes 21 399   
CKD Stage Overall Atrial 
fibrillation at 
baseline 
Overall . . 2.36 (0.27, 20.3) 6.696, 2, 0.0352 
CKD Stage eGFR 
>=90 
Atrial 
fibrillation at 
baseline 
Overall . . . (., .)  
CKD Stage eGFR 
>=90 
Atrial 
fibrillation at 
baseline 
No 41 580   
CKD Stage eGFR 
>=90 
Atrial 
fibrillation at 
baseline 
Yes 1 0   
CKD Stage 90 > 
eGFR 
>=60 
Atrial 
fibrillation at 
baseline 
Overall . . 0 (., .)  
CKD Stage 90 > 
eGFR 
>=60 
Atrial 
fibrillation at 
baseline 
No 108 1430   
CKD Stage 90 > 
eGFR 
>=60 
Atrial 
fibrillation at 
baseline 
Yes 0 4   
CKD Stage 60 > 
eGFR 
>=30 
Atrial 
fibrillation at 
baseline 
Overall . . 0 (., .)  
CKD Stage 60 > 
eGFR 
>=30 
Atrial 
fibrillation at 
baseline 
No 82 725   
CKD Stage 60 > 
eGFR 
>=30 
Atrial 
fibrillation at 
baseline 
Yes 0 1   
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST 
 
LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
CKD Stage 30 > 
eGFR >= 
0 
Atrial 
fibrillation at 
baseline 
Overall . . N/A  
CKD Stage 30 > 
eGFR >= 
0 
Atrial 
fibrillation at 
baseline 
No 6 58   
CKD Stage 30 > 
eGFR >= 
0 
Atrial 
fibrillation at 
baseline 
Yes 0 0   
CKD Stage Overall Endarterectom
y at baseline 
Overall . . 1.36 (0.85, 2.18) 8.5925, 3, 0.0352
CKD Stage eGFR 
>=90 
Endarterectom
y at baseline 
Overall . . 0.39 (0.05, 2.94)  
CKD Stage eGFR 
>=90 
Endarterectom
y at baseline 
No 41 548   
CKD Stage eGFR 
>=90 
Endarterectom
y at baseline 
Yes 1 34   
CKD Stage 90 > 
eGFR 
>=60 
Endarterectom
y at baseline 
Overall . . 1.66 (0.86, 3.21)  
CKD Stage 90 > 
eGFR 
>=60 
Endarterectom
y at baseline 
No 97 1350   
CKD Stage 90 > 
eGFR 
>=60 
Endarterectom
y at baseline 
Yes 11 92   
CKD Stage 60 > 
eGFR 
>=30 
Endarterectom
y at baseline 
Overall . . 0.97 (0.4, 2.33)  
CKD Stage 60 > 
eGFR 
>=30 
Endarterectom
y at baseline 
No 76 675   
CKD Stage 60 > 
eGFR 
>=30 
Endarterectom
y at baseline 
Yes 6 55   
CKD Stage 30 > 
eGFR >= 
0 
Endarterectom
y at baseline 
Overall . . 10.6 (1.68, 
67.04) 
 
CKD Stage 30 > 
eGFR >= 
0 
Endarterectom
y at baseline 
No 3 53   
CKD Stage 30 > 
eGFR >= 
0 
Endarterectom
y at baseline 
Yes 3 5   
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST 
 
LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Pooled 
psychoneurologi
cal impairment at 
baseline  
Overall Nonwhite 
ancestry 
Overall . . 1.35 (0.99, 1.84) 9.1353, 3, 0.0275
Pooled 
psychoneurologi
cal impairment at 
baseline  
No Nonwhite 
ancestry 
Overall . . 0.82 (0.19, 3.64)  
Pooled 
psychoneurologi
cal impairment at 
baseline  
No Nonwhite 
ancestry 
No 19 391   
Pooled 
psychoneurologi
cal impairment at 
baseline  
No Nonwhite 
ancestry 
Yes 2 50   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Mild Nonwhite 
ancestry 
Overall . . 1.01 (0.68, 1.49)  
Pooled 
psychoneurologi
cal impairment at 
baseline  
Mild Nonwhite 
ancestry 
No 134 1629   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Mild Nonwhite 
ancestry 
Yes 34 410   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Moderate Nonwhite 
ancestry 
Overall . . 2.67 (1.41, 5.05)  
Pooled 
psychoneurologi
cal impairment at 
baseline  
Moderate Nonwhite 
ancestry 
No 26 257   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Moderate Nonwhite 
ancestry 
Yes 20 74   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Severe Nonwhite 
ancestry 
Overall . . . (., .)  
Pooled 
psychoneurologi
cal impairment at 
baseline  
Severe Nonwhite 
ancestry 
No 2 7   
  
198
 
STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST 
 
LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Pooled 
psychoneurologi
cal impairment at 
baseline  
Severe Nonwhite 
ancestry 
Yes 1 0   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Overall Aspirin use at 
baseline 
Overall . . 1.11 (0.85, 1.47) 11.8064, 3, 
0.0081 
Pooled 
psychoneurologi
cal impairment at 
baseline  
No Aspirin use at 
baseline 
Overall . . 0.53 (0.22, 1.28)  
Pooled 
psychoneurologi
cal impairment at 
baseline  
No Aspirin use at 
baseline 
No 10 144   
Pooled 
psychoneurologi
cal impairment at 
baseline  
No Aspirin use at 
baseline 
Yes 11 297   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Mild Aspirin use at 
baseline 
Overall . . 1.54 (1.1, 2.17)  
Pooled 
psychoneurologi
cal impairment at 
baseline  
Mild Aspirin use at 
baseline 
No 51 820   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Mild Aspirin use at 
baseline 
Yes 117 1219   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Moderate Aspirin use at 
baseline 
Overall . . 0.69 (0.37, 1.28)  
Pooled 
psychoneurologi
cal impairment at 
baseline  
Moderate Aspirin use at 
baseline 
No 23 135   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Moderate Aspirin use at 
baseline 
Yes 23 196   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Severe Aspirin use at 
baseline 
Overall . . 0 (., .)  
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST 
 
LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Pooled 
psychoneurologi
cal impairment at 
baseline  
Severe Aspirin use at 
baseline 
No 3 3   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Severe Aspirin use at 
baseline 
Yes 0 4   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Overall Nonwhite 
ancestry 
Overall . . 1.35 (0.99, 1.84) 7.3521, 2, 0.0253
Pooled 
psychoneurologi
cal impairment at 
baseline  
No Nonwhite 
ancestry 
Overall . . 0.82 (0.19, 3.64)  
Pooled 
psychoneurologi
cal impairment at 
baseline  
No Nonwhite 
ancestry 
No 19 391   
Pooled 
psychoneurologi
cal impairment at 
baseline  
No Nonwhite 
ancestry 
Yes 2 50   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Mild Nonwhite 
ancestry 
Overall . . 1.01 (0.68, 1.49)  
Pooled 
psychoneurologi
cal impairment at 
baseline  
Mild Nonwhite 
ancestry 
No 134 1629   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Mild Nonwhite 
ancestry 
Yes 34 410   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Moderate Nonwhite 
ancestry 
Overall . . 2.68 (1.44, 4.98)  
Pooled 
psychoneurologi
cal impairment at 
baseline  
Moderate Nonwhite 
ancestry 
No 28 264   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Moderate Nonwhite 
ancestry 
Yes 21 74   
  
200
 
STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST 
 
LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Pooled 
psychoneurologi
cal impairment at 
baseline  
Overall Aspirin use at 
baseline 
Overall . . 1.11 (0.85, 1.47) 10.293, 2, 0.0058
Pooled 
psychoneurologi
cal impairment at 
baseline  
No Aspirin use at 
baseline 
Overall . . 0.53 (0.22, 1.28)  
Pooled 
psychoneurologi
cal impairment at 
baseline  
No Aspirin use at 
baseline 
No 10 144   
Pooled 
psychoneurologi
cal impairment at 
baseline  
No Aspirin use at 
baseline 
Yes 11 297   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Mild Aspirin use at 
baseline 
Overall . . 1.54 (1.1, 2.17)  
Pooled 
psychoneurologi
cal impairment at 
baseline  
Mild Aspirin use at 
baseline 
No 51 820   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Mild Aspirin use at 
baseline 
Yes 117 1219   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Moderate Aspirin use at 
baseline 
Overall . . 0.61 (0.33, 1.11)  
Pooled 
psychoneurologi
cal impairment at 
baseline  
Moderate Aspirin use at 
baseline 
No 26 138   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Moderate Aspirin use at 
baseline 
Yes 23 200   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Overall Six month 
SBP >=120 
Overall . . 1.17 (0.76, 1.8) 7.0291, 2, 0.0298
Pooled 
psychoneurologi
cal impairment at 
baseline  
No Six month 
SBP >=120 
Overall . . 0.35 (0.12, 0.99)  
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST 
 
LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Pooled 
psychoneurologi
cal impairment at 
baseline  
No Six month 
SBP >=120 
No 5 43   
Pooled 
psychoneurologi
cal impairment at 
baseline  
No Six month 
SBP >=120 
Yes 16 398   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Mild Six month 
SBP >=120 
Overall . . 1.58 (0.9, 2.77)  
Pooled 
psychoneurologi
cal impairment at 
baseline  
Mild Six month 
SBP >=120 
No 14 256   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Mild Six month 
SBP >=120 
Yes 154 1783   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Moderate Six month 
SBP >=120 
Overall . . 1.02 (0.41, 2.53)  
Pooled 
psychoneurologi
cal impairment at 
baseline  
Moderate Six month 
SBP >=120 
No 6 42   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Moderate Six month 
SBP >=120 
Yes 43 296   
Pooled 
neurological 
deficit and 
disability  
Overall Anti-DM med 
use at baseline 
Overall . . 1.29 (0.96, 1.72) 6.8782, 2, 0.0321
Pooled 
neurological 
deficit and 
disability  
No Anti-DM med 
use at baseline 
Overall . . 2.72 (1.36, 5.46)  
Pooled 
neurological 
deficit and 
disability  
No Anti-DM med 
use at baseline 
No 23 487   
Pooled 
neurological 
deficit and 
disability  
No Anti-DM med 
use at baseline 
Yes 14 109   
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST 
 
LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Pooled 
neurological 
deficit and 
disability  
Mild Anti-DM med 
use at baseline 
Overall . . 0.97 (0.66, 1.41)  
Pooled 
neurological 
deficit and 
disability  
Mild Anti-DM med 
use at baseline 
No 118 1433   
Pooled 
neurological 
deficit and 
disability  
Mild Anti-DM med 
use at baseline 
Yes 38 478   
Pooled 
neurological 
deficit and 
disability  
Moderate Anti-DM med 
use at baseline 
Overall . . 1.35 (0.71, 2.56)  
Pooled 
neurological 
deficit and 
disability  
Moderate Anti-DM med 
use at baseline 
No 27 208   
Pooled 
neurological 
deficit and 
disability  
Moderate Anti-DM med 
use at baseline 
Yes 18 103   
Pooled 
neurological 
deficit and 
disability  
Overall Nonwhite 
ancestry 
Overall . . 1.35 (0.99, 1.84) 7.8762, 2, 0.0195
Pooled 
neurological 
deficit and 
disability  
No Nonwhite 
ancestry 
Overall . . 1.33 (0.57, 3.12)  
Pooled 
neurological 
deficit and 
disability  
No Nonwhite 
ancestry 
No 30 507   
Pooled 
neurological 
deficit and 
disability  
No Nonwhite 
ancestry 
Yes 7 89   
Pooled 
neurological 
deficit and 
disability  
Mild Nonwhite 
ancestry 
Overall . . 0.99 (0.66, 1.49)  
Pooled 
neurological 
deficit and 
disability  
Mild Nonwhite 
ancestry 
No 125 1528   
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST 
 
LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Pooled 
neurological 
deficit and 
disability  
Mild Nonwhite 
ancestry 
Yes 31 383   
Pooled 
neurological 
deficit and 
disability  
Moderate Nonwhite 
ancestry 
Overall . . 2.93 (1.53, 5.64)  
Pooled 
neurological 
deficit and 
disability  
Moderate Nonwhite 
ancestry 
No 26 249   
Pooled 
neurological 
deficit and 
disability  
Moderate Nonwhite 
ancestry 
Yes 19 62   
Diabetes at 
baseline 
Overall Anti-DM med 
use at six mos.
Overall . . 1.17 (0.87, 1.57) 5.4019, 1, 0.0201
Diabetes at 
baseline 
No Anti-DM med 
use at six mos.
Overall . . 2.01 (0.45, 8.95)  
Diabetes at 
baseline 
No Anti-DM med 
use at six mos.
No 142 2002   
Diabetes at 
baseline 
No Anti-DM med 
use at six mos.
Yes 2 14   
Diabetes at 
baseline 
Yes Anti-DM med 
use at six mos.
Overall . . 0.37 (0.23, 0.59)  
Diabetes at 
baseline 
Yes Anti-DM med 
use at six mos.
No 30 118   
Diabetes at 
baseline 
Yes Anti-DM med 
use at six mos.
Yes 64 684   
Diabetes at 
baseline 
Overall Aspirin use at 
six mos. 
Overall . . 0.98 (0.75, 1.28) 4.8547, 1, 0.0276
Diabetes at 
baseline 
No Aspirin use at 
six mos. 
Overall . . 1.3 (0.91, 1.86)  
Diabetes at 
baseline 
No Aspirin use at 
six mos. 
No 48 794   
Diabetes at 
baseline 
No Aspirin use at 
six mos. 
Yes 96 1222   
Diabetes at 
baseline 
Yes Aspirin use at 
six mos. 
Overall . . 0.7 (0.45, 1.07)  
Diabetes at 
baseline 
Yes Aspirin use at 
six mos. 
No 50 354   
Diabetes at 
baseline 
Yes Aspirin use at 
six mos. 
Yes 44 448   
Diabetes at 
baseline 
Overall Baseline SBP 
>= median 
Overall . . 1.21 (0.93, 1.58) 9.4846, 1, 0.0021
  
204
 
STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST 
 
LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Diabetes at 
baseline 
No Baseline SBP 
>= median 
Overall . . 1.65 (1.17, 2.33)  
Diabetes at 
baseline 
No Baseline SBP 
>= median 
No 56 1033   
Diabetes at 
baseline 
No Baseline SBP 
>= median 
Yes 88 983   
Diabetes at 
baseline 
Yes Baseline SBP 
>= median 
Overall . . 0.7 (0.46, 1.07)  
Diabetes at 
baseline 
Yes Baseline SBP 
>= median 
No 50 355   
Diabetes at 
baseline 
Yes Baseline SBP 
>= median 
Yes 44 447   
Diabetes at six 
mos. 
Overall Aspirin use at 
six mos. 
Overall . . 0.98 (0.75, 1.28) 5.2625, 1, 0.0218
Diabetes at six 
mos. 
No Aspirin use at 
six mos. 
Overall . . 1.32 (0.92, 1.89)  
Diabetes at six 
mos. 
No Aspirin use at 
six mos. 
No 47 789   
Diabetes at six 
mos. 
No Aspirin use at 
six mos. 
Yes 95 1210   
Diabetes at six 
mos. 
Yes Aspirin use at 
six mos. 
Overall . . 0.69 (0.45, 1.05)  
Diabetes at six 
mos. 
Yes Aspirin use at 
six mos. 
No 51 359   
Diabetes at six 
mos. 
Yes Aspirin use at 
six mos. 
Yes 45 460   
Diabetes at six 
mos. 
Overall Baseline SBP 
>= median 
Overall . . 1.21 (0.93, 1.58) 8.6876, 1, 0.0032
Diabetes at six 
mos. 
No Baseline SBP 
>= median 
Overall . . 1.63 (1.15, 2.31)  
Diabetes at six 
mos. 
No Baseline SBP 
>= median 
No 56 1029   
Diabetes at six 
mos. 
No Baseline SBP 
>= median 
Yes 86 970   
Diabetes at six 
mos. 
Yes Baseline SBP 
>= median 
Overall . . 0.72 (0.47, 1.1)  
Diabetes at six 
mos. 
Yes Baseline SBP 
>= median 
No 50 359   
Diabetes at six 
mos. 
Yes Baseline SBP 
>= median 
Yes 46 460   
Endarterectomy 
at baseline 
Overall Blood-
pressure-
lowering med 
use at baseline 
Overall . . 1.16 (0.89, 1.51) 6.5527, 1, 0.0105
  
205
 
STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST 
 
LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Endarterectomy 
at baseline 
No Blood-
pressure-
lowering med 
use at baseline 
Overall . . 1.04 (0.79, 1.37)  
Endarterectomy 
at baseline 
No Blood-
pressure-
lowering med 
use at baseline 
No 109 1348   
Endarterectomy 
at baseline 
No Blood-
pressure-
lowering med 
use at baseline 
Yes 108 1283   
Endarterectomy 
at baseline 
Yes Blood-
pressure-
lowering med 
use at baseline 
Overall . . 4.01 (1.41, 11.4)  
Endarterectomy 
at baseline 
Yes Blood-
pressure-
lowering med 
use at baseline 
No 5 104   
Endarterectomy 
at baseline 
Yes Blood-
pressure-
lowering med 
use at baseline 
Yes 16 83   
Hypertensive at 
baseline 
Overall Anti-DM med 
use at baseline 
Overall . . 1.29 (0.96, 1.72) 4.2337, 1, 0.0396
Hypertensive at 
baseline 
No Anti-DM med 
use at baseline 
Overall . . 2.31 (1.18, 4.52)  
Hypertensive at 
baseline 
No Anti-DM med 
use at baseline 
No 34 671   
Hypertensive at 
baseline 
No Anti-DM med 
use at baseline 
Yes 13 111   
Hypertensive at 
baseline 
Yes Anti-DM med 
use at baseline 
Overall . . 1.07 (0.77, 1.48)  
Hypertensive at 
baseline 
Yes Anti-DM med 
use at baseline 
No 134 1457   
Hypertensive at 
baseline 
Yes Anti-DM med 
use at baseline 
Yes 57 579   
Hyperlipidemic 
at baseline 
Overall Diabetes at 
baseline 
Overall . . 1.64 (1.25, 2.15) 4.0533, 1, 0.0441
Hyperlipidemic 
at baseline 
No Diabetes at 
baseline 
Overall . . 1.03 (0.6, 1.77)  
Hyperlipidemic 
at baseline 
No Diabetes at 
baseline 
No 50 575   
Hyperlipidemic 
at baseline 
No Diabetes at 
baseline 
Yes 20 223   
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST 
 
LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Hyperlipidemic 
at baseline 
Yes Diabetes at 
baseline 
Overall . . 1.96 (1.42, 2.7)  
Hyperlipidemic 
at baseline 
Yes Diabetes at 
baseline 
No 94 1441   
Hyperlipidemic 
at baseline 
Yes Diabetes at 
baseline 
Yes 74 579   
Hyperlipidemic 
at 6 mos. 
Overall Blood-
pressure-
lowering med 
use at six mos.
Overall . . 1.18 (0.91, 1.55) 4.361, 1, 0.0368 
Hyperlipidemic 
at 6 mos. 
No Blood-
pressure-
lowering med 
use at six mos.
Overall . . 0.7 (0.4, 1.23)  
Hyperlipidemic 
at 6 mos. 
No Blood-
pressure-
lowering med 
use at six mos.
No 28 288   
Hyperlipidemic 
at 6 mos. 
No Blood-
pressure-
lowering med 
use at six mos.
Yes 24 354   
Hyperlipidemic 
at 6 mos. 
Yes Blood-
pressure-
lowering med 
use at six mos.
Overall . . 1.38 (1.01, 1.87)  
Hyperlipidemic 
at 6 mos. 
Yes Blood-
pressure-
lowering med 
use at six mos.
No 73 1025   
Hyperlipidemic 
at 6 mos. 
Yes Blood-
pressure-
lowering med 
use at six mos.
Yes 113 1151   
Hyperlipidemic 
at 6 mos. 
Overall Diabetes at 
baseline 
Overall . . 1.64 (1.25, 2.15) 4.6566, 1, 0.0309
Hyperlipidemic 
at 6 mos. 
No Diabetes at 
baseline 
Overall . . 0.88 (0.46, 1.68)  
Hyperlipidemic 
at 6 mos. 
No Diabetes at 
baseline 
No 39 465   
Hyperlipidemic 
at 6 mos. 
No Diabetes at 
baseline 
Yes 13 177   
Hyperlipidemic 
at 6 mos. 
Yes Diabetes at 
baseline 
Overall . . 1.91 (1.41, 2.6)  
Hyperlipidemic 
at 6 mos. 
Yes Diabetes at 
baseline 
No 105 1551   
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST 
 
LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Hyperlipidemic 
at 6 mos. 
Yes Diabetes at 
baseline 
Yes 81 625   
Hyperlipidemic 
at 6 mos. 
Overall Diabetes at six 
mos. 
Overall . . 1.65 (1.26, 2.16) 5.2391, 1, 0.0221
Hyperlipidemic 
at 6 mos. 
No Diabetes at six 
mos. 
Overall . . 0.85 (0.44, 1.63)  
Hyperlipidemic 
at 6 mos. 
No Diabetes at six 
mos. 
No 39 461   
Hyperlipidemic 
at 6 mos. 
No Diabetes at six 
mos. 
Yes 13 181   
Hyperlipidemic 
at 6 mos. 
Yes Diabetes at six 
mos. 
Overall . . 1.94 (1.43, 2.63)  
Hyperlipidemic 
at 6 mos. 
Yes Diabetes at six 
mos. 
No 103 1538   
Hyperlipidemic 
at 6 mos. 
Yes Diabetes at six 
mos. 
Yes 83 638   
Hyperlipidemic 
at 6 mos. 
Overall Hypertensive 
at 6 mos. 
Overall . . 1.62 (1.08, 2.45) 4.8475, 1, 0.0277
Hyperlipidemic 
at 6 mos. 
No Hypertensive 
at 6 mos. 
Overall . . 0.83 (0.41, 1.66)  
Hyperlipidemic 
at 6 mos. 
No Hypertensive 
at 6 mos. 
No 11 117   
Hyperlipidemic 
at 6 mos. 
No Hypertensive 
at 6 mos. 
Yes 41 525   
Hyperlipidemic 
at 6 mos. 
Yes Hypertensive 
at 6 mos. 
Overall . . 2.16 (1.28, 3.65)  
Hyperlipidemic 
at 6 mos. 
Yes Hypertensive 
at 6 mos. 
No 16 368   
Hyperlipidemic 
at 6 mos. 
Yes Hypertensive 
at 6 mos. 
Yes 170 1808   
Aspirin use at 
baseline 
Overall BMI at six 
mos. >= 
median 
Overall . . 1.15 (0.88, 1.5) 5.6917, 1, 0.017 
Aspirin use at 
baseline 
No BMI at six 
mos. >= 
median 
Overall . . 0.76 (0.49, 1.17)  
Aspirin use at 
baseline 
No BMI at six 
mos. >= 
median 
No 48 531   
Aspirin use at 
baseline 
No BMI at six 
mos. >= 
median 
Yes 39 571   
Aspirin use at 
baseline 
Yes BMI at six 
mos. >= 
median 
Overall . . 1.48 (1.05, 2.07)  
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST 
 
LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Aspirin use at 
baseline 
Yes BMI at six 
mos. >= 
median 
No 63 882   
Aspirin use at 
baseline 
Yes BMI at six 
mos. >= 
median 
Yes 88 834   
Aspirin use at 
baseline 
Overall Six month TC 
>= median 
Overall . . 1 (0.77, 1.3) 4.247, 1, 0.0393 
Aspirin use at 
baseline 
No Six month TC 
>= median 
Overall . . 1.44 (0.93, 2.25)  
Aspirin use at 
baseline 
No Six month TC 
>= median 
No 36 556   
Aspirin use at 
baseline 
No Six month TC 
>= median 
Yes 51 546   
Aspirin use at 
baseline 
Yes Six month TC 
>= median 
Overall . . 0.81 (0.58, 1.13)  
Aspirin use at 
baseline 
Yes Six month TC 
>= median 
No 82 840   
Aspirin use at 
baseline 
Yes Six month TC 
>= median 
Yes 69 876   
Six month SBP 
>=120  
Overall Blood-
pressure-
lowering med 
use at baseline 
Overall . . 1.16 (0.89, 1.51) 4.31, 1, 0.0379 
Six month SBP 
>=120  
No Blood-
pressure-
lowering med 
use at baseline 
Overall . . 2.59 (1.13, 5.94)  
Six month SBP 
>=120  
No Blood-
pressure-
lowering med 
use at baseline 
No 10 216   
Six month SBP 
>=120  
No Blood-
pressure-
lowering med 
use at baseline 
Yes 15 125   
Six month SBP 
>=120  
Yes Blood-
pressure-
lowering med 
use at baseline 
Overall . . 1.04 (0.79, 1.38)  
Six month SBP 
>=120  
Yes Blood-
pressure-
lowering med 
use at baseline 
No 104 1236   
Six month SBP 
>=120  
Yes Blood-
pressure-
lowering med 
use at baseline 
Yes 109 1241   
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST 
 
LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Six month SBP 
>=120  
Overall Six month TC 
>= median 
Overall . . 1 (0.77, 1.3) 5.0533, 1, 0.0246
Six month SBP 
>=120  
No Six month TC 
>= median 
Overall . . 0.37 (0.14, 0.95)  
Six month SBP 
>=120  
No Six month TC 
>= median 
No 19 184   
Six month SBP 
>=120  
No Six month TC 
>= median 
Yes 6 157   
Six month SBP 
>=120  
Yes Six month TC 
>= median 
Overall . . 1.1 (0.83, 1.46)  
Six month SBP 
>=120  
Yes Six month TC 
>= median 
No 99 1212   
Six month SBP 
>=120  
Yes Six month TC 
>= median 
Yes 114 1265   
Change in TC 
adherence  
Overall Lipid-lowering 
med use at 
baseline 
Overall . . 0.98 (0.75, 1.28) 11.2859, 5, 0.046
Change in TC 
adherence  
Stayed < 
200 
Lipid-lowering 
med use at 
baseline 
Overall . . 0.83 (0.56, 1.24)  
Change in TC 
adherence  
Stayed < 
200 
Lipid-lowering 
med use at 
baseline 
No 63 719   
Change in TC 
adherence  
Stayed < 
200 
Lipid-lowering 
med use at 
baseline 
Yes 44 604   
Change in TC 
adherence  
>=200 to 
< 200 
Lipid-lowering 
med use at 
baseline 
Overall . . 0.98 (0.43, 2.24)  
Change in TC 
adherence  
>=200 to 
< 200 
Lipid-lowering 
med use at 
baseline 
No 12 100   
Change in TC 
adherence  
>=200 to 
< 200 
Lipid-lowering 
med use at 
baseline 
Yes 13 111   
Change in TC 
adherence  
<200 to 
>=200 
Lipid-lowering 
med use at 
baseline 
Overall . . 0.45 (0.09, 2.26)  
Change in TC 
adherence  
<200 to 
>=200 
Lipid-lowering 
med use at 
baseline 
No 7 79   
Change in TC 
adherence  
<200 to 
>=200 
Lipid-lowering 
med use at 
baseline 
Yes 2 50   
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST 
 
LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Change in TC 
adherence  
>=200 to 
>=200, 
>=.25SD 
decr 
Lipid-lowering 
med use at 
baseline 
Overall . . 1.02 (0.48, 2.16)  
Change in TC 
adherence  
>=200 to 
>=200, 
>=.25SD 
decr 
Lipid-lowering 
med use at 
baseline 
No 15 238   
Change in TC 
adherence  
>=200 to 
>=200, 
>=.25SD 
decr 
Lipid-lowering 
med use at 
baseline 
Yes 14 218   
Change in TC 
adherence  
>=200 to 
>=200, no 
change 
Lipid-lowering 
med use at 
baseline 
Overall . . 0.9 (0.48, 1.68)  
Change in TC 
adherence  
>=200 to 
>=200, no 
change 
Lipid-lowering 
med use at 
baseline 
No 28 291   
Change in TC 
adherence  
>=200 to 
>=200, no 
change 
Lipid-lowering 
med use at 
baseline 
Yes 17 197   
Change in TC 
adherence  
>=200 to 
>=200, 
>=.25SD 
incr 
Lipid-lowering 
med use at 
baseline 
Overall . . 3.69 (1.53, 8.89)  
Change in TC 
adherence  
>=200 to 
>=200, 
>=.25SD 
incr  
Lipid-lowering 
med use at 
baseline 
No 10 156   
Change in TC 
adherence  
>=200 to 
>=200, 
>=.25SD 
incr 
Lipid-lowering 
med use at 
baseline 
Yes 13 55   
 
Table A.14. Summary table of significant (p<0.05) Breslow-Day test results for check of 
EMM using baseline risk factors, twelve month risk factors and change in medication 
and risk factor adherence (for analysis results shown in Tables 4.10, 4.11, and 4.12) 
 
STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Baseline age 
>=60y 
Overall Lipid-
lowering 
med use at 
baseline 
Overall . . 1.01 (0.76, 1.35) 7.0737, 1, 0.0078 
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Baseline age 
>=60y 
No Lipid-
lowering 
med use at 
baseline 
Overall . . 2.05 (1.12, 3.77)  
Baseline age 
>=60y 
No Lipid-
lowering 
med use at 
baseline 
No 19 390   
Baseline age 
>=60y 
No Lipid-
lowering 
med use at 
baseline 
Yes 27 270   
Baseline age 
>=60y 
Yes Lipid-
lowering 
med use at 
baseline 
Overall . . 0.81 (0.58, 1.13)  
Baseline age 
>=60y 
Yes Lipid-
lowering 
med use at 
baseline 
No 96 1051   
Baseline age 
>=60y 
Yes Lipid-
lowering 
med use at 
baseline 
Yes 62 835   
Baseline age 
>=60y 
Overall Blood-
pressure-
lowering 
med use at 
twelve mos. 
Overall . . 1.21 (0.91, 1.62) 5.6842, 1, 0.0171 
Baseline age 
>=60y 
No Blood-
pressure-
lowering 
med use at 
twelve mos. 
Overall . . 2.46 (1.25, 4.84)  
Baseline age 
>=60y 
No Blood-
pressure-
lowering 
med use at 
twelve mos. 
No 12 307   
Baseline age 
>=60y 
No Blood-
pressure-
lowering 
med use at 
twelve mos. 
Yes 34 353   
Baseline age 
>=60y 
Yes Blood-
pressure-
lowering 
med use at 
twelve mos. 
Overall . . 1 (0.72, 1.39)  
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Baseline age 
>=60y 
Yes Blood-
pressure-
lowering 
med use at 
twelve mos. 
No 72 861   
Baseline age 
>=60y 
Yes Blood-
pressure-
lowering 
med use at 
twelve mos. 
Yes 86 1025   
12 mo. age >=60 Overall Anti-DM 
med use at 
baseline 
Overall . . 1.19 (0.86, 1.63) 3.9529, 1, 0.0468 
12 mo. age >=60 No Anti-DM 
med use at 
baseline 
Overall . . 2.06 (1.1, 3.85)  
12 mo. age >=60 No Anti-DM 
med use at 
baseline 
No 27 467   
12 mo. age >=60 No Anti-DM 
med use at 
baseline 
Yes 18 151   
12 mo. age >=60 Yes Anti-DM 
med use at 
baseline 
Overall . . 0.99 (0.68, 1.44)  
12 mo. age >=60 Yes Anti-DM 
med use at 
baseline 
No 120 1452   
12 mo. age >=60 Yes Anti-DM 
med use at 
baseline 
Yes 39 476   
12 mo. age >=60 Overall Anti-DM 
med use at 
twelve mos. 
Overall . . 1.24 (0.91, 1.7) 4.0765, 1, 0.0435 
12 mo. age >=60 No Anti-DM 
med use at 
twelve mos. 
Overall . . 2.16 (1.17, 4.02)  
12 mo. age >=60 No Anti-DM 
med use at 
twelve mos. 
No 26 462   
12 mo. age >=60 No Anti-DM 
med use at 
twelve mos. 
Yes 19 156   
12 mo. age >=60 Yes Anti-DM 
med use at 
twelve mos. 
Overall . . 1.04 (0.72, 1.5)  
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
12 mo. age >=60 Yes Anti-DM 
med use at 
twelve mos. 
No 118 1444   
12 mo. age >=60 Yes Anti-DM 
med use at 
twelve mos. 
Yes 41 484   
12 mo. age >=60 Overall Lipid-
lowering 
med use at 
baseline 
Overall . . 1.01 (0.76, 1.35) 7.285, 1, 0.007 
12 mo. age >=60 No Lipid-
lowering 
med use at 
baseline 
Overall . . 2.11 (1.14, 3.91)  
12 mo. age >=60 No Lipid-
lowering 
med use at 
baseline 
No 18 361   
12 mo. age >=60 No Lipid-
lowering 
med use at 
baseline 
Yes 27 257   
12 mo. age >=60 Yes Lipid-
lowering 
med use at 
baseline 
Overall . . 0.81 (0.58, 1.13)  
12 mo. age >=60 Yes Lipid-
lowering 
med use at 
baseline 
No 97 1080   
12 mo. age >=60 Yes Lipid-
lowering 
med use at 
baseline 
Yes 62 848   
12 mo. age >=60 Overall Blood-
pressure-
lowering 
med use at 
twelve mos. 
Overall . . 1.21 (0.91, 1.62) 5.2729, 1, 0.0217 
12 mo. age >=60 No Blood-
pressure-
lowering 
med use at 
twelve mos. 
Overall . . 2.42 (1.22, 4.77)  
12 mo. age >=60 No Blood-
pressure-
lowering 
med use at 
twelve mos. 
No 12 289   
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
12 mo. age >=60 No Blood-
pressure-
lowering 
med use at 
twelve mos. 
Yes 33 329   
12 mo. age >=60 Yes Blood-
pressure-
lowering 
med use at 
twelve mos. 
Overall . . 1.01 (0.73, 1.4)  
12 mo. age >=60 Yes Blood-
pressure-
lowering 
med use at 
twelve mos. 
No 72 879   
12 mo. age >=60 Yes Blood-
pressure-
lowering 
med use at 
twelve mos. 
Yes 87 1049   
Anti-DM med 
use at baseline 
Overall Baseline 
SBP >= 
median 
Overall . . 1.4 (1.05, 1.87) 10.6151, 1, 0.0011
Anti-DM med 
use at baseline 
No Baseline 
SBP >= 
median 
Overall . . 1.88 (1.33, 2.66)  
Anti-DM med 
use at baseline 
No Baseline 
SBP >= 
median 
No 53 987   
Anti-DM med 
use at baseline 
No Baseline 
SBP >= 
median 
Yes 94 932   
Anti-DM med 
use at baseline 
Yes Baseline 
SBP >= 
median 
Overall . . 0.65 (0.38, 1.12)  
Anti-DM med 
use at baseline 
Yes Baseline 
SBP >= 
median 
No 31 274   
Anti-DM med 
use at baseline 
Yes Baseline 
SBP >= 
median 
Yes 26 353   
Anti-DM med 
use at twelve 
mos. 
Overall Baseline 
SBP >= 
median 
Overall . . 1.4 (1.05, 1.87) 5.452, 1, 0.0195 
Anti-DM med 
use at twelve 
mos. 
No Baseline 
SBP >= 
median 
Overall . . 1.73 (1.22, 2.45)  
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Anti-DM med 
use at twelve 
mos. 
No Baseline 
SBP >= 
median 
No 55 984   
Anti-DM med 
use at twelve 
mos. 
No Baseline 
SBP >= 
median 
Yes 89 922   
Anti-DM med 
use at twelve 
mos. 
Yes Baseline 
SBP >= 
median 
Overall . . 0.82 (0.48, 1.39)  
Anti-DM med 
use at twelve 
mos. 
Yes Baseline 
SBP >= 
median 
No 29 277   
Anti-DM med 
use at twelve 
mos. 
Yes Baseline 
SBP >= 
median 
Yes 31 363   
Lipid-lowering 
med use at 
baseline 
Overall Baseline age 
>= median 
Overall . . 1.27 (0.96, 1.7) 4.6121, 1, 0.0317 
Lipid-lowering 
med use at 
baseline 
No Baseline age 
>= median 
Overall . . 1.69 (1.14, 2.5)  
Lipid-lowering 
med use at 
baseline 
No Baseline age 
>= median 
No 43 724   
Lipid-lowering 
med use at 
baseline 
No Baseline age 
>= median 
Yes 72 717   
Lipid-lowering 
med use at 
baseline 
Yes Baseline age 
>= median 
Overall . . 0.89 (0.58, 1.38)  
Lipid-lowering 
med use at 
baseline 
Yes Baseline age 
>= median 
No 48 565   
Lipid-lowering 
med use at 
baseline 
Yes Baseline age 
>= median 
Yes 41 540   
Lipid-lowering 
med use at 
baseline 
Overall 12 mo. age 
>= median 
Overall . . 1.27 (0.96, 1.7) 4.6121, 1, 0.0317 
Lipid-lowering 
med use at 
baseline 
No 12 mo. age 
>= median 
Overall . . 1.69 (1.14, 2.5)  
Lipid-lowering 
med use at 
baseline 
No 12 mo. age 
>= median 
No 43 724   
Lipid-lowering 
med use at 
baseline 
No 12 mo. age 
>= median 
Yes 72 717   
  
216
 
STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Lipid-lowering 
med use at 
baseline 
Yes 12 mo. age 
>= median 
Overall . . 0.89 (0.58, 1.38)  
Lipid-lowering 
med use at 
baseline 
Yes 12 mo. age 
>= median 
No 48 565   
Lipid-lowering 
med use at 
baseline 
Yes 12 mo. age 
>= median 
Yes 41 540   
Lipid-lowering 
med use at 
baseline 
Overall 12 mo. SBP 
>= median 
Overall . . 1.31 (0.98, 1.75) 6.7439, 1, 0.0094 
Lipid-lowering 
med use at 
baseline 
No 12 mo. SBP 
>= median 
Overall . . 1.86 (1.25, 2.76)  
Lipid-lowering 
med use at 
baseline 
No 12 mo. SBP 
>= median 
No 40 717   
Lipid-lowering 
med use at 
baseline 
No 12 mo. SBP 
>= median 
Yes 75 724   
Lipid-lowering 
med use at 
baseline 
Yes 12 mo. SBP 
>= median 
Overall . . 0.86 (0.55, 1.32)  
Lipid-lowering 
med use at 
baseline 
Yes 12 mo. SBP 
>= median 
No 48 553   
Lipid-lowering 
med use at 
baseline 
Yes 12 mo. SBP 
>= median 
Yes 41 552   
Change in lipid-
lowering med 
adherence 
Overall 12 mo. SBP 
>= median 
Overall . . 1.31 (0.98, 1.75) 9.1279, 3, 0.0276 
Change in lipid-
lowering med 
adherence 
Adherent 12 mo. SBP 
>= median 
Overall . . 0.94 (0.65, 1.35)  
Change in lipid-
lowering med 
adherence 
Adherent 12 mo. SBP 
>= median 
No 65 798   
Change in lipid-
lowering med 
adherence 
Adherent 12 mo. SBP 
>= median 
Yes 58 761   
Change in lipid-
lowering med 
adherence 
Started 
using 
12 mo. SBP 
>= median 
Overall . . 2.63 (0.8, 8.65)  
Change in lipid-
lowering med 
adherence 
Started 
using 
12 mo. SBP 
>= median 
No 4 104   
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Change in lipid-
lowering med 
adherence 
Started 
using 
12 mo. SBP 
>= median 
Yes 10 99   
Change in lipid-
lowering med 
adherence 
Stopped 
using 
12 mo. SBP 
>= median 
Overall . . 1.61 (0.69, 3.78)  
Change in lipid-
lowering med 
adherence 
Stopped 
using 
12 mo. SBP 
>= median 
No 9 126   
Change in lipid-
lowering med 
adherence 
Stopped 
using 
12 mo. SBP 
>= median 
Yes 16 139   
Change in lipid-
lowering med 
adherence 
Never 
used 
12 mo. SBP 
>= median 
Overall . . 2.8 (1.35, 5.81)  
Change in lipid-
lowering med 
adherence 
Never 
used 
12 mo. SBP 
>= median 
No 10 242   
Change in lipid-
lowering med 
adherence 
Never 
used 
12 mo. SBP 
>= median 
Yes 32 277   
Change in lipid-
lowering med 
adherence 
Overall 12 mo. TC 
>= median 
Overall . . 0.98 (0.74, 1.31) 13.1603, 3, 0.0043
Change in lipid-
lowering med 
adherence 
Adherent 12 mo. TC 
>= median 
Overall . . 1.16 (0.79, 1.7)  
Change in lipid-
lowering med 
adherence 
Adherent 12 mo. TC 
>= median 
No 80 1065   
Change in lipid-
lowering med 
adherence 
Adherent 12 mo. TC 
>= median 
Yes 43 494   
Change in lipid-
lowering med 
adherence 
Started 
using 
12 mo. TC 
>= median 
Overall . . 2.09 (0.68, 6.45)  
Change in lipid-
lowering med 
adherence 
Started 
using 
12 mo. TC 
>= median 
No 5 109   
Change in lipid-
lowering med 
adherence 
Started 
using 
12 mo. TC 
>= median 
Yes 9 94   
Change in lipid-
lowering med 
adherence 
Stopped 
using 
12 mo. TC 
>= median 
Overall . . 0.3 (0.12, 0.76)  
Change in lipid-
lowering med 
adherence 
Stopped 
using 
12 mo. TC 
>= median 
No 8 33   
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Change in lipid-
lowering med 
adherence 
Stopped 
using 
12 mo. TC 
>= median 
Yes 17 232   
Change in lipid-
lowering med 
adherence 
Never 
used 
12 mo. TC 
>= median 
Overall . . 0.44 (0.2, 0.97)  
Change in lipid-
lowering med 
adherence 
Never 
used 
12 mo. TC 
>= median 
No 9 56   
Change in lipid-
lowering med 
adherence 
Never 
used 
12 mo. TC 
>= median 
Yes 33 463   
Lipid-lowering 
med use at 
twelve mos. 
Overall Baseline age 
>= median 
Overall . . 1.27 (0.96, 1.7) 4.2825, 1, 0.0385 
Lipid-lowering 
med use at 
twelve mos. 
No Baseline age 
>= median 
Overall . . 1.72 (1.14, 2.6)  
Lipid-lowering 
med use at 
twelve mos. 
No Baseline age 
>= median 
No 38 615   
Lipid-lowering 
med use at 
twelve mos. 
No Baseline age 
>= median 
Yes 67 630   
Lipid-lowering 
med use at 
twelve mos. 
Yes Baseline age 
>= median 
Overall . . 0.93 (0.62, 1.41)  
Lipid-lowering 
med use at 
twelve mos. 
Yes Baseline age 
>= median 
No 53 674   
Lipid-lowering 
med use at 
twelve mos. 
Yes Baseline age 
>= median 
Yes 46 627   
Lipid-lowering 
med use at 
twelve mos. 
Overall 12 mo. age 
>= median 
Overall . . 1.27 (0.96, 1.7) 4.1944, 1, 0.0406 
Lipid-lowering 
med use at 
twelve mos. 
No 12 mo. age 
>= median 
Overall . . 1.72 (1.13, 2.59)  
Lipid-lowering 
med use at 
twelve mos. 
No 12 mo. age 
>= median 
No 38 614   
Lipid-lowering 
med use at 
twelve mos. 
No 12 mo. age 
>= median 
Yes 67 631   
Lipid-lowering 
med use at 
twelve mos. 
Yes 12 mo. age 
>= median 
Overall . . 0.94 (0.62, 1.41)  
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Lipid-lowering 
med use at 
twelve mos. 
Yes 12 mo. age 
>= median 
No 53 675   
Lipid-lowering 
med use at 
twelve mos. 
Yes 12 mo. age 
>= median 
Yes 46 626   
Lipid-lowering 
med use at 
twelve mos. 
Overall 12 mo. SBP 
>= median 
Overall . . 1.31 (0.98, 1.75) 6.8166, 1, 0.009 
Lipid-lowering 
med use at 
twelve mos. 
No 12 mo. SBP 
>= median 
Overall . . 1.93 (1.27, 2.94)  
Lipid-lowering 
med use at 
twelve mos. 
No 12 mo. SBP 
>= median 
No 35 612   
Lipid-lowering 
med use at 
twelve mos. 
No 12 mo. SBP 
>= median 
Yes 70 633   
Lipid-lowering 
med use at 
twelve mos. 
Yes 12 mo. SBP 
>= median 
Overall . . 0.89 (0.59, 1.34)  
Lipid-lowering 
med use at 
twelve mos. 
Yes 12 mo. SBP 
>= median 
No 53 658   
Lipid-lowering 
med use at 
twelve mos. 
Yes 12 mo. SBP 
>= median 
Yes 46 643   
Blood-pressure-
lowering med 
use at baseline 
Overall Baseline 
SBP >= 
median 
Overall . . 1.4 (1.05, 1.87) 6.3035, 1, 0.0121 
Blood-pressure-
lowering med 
use at baseline 
No Baseline 
SBP >= 
median 
Overall . . 2.03 (1.33, 3.12)  
Blood-pressure-
lowering med 
use at baseline 
No Baseline 
SBP >= 
median 
No 36 730   
Blood-pressure-
lowering med 
use at baseline 
No Baseline 
SBP >= 
median 
Yes 59 588   
Blood-pressure-
lowering med 
use at baseline 
Yes Baseline 
SBP >= 
median 
Overall . . 0.97 (0.65, 1.44)  
Blood-pressure-
lowering med 
use at baseline 
Yes Baseline 
SBP >= 
median 
No 48 531   
Blood-pressure-
lowering med 
use at baseline 
Yes Baseline 
SBP >= 
median 
Yes 61 697   
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Blood-pressure-
lowering med 
use at baseline 
Overall Baseline TC 
>= median 
Overall . . 1.21 (0.91, 1.61) 5.0447, 1, 0.0247 
Blood-pressure-
lowering med 
use at baseline 
No Baseline TC 
>= median 
Overall . . 1.78 (1.14, 2.75)  
Blood-pressure-
lowering med 
use at baseline 
No Baseline TC 
>= median 
No 32 625   
Blood-pressure-
lowering med 
use at baseline 
No Baseline TC 
>= median 
Yes 63 693   
Blood-pressure-
lowering med 
use at baseline 
Yes Baseline TC 
>= median 
Overall . . 0.91 (0.61, 1.34)  
Blood-pressure-
lowering med 
use at baseline 
Yes Baseline TC 
>= median 
No 61 657   
Blood-pressure-
lowering med 
use at baseline 
Yes Baseline TC 
>= median 
Yes 48 571   
Change in blood-
pressure-
lowering med 
adherence  
Overall Aspirin use 
at baseline 
Overall . . 1.05 (0.78, 1.41) 8.3524, 3, 0.0393 
Change in blood-
pressure-
lowering med 
adherence  
Adherent Aspirin use 
at baseline 
Overall . . 0.9 (0.62, 1.32)  
Change in blood-
pressure-
lowering med 
adherence  
Adherent Aspirin use 
at baseline 
No 50 619   
Change in blood-
pressure-
lowering med 
adherence  
Adherent Aspirin use 
at baseline 
Yes 69 945   
Change in blood-
pressure-
lowering med 
adherence  
Started 
using 
Aspirin use 
at baseline 
Overall . . 4.16 (0.91, 
19.14) 
 
Change in blood-
pressure-
lowering med 
adherence  
Started 
using 
Aspirin use 
at baseline 
No 2 57   
Change in blood-
pressure-
lowering med 
adherence  
Started 
using 
Aspirin use 
at baseline 
Yes 13 89   
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Change in blood-
pressure-
lowering med 
adherence  
Stopped 
using 
Aspirin use 
at baseline 
Overall . . 2.46 (0.9, 6.7)  
Change in blood-
pressure-
lowering med 
adherence  
Stopped 
using 
Aspirin use 
at baseline 
No 5 142   
Change in blood-
pressure-
lowering med 
adherence  
Stopped 
using 
Aspirin use 
at baseline 
Yes 20 231   
Change in blood-
pressure-
lowering med 
adherence  
Never 
used 
Aspirin use 
at baseline 
Overall . . 0.74 (0.4, 1.37)  
Change in blood-
pressure-
lowering med 
adherence  
Never 
used 
Aspirin use 
at baseline 
No 20 172   
Change in blood-
pressure-
lowering med 
adherence  
Never 
used 
Aspirin use 
at baseline 
Yes 25 291   
Blood-pressure-
lowering med 
use at twelve 
mos. 
Overall Baseline age 
>= median 
Overall . . 1.27 (0.96, 1.7) 4.4893, 1, 0.0341 
Blood-pressure-
lowering med 
use at twelve 
mos. 
No Baseline age 
>= median 
Overall . . 1.88 (1.18, 2.99)  
Blood-pressure-
lowering med 
use at twelve 
mos. 
No Baseline age 
>= median 
No 29 581   
Blood-pressure-
lowering med 
use at twelve 
mos. 
No Baseline age 
>= median 
Yes 55 587   
Blood-pressure-
lowering med 
use at twelve 
mos. 
Yes Baseline age 
>= median 
Overall . . 0.99 (0.68, 1.44)  
Blood-pressure-
lowering med 
use at twelve 
mos. 
Yes Baseline age 
>= median 
No 62 708   
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Blood-pressure-
lowering med 
use at twelve 
mos. 
Yes Baseline age 
>= median 
Yes 58 670   
Blood-pressure-
lowering med 
use at twelve 
mos. 
Overall 12 mo. age 
>= median 
Overall . . 1.27 (0.96, 1.7) 4.6698, 1, 0.0307 
Blood-pressure-
lowering med 
use at twelve 
mos. 
No 12 mo. age 
>= median 
Overall . . 1.89 (1.19, 3.01)  
Blood-pressure-
lowering med 
use at twelve 
mos. 
No 12 mo. age 
>= median 
No 29 583   
Blood-pressure-
lowering med 
use at twelve 
mos. 
No 12 mo. age 
>= median 
Yes 55 585   
Blood-pressure-
lowering med 
use at twelve 
mos. 
Yes 12 mo. age 
>= median 
Overall . . 0.98 (0.68, 1.43)  
Blood-pressure-
lowering med 
use at twelve 
mos. 
Yes 12 mo. age 
>= median 
No 62 706   
Blood-pressure-
lowering med 
use at twelve 
mos. 
Yes 12 mo. age 
>= median 
Yes 58 672   
Blood-pressure-
lowering med 
use at twelve 
mos. 
Overall Baseline 
SBP >= 
median 
Overall . . 1.4 (1.05, 1.87) 8.9565, 1, 0.0028 
Blood-pressure-
lowering med 
use at twelve 
mos. 
No Baseline 
SBP >= 
median 
Overall . . 2.32 (1.47, 3.66)  
Blood-pressure-
lowering med 
use at twelve 
mos. 
No Baseline 
SBP >= 
median 
No 31 672   
Blood-pressure-
lowering med 
use at twelve 
mos. 
No Baseline 
SBP >= 
median 
Yes 53 496   
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Blood-pressure-
lowering med 
use at twelve 
mos. 
Yes Baseline 
SBP >= 
median 
Overall . . 0.94 (0.65, 1.37)  
Blood-pressure-
lowering med 
use at twelve 
mos. 
Yes Baseline 
SBP >= 
median 
No 53 589   
Blood-pressure-
lowering med 
use at twelve 
mos. 
Yes Baseline 
SBP >= 
median 
Yes 67 789   
Blood-pressure-
lowering med 
use at twelve 
mos. 
Overall Baseline TC 
>= median 
Overall . . 1.21 (0.91, 1.61) 4.0412, 1, 0.0444 
Blood-pressure-
lowering med 
use at twelve 
mos. 
No Baseline TC 
>= median 
Overall . . 1.77 (1.11, 2.83)  
Blood-pressure-
lowering med 
use at twelve 
mos. 
No Baseline TC 
>= median 
No 28 549   
Blood-pressure-
lowering med 
use at twelve 
mos. 
No Baseline TC 
>= median 
Yes 56 619   
Blood-pressure-
lowering med 
use at twelve 
mos. 
Yes Baseline TC 
>= median 
Overall . . 0.96 (0.66, 1.4)  
Blood-pressure-
lowering med 
use at twelve 
mos. 
Yes Baseline TC 
>= median 
No 65 733   
Blood-pressure-
lowering med 
use at twelve 
mos. 
Yes Baseline TC 
>= median 
Yes 55 645   
CKD stage Overall Atrial 
fibrillation at 
baseline 
Overall . . 2.49 (0.29, 
21.43) 
6.905, 2, 0.0317 
CKD stage eGFR 
>=90 
Atrial 
fibrillation at 
baseline 
Overall . . . (., .)  
CKD stage eGFR 
>=90 
Atrial 
fibrillation at 
baseline 
No 34 528   
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
CKD stage eGFR 
>=90 
Atrial 
fibrillation at 
baseline 
Yes 1 0   
CKD stage 90 > 
eGFR 
>=60 
Atrial 
fibrillation at 
baseline 
Overall . . 0 (., .)  
CKD stage 90 > 
eGFR 
>=60 
Atrial 
fibrillation at 
baseline 
No 92 1294   
CKD stage 90 > 
eGFR 
>=60 
Atrial 
fibrillation at 
baseline 
Yes 0 4   
CKD stage 60 > 
eGFR 
>=30 
Atrial 
fibrillation at 
baseline 
Overall . . 0 (., .)  
CKD stage 60 > 
eGFR 
>=30 
Atrial 
fibrillation at 
baseline 
No 72 654   
CKD stage 60 > 
eGFR 
>=30 
Atrial 
fibrillation at 
baseline 
Yes 0 1   
CKD stage 30 > 
eGFR >= 
0 
Atrial 
fibrillation at 
baseline 
Overall . . N/A  
CKD stage 30 > 
eGFR >= 
0 
Atrial 
fibrillation at 
baseline 
No 5 48   
CKD stage 30 > 
eGFR >= 
0 
Atrial 
fibrillation at 
baseline 
Yes 0 0   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Overall Nonwhite 
ancestry 
Overall . . 1.37 (0.97, 1.92) 6.1212, 2, 0.0469 
Pooled 
psychoneurologi
cal impairment at 
baseline  
No Nonwhite 
ancestry 
Overall . . 0.51 (0.07, 3.92)  
Pooled 
psychoneurologi
cal impairment at 
baseline  
No Nonwhite 
ancestry 
No 17 354   
Pooled 
psychoneurologi
cal impairment at 
baseline  
No Nonwhite 
ancestry 
Yes 1 41   
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Pooled 
psychoneurologi
cal impairment at 
baseline  
Mild Nonwhite 
ancestry 
Overall . . 1.07 (0.7, 1.64)  
Pooled 
psychoneurologi
cal impairment at 
baseline  
Mild Nonwhite 
ancestry 
No 115 1504   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Mild Nonwhite 
ancestry 
Yes 29 354   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Moderate Nonwhite 
ancestry 
Overall . . 2.69 (1.36, 5.36)  
Pooled 
psychoneurologi
cal impairment at 
baseline  
Moderate Nonwhite 
ancestry 
No 23 226   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Moderate Nonwhite 
ancestry 
Yes 17 62   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Severe Nonwhite 
ancestry 
Overall . . N/A  
Pooled 
psychoneurologi
cal impairment at 
baseline  
Severe Nonwhite 
ancestry 
No 2 5   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Severe Nonwhite 
ancestry 
Yes 0 0   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Overall Aspirin use 
at baseline 
Overall . . 1.05 (0.78, 1.41) 6.2512, 2, 0.0439 
Pooled 
psychoneurologi
cal impairment at 
baseline  
None Aspirin use 
at baseline 
Overall . . 0.63 (0.24, 1.63)  
Pooled 
psychoneurologi
cal impairment at 
baseline  
None Aspirin use 
at baseline 
No 8 132   
  
226
 
STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Pooled 
psychoneurologi
cal impairment at 
baseline  
None Aspirin use 
at baseline 
Yes 10 263   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Mild Aspirin use 
at baseline 
Overall . . 1.39 (0.97, 2)  
Pooled 
psychoneurologi
cal impairment at 
baseline  
Mild Aspirin use 
at baseline 
No 46 734   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Mild Aspirin use 
at baseline 
Yes 98 1124   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Moderate Aspirin use 
at baseline 
Overall . . 0.61 (0.32, 1.16)  
Pooled 
psychoneurologi
cal impairment at 
baseline  
Moderate Aspirin use 
at baseline 
No 23 124   
Pooled 
psychoneurologi
cal impairment at 
baseline  
Moderate Aspirin use 
at baseline 
Yes 19 169   
Diabetes at 
baseline 
Overall Baseline 
SBP >= 
median 
Overall . . 1.4 (1.05, 1.87) 9.1512, 1, 0.0025 
Diabetes at 
baseline 
No Baseline 
SBP >= 
median 
Overall . . 1.94 (1.34, 2.83)  
Diabetes at 
baseline 
No Baseline 
SBP >= 
median 
No 45 940   
Diabetes at 
baseline 
No Baseline 
SBP >= 
median 
Yes 82 881   
Diabetes at 
baseline 
Yes Baseline 
SBP >= 
median 
Overall . . 0.77 (0.48, 1.24)  
Diabetes at 
baseline 
Yes Baseline 
SBP >= 
median 
No 39 321   
Diabetes at 
baseline 
Yes Baseline 
SBP >= 
median 
Yes 38 404   
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Diabetes at 12 
mos. 
Overall Baseline 
SBP >= 
median 
Overall . . 1.4 (1.05, 1.87) 8.614, 1, 0.0033 
Diabetes at 12 
mos. 
No Baseline 
SBP >= 
median 
Overall . . 1.93 (1.32, 2.81)  
Diabetes at 12 
mos. 
No Baseline 
SBP >= 
median 
No 45 929   
Diabetes at 12 
mos. 
No Baseline 
SBP >= 
median 
Yes 80 856   
Diabetes at 12 
mos. 
Yes Baseline 
SBP >= 
median 
Overall . . 0.79 (0.5, 1.26)  
Diabetes at 12 
mos. 
Yes Baseline 
SBP >= 
median 
No 39 332   
Diabetes at 12 
mos. 
Yes Baseline 
SBP >= 
median 
Yes 40 429   
Endarterectomy 
at baseline 
Overall Blood-
pressure-
lowering 
med use at 
baseline 
Overall . . 1.23 (0.93, 1.64) 6.4326, 1, 0.0112 
Endarterectomy 
at baseline 
No Blood-
pressure-
lowering 
med use at 
baseline 
Overall . . 1.11 (0.82, 1.49)  
Endarterectomy 
at baseline 
No Blood-
pressure-
lowering 
med use at 
baseline 
No 92 1221   
Endarterectomy 
at baseline 
No Blood-
pressure-
lowering 
med use at 
baseline 
Yes 96 1151   
Endarterectomy 
at baseline 
Yes Blood-
pressure-
lowering 
med use at 
baseline 
Overall . . 5.46 (1.5, 19.84)  
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Endarterectomy 
at baseline 
Yes Blood-
pressure-
lowering 
med use at 
baseline 
No 3 97   
Endarterectomy 
at baseline 
Yes Blood-
pressure-
lowering 
med use at 
baseline 
Yes 13 77   
Hypertensive at 
baseline 
Overall Anti-DM 
med use at 
baseline 
Overall . . 1.19 (0.86, 1.63) 4.3702, 1, 0.0366 
Hypertensive at 
baseline 
No Anti-DM 
med use at 
baseline 
Overall . . 2.33 (1.09, 4.99)  
Hypertensive at 
baseline 
No Anti-DM 
med use at 
baseline 
No 25 605   
Hypertensive at 
baseline 
No Anti-DM 
med use at 
baseline 
Yes 10 104   
Hypertensive at 
baseline 
Yes Anti-DM 
med use at 
baseline 
Overall . . 0.97 (0.68, 1.38)  
Hypertensive at 
baseline 
Yes Anti-DM 
med use at 
baseline 
No 122 1314   
Hypertensive at 
baseline 
Yes Anti-DM 
med use at 
baseline 
Yes 47 523   
Hyperlipidemic 
at 12 mos. 
Overall Diabetes at 
baseline 
Overall . . 1.52 (1.13, 2.05) 4.6653, 1, 0.0308 
Hyperlipidemic 
at 12 mos. 
No Diabetes at 
baseline 
Overall . . 0.69 (0.31, 1.55)  
Hyperlipidemic 
at 12 mos. 
No Diabetes at 
baseline 
No 30 333   
Hyperlipidemic 
at 12 mos. 
No Diabetes at 
baseline 
Yes 8 128   
Hyperlipidemic 
at 12 mos. 
Yes Diabetes at 
baseline 
Overall . . 1.77 (1.28, 2.45)  
Hyperlipidemic 
at 12 mos. 
Yes Diabetes at 
baseline 
No 97 1488   
Hyperlipidemic 
at 12 mos. 
Yes Diabetes at 
baseline 
Yes 69 597   
Hyperlipidemic 
at 12 mos. 
Overall Diabetes at 
12 mos. 
Overall . . 1.48 (1.1, 1.99) 5.0066, 1, 0.0253 
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Hyperlipidemic 
at 12 mos. 
No Diabetes at 
12 mos. 
Overall . . 0.66 (0.29, 1.47)  
Hyperlipidemic 
at 12 mos. 
No Diabetes at 
12 mos. 
No 30 328   
Hyperlipidemic 
at 12 mos. 
No Diabetes at 
12 mos. 
Yes 8 133   
Hyperlipidemic 
at 12 mos. 
Yes Diabetes at 
12 mos. 
Overall . . 1.73 (1.26, 2.39)  
Hyperlipidemic 
at 12 mos. 
Yes Diabetes at 
12 mos. 
No 95 1457   
Hyperlipidemic 
at 12 mos. 
Yes Diabetes at 
12 mos. 
Yes 71 628   
Aspirin use at 
baseline 
Overall Baseline 
BMI >= 
median 
Overall . . 1.25 (0.94, 1.67) 4.1434, 1, 0.0418 
Aspirin use at 
baseline 
No Baseline 
BMI >= 
median 
Overall . . 0.86 (0.54, 1.36)  
Aspirin use at 
baseline 
No Baseline 
BMI >= 
median 
No 41 489   
Aspirin use at 
baseline 
No Baseline 
BMI >= 
median 
Yes 36 501   
Aspirin use at 
baseline 
Yes Baseline 
BMI >= 
median 
Overall . . 1.58 (1.09, 2.29)  
Aspirin use at 
baseline 
Yes Baseline 
BMI >= 
median 
No 50 789   
Aspirin use at 
baseline 
Yes Baseline 
BMI >= 
median 
Yes 77 767   
Aspirin use at 
baseline 
Overall 12 mo. BMI 
>= median 
Overall . . 1.13 (0.85, 1.5) 4.2611, 1, 0.039 
Aspirin use at 
baseline 
No 12 mo. BMI 
>= median 
Overall . . 0.77 (0.48, 1.23)  
Aspirin use at 
baseline 
No 12 mo. BMI 
>= median 
No 43 488   
Aspirin use at 
baseline 
No 12 mo. BMI 
>= median 
Yes 34 502   
Aspirin use at 
baseline 
Yes 12 mo. BMI 
>= median 
Overall . . 1.43 (0.99, 2.07)  
Aspirin use at 
baseline 
Yes 12 mo. BMI 
>= median 
No 53 788   
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Aspirin use at 
baseline 
Yes 12 mo. BMI 
>= median 
Yes 74 768   
Aspirin use at 
baseline 
Overall 12 mo. TC 
>= median 
Overall . . 0.98 (0.74, 1.31) 7.1268, 1, 0.0076 
Aspirin use at 
baseline 
No 12 mo. TC 
>= median 
Overall . . 1.63 (1.01, 2.62)  
Aspirin use at 
baseline 
No 12 mo. TC 
>= median 
No 30 505   
Aspirin use at 
baseline 
No 12 mo. TC 
>= median 
Yes 47 485   
Aspirin use at 
baseline 
Yes 12 mo. TC 
>= median 
Overall . . 0.73 (0.5, 1.05)  
Aspirin use at 
baseline 
Yes 12 mo. TC 
>= median 
No 72 758   
Aspirin use at 
baseline 
Yes 12 mo. TC 
>= median 
Yes 55 798   
Change in 
aspirin adherence  
Overall Baseline 
BMI >= 
median 
Overall . . 1.25 (0.94, 1.67) 9.6046, 3, 0.0222 
Change in 
aspirin adherence  
Adherent Baseline 
BMI >= 
median 
Overall . . 1.67 (1.07, 2.6)  
Change in 
aspirin adherence  
Adherent Baseline 
BMI >= 
median 
No 34 661   
Change in 
aspirin adherence  
Adherent Baseline 
BMI >= 
median 
Yes 54 629   
Change in 
aspirin adherence  
Started 
using 
Baseline 
BMI >= 
median 
Overall . . 0.35 (0.14, 0.89)  
Change in 
aspirin adherence  
Started 
using 
Baseline 
BMI >= 
median 
No 17 100   
Change in 
aspirin adherence  
Started 
using 
Baseline 
BMI >= 
median 
Yes 7 116   
Change in 
aspirin adherence  
Stopped 
using 
Baseline 
BMI >= 
median 
Overall . . 1.33 (0.67, 2.64)  
Change in 
aspirin adherence  
Stopped 
using 
Baseline 
BMI >= 
median 
No 16 128   
Change in 
aspirin adherence  
Stopped 
using 
Baseline 
BMI >= 
median 
Yes 23 138   
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Change in 
aspirin adherence  
Never 
used 
Baseline 
BMI >= 
median 
Overall . . 1.22 (0.7, 2.14)  
Change in 
aspirin adherence  
Never 
used 
Baseline 
BMI >= 
median 
No 24 389   
Change in 
aspirin adherence  
Never 
used 
Baseline 
BMI >= 
median 
Yes 29 385   
Change in 
aspirin adherence  
Overall 12 mo. BMI 
>= median 
Overall . . 1.13 (0.85, 1.5) 9.4335, 3, 0.024 
Change in 
aspirin adherence  
Adherent 12 mo. BMI 
>= median 
Overall . . 1.49 (0.96, 2.31)  
Change in 
aspirin adherence  
Adherent 12 mo. BMI 
>= median 
No 36 655   
Change in 
aspirin adherence  
Adherent 12 mo. BMI 
>= median 
Yes 52 635   
Change in 
aspirin adherence  
Started 
using 
12 mo. BMI 
>= median 
Overall . . 0.31 (0.12, 0.81)  
Change in 
aspirin adherence  
Started 
using 
12 mo. BMI 
>= median 
No 18 104   
Change in 
aspirin adherence  
Started 
using 
12 mo. BMI 
>= median 
Yes 6 112   
Change in 
aspirin adherence  
Stopped 
using 
12 mo. BMI 
>= median 
Overall . . 1.29 (0.66, 2.55)  
Change in 
aspirin adherence  
Stopped 
using 
12 mo. BMI 
>= median 
No 17 133   
Change in 
aspirin adherence  
Stopped 
using 
12 mo. BMI 
>= median 
Yes 22 133   
Change in 
aspirin adherence  
Never 
used 
12 mo. BMI 
>= median 
Overall . . 1.1 (0.63, 1.93)  
Change in 
aspirin adherence  
Never 
used 
12 mo. BMI 
>= median 
No 25 384   
Change in 
aspirin adherence  
Never 
used 
12 mo. BMI 
>= median 
Yes 28 390   
Change in 
aspirin adherence  
Overall 12 mo. TC 
>= median 
Overall . . 0.98 (0.74, 1.31) 10.2328, 3, 0.0167
Change in 
aspirin adherence  
Adherent 12 mo. TC 
>= median 
Overall . . 0.82 (0.53, 1.26)  
Change in 
aspirin adherence  
Adherent 12 mo. TC 
>= median 
No 47 624   
Change in 
aspirin adherence  
Adherent 12 mo. TC 
>= median 
Yes 41 666   
Change in 
aspirin adherence  
Started 
using 
12 mo. TC 
>= median 
Overall . . 3.23 (1.23, 8.45)  
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Change in 
aspirin adherence  
Started 
using 
12 mo. TC 
>= median 
No 6 112   
Change in 
aspirin adherence  
Started 
using 
12 mo. TC 
>= median 
Yes 18 104   
Change in 
aspirin adherence  
Stopped 
using 
12 mo. TC 
>= median 
Overall . . 0.57 (0.28, 1.14)  
Change in 
aspirin adherence  
Stopped 
using 
12 mo. TC 
>= median 
No 25 134   
Change in 
aspirin adherence  
Stopped 
using 
12 mo. TC 
>= median 
Yes 14 132   
Change in 
aspirin adherence  
Never 
used 
12 mo. TC 
>= median 
Overall . . 1.25 (0.71, 2.18)  
Change in 
aspirin adherence  
Never 
used 
12 mo. TC 
>= median 
No 24 393   
Change in 
aspirin adherence  
Never 
used 
12 mo. TC 
>= median 
Yes 29 381   
Baseline SBP >= 
120 
Overall Aspirin use 
at twelve 
mos. 
Overall . . 0.84 (0.63, 1.12) 4.0098, 1, 0.0452 
Baseline SBP >= 
120 
No Aspirin use 
at twelve 
mos. 
Overall . . 1.97 (0.79, 4.89)  
Baseline SBP >= 
120 
No Aspirin use 
at twelve 
mos. 
No 7 133   
Baseline SBP >= 
120 
No Aspirin use 
at twelve 
mos. 
Yes 17 164   
Baseline SBP >= 
120 
Yes Aspirin use 
at twelve 
mos. 
Overall . . 0.76 (0.56, 1.02)  
Baseline SBP >= 
120 
Yes Aspirin use 
at twelve 
mos. 
No 85 907   
Baseline SBP >= 
120 
Yes Aspirin use 
at twelve 
mos. 
Yes 95 1342   
12 mo. SBP >= 
120 
Overall Blood-
pressure-
lowering 
med use at 
twelve mos. 
Overall . . 1.21 (0.91, 1.62) 4.1118, 1, 0.0426 
12 mo. SBP >= 
120 
No Blood-
pressure-
lowering 
med use at 
twelve mos. 
Overall . . 2.74 (1.16, 6.5)  
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
12 mo. SBP >= 
120 
No Blood-
pressure-
lowering 
med use at 
twelve mos. 
No 8 167   
12 mo. SBP >= 
120 
No Blood-
pressure-
lowering 
med use at 
twelve mos. 
Yes 18 137   
12 mo. SBP >= 
120 
Yes Blood-
pressure-
lowering 
med use at 
twelve mos. 
Overall . . 1.08 (0.8, 1.47)  
12 mo. SBP >= 
120 
Yes Blood-
pressure-
lowering 
med use at 
twelve mos. 
No 76 1001   
12 mo. SBP >= 
120 
Yes Blood-
pressure-
lowering 
med use at 
twelve mos. 
Yes 102 1241   
12 mo. TC >= 
median 
Overall Baseline 
BMI >= 
median 
Overall . . 1.25 (0.94, 1.67) 7.2807, 1, 0.007 
12 mo. TC >= 
median 
No Baseline 
BMI >= 
median 
Overall . . 1.89 (1.24, 2.88)  
12 mo. TC >= 
median 
No Baseline 
BMI >= 
median 
No 35 627   
12 mo. TC >= 
median 
No Baseline 
BMI >= 
median 
Yes 67 636   
12 mo. TC >= 
median 
Yes Baseline 
BMI >= 
median 
Overall . . 0.85 (0.56, 1.27)  
12 mo. TC >= 
median 
Yes Baseline 
BMI >= 
median 
No 56 651   
12 mo. TC >= 
median 
Yes Baseline 
BMI >= 
median 
Yes 46 632   
12 mo. TC >= 
median 
Overall 12 mo. BMI 
>= median 
Overall . . 1.13 (0.85, 1.5) 5.2412, 1, 0.0221 
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
12 mo. TC >= 
median 
No 12 mo. BMI 
>= median 
Overall . . 1.59 (1.05, 2.4)  
12 mo. TC >= 
median 
No 12 mo. BMI 
>= median 
No 40 639   
12 mo. TC >= 
median 
No 12 mo. BMI 
>= median 
Yes 62 624   
12 mo. TC >= 
median 
Yes 12 mo. BMI 
>= median 
Overall . . 0.81 (0.54, 1.21)  
12 mo. TC >= 
median 
Yes 12 mo. BMI 
>= median 
No 56 637   
12 mo. TC >= 
median 
Yes 12 mo. BMI 
>= median 
Yes 46 646   
12 mo. TC >= 
median 
Overall 12 mo. SBP 
>= median 
Overall . . 1.31 (0.98, 1.75) 3.998, 1, 0.0456 
12 mo. TC >= 
median 
No 12 mo. SBP 
>= median 
Overall . . 0.99 (0.66, 1.48)  
12 mo. TC >= 
median 
No 12 mo. SBP 
>= median 
No 54 664   
12 mo. TC >= 
median 
No 12 mo. SBP 
>= median 
Yes 48 599   
12 mo. TC >= 
median 
Yes 12 mo. SBP 
>= median 
Overall . . 1.79 (1.17, 2.74)  
12 mo. TC >= 
median 
Yes 12 mo. SBP 
>= median 
No 34 606   
12 mo. TC >= 
median 
Yes 12 mo. SBP 
>= median 
Yes 68 677   
Change in TC 
adherence  
Overall Lipid-
lowering 
med use at 
twelve mos. 
Overall . . 0.9 (0.68, 1.2) 15.733, 5, 0.0076 
Change in TC 
adherence  
Stayed < 
200 
Lipid-
lowering 
med use at 
twelve mos. 
Overall . . 0.75 (0.48, 1.19)  
Change in TC 
adherence  
Stayed < 
200 
Lipid-
lowering 
med use at 
twelve mos. 
No 43 495   
Change in TC 
adherence  
Stayed < 
200 
Lipid-
lowering 
med use at 
twelve mos. 
Yes 36 551   
Change in TC 
adherence  
>=200 to 
< 200 
Lipid-
lowering 
med use at 
twelve mos. 
Overall . . 0.36 (0.19, 0.7)  
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Change in TC 
adherence  
>=200 to 
< 200 
Lipid-
lowering 
med use at 
twelve mos. 
No 17 95   
Change in TC 
adherence  
>=200 to 
< 200 
Lipid-
lowering 
med use at 
twelve mos. 
Yes 24 372   
Change in TC 
adherence  
<200 to 
>=200 
Lipid-
lowering 
med use at 
twelve mos. 
Overall . . 1.13 (0.41, 3.17)  
Change in TC 
adherence  
<200 to 
>=200 
Lipid-
lowering 
med use at 
twelve mos. 
No 11 181   
Change in TC 
adherence  
<200 to 
>=200 
Lipid-
lowering 
med use at 
twelve mos. 
Yes 6 87   
Change in TC 
adherence  
>=200 to 
>=200, 
>=.25SD 
decr 
Lipid-
lowering 
med use at 
twelve mos. 
Overall . . 1.39 (0.6, 3.23)  
Change in TC 
adherence  
>=200 to 
>=200, 
>=.25SD 
decr 
Lipid-
lowering 
med use at 
twelve mos. 
No 10 148   
Change in TC 
adherence  
>=200 to 
>=200, 
>=.25SD 
decr 
Lipid-
lowering 
med use at 
twelve mos. 
Yes 14 149   
Change in TC 
adherence  
>=200 to 
>=200, no 
change 
Lipid-
lowering 
med use at 
twelve mos. 
Overall . . 1.53 (0.53, 4.37)  
Change in TC 
adherence  
>=200 to 
>=200, no 
change 
Lipid-
lowering 
med use at 
twelve mos. 
No 8 136   
Change in TC 
adherence  
>=200 to 
>=200, no 
change 
Lipid-
lowering 
med use at 
twelve mos. 
Yes 7 78   
Change in TC 
adherence  
>=200 to 
>=200, 
>=.25SD 
incr 
Lipid-
lowering 
med use at 
twelve mos. 
Overall . . 2.23 (1, 4.96)  
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Change in TC 
adherence  
>=200 to 
>=200, 
>=.25SD 
incr  
Lipid-
lowering 
med use at 
twelve mos. 
No 16 190   
Change in TC 
adherence  
>=200 to 
>=200, 
>=.25SD 
incr 
Lipid-
lowering 
med use at 
twelve mos. 
Yes 12 64   
Change in TC 
adherence  
Overall 12 mo. BMI 
>= median 
Overall . . 1.13 (0.85, 1.5) 12.8184, 5, 0.0251
Change in TC 
adherence  
Stayed < 
200 
12 mo. BMI 
>= median 
Overall . . 1.67 (1.05, 2.67)  
Change in TC 
adherence  
Stayed < 
200 
12 mo. BMI 
>= median 
No 31 543   
Change in TC 
adherence  
Stayed < 
200 
12 mo. BMI 
>= median 
Yes 48 503   
Change in TC 
adherence  
>=200 to 
< 200 
12 mo. BMI 
>= median 
Overall . . 1.57 (0.81, 3.04)  
Change in TC 
adherence  
>=200 to 
< 200 
12 mo. BMI 
>= median 
No 15 222   
Change in TC 
adherence  
>=200 to 
< 200 
12 mo. BMI 
>= median 
Yes 26 245   
Change in TC 
adherence  
<200 to 
>=200 
12 mo. BMI 
>= median 
Overall . . 0.63 (0.23, 1.71)  
Change in TC 
adherence  
<200 to 
>=200 
12 mo. BMI 
>= median 
No 10 127   
Change in TC 
adherence  
<200 to 
>=200 
12 mo. BMI 
>= median 
Yes 7 141   
Change in TC 
adherence  
>=200 to 
>=200, 
>=.25SD 
decr 
12 mo. BMI 
>= median 
Overall . . 0.59 (0.25, 1.43)  
Change in TC 
adherence  
>=200 to 
>=200, 
>=.25SD 
decr 
12 mo. BMI 
>= median 
No 16 161   
Change in TC 
adherence  
>=200 to 
>=200, 
>=.25SD 
decr 
12 mo. BMI 
>= median 
Yes 8 136   
Change in TC 
adherence  
>=200 to 
>=200, no 
change 
12 mo. BMI 
>= median 
Overall . . 0.3 (0.09, 0.96)  
Change in TC 
adherence  
>=200 to 
>=200, no 
change 
12 mo. BMI 
>= median 
No 11 96   
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STRATIFYING 
VARIABLE LEVEL 
VARIABLE
OF 
INTEREST LEVEL 
N 
STROKE
(+) 
N 
STROKE
(-) 
OR 
(95% CI) 
BRESLOW-
DAY 
χ2,DF,P 
Change in TC 
adherence  
>=200 to 
>=200, no 
change 
12 mo. BMI 
>= median 
Yes 4 118   
Change in TC 
adherence  
>=200 to 
>=200, 
>=.25SD 
incr 
12 mo. BMI 
>= median 
Overall . . 1.15 (0.53, 2.52)  
Change in TC 
adherence  
>=200 to 
>=200, 
>=.25SD 
incr  
12 mo. BMI 
>= median 
No 13 127   
Change in TC 
adherence  
>=200 to 
>=200, 
>=.25SD 
incr 
12 mo. BMI 
>= median 
Yes 15 127   
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Table A.15. Evaluation of possible PHA violations (for analysis results shown in Table 
4.10) – time and LOG(time) score tests for baseline to six months medication adherence 
model 
 
Covariate 
Time LOG (time) 
Rho χ2 df P Rho χ2 df P 
Age at six months (std) 0.1627 3.4334 1 0.0639 0.1356 2.3842 1 0.1226
Nonwhite ancestry 0.1444 2.8630 1 0.0906 0.1649 3.7361 1 0.0533
Male gender 0.0357 0.1706 1 0.6796 -0.0080 0.0085 1 0.9266
Started using aspirin 0.0689 0.6361 1 0.4251 0.0477 0.3050 1 0.5808
Stopped using or never used aspirin -0.2188 6.3119 1 0.0120 -0.2041 5.4896 1 0.0191
BMI >=25 to <25 -0.0065 0.0055 1 0.9409 -0.0410 0.2198 1 0.6392
BMI <25 to >=25 or >=25 to >=25 -0.0553 0.4081 1 0.5230 -0.0444 0.2627 1 0.6083
Stopped using cigarettes -0.0176 0.0391 1 0.8433 -0.0694 0.6070 1 0.4359
Started using cigarettes/didn’t stop using 0.0187 0.0428 1 0.8361 0.0126 0.0193 1 0.8894
Started using anti-DM meds -0.0834 0.9425 1 0.3316 -0.0692 0.6477 1 0.4210
Stopped using anti-DM meds/never used -0.0899 1.0695 1 0.3011 -0.1164 1.7945 1 0.1804
Started using blood-pressure-lowering 
meds 
-0.0521 0.3499 1 0.5542 -0.0962 1.1939 1 0.2746
Stopped using blood-pressure-lowering 
meds/never used 
0.1152 1.6693 1 0.1964 0.1411 2.5032 1 0.1136
Started using lipid-lowering meds 0.0503 0.3327 1 0.5641 0.0621 0.5080 1 0.4760
Stopped using lipid-lowering meds/never 
used 
-0.0022 0.0006 1 0.9805 -0.0491 0.3094 1 0.5781
Global test . 19.1201 15 0.2083 . 20.7954 15 0.1435
 
Table A.16. Evaluation of possible PHA violations (for analysis results shown in Table 
4.10) – rank(time) and Kaplan-Meier(time) score tests for baseline to six months 
medication adherence model 
 
Covariate 
RANK (time) Kaplan-Meier (time) 
Rho χ2 df P Rho χ2 df P 
Age at six months (std) 0.1759 4.0138 1 0.0451 0.1735 3.9026 1 0.0482
Nonwhite ancestry 0.1655 3.7639 1 0.0524 0.1585 3.4493 1 0.0633
Male gender 0.0374 0.1870 1 0.6654 0.0381 0.1943 1 0.6594
Started using aspirin 0.0674 0.6088 1 0.4352 0.0682 0.6221 1 0.4303
Stopped using or never used aspirin -0.2226 6.5345 1 0.0106 -0.2224 6.5224 1 0.0107
BMI >=25 to <25 -0.0055 0.0040 1 0.9495 -0.0059 0.0045 1 0.9463
BMI <25 to >=25 or >=25 to >=25 -0.0553 0.4075 1 0.5233 -0.0551 0.4049 1 0.5246
Stopped using cigarettes -0.0252 0.0801 1 0.7772 -0.0223 0.0625 1 0.8026
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Covariate 
RANK (time) Kaplan-Meier (time) 
Rho χ2 df P Rho χ2 df P 
Started using cigarettes/didn’t stop 
using 
0.0011 0.0002 1 0.9902 0.0063 0.0048 1 0.9449
Started using anti-DM meds -0.0936 1.1863 1 0.2761 -0.0914 1.1299 1 0.2878
Stopped using anti-DM meds/never 
used 
-0.0889 1.0476 1 0.3061 -0.0868 0.9981 1 0.3178
Started using blood-pressure-lowering 
meds 
-0.0536 0.3712 1 0.5423 -0.0543 0.3807 1 0.5372
Stopped using blood-pressure-lowering 
meds/never used 
0.1164 1.7042 1 0.1917 0.1145 1.6488 1 0.1991
Started using lipid-lowering meds 0.0565 0.4201 1 0.5169 0.0560 0.4124 1 0.5208
Stopped using lipid-lowering 
meds/never used 
0.0007 0.0001 1 0.9933 0.0010 0.0001 1 0.9906
Global test . 21.0131 15 0.1364 . 20.4842 15 0.1541
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Table A.17. Evaluation of possible PHA violations (for analysis results shown in Table 
4.12) – time and LOG(time) score tests for baseline to six months continuous variable 
adherence model 
 
Covariate 
Time LOG (time) 
Rho χ2 df P Rho χ2 df P 
Age at six months (std) 0.1590 3.4672 1 0.0626 0.1330 2.4285 1 0.1191
Nonwhite ancestry 0.1268 2.1514 1 0.1424 0.1447 2.8019 1 0.0942
Male gender 0.0390 0.2008 1 0.6541 0.0008 0.0001 1 0.9932
BMI >=25 to <25 -0.0049 0.0031 1 0.9553 -0.0422 0.2285 1 0.6327
BMI <25 to >=25 or >=25 to >=25 -0.0459 0.2767 1 0.5989 -0.0346 0.1576 1 0.6914
Stopped using cigarettes -0.0128 0.0208 1 0.8854 -0.0600 0.4575 1 0.4988
Started using cigarettes/never stopped 0.0405 0.1981 1 0.6563 0.0329 0.1306 1 0.7178
SBP >=120 to 120 > -0.0746 0.7409 1 0.3894 -0.0438 0.2551 1 0.6135
SBP 120> to >=120 or >=120 to >=120 -0.0463 0.2848 1 0.5936 -0.0693 0.6398 1 0.4238
TC >=200 to 200> 0.0325 0.1402 1 0.7081 0.0318 0.1346 1 0.7137
TC 200> to >=200 or >=200 to >=200 0.0151 0.0230 1 0.8625 0.0602 0.4765 1 0.4900
Global test . 6.6339 11 0.8279 . 7.2444 11 0.7790
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Table A.18. Evaluation of possible PHA violations (for analysis results shown in Table 
4.12) – rank(time) and Kaplan-Meier (time) score tests for baseline to six months 
continuous variable adherence model 
 
 
Covariate 
RANK (time) Kaplan-Meier (time) 
Rho χ2 df P Rho χ2 df P 
Age at six months (std) 0.1716 4.0425 1 0.0444 0.1692 3.9272 1 0.0475
Nonwhite ancestry 0.1480 2.9298 1 0.0870 0.1412 2.6657 1 0.1025
Male gender 0.0403 0.2147 1 0.6431 0.0410 0.2221 1 0.6374
BMI >=25 to <25 -0.0038 0.0019 1 0.9654 -0.0042 0.0022 1 0.9624
BMI <25 to >=25 or >=25 to >=25 -0.0458 0.2762 1 0.5992 -0.0457 0.2744 1 0.6004
Stopped using cigarettes -0.0194 0.0478 1 0.8270 -0.0169 0.0362 1 0.8490
Started using cigarettes/never stopped 0.0233 0.0657 1 0.7977 0.0283 0.0969 1 0.7556
SBP >=120 to 120 > -0.0649 0.5604 1 0.4541 -0.0680 0.6150 1 0.4329
SBP 120> to >=120 or >=120 to >=120 -0.0450 0.2690 1 0.6040 -0.0457 0.2776 1 0.5983
TC >=200 to 200> 0.0291 0.1124 1 0.7375 0.0311 0.1282 1 0.7204
TC 200> to >=200 or >=200 to >=200 0.0335 0.1476 1 0.7008 0.0267 0.0941 1 0.7590
Global test . 7.7219 11 0.7380 . 7.4038 11 0.7655
 
 
Table A.19. Evaluation of possible PHA violations (for analysis results shown in Table 
4.11) – time and LOG(time) score tests for baseline to twelve months medication 
adherence model 
 
Covariate 
Time LOG (time) 
Rho χ2 df P Rho χ2 df P 
Age at twelve months (std) 0.0423 0.1156 1 0.7339 0.0344 0.0766 1 0.7820
Nonwhite ancestry -0.0480 0.1854 1 0.6668 -0.0041 0.0014 1 0.9707
Male gender 0.0925 0.6591 1 0.4169 0.1150 1.0186 1 0.3129
Started using aspirin -0.1564 1.8668 1 0.1718 -0.0780 0.4639 1 0.4958
Stopped using or never used aspirin -0.0564 0.2410 1 0.6235 0.0338 0.0865 1 0.7687
BMI >=25 to <25 -0.1526 1.7526 1 0.1855 -0.0951 0.6811 1 0.4092
BMI <25 to >=25 or >=25 to >=25 0.1635 2.0196 1 0.1553 0.1310 1.2974 1 0.2547
Stopped using cigarettes 0.0462 0.1516 1 0.6971 0.0737 0.3863 1 0.5343
Started using cigarettes/never stopped 0.2029 3.0546 1 0.0805 0.2052 3.1239 1 0.0772
Started using anti-DM meds 0.2200 3.7820 1 0.0518 0.1739 2.3623 1 0.1243
Stopped using anti-DM meds/never used -0.1731 2.2673 1 0.1321 -0.1027 0.7982 1 0.3716
Started using blood-pressure-lowering 
meds 
-0.1147 0.9792 1 0.3224 -0.1232 1.1289 1 0.2880
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Covariate 
Time LOG (time) 
Rho χ2 df P Rho χ2 df P 
Stopped using blood-pressure-lowering 
meds/never used 
0.0873 0.5572 1 0.4554 0.0965 0.6809 1 0.4093
Started using lipid-lowering meds -0.1584 1.8823 1 0.1701 -0.2517 4.7549 1 0.0292
Stopped using lipid-lowering meds/never 
used 
-0.1374 1.4384 1 0.2304 -0.0914 0.6367 1 0.4249
Global test . 20.8891 15 0.1404 . 18.2933 15 0.2476
 
Table A.20. Evaluation of possible PHA violations (for analysis results shown in Table 
4.11) – rank(time) and Kaplan-Meier(time) score tests for baseline to twelve months 
medication adherence model 
 
Covariate 
RANK (time) Kaplan-Meier (time) 
Rho χ2 df P Rho χ2 df P 
Age at twelve months (std) 0.0394 0.1003 1 0.7515 0.0403 0.1048 1 0.7461
Nonwhite ancestry -0.0301 0.0729 1 0.7871 -0.0398 0.1279 1 0.7206
Male gender 0.1030 0.8159 1 0.3664 0.0971 0.7255 1 0.3944
Started using aspirin -0.1487 1.6880 1 0.1939 -0.1520 1.7640 1 0.1841
Stopped using or never used aspirin -0.0518 0.2030 1 0.6523 -0.0571 0.2466 1 0.6195
BMI >=25 to <25 -0.1532 1.7666 1 0.1838 -0.1527 1.7552 1 0.1852
BMI <25 to >=25 or >=25 to >=25 0.1618 1.9776 1 0.1596 0.1627 1.9998 1 0.1573
Stopped using cigarettes 0.0532 0.2012 1 0.6538 0.0479 0.1627 1 0.6867
Started using cigarettes/never stopped 0.2060 3.1492 1 0.0760 0.2033 3.0661 1 0.0799
Started using anti-DM meds 0.2186 3.7343 1 0.0533 0.2178 3.7039 1 0.0543
Stopped using anti-DM meds/never used -0.1839 2.5580 1 0.1097 -0.1833 2.5428 1 0.1108
Started using blood-pressure-lowering 
meds 
-0.1243 1.1498 1 0.2836 -0.1242 1.1483 1 0.2839
Stopped using blood-pressure-lowering 
meds/never used 
0.0918 0.6159 1 0.4326 0.0841 0.5170 1 0.4721
Started using lipid-lowering meds -0.1682 2.1214 1 0.1453 -0.1613 1.9513 1 0.1625
Stopped using lipid-lowering meds/never 
used 
-0.1507 1.7313 1 0.1883 -0.1476 1.6602 1 0.1976
Global test . 21.9317 15 0.1096 . 21.4428 15 0.1233
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Table A.21. Evaluation of possible PHA violations (for analysis results shown in Table 
4.12) – time and LOG(time) score tests for baseline to twelve months continuous 
variable adherence model 
 
Covariate 
Time LOG (time) 
Rho χ2 df P Rho χ2 df P 
Age at twelve months (std) 0.0558 0.2136 1 0.6440 0.0639 0.2810 1 0.5961
Nonwhite ancestry -0.0551 0.2385 1 0.6253 -0.0032 0.0008 1 0.9772
Male gender 0.1205 1.1180 1 0.2904 0.1364 1.4326 1 0.2313
BMI >=25 to <25 -0.1590 1.9056 1 0.1675 -0.1006 0.7625 1 0.3826
BMI <25 to >=25 or >=25 to >=25 0.1634 2.0308 1 0.1541 0.1358 1.4024 1 0.2363
Stopped using cigarettes 0.0564 0.2326 1 0.6296 0.0887 0.57605 1 0.4479
Started using cigarettes/never stopped 0.2066 3.0800 1 0.0793 0.2074 3.1062 1 0.0780
SBP >=120 to 120 > -0.0564 0.2478 1 0.6186 -0.0763 0.4539 1 0.5005
SBP 120> to >=120 or >=120 to >=120 0.0080 0.0050 1 0.9435 0.0599 0.2798 1 0.5969
TC >=200 to 200> 0.0271 0.0562 1 0.8125 0.0683 0.3578 1 0.5497
TC 200> to >=200 or >=200 to >=200 -0.1686 2.1819 1 0.1396 -0.1561 1.8704 1 0.1714
Global test . 10.7272 11 0.4664 . 9.9635 11 0.5337
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Table A.22. Evaluation of possible PHA violations (for analysis results shown in Table 
4.12) – rank(time) and Kaplan-Meier(time) score tests for baseline to twelve months 
continuous variable adherence model 
 
 
Covariate 
RANK (time) Kaplan-Meier (time) 
Rho χ2 df P Rho χ2 df P 
Age at twelve months (std) 0.0572 0.2251 1 0.6352 0.0559 0.2149 1 0.6429
Nonwhite ancestry -0.0361 0.1023 1 0.7491 -0.0461 0.1670 1 0.6828
Male gender 0.1325 1.3517 1 0.2450 0.1265 1.2322 1 0.2670
BMI >=25 to <25 -0.1598 1.9249 1 0.1653 -0.1593 1.9113 1 0.1668
BMI <25 to >=25 or >=25 to >=25 0.1614 1.9815 1 0.1592 0.1622 2.0022 1 0.1571
Stopped using cigarettes 0.0657 0.3157 1 0.5742 0.0592 0.2566 1 0.6125
Started using cigarettes/never stopped 0.2106 3.2029 1 0.0735 0.2077 3.1140 1 0.0776
SBP >=120 to 120 > -0.0425 0.1412 1 0.7071 -0.0441 0.1514 1 0.6972
SBP 120> to >=120 or >=120 to >=120 0.0383 0.1140 1 0.7357 0.0293 0.0668 1 0.7960
TC >=200 to 200> 0.0379 0.1104 1 0.7397 0.0329 0.0831 1 0.7731
TC 200> to >=200 or >=200 to >=200 -0.1741 2.3255 1 0.1273 -0.1763 2.3844 1 0.1226
Global test . 11.1952 11 0.4271 . 11.0072 11 0.4427
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Table A.23. Profile of full cohort and those participants for whom baseline-to-six 
months medication adherence model had poor fit  
 
Variable 
Variable
level 
Full dataset
(N (%)) 
Poor fit cases 
(N (%)) 
Recurrent stroke No 2619 (95) 56 (55) 
 Yes 131 (5) 45 (45) 
Nonwhite ancestry No 2246 (82) 83 (82) 
 Yes 504 (18) 18 (18) 
Male gender No 1021 (37) 31 (31) 
 Yes 1729 (63) 70 (69) 
Started taking aspirin  No 2549 (93) 92 (91) 
 Yes 201 (7) 9 (9) 
Stopped taking aspirin or never used aspirin No 1642 (60) 52 (51) 
 Yes 1108 (40) 49 (49) 
BMI change from >=25 to 25 > No 2666 (97) 97 (96) 
 Yes 84 (3) 4 (4) 
BMI change from 25> to >=25 or >=25 to >=25 No 2662 (97) 98 (97) 
 Yes 88 (3) 3 (3) 
Stopped cigarette smoking No 2675 (97) 96 (95) 
 Yes 75 (3) 5 (5) 
Started cigarette smoking or never stopped No 2296 (83) 86 (85) 
 Yes 454 (17) 15 (15) 
Started using anti-diabetic meds No 2723 (99) 100 (99) 
 Yes 27 (1) 1 (1) 
Stopped using anti-diabetic medss or never used No 2619 (95) 93 (92) 
 Yes 131 (5) 8 (8) 
Started using blood-pressure-lowering meds No 2614 (95) 91 (90) 
 Yes 136 (5) 10 (10) 
Stopped using blood-pressure-lowering meds or 
never used 
No 1930 (70) 72 (71) 
 Yes 820 (30) 29 (29) 
Started using lipid-lowering meds No 2588 (94) 94 (93) 
 Yes 162 (6) 7 (7) 
Stopped using lipid-lowering meds or never used No 1959 (71) 64 (63) 
 Yes 791 (29) 37 (37) 
 
 
 
 
 
246 
 
REFERENCES 
 
1. Samsa GP, Bian J, Lipscomb J, Matchar DB. Epidemiology of recurrent cerebral 
infarction: A medicare claims-based comparison of first and recurrent strokes on 2-
year survival and cost. Stroke. 1999;30:338-349 
2. Jorgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Stroke recurrence: 
Predictors, severity, and prognosis. The copenhagen stroke study. Neurology. 
1997;48:891-895 
3. Schneider JA, Wilson RS, Cochran EJ, Bienias JL, Arnold SE, Evans DA, Bennett 
DA. Relation of cerebral infarctions to dementia and cognitive function in older 
persons. Neurology. 2003;60:1082-1088 
4. Qureshi AI, Suri MF, Guterman LR, Hopkins LN. Ineffective secondary prevention 
in survivors of cardiovascular events in the us population: Report from the third 
national health and nutrition examination survey. Arch Intern Med. 2001;161:1621-
1628 
5. Leys D, Deplanque D, Mounier-Vehier C, Mackowiak-Cordoliani MA, Lucas C, 
Bordet R. Stroke prevention: Management of modifiable vascular risk factors. J 
Neurol. 2002;249:507-517 
6. Raps EC, Galetta SL. Stroke prevention therapies and management of patient 
subgroups. Neurology. 1995;45:S19-24 
7. Redfern J, McKevitt C, Wolfe CD. Development of complex interventions in stroke 
care: A systematic review. Stroke. 2006;37:2410-2419 
8. Spence JD, Howard VJ, Chambless LE, Malinow MR, Pettigrew LC, Stampfer M, 
Toole JF. Vitamin intervention for stroke prevention (visp) trial: Rationale and 
design. Neuroepidemiology. 2001;20:16-25 
9. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides 
EG, Wang CH, Stampfer M. Lowering homocysteine in patients with ischemic stroke 
to prevent recurrent stroke, myocardial infarction, and death: The vitamin 
intervention for stroke prevention (visp) randomized controlled trial. Journal of the 
American Medical Association. 2004;291:565-575 
  
247
 
10. Muntner P, Garrett E, Klag MJ, Coresh J. Trends in stroke prevalence between 1973 
and 1991 in the us population 25 to 74 years of age. Stroke. 2002;33:1209-1213 
11. Williams GR. Incidence and characteristics of total stroke in the united states. BMC 
Neurol. 2001;1:2 
12. Justice AC, Covinsky KE, Berlin JA. Assessing the generalizability of prognostic 
information. Ann Intern Med. 1999;130:515-524 
13. Olesen J, Leonardi M. The burden of brain diseases in europe. Eur J Neurol. 
2003;10:471-477 
14. McGovern PG, Burke GL, Sprafka JM, Xue S, Folsom AR, Blackburn H. Trends in 
mortality, morbidity, and risk factor levels for stroke from 1960 through 1990. The 
minnesota heart survey. Jama. 1992;268:753-759 
15. Wing S, Casper M, Davis WB, Pellom A, Riggan W, Tyroler HA. Stroke mortality 
maps. United states whites aged 35-74 years, 1962-1982. Stroke. 1988;19:1507-1513 
16. Cooper R, Sempos C, Hsieh SC, Kovar MG. Slowdown in the decline of stroke 
mortality in the united states, 1978-1986. Stroke. 1990;21:1274-1279 
17. Arias E, Anderson RN, Kung HC, Murphy SL, Kochanek KD. Deaths: Final data for 
2001. Natl Vital Stat Rep. 2003;52:1-115 
18. Fang J, Alderman MH. Trend of stroke hospitalization, united states, 1988-1997. 
Stroke. 2001;32:2221-2226 
19. Wolf PA, D'Agostino RB. Secular trends in stroke in the framingham study. Ann 
Epidemiol. 1993;3:471-475 
20. Gillum RF, Gomez-Marin O, Kottke TE, Jacobs DR, Jr., Prineas RJ, Folsom AR, 
Luepker RV, Blackburn H. Acute stroke in a metropolitan area, 1970 and 1980. The 
minnesota heart survey. J Chronic Dis. 1985;38:891-898 
21. Petty GW, Brown RD, Jr., Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. 
Survival and recurrence after first cerebral infarction: A population-based study in 
rochester, minnesota, 1975 through 1989. Neurology. 1998;50:208-216 
  
248
 
22. Hankey GJ, Jamrozik K, Broadhurst RJ, Forbes S, Anderson CS. Long-term disability 
after first-ever stroke and related prognostic factors in the perth community stroke 
study, 1989-1990. Stroke. 2002;33:1034-1040 
23. Desmond DW, Moroney JT, Sano M, Stern Y. Incidence of dementia after ischemic 
stroke: Results of a longitudinal study. Stroke. 2002;33:2254-2260 
24. Roth EJ, Lovell L. Seven-year trends in stroke rehabilitation: Patient characteristics, 
medical complications, and functional outcomes. Top Stroke Rehabil. 2003;9:1-9 
25. Carlsson GE, Moller A, Blomstrand C. Consequences of mild stroke in persons <75 
years -- a 1-year follow-up. Cerebrovasc Dis. 2003;16:383-388 
26. Jorgensen HS, Nakayama H, Raaschou HO, Olsen TS. Acute stroke: Prognosis and a 
prediction of the effect of medical treatment on outcome and health care utilization. 
The copenhagen stroke study. Neurology. 1997;49:1335-1342 
27. Caro JJ, Huybrechts KF, Kelley HE. Predicting treatment costs after acute ischemic 
stroke on the basis of patient characteristics at presentation and early dysfunction. 
Stroke. 2001;32:100-106 
28. Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF. Lifetime cost 
of stroke in the united states. Stroke. 1996;27:1459-1466 
29. MMWR. Public health and aging: Hospitalizations for stroke among adults aged >65 
years - united states. MMWR. 2003;52:586-589 
30. Williams GR, Jiang JG, Matchar DB, Samsa GP. Incidence and occurrence of total 
(first-ever and recurrent) stroke. Stroke. 1999;30:2523-2528 
31. Hardie K, Hankey GJ, Jamrozik K, Broadhurst RJ, Anderson C. Ten-year risk of first 
recurrent stroke and disability after first-ever stroke in the perth community stroke 
study. Stroke. 2004;35:731-735 
32. Modrego PJ, Pina MA, Fraj MM, Llorens N. Type, causes, and prognosis of stroke 
recurrence in the province of teruel, spain. A 5-year analysis. Neurol Sci. 
2000;21:355-360 
  
249
 
33. Sacco RL. Identifying patient populations at high risk for stroke. Neurology. 
1998;51:S27-30 
34. Hankey GJ, Jamrozik K, Broadhurst RJ, Forbes S, Burvill PW, Anderson CS, 
Stewart-Wynne EG. Long-term risk of first recurrent stroke in the perth community 
stroke study. Stroke. 1998;29:2491-2500 
35. Boysen G, Truelsen T. Prevention of recurrent stroke. Neurol Sci. 2000;21:67-72 
36. Petty GW, Brown RD, Jr., Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. 
Ischemic stroke subtypes : A population-based study of functional outcome, survival, 
and recurrence. Stroke. 2000;31:1062-1068 
37. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention 
of stroke and other vascular events: A systematic review. Stroke. 2003;34:2741-2748 
38. Quilliam BJ, Lapane KL. Clinical correlates and drug treatment of residents with 
stroke in long-term care. Stroke. 2001;32:1385-1393 
39. Redfern J, McKevitt C, Dundas R, Rudd AG, Wolfe CD. Behavioral risk factor 
prevalence and lifestyle change after stroke: A prospective study. Stroke. 
2000;31:1877-1881 
40. Leonberg SC, Jr., Elliott FA. Prevention of recurrent stroke. Stroke. 1981;12:731-735 
41. O'Neill BJ, Geis CC, Bogey RA, Moroz A, Bryant PR. Stroke and neurodegenerative 
disorders. 1. Acute stroke evaluation, management, risks, prevention, and prognosis. 
Arch Phys Med Rehabil. 2004;85:S3-10 
42. Halar EM. Management of stroke risk factors during the process of rehabilitation. 
Secondary stroke prevention. Phys Med Rehabil Clin N Am. 1999;10:839-856, viii 
43. Short D, Frischer M, Bashford J. The development and evaluation of a computerised 
decision support system for primary care based upon 'patient profile decision 
analysis'. Inform Prim Care. 2003;11:195-202 
44. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk 
profiles. Am Heart J. 1991;121:293-298 
  
250
 
45. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: A risk 
profile from the framingham study. Stroke. 1991;22:312-318 
46. Bastuji-Garin S, Deverly A, Moyse D, Castaigne A, Mancia G, de Leeuw PW, 
Ruilope LM, Rosenthal T, Chatellier G. The framingham prediction rule is not valid 
in a european population of treated hypertensive patients. J Hypertens. 2002;20:1973-
1980 
47. Truelsen T, Lindenstrom E, Boysen G. Comparison of probability of stroke between 
the copenhagen city heart study and the framingham study. Stroke. 1994;25:802-807 
48. D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: Adjustment 
for antihypertensive medication. The framingham study. Stroke. 1994;25:40-43 
49. Menotti A, Lanti M, Puddu PE, Carratelli L, Mancini M, Motolese M, Prati P, 
Zanchetti A. The risk functions incorporated in riscard 2002: A software for the 
prediction of cardiovascular risk in the general population based on italian data. Ital 
Heart J. 2002;3:114-121 
50. Lumley T, Kronmal RA, Cushman M, Manolio TA, Goldstein S. A stroke prediction 
score in the elderly: Validation and web-based application. J Clin Epidemiol. 
2002;55:129-136 
51. Kernan WN, Viscoli CM, Brass LM, Makuch RW, Sarrel PM, Roberts RS, Gent M, 
Rothwell P, Sacco RL, Liu RC, Boden-Albala B, Horwitz RI. The stroke prognosis 
instrument ii (spi-ii) : A clinical prediction instrument for patients with transient 
ischemia and nondisabling ischemic stroke. Stroke. 2000;31:456-462 
52. Friday G, Alter M, Lai SM. Control of hypertension and risk of stroke recurrence. 
Stroke. 2002;33:2652-2657 
53. Davis PH, Dambrosia JM, Schoenberg BS, Schoenberg DG, Pritchard DA, Lilienfeld 
AM, Whisnant JP. Risk factors for ischemic stroke: A prospective study in rochester, 
minnesota. Ann Neurol. 1987;22:319-327 
54. Rockhill B. Theorizing about causes at the individual level while estimating effects at 
the population level: Implications for prevention. Epidemiology. 2005;16:124-129 
  
251
 
55. Wolf PA, Clagett GP, Easton JD, Goldstein LB, Gorelick PB, Kelly-Hayes M, Sacco 
RL, Whisnant JP. Preventing ischemic stroke in patients with prior stroke and 
transient ischemic attack : A statement for healthcare professionals from the stroke 
council of the american heart association. Stroke. 1999;30:1991-1994 
56. Boden-Albala B, Litwak E, Elkind MS, Rundek T, Sacco RL. Social isolation and 
outcomes post stroke. Neurology. 2005;64:1888-1892 
57. Appelros P, Nydevik I, Viitanen M. Poor outcome after first-ever stroke: Predictors 
for death, dependency, and recurrent stroke within the first year. Stroke. 2003;34:122-
126 
58. Moroney JT, Bagiella E, Tatemichi TK, Paik MC, Stern Y, Desmond DW. Dementia 
after stroke increases the risk of long-term stroke recurrence. Neurology. 
1997;48:1317-1325 
59. Mouradian MS, Majumdar SR, Senthilselvan A, Khan K, Shuaib A. How well are 
hypertension, hyperlipidemia, diabetes, and smoking managed after a stroke or 
transient ischemic attack? Stroke. 2002;33:1656-1659 
60. Claesson L, Gosman-Hedstrom G, Lundgren-Lindquist B, Fagerberg B, Blomstrand 
C. Characteristics of elderly people readmitted to the hospital during the first year 
after stroke. The goteborg 70+ stroke study. Cerebrovasc Dis. 2002;14:169-176 
61. Meschia JF. Clinically translated ischemic stroke genomics. Stroke. 2004;35:2735-
2739 
62. Hoekstra T, Geleijnse JM, Kluft C, Giltay EJ, Kok FJ, Schouten EG. 4g/4g genotype 
of pai-1 gene is associated with reduced risk of stroke in elderly. Stroke. 
2003;34:2822-2828 
63. Ghilardi G, Biondi ML, Turri O, Guagnellini E, Scorza R. Internal carotid artery 
occlusive disease and polymorphisms of fractalkine receptor cx3cr1: A genetic risk 
factor. Stroke. 2004;35:1276-1279 
64. Agnarsson U, Thorgeirsson G, Sigvaldason H, Sigfusson N. Effects of leisure-time 
physical activity and ventilatory function on risk for stroke in men: The reykjavik 
study. Ann Intern Med. 1999;130:987-990 
  
252
 
65. Hu FB, Stampfer MJ, Colditz GA, Ascherio A, Rexrode KM, Willett WC, Manson 
JE. Physical activity and risk of stroke in women. Jama. 2000;283:2961-2967 
66. Kiely DK, Wolf PA, Cupples LA, Beiser AS, Kannel WB. Physical activity and 
stroke risk: The framingham study. Am J Epidemiol. 1994;140:608-620 
67. Biolo G, Ciocchi B, Stulle M, Piccoli A, Lorenzon S, Dal Mas V, Barazzoni R, 
Zanetti M, Guarnieri G. Metabolic consequences of physical inactivity. J Ren Nutr. 
2005;15:49-53 
68. Millen BE, Quatromoni PA, Nam BH, Pencina MJ, Polak JF, Kimokoti RW, Ordovas 
JM, D'Agostino RB. Compliance with expert population-based dietary guidelines and 
lower odds of carotid atherosclerosis in women: The framingham nutrition studies. 
Am J Clin Nutr. 2005;82:174-180 
69. Elwood PC, Pickering JE, Fehily AM, Hughes J, Ness AR. Milk drinking, ischaemic 
heart disease and ischaemic stroke i. Evidence from the caerphilly cohort. Eur J Clin 
Nutr. 2004;58:711-717 
70. Elwood PC, Pickering JE, Hughes J, Fehily AM, Ness AR. Milk drinking, ischaemic 
heart disease and ischaemic stroke ii. Evidence from cohort studies. Eur J Clin Nutr. 
2004;58:718-724 
71. Elwood PC, Strain JJ, Robson PJ, Fehily AM, Hughes J, Pickering J, Ness A. Milk 
consumption, stroke, and heart attack risk: Evidence from the caerphilly cohort of 
older men. J Epidemiol Community Health. 2005;59:502-505 
72. Mozaffarian D, Longstreth WT, Jr., Lemaitre RN, Manolio TA, Kuller LH, Burke 
GL, Siscovick DS. Fish consumption and stroke risk in elderly individuals: The 
cardiovascular health study. Arch Intern Med. 2005;165:200-206 
73. Smoking, quitting, and the risk of cardiovascular disease among women and men in 
the asia-pacific region. Int J Epidemiol. 2005 
74. Zhang X, Shu XO, Yang G, Li HL, Xiang YB, Gao YT, Li Q, Zheng W. Association 
of passive smoking by husbands with prevalence of stroke among chinese women 
nonsmokers. Am J Epidemiol. 2005;161:213-218 
  
253
 
75. Mukamal KJ, Chung H, Jenny NS, Kuller LH, Longstreth WT, Jr., Mittleman MA, 
Burke GL, Cushman M, Beauchamp NJ, Jr., Siscovick DS. Alcohol use and risk of 
ischemic stroke among older adults: The cardiovascular health study. Stroke. 
2005;36:1830-1834 
76. McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, 
Ballantyne CM, Heiss G. The metabolic syndrome and 11-year risk of incident 
cardiovascular disease in the atherosclerosis risk in communities study. Diabetes 
Care. 2005;28:385-390 
77. Mankovsky BN, Ziegler D. Stroke in patients with diabetes mellitus. Diabetes Metab 
Res Rev. 2004;20:268-287 
78. Nilsson PM. Reducing the risk of stroke in elderly patients with hypertension: A 
critical review of the efficacy of antihypertensive drugs. Drugs Aging. 2005;22:517-
524 
79. Milionis HJ, Liberopoulos E, Goudevenos J, Bairaktari ET, Seferiadis K, Elisaf MS. 
Risk factors for first-ever acute ischemic non-embolic stroke in elderly individuals. 
Int J Cardiol. 2005;99:269-275 
80. Wilterdink JL, Easton JD. Vascular event rates in patients with atherosclerotic 
cerebrovascular disease. Arch Neurol. 1992;49:857-863 
81. Moroney JT, Bagiella E, Paik MC, Sacco RL, Desmond DW. Risk factors for early 
recurrence after ischemic stroke: The role of stroke syndrome and subtype. Stroke. 
1998;29:2118-2124 
82. Hata J, Tanizaki Y, Kiyohara Y, Kato I, Kubo M, Tanaka K, Okubo K, Nakamura H, 
Oishi Y, Ibayashi S, Iida M. Ten year recurrence after first ever stroke in a japanese 
community: The hisayama study. J Neurol Neurosurg Psychiatry. 2005;76:368-372 
83. Wu TH, Chen HH, Lee TK. Factors affecting the first recurrence of 
noncardioembolic ischemic stroke. Thromb Res. 2000;97:95-103 
84. Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic 
stroke in population-based incidence studies. Neurology. 2004;62:569-573 
  
254
 
85. Handa N, Matsumoto M, Maeda H, Hougaku H, Kamada T. Ischemic stroke events 
and carotid atherosclerosis. Results of the osaka follow-up study for ultrasonographic 
assessment of carotid atherosclerosis (the osaca study). Stroke. 1995;26:1781-1786 
86. Di Napoli M, Papa F. Inflammation, hemostatic markers, and antithrombotic agents 
in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke 
patients. Stroke. 2002;33:1763-1771 
87. Weinberger J. Adverse effects and drug interactions of antithrombotic agents used in 
prevention of ischaemic stroke. Drugs. 2005;65:461-471 
88. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers 
GW, Pettigrew LC, Adams HP, Jr., Jackson CM, Pullicino P. A comparison of 
warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 
2001;345:1444-1451 
89. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, 
Matias-Guiu J, Rupprecht HJ. Aspirin and clopidogrel compared with clopidogrel 
alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients 
(match): Randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:331-
337 
90. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, 
Bluhmki E, Hoxter G, Mahagne MH, et al. Intravenous thrombolysis with 
recombinant tissue plasminogen activator for acute hemispheric stroke. The european 
cooperative acute stroke study (ecass). Jama. 1995;274:1017-1025 
91. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, 
Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P. 
Randomised double-blind placebo-controlled trial of thrombolytic therapy with 
intravenous alteplase in acute ischaemic stroke (ecass ii). Second european-
australasian acute stroke study investigators. Lancet. 1998;352:1245-1251 
92. Alvarez-Sabin J, Molina CA, Montaner J, Arenillas JF, Huertas R, Ribo M, Codina 
A, Quintana M. Effects of admission hyperglycemia on stroke outcome in reperfused 
tissue plasminogen activator--treated patients. Stroke. 2003;34:1235-1241 
93. Wong KS, Li H. Long-term mortality and recurrent stroke risk among chinese stroke 
patients with predominant intracranial atherosclerosis. Stroke. 2003;34:2361-2366 
  
255
 
94. Chambers M, Hutton J, Gladman J. Cost-effectiveness analysis of antiplatelet therapy 
in the prevention of recurrent stroke in the uk. Aspirin, dipyridamole and aspirin-
dipyridamole. Pharmacoeconomics. 1999;16:577-593 
95. Chambers MG, Koch P, Hutton J. Development of a decision-analytic model of 
stroke care in the united states and europe. Value Health. 2002;5:82-97 
96. Samsa GP, Reutter RA, Parmigiani G, Ancukiewicz M, Abrahamse P, Lipscomb J, 
Matchar DB. Performing cost-effectiveness analysis by integrating randomized trial 
data with a comprehensive decision model: Application to treatment of acute 
ischemic stroke. J Clin Epidemiol. 1999;52:259-271 
97. Howard G, Howard VJ, Katholi C, Oli MK, Huston S. Decline in us stroke mortality: 
An analysis of temporal patterns by sex, race, and geographic region. Stroke. 
2001;32:2213-2220 
98. Cushman WC, Reda DJ, Perry HM, Williams D, Abdellatif M, Materson BJ. 
Regional and racial differences in response to antihypertensive medication use in a 
randomized controlled trial of men with hypertension in the united states. Department 
of veterans affairs cooperative study group on antihypertensive agents. Arch Intern 
Med. 2000;160:825-831 
99. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, Poulter 
N, Primatesta P, Stegmayr B, Thamm M. Hypertension treatment and control in five 
european countries, canada, and the united states. Hypertension. 2004;43:10-17 
100. Moonis M, Fisher M. Considering the role of heparin and low-molecular-weight 
heparins in acute ischemic stroke. Stroke. 2002;33:1927-1933 
101. Hosmer J, David W., Lemeshow S. Applied survival analysis: Regression modeling 
of time to event data. New York: John Wiley & Sons, Inc.; 1999. 
102. Chambless LE, McMahon RP, Brown SA, Patsch W, Heiss G, Shen YL. Short-term 
intraindividual variability in lipoprotein measurements: The atherosclerosis risk in 
communities (aric) study. Am J Epidemiol. 1992;136:1069-1081 
103. Gilbert RK. A comparison of participant mean values of duplicate specimens in the 
cap chemistry survey program. Am J Clin Pathol. 1976;66:184-192 
  
256
 
104. Hart RG, Bailey RD. An assessment of guidelines for prevention of ischemic stroke. 
Neurology. 2002;59:977-982 
105. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, 
Gorelick P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton 
EJ, Marks M, Schwamm LH, Tomsick T. Guidelines for prevention of stroke in 
patients with ischemic stroke or transient ischemic attack: A statement for healthcare 
professionals from the american heart association/american stroke association council 
on stroke: Co-sponsored by the council on cardiovascular radiology and intervention: 
The american academy of neurology affirms the value of this guideline. Stroke. 
2006;37:577-617 
106. Therneau TM, Grambsch PM. Modeling survival data: Extending the cox model. New 
York: Springer-Verlag; 2000. 
107. Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram 
for cancer prognosis. J Clin Oncol. 2008;26:1364-1370 
108. Charlesworth DC, Likosky DS, Marrin CA, Maloney CT, Quinton HB, Morton JR, 
Leavitt BJ, Clough RA, O'Connor GT. Development and validation of a prediction 
model for strokes after coronary artery bypass grafting. Ann Thorac Surg. 
2003;76:436-443 
109. Redfern J, Rudd AD, Wolfe CD, McKevitt C. Stop stroke: Development of an 
innovative intervention to improve risk factor management after stroke. Patient Educ 
Couns. 2008;72:201-209 
110. Ovbiagele B, Campbell S, Faiz A, Chambless LE. Relationship between non-specific 
prescription pill adherence and ischemic stroke outcomes. Cerebrovasc Dis.29:146-
153 
111. McManus JA, Craig A, McAlpine C, Langhorne P, Ellis G. Does behaviour 
modification affect post-stroke risk factor control? Three-year follow-up of a 
randomized controlled trial. Clin Rehabil. 2009;23:99-105 
112. Predictors of major vascular events in patients with a transient ischemic attack or 
nondisabling stroke. The dutch tia trial study group. Stroke. 1993;24:527-531 
  
257
 
113. Kesarwani M, Perez A, Lopez VA, Wong ND, Franklin SS. Cardiovascular 
comorbidities and blood pressure control in stroke survivors. J Hypertens. 
2009;27:1056-1063 
114. Cheng EM, Cunningham WE, Towfighi A, Sanossian N, Bryg RJ, Anderson TL, 
Guterman JJ, Gross-Schulman SG, Beanes S, Jones AS, Liu H, Ettner SL, Saver JL, 
Vickrey BG. Randomized, controlled trial of an intervention to enable stroke 
survivors throughout the los angeles county safety net to "Stay with the guidelines". 
Circ Cardiovasc Qual Outcomes.4:229-234 
115. Burke JP, Sander S, Shah H, Zarotsky V, Henk H. Impact of persistence with 
antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence 
among ischemic stroke survivors. Curr Med Res Opin.26:1023-1030 
116. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic 
and cox regression. Am J Epidemiol. 2007;165:710-718 
117. Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, Janis LS, 
Lutsep HL, Barnwell SL, Waters MF, Hoh BL, Hourihane JM, Levy EI, Alexandrov 
AV, Harrigan MR, Chiu D, Klucznik RP, Clark JM, McDougall CG, Johnson MD, 
Pride GL, Jr., Torbey MT, Zaidat OO, Rumboldt Z, Cloft HJ. Stenting versus 
aggressive medical therapy for intracranial arterial stenosis. N Engl J Med.365:993-
1003 
118. Powers WJ. Management of patients with atherosclerotic carotid occlusion. Curr 
Treat Options Neurol.  
119. Carswell JL, Beard KA, Chevrette MM, Pardue CN, Hess DC, Fagan SC. Tracking 
trends in secondary stroke prevention strategies. Ann Pharmacother. 2004;38:215-
219 
120. Redfern J, McKevitt C, Rudd AG, Wolfe CD. Health care follow-up after stroke: 
Opportunities for secondary prevention. Fam Pract. 2002;19:378-382 
121. Kalra L, Evans A, Perez I, Knapp M, Swift C, Donaldson N. A randomised controlled 
comparison of alternative strategies in stroke care. Health Technol Assess. 2005;9:1-
94 
  
258
 
122. Telman G, Sprecher E, Namestnikov O, Kouperberg E. Comparison of risk factors 
and work-up in young and middle-aged patients with tia and ischaemic stroke. Eur J 
Neurol.17:567-571 
123. Chandratheva A, Geraghty OC, Rothwell PM. Poor performance of current 
prognostic scores for early risk of recurrence after minor stroke. Stroke.42:632-637 
124. Wijnhoud AD, Maasland L, Lingsma HF, Steyerberg EW, Koudstaal PJ, Dippel DW. 
Prediction of major vascular events in patients with transient ischemic attack or 
ischemic stroke: A comparison of 7 models. Stroke.41:2178-2185 
125. Sacco RL, Kargman DE, Gu Q, Zamanillo MC. Race-ethnicity and determinants of 
intracranial atherosclerotic cerebral infarction. The northern manhattan stroke study. 
Stroke. 1995;26:14-20 
126. Cruz-Flores S, Rabinstein A, Biller J, Elkind MS, Griffith P, Gorelick PB, Howard G, 
Leira EC, Morgenstern LB, Ovbiagele B, Peterson E, Rosamond W, Trimble B, 
Valderrama AL. Racial-ethnic disparities in stroke care: The american experience: A 
statement for healthcare professionals from the american heart association/american 
stroke association. Stroke.42:2091-2116 
127. Lin HJ, Chang WL, Tseng MC. Readmission after stroke in a hospital-based registry: 
Risk, etiologies, and risk factors. Neurology.76:438-443 
128. Hankey GJ, Jamrozik K, Broadhurst RJ, Forbes S, Burvill PW, Anderson CS, 
Stewart-Wynne EG. Five-year survival after first-ever stroke and related prognostic 
factors in the perth community stroke study. Stroke. 2000;31:2080-2086 
129. Rothman KJ. Modern epidemiology. Philadelphia, PA: Lippincott Williams & 
Wilkins; 1998. 
130. From Attebring M, Herlitz J, Berndt AK, Karlsson T, Hjalmarson A. Are patients 
truthful about their smoking habits? A validation of self-report about smoking 
cessation with biochemical markers of smoking activity amongst patients with 
ischaemic heart disease. J Intern Med. 2001;249:145-151 
131. Colditz GA, Coakley E. Weight, weight gain, activity, and major illnesses: The 
nurses' health study. Int J Sports Med. 1997;18 Suppl 3:S162-170 
  
259
 
132. Rexrode KM, Hennekens CH, Willett WC, Colditz GA, Stampfer MJ, Rich-Edwards 
JW, Speizer FE, Manson JE. A prospective study of body mass index, weight change, 
and risk of stroke in women. Jama. 1997;277:1539-1545 
133. Abbott RD, Rodriguez BL, Burchfiel CM, Curb JD. Physical activity in older middle-
aged men and reduced risk of stroke: The honolulu heart program. Am J Epidemiol. 
1994;139:881-893 
134. Koukouli S, Vlachonikolis IG, Philalithis A. Socio-demographic factors and self-
reported functional status: The significance of social support. BMC Health Serv Res. 
2002;2:20 
 
 
